{"IQVXMLPath": "\\\\quintiles.net\\enterprise\\Services\\protdigtest\\pilot_iqvxml\\0ce056ac-4360-4920-9443-4396b9c2c391\\R01FIN_R01SE_R01OU_R01D2_D1_Protocol-2014-05-08-DOD-V1---000001.20211108084837.xml.zip", "id": "0ce056ac-4360-4920-9443-4396b9c2c391", "FeedbackRunId": 1, "OutputFilePrefix": "R01", "db_data": {"AiDocId": "0ce056ac-4360-4920-9443-4396b9c2c391", "Unmapped": "    08nov modified Study drugs: Samatasvir (IDX719) and IDX21437 08nov deleted Protocol number: IDX-04B-004 08nov deleted Protocol number: IDX-04B-004 A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection Author(s): Frank D, Zhou XJ, Sullivan-B\u00f3lyai JZ Idenix Pharmaceuticals, Inc. 320 Bent Street Eudract Number: 2014-001378-33 Document type: Protocol Development phase: II Version date: 08-May-2014 Property of Idenix Pharmaceuticals, Inc. Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Idenix Pharmaceuticals, Inc.    Investigator statement Protocol Number:  IDX-04B-004 Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection I understand that all documentation provided to me by Idenix Pharmaceuticals, Inc. or its designated representative(s) concerning this study that has not been published previously will be kept in the strictest confidence. This documentation includes the study protocol, Investigator\u2019s Brochure, case report forms, and other scientific data. This study will not commence without the prior written approval of a properly constituted Institutional Review Board or Ethics Committee. No changes will be made to the study protocol without the prior written approval of Idenix Pharmaceuticals, Inc. and the Institutional Review Board/Ethics Committee, except where necessary to eliminate an immediate hazard to the subject. All subjects will provide a written informed consent prior to participation. I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I have read, understood, and agree to abide by all the conditions and instructions contained in this protocol, and in compliance with ICH, GCP and other applicable regulatory requirements.       Investigator Signature   Date        Investigator Name (Printed)    Table of contents List of tables 6 List of abbreviations 7 Protocol synopsis 9 1 Background 14 1.1 Justification of selected doses 15 1.2 Ri sk/benefit assessment 15 1.2.1 Known Benefits 15 1.2.2 Potential Benefits 16 1.2.3 Known Risk s 16 1.2.4 Potential Risks 16 1.2.5 Risk mitigation 17 1.2.6 Overall benefit/risk assessment 17 2 Study purpose 18 3 Objectives 18 3.1 Primary objectives 18 3.2 Secondary objectiv es 18 4 Study design 18 4.1 Data Safety Monitoring Board 19 4.2 Stop ping rules 19 4.2.1 Study safety stopping rules 19 4.2.2 Futility rules (criteria for closing a treatment arm due to inadequate antiviral response) 20 4.2.3 Individual subject stopping rules 20 4.2.4 Virologic failure 21 5 Population 21 5.1 Inclusion/exclusion criteria 21 5.1.1 Inclusion criteria 21 5.1.2 Exclusion criteria 22 5.2 Prematur e subject withdrawal 25 6 Treatment 25 6.1 Subject numbering 25 6.2 Investigational and control drugs 26 6.3 Treatment arms 26 6.4 Treatment assignment 26 6.5 Treatment bl inding 26 6.6 Treating the subject 26 6.6.1 Dispensing the study drug 26 6.6.2 Instructions for prescribing and taking the study drug 26 6.6.3 Permitted study drug dose modifications or interruptions 27 6.6.4 Study drug discontinuation 27 6.6.5 Concomitant medications 28 6.6.6 Prohibited medications 28 6.6.7 Emergency unblinding of treatment assignment 29 7 Visit schedule and assessments 29 7.1 Information to be collected on screening failures 32 7.2 Subject demographics/other baseline characteristics 33 7.3 Treatment exposure and compliance 33 7.4 Antiviral activity 33 7.5 Safety 34 7.5.1 Adverse events 34 7.5.2 Management of anemia 36 7.5.3 Physical examination 36 7.5.4 Vital signs 36 7.5.5 Laboratory evaluations 36 7.5.6 12-lead electrocardiogram (ECG) 37 7.5.7 Echocardiogram 37 7.6 Pharmacokinetics 37 7.6.1 Pharmacokinetic blood sampling and processing 38 7.7 Pharmacodynamics 38 8 Safety monitoring 38 8.1 Serious adverse event (SAE) reporting 38 8 .2 Follow-up of adverse events 39 8.3 Reporting safety information to the IRB/EC 40 8.4 Pregnancies 40 9 Data review and database management 41 9.1 Site monitoring 41 9.2 Data collection 41 9.3 Database management and quality control 41 9.4 Archival of study records 42 10 Statistical analyses 42 10.1 Populations for analysis 42 10.1.1 Protocol deviations 42 10.2 Subject demographics/other baseline characteristics 43 10.3 Analysis of the primary objective(s) 43 10.3.1 Safety para meters 43 7.4 10.3.2 Antiviral activity 43 10.4 Analysis of secondary objective(s) 43 10. 4.1 Pharmacokinetic parameters 43 10.4.2 Pharmacokinetic/pharmacodynamic relationships 43 10.4.3 Emergence of resistance mutations 43 10.4.4 Durability of SVR and the kinetics of antiviral resistant HCV 44 10.5 Missing, unused and spurious data 44 10.6 Ongoing data analysis 44 10.7 Sample size consideration 44 11 Referenc es 45 Appendix 1:  Administrative procedures 46 Appendix 2:  Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004, Clarification August 2009) 49   List of tables Table 4-1   Study design..........................................................................................19  Table 6-1   Ribavirin dosing schedule.....................................................................27  Table 7-1   Schedule of assessments .......................................................................30  Table 7-2   Schedule of assessments \u2013 Extended observational follow-on phase...31  Table 7-3   Schedule of PK assessments .................................................................32  Table 10-1   Levels of detection \u2013 primary efficacy endpoint vs. the reference (SOVALDI\u2122).......................................................................................44   List of abbreviations \u03b2-HCG Beta-human chorionic gonadotropin AE Adverse event ALT Alanine aminotransferase AST Aspartate aminotransferase AUC 0-t  Area under the concentration-time curve from time zero to t BID Bis in die or twice a day BMI Body mass index C 24h  Drug concentration 24 h after dosing or the predose trough drug concentration following multiple dosing CK Creatine kinase C max  Maximum observed drug concentration CRF Case report form C trough  Trough drug concentration CYP3A4  Cytochrome P450 3A4 DAA Direct-acting antiviral DAIDS Division of AIDS DSMB Data safety monitoring board EC Ethics committee ECG Electrocardiogram EDC Electronic data capture EOT End of treatment FSH Follicle stimulating hormone GCP Good clinical practices GFR Glomerular filtration rate GT genotype h or hr hour(s) HBsAg Hepatitis B surface antigen HBV Hepatitis B virus HCC Hepatocellular carcinoma HCV Hepatitis C virus HCV RNA Hepatitis C virus ribonucleic acid Hgb Hemoglobin HIV Human immunodeficiency virus ICF Informed consent form ICH International Conference on Harmonisation IEC  Independent Ethics Committee IRB Institutional review board IU International units IWR Interactive Web Response kg kilogram LLOQ Lower limit of quantitation MDRD Modification of Diet in Renal Disease  MedDRA Medical Dictionary for Regulatory Activities mg milligram min minute(s) mL milliliter ms millisecond NS5A Nonstructural protein 5A PD Pharmacodynamics Peg-IFN Pegylated interferon P-gp permeability glycoprotein (transporter) pH Measure of acidity or basicity of an aqueous solution PK Pharmacokinetic(s) QD Quaque die or once a day QT QT interval QTcF QT interval corrected for heart rate using Fridericia's formula RBV Ribavirin REB Research ethics board RNA Ribonucleic acid SAE Serious adverse event Samatasvir IDX719 SAP Statistical analysis plan SD Standard deviation SEM Standard error of the mean SVR Sustained virologic response T max  Time to maximum drug concentration (C max ) TSH Thyroid stimulating hormone ULN Upper limit of normal WBC White blood cell WHO World Health Organization Protocol synopsis Protocol Title:  A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection Protocol Number: IDX-04B-004 Clinical Phase: II Principal Investigator & Study Site: Site specific information provided on separate site contact list Objectives: Primary : \u2022 Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) \u2022 Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : \u2022 Treatment duration \u2022 Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites \u2022 PK/Pharmacodynamics (PK/PD) of samatasvir, IDX21437 and their metabolites \u2022 Emergence of resistance mutations during treatment and in the post-treatment period Key Safety Parameters: Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests Key Antiviral Activity Parameters:  \u2022 lower limit o o  Proportion of subjects with plasma hepatitis C virus (HCV) RNA below the f quantitation (<LLOQ)  Primary:  \u2212   SVR 12 :  12 weeks after the end of treatment  o  Second \u2212  ary Week 4 during treatment   \u2212  End of treatment   \u2212  SVR 4 :  4 weeks after the end of treatment   \u2212  SVR 8: :  8 weeks after the end of treatment   \u2212  SVR 24 :  24 weeks after the end of treatment  \u2022 Emergence of resistance mutations \u2022 Durability of SVR and the kinetics of antiviral resistant HCV Key Pharmacokinetic Parameters: Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable Study Design: \u2022 Treatment-na\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects \u2022 Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. \u2022 The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). \u2022 Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-   Treatment (EOT) visit for monitoring of study drug concentrations.  o   Intensive PK/PD on Day 1 and Day 15, and a single blood sample on Day 2, will be optional for all subjects (see Table 7-3).    GT Group N=240 Samatasvir (mg QD) IDX21437 (mg QD) RBV 1 Weeks of treatment 1 A 20 50 300 No 8 1 B 20 50 300 No 12 1 C 60 100 300 No 8 1 D 60 100 300 No 12 3 E 40 100 300 Yes 12 3 F 40 100 300 No 12 1 RBV dosing weight-based, according to product label \u2022 The occurrence of one of the following rules will constitute virologic failure: o HCV RNA above LLOQ for two consecutive measurements (second measurement to be collected as soon as possible) in a subject in whom HCV RNA was below LLOQ, OR o >1 log 10 increase in HCV RNA above nadir for two consecutive measurements. \u2022 Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2). Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase. Duration: Up to 832 days, including Screening, Treatment, Post EOT follow-up and the Extended observational follow-on phase. Number of Subjects: Approximately 240 randomized and treated Inclusion Criteria: 1. 18 (or the legal age of consent per local regulations, if greater than 18 years) to 65 years of age, inclusive. 2. Female subjects of both childbearing potential and non-childbearing potential may be included, unless the local regulatory authority requires that only females of non-childbearing potential be included. Non-childbearing potential is defined as one of the following: \u2022 Postmenopausal, defined as amenorrheic for at least 2 years and serum follicle stimulating hormone (FSH) level consistent with postmenopausal status at Screening, or \u2022 A documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation at least 6 months prior to study initiation. 3. All female subjects must have a negative serum beta-human chorionic gonadotropin (\u03b2-HCG) at Screening and a negative urine pregnancy test prior to the first dose of study medication on Day 1. 4. Women of childbearing potential and men must have agreed to use an acceptable double method of birth control (one of which must be a barrier method) from Screening through at least 7 months after the last dose of study drugs. 5. Male subjects must have agreed not to donate sperm from the first dose through at least 7 months after the last dose of study drugs.   1. QTcF interval \u2264 450 ms at Screening and prior to dosing on Day 1. 2. Documented clinical history compatible with chronic hepatitis C, including any one of the following: \u2022 anti-HCV antibody positive at least 6 months prior to Screening or dosing, OR \u2022 HCV RNA present in plasma by a sensitive and specific assay at least 6 months prior to Screening or dosing, OR \u2022 HCV genotype determined at least 6 months prior to Screening or dosing, OR \u2022 Histologic evidence of chronic hepatitis C infection. 3. Plasma HCV RNA positive at Screening with minimal viral load of 4 log 10 IU/mL. 4. HCV GT 1 or 3 by HCV genotyping performed at Screening ( Note : Mixed subtypes are not acceptable for GT 1 ). 5. Documented absence of cirrhosis within 36 months of Screening or dosing (histology or non-invasive equivalent, according to local standard of care). Note: A score of F4 on any test is exclusionary.  6. Must not have received prior approved or investigational antiviral treatment for HCV infection (Note: Non-cirrhotic, pegylated interferon/RBV-na\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3-month washout period) . 7. Subject is, in the opinion of the investigator, willing and able to comply with the protocol and all other study requirements. 8. Subject has provided written informed consent to participate in the study. Exclusion Criteria: Female subjects who are pregnant or breastfeeding. 2. Body Mass Index (BMI) > 36 kg/m 2 . 3. Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen (HBsAg) positive) and/or human immunodeficiency virus (HIV). 4. History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC. 5. History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency. 6. One or more known primary or secondary causes of liver disease, other than hepatitis C (e.g., alcoholism, autoimmune hepatitis, nonalcoholic steatohepatitis, drug-related liver disease, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson Disease, Dubin-Johnson syndrome, other congenital or metabolic conditions affecting the liver (with the exception of Gilbert\u2019s syndrome), etc.). Steatosis is allowed, if clinically asymptomatic. 7. History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, non-HCV viral hepatitis, gallstones or other etiologies. 8. Active, clinically significant (per judgment of the Principal Investigator) disease including: \u2022 Acute or chronic kidney disease, \u2022 Malignant disease or suspicion or history of malignant disease within previous 5 years (except for adequately treated basal cell carcinoma or other localized, non-metastatic cancer),   \u2022 Uncontrolled depressive illness, \u2022 Uncontrolled thyroid disease; thyroid stimulating hormone (TSH) must be normal at Screening, \u2022 Uncontrolled hypertension, \u2022 Poorly controlled diabetes mellitus as evidenced by hemoglobin A 1c \u2265 8.5% or equivalent at Screening, \u2022 Neurological disease, \u2022 Acute or chronic pancreatitis, \u2022 Infections (e.g., tuberculosis), \u2022 Intestinal malabsorption (e.g., structural defects, digestive failure, enzyme deficiencies with the exception of lactose intolerance, etc.), \u2022 Pulmonary disease associated with ongoing functional impairment, \u2022 Cardiac disease, clinically significant arrhythmia, family history of congenital heart disease, family history of prolonged QT, or family history of sudden death of unknown etiology, OR \u2022 Any other condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results. 1. Donated blood or had significant blood loss 30 days prior to dosing. 2. Use of alcohol and/or drugs that could interfere with adherence to study requirements as judged by the investigator. 3. Concomitant use of any major inhibitors or inducers of CYP3A (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. 4. Concomitant use of any major inhibitors, inducers or substrates of permeability glycoprotein (P-gp) transporter (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. 5. Based on limited in vitro metabolic results, the concomitant use of other drugs is prohibited until further information is available to guide their use (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. 6. Concomitant use of drugs contraindicated in the RBV product label. A washout period of at least 5 half-lives of the contraindicated drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study. 7. Subjects who require frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions); required use for greater than 5 days should be discussed with the Sponsor during Screening ( Note : Topical or inhaled corticosteroids are permitted).  8. Concomitant use of antacids or acid blockers. For acid blockers, a washout period of at least 5 half-lives must be observed prior to study drug dosing, if the Principal Investigator feels that the drug can be safely discontinued or substituted for the duration of the study. 9. Concomitant use of herbal medications (e.g., St. John\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements. 10. Concomitant use of opioid substitution drugs (e.g., buprenorphine and   methadone). 1. Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study. 2. Subject with known allergy/hypersensitivity/intolerance to any of the study drugs, or any of their components. 3. Clinically significant abnormal ECG at Screening or prior to dosing on Day 1. 4. Abnormal values at Screening: \u2022 hemoglobin (Hgb) < 10.0 g/dL \u2022 absolute neutrophil count (ANC) < 1.0 x 10 9 /L \u2022 platelets < 120 x 10 9 /L \u2022 ALT or AST > 5 x upper limit of normal (ULN) \u2022 total bilirubin > 1.1 x ULN (subjects with history of Gilbert\u2019s syndrome > 2 x ULN) \u2022 serum albumin < 3.5 g/dL \u2022 alkaline phosphatase > 1.25 x ULN \u2022 serum creatinine > 1.1 x ULN \u2022 pancreatic amylase > 1.5 x ULN 5. Any other laboratory abnormalities > Grade 1, as defined in (Appendix 2), considered clinically significant by the investigators. Test Product: \u2022 Samatasvir:  50 mg tablets \u2022 IDX21437:  150 mg tablets \u2022 Ribavirin:  200 mg tablets Dose and Mode of Administration: \u2022 Study drug dosing is described in the Study Design Section. \u2022 RBV will be administered orally with food starting on Day 1 per RBV label (for 12 weeks) as per Table 4-1. \uf0be 1,000-1,200 mg/day in two divided doses (weight based) \u0083 <75 kg = 1,000 mg/day \u0083 \u226575 kg = 1,200 mg/day \u2022 Samatasvir, IDX21437 dose modifications are not allowed without prior discussion with the Sponsor. \u2022 RBV dose modifications are allowed per RBV product label. Statistical Methods: Data will be summarized using descriptive statistics. 1 Background Hepatitis C virus (HCV) infection is a global public health problem. The global prevalence of chronic hepatitis C infection is estimated to be approximately 150 million people. An estimated 20-50% of patients with chronic HCV infection are at risk for developing such long-term complications as cirrhosis and hepatocellular carcinoma (HCC) (World Health Organization (WHO) (2013)). It is anticipated that combinations of all oral, direct-acting antivirals (DAAs) will soon become the treatment of choice for chronic HCV infection for both treatment-na\u00efve and -experienced subjects across multiple genotypes. The standard duration of treatment in multiple ongoing and completed Phase II, III and IV studies of HCV DAAs is 12 weeks or less. Similarly, the same studies are testing whether ribavirin (RBV) is a necessary component of treatment. Sofosbuvir (SOVALDI\u2122 (2013)), a licensed uridine nucleotide prodrug, in combination with a second DAA, has been demonstrated to be efficacious without RBV for the treatment of HCV Genotype (GT) 1 infection (Lawitz E, et al. (2013)).  Sofosbuvir, with and without RBV, has been less effective against GT 3 (SOVALDI\u2122 (2013)). The present study has been designed to explore whether samatasvir and IDX21437, with or without RBV, can achieve comparable results. IDX21437 Idenix Pharmaceuticals is developing IDX21437, a novel uridine nucleotide analog prodrug. IDX21437 is designed to generate high levels of the active uridine analog triphosphate in the liver, the site of HCV replication. IDX21437 is anticipated to have pan-genotypic activity and to exhibit a high barrier to resistance. Summaries of nonclinical studies conducted are described in the [IDX21437 Investigator\u2019s Brochure]. In an ongoing, first-in-human IDX21437 study [IDX-04B-001], multiple doses up to a total daily dose of 300 mg IDX21437 for 7 days were found to be safe and well tolerated in healthy and HCV-infected subjects. There were no treatment-emergent serious adverse events (SAEs) or safety related discontinuations ([IDX-04B-001], data on file). Samatasvir Idenix Pharmaceuticals is also developing samatasvir (IDX719), a novel HCV nonstructural protein 5A (NS5A) inhibitor agent for the therapy of chronic hepatitis C. Multiple doses up to a total daily dose of samatasvir 150 mg were found to be safe and well tolerated in healthy subjects when administered for up to 14 days ([IDX-06A-004], data on file) and in HCV-infected subjects when administered for up to 12 weeks ([IDX-06A-005], data on file). In treatment-naive HCV-infected subjects, administration of samatasvir QD or BID for 3 days at a total daily dose of 100 mg resulted in mean maximal viral load reductions of 3.5, 2.0, 3.4 and 3.9 log 10 IU/mL in GT 1, 2, 3 and 4 HCV infections, respectively ([IDX06A-001] [IDX719 Investigator\u2019s Brochure]). Interim analyses of safety and antiviral activity data from the ongoing 12-week study of samatasvir (25 mg, 50 mg, 100 mg or 150 mg) in combination with simeprevir and RBV have shown the combination to be safe and well tolerated and have demonstrated antiviral activity against HCV GT 1b and 4 ([IDX-06A-005],  data on file). Results of in vitro studies suggest samatasvir has a limited potential for drug-drug interactions, making it possible to test samatasvir with various combinations of other DAAs. Summaries of nonclinical studies conducted are described in the [IDX719 Investigator\u2019s Brochure]. 1.1 Justification of selected doses IDX21437 The selected IDX21437 dose for this study, 300 mg QD, is supported by 3-month repeat-dose toxicology studies in the rat and monkey. IDX21437 was well tolerated up to 1000 mg/kg/day in the rat and monkey [IDX21437 Investigator\u2019s Brochure]. In an ongoing, first-in-human IDX21437 study [IDX-04B-001], multiple doses up to a total daily dose of 300 mg IDX21437 for 7 days were found to be safe and well tolerated in healthy subjects. There were no treatment-emergent serious adverse events (SAEs) or safety related discontinuations. Single doses from 10 to 300 mg administered to HCV-infected subjects demonstrated antiviral activity ([IDX-04B-001], data on file). Testing of daily doses ranging from 50 to 300 mg for 7 days in approximately 35 GT 1-3, HCV-infected subjects has demonstrated that 300 mg QD is the most active dose producing mean maximal viral load reductions of >4 log 10 IU/mL, and is safe and well tolerated [IDX21437 Investigator\u2019s Brochure]. Samatasvir The selected samatasvir doses for this study, 50 or 100 mg QD for 8 or 12 weeks, are supported by the repeat-dose toxicology studies with durations of up to 13 weeks at doses up to 250 mg/kg/day [IDX719 Investigator\u2019s Brochure]. The antiviral activity of samatasvir has been demonstrated by 3 days of monotherapy in the proof-of-concept study [IDX-06A-001]. At a total daily dose of 50 or 100 mg x 3 days, mean HCV RNA reductions were similar in GT 1 HCV-infected subjects [IDX719 Investigator\u2019s Brochure]. Interim analyses of safety and antiviral activity data from the ongoing study of samatasvir 25 mg, 50 mg, 100 mg or 150 mg, in combination with simeprevir and RBV [IDX-06A-005], also support the use of samatasvir 50 mg QD and 100 mg QD [IDX719 Investigator\u2019s Brochure] in the current study. 1.2 Risk/benefit assessment Phase II combination studies of DAAs for the treatment of chronic HCV infection have been promising at demonstrating rapid and early viral response without pegylated interferon (PegIFN). While additional trials are required to confirm that these results translate into clinical benefit, combinations of DAAs with different modes of action and complementary resistance profiles likely represent the future of HCV care. 1.2.1 Known Benefits There is no known benefit for participants in this study. 1.2.2 Potential Benefits The potential benefit for participants in this study is in achieving a cure from HCV infection. The results may be useful in developing new therapies and treatment strategies for individuals with HCV infection. 1.2.3 Known Risks Every medication can have undesirable effects . Adverse events for IDX21437 IDX21437 has been safe and well tolerated in a limited number of healthy and HCV-infected subjects up to doses of 300 mg QD x 7 days (Section 1.1). To date, there is no observed doserelated or other pattern in the clinical or laboratory data. Studies in rats and monkeys administered up to 1000 mg/kg/day for 3 months indicate that the kidney and liver are potential target organs. While in vitro and animal toxicology data are consistent with IDX21437 having a low potential for cardiac or mitochondrial toxicity, nucleoside analogues as a class have been associated with mitochondrial toxicity, resulting in symptoms such as pancreatitis, lactic acidosis, severe hepatomegaly, peripheral neuropathy, and myopathy, including cardiomyopathy. Adverse events for samatasvir (IDX719) Approximately 200 healthy subjects have received samatasvir from 5 mg to 200 mg per day, for up to 14 days. In an ongoing phase II study, approximately 100 HCV-infected subjects have received samatasvir, ranging from 50 to 150 mg QD, + simeprevir + RBV for 12 weeks. An additional 44 subjects received samatasvir in combination with simeprevir, TMC647055, ritonavir and RBV. The safety profile of samatasvir has been consistent with the known safety profile of the same combinations without samatasvir. When samatasvir was administered alone, there was no observed dose-related or other pattern in the clinical or laboratory data. The majority of observed adverse events have been mild or moderate. Ribavirin Refer to the U.S. summary of product information (package insert) for RBV (Ribavirin Tablets (2013)), and/or to the local country summary of product information, as applicable, for the associated risks of taking RBV. 1.2.4 Potential Risks Reproductive risk It is not known at this time whether samatasvir or IDX21437 has any impact on reproductive function. Pregnant subjects must not be included in this study. Subjects of child-bearing potential must be informed to use a double-method of birth control (one of which must be a barrier) while participating in this study. It is not known whether samatasvir or IDX21437 is excreted in human milk. Nursing mothers must not be included in clinical trials with samatasvir or IDX21437. Potential genotoxicity Samatasvir and IDX21437 are non-genotoxic compounds [IDX719 Investigator\u2019s Brochure] [IDX21437 Investigator\u2019s Brochure]. QT prolongation The available data indicate that samatasvir and IDX21437 have very limited potential for QT prolongation at clinical exposures. 1.2.5 Risk mitigation Liver and renal function laboratory parameters will be monitored (Table 7-1). These will include the clinical chemistry parameters defined in Section 7.5.5 Cardiac parameters, including ECGs and creatine kinase (CK) isoenzyme levels will be monitored, although these investigational modalities have not been shown to fully predict the presence of human cardiac injury. While in vitro and animal toxicology data are consistent with IDX21437 having a low potential for cardiac or mitochondrial toxicity, nucleoside analogues as a class have been associated with mitochondrial toxicity, resulting in symptoms such as pancreatitis, lactic acidosis, severe hepatomegaly, peripheral neuropathy, and myopathy, including cardiomyopathy. Amylase and anion gap will be monitored. In addition, standard serum chemistries, complete blood counts (CBC) with differentials and clinical adverse events will be monitored. A baseline echocardiogram will be performed and archived, as a contingency, for comparisons to unplanned evaluations after study drug exposure, should such comparisons be needed. 1.2.6 Overall benefit/risk assessment Based on the available data and proposed safety measures, the overall risk/benefit assessment for this clinical study in HCV-infected subjects is acceptable for the following reasons: \u2022 There is a high unmet medical need for new therapies for the treatment of chronic HCV infection. \u2022 Samatasvir and IDX21437 have demonstrated clinical antiviral activity against HCV genotypes 1 and 3. Each compound has a favorable safety profile in preclinical and clinical studies, to date. 5.1.2 \u2022 Only subjects who meet all of the inclusion criteria and none of the exclusion criteria (as specified in the protocol) will be allowed to participate in this study. The selection criteria include adequate provisions to minimize the risk and protect the well-being of subjects in the study. \u2022 Safety will be closely monitored by the investigator throughout the study. Safety and tolerability assessments (including clinical laboratory tests, ECG, vital signs, physical examination) will be performed at scheduled visits throughout the study. \u2022 The study is being conducted under Data Safety Monitoring Board (DSMB) supervision (Section 4.1). Study and individual safety stopping rules and futility rules have been included in the protocol (Section 4.2). \u2022 Any clinically significant abnormalities persisting at the end of the study/early withdrawal will be followed by the investigator until resolution or until a clinically stable endpoint is reached. 2 Study purpose The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and IDX21437 when administered in combination with and without RBV for 8 or 12 weeks in treatment-na\u00efve, GT 1 or 3 HCV-infected subjects. 3 Objectives 3.1 Primary objectives The primary objectives are to evaluate the: \u2022 Safety of samatasvir plus IDX21437 with and without RBV \u2022 Efficacy of samatasvir plus IDX21437 with and without RBV 3.2 Secondary objectives The secondary objectives are to evaluate the: \u2022 Treatment duration \u2022 Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites \u2022 PK/Pharmacodynamics (PK/PD) of samatasvir, IDX21437 and their metabolites \u2022 Emergence of resistance mutations during treatment and in the post-treatment period 4 Study design This will be an open-label, randomized study in treatment-na\u00efve, GT 1 and 3 HCV-infected subjects. Each subject will receive the study drugs with or without RBV for 8 or 12 weeks, as shown in Table 4-1, followed by a 24-week follow-up to determine sustained virologic response (SVR). Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. An independent DSMB will review the PK, safety and antiviral activity data of the first 40 subjects after they have completed 4 weeks of treatment. Screening and dosing of new subjects will not pause during the DSMB review. Table 4-1  Study design GT Group N=240 Samatasvir (mg QD) IDX21437 (mg QD) RBV 1 Weeks of treatment 1 A 20 50 300 No 8 1 B 20 50 300 No 12 1 C 60 100 300 No 8 1 D 60 100 300 No 12 3 E 40 100 300 Yes 12 3 F 40 100 300 No 12 1 RBV dosing weight-based, according to product label A single blood sample per visit will be collected postdose on Day 1 through the 28-day post End-of-Treatment (EOT) visit from all subjects to monitor study drug concentrations. Intensive PK sampling on Day 1 and Day 15, and a single blood sample on Day 2, as detailed in Table 7-3, will be optional for all study subjects. HCV RNA timepoints will be timematched to the PK timepoints for subjects participating in the optional Day 1 intensive PK sampling. Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will be followed in the extended observational follow-on phase in which a blood sample is collected every 12 weeks to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2). If another antiviral treatment for HCV is initiated, participation in the observational follow-on phase will be terminated. 4.1 Data Safety Monitoring Board An independent DSMB, constituted according to applicable international and local regulations, will review the available PK, safety and antiviral activity data after the first 40 subjects have completed 4 weeks of treatment. Screening and dosing of new subjects will not pause during the DSMB reviews. Subsequent DSMB meetings will occur approximately every 2 months to review the available PK, safety and antiviral activity data or, as needed, when triggered by the study stopping rules (Section 4.2.1). 4.2 Stopping rules 4.2.1 Study safety stopping rules If any of the following rules are triggered, the cases will be immediately reviewed with the DSMB Chairperson. If the DSMB Chairperson feels there is a possible relationship with IDX21437, samatasvir, or any combination of these drugs, the Chairperson will call an ad hoc DSMB meeting to review the data with the full DSMB. \u2022 Any single subject who has a confirmed alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x baseline and total bilirubin > 2x upper limit of normal (ULN), without any reason to explain a concurrent increase of ALT/AST and total bilirubin  ( Note :  If ALT or AST are in the normal range at study entry, \u201cbaseline\u201d will be considered the upper limit of normal), OR For the first 40 subjects: \u2022 If  \u2265 2 subjects experience a similar unexpected and treatment-related SAE, OR \u2022  If 25% (10/40) of subjects experience: o Grade 3/4 AE or confirmed Grade 3/4 laboratory abnormality affecting the same organ system, with the exception of asymptomatic increases in cholesterol and triglyceride. \u2212  Exception for ALT/AST: Because HCV-infected subjects are likely to have improved ALT or AST parameters on-treatment, a two-grade shift from ontreatment nadir levels for either ALT or AST, as opposed to an absolute Grade 3/4 level, will trigger the rule above. The rule does not apply to ALT/AST rebound in the case of treatment failure. o Any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug. o  Any confirmed serum creatinine of \u2265 Grade 2. For the criteria above, \u201cconfirmed\u201d is defined as an equivalent or higher grade value on a second, sequential determination. All laboratory abnormalities meeting the above criteria must be repeated as soon as possible, preferably within 24-48 hours of the results being available to the investigator. 4.2.2 Futility rules (criteria for closing a treatment arm due to inadequate antiviral response) If > 33% of subjects within any given treatment arm that has enrolled at least 10 subjects experience virologic failure (as defined in Section 4.2.4), including failure to respond to treatment, on-treatment virologic breakthrough, or post-treatment virologic relapse, the arm will be closed to enrollment, and an ad hoc DSMB meeting will be called to review the data. Continued treatment of subjects in the closed treatment arm who are still receiving treatment and who have not experienced virologic failure will be determined after discussion with the DSMB. 4.2.3 Individual subject stopping rules A subject\u2019s study treatment should be discontinued if: \u2022 The subject has a confirmed ALT or AST > 3x baseline and total bilirubin > 2x upper limit of normal (ULN), without any reason to explain a concurrent increase of ALT/AST and total bilirubin.  Note :  If ALT or AST are in the normal range at study entry, \u201cbaseline\u201d will be considered the upper limit of normal. \u2022 If the subject has any Grade 3/4 AE or confirmed Grade 3/4 laboratory abnormality which is felt to be at least reasonably or possibly related to study drug and clinically significant by the investigator. \u2212  Exception for ALT/AST: Because HCV-infected subjects are likely to have improved ALT or AST parameters on-treatment, a two-grade shift from on-treatment nadir levels for either ALT or AST, as opposed to an absolute Grade 3/4 level, will trigger the rule above. The rule does not apply to ALT/AST rebound in the case of treatment failure. \u2022 If the subject has any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug. \u2022 If the subject has a confirmed serum creatinine of \u2265 Grade 2. \u2022 If the subject has a confirmed increase in QTcF \u2265 60 milliseconds (ms) over Baseline or absolute QTcF \u2265 500 ms. \u2022 If the subject becomes pregnant. For the criteria above, \u201cconfirmed\u201d is defined as an equivalent or higher grade value on a second, sequential determination. All laboratory abnormalities meeting the above criteria must be repeated as soon as possible, preferably within 24-48 hours of the results being available to the investigator. 4.2.4 Virologic failure The occurrence of one of the following rules will constitute virologic failure: \u2022 HCV RNA above LLOQ for two consecutive measurements (second measurement to be collected as soon as possible) in a subject in whom HCV RNA was below LLOQ, OR \u2022 > 1 log 10 increase in HCV RNA above nadir for two consecutive measurements. HCV RNA levels will be unblinded to the investigators so that he/she can assess in real-time whether subjects fail during the treatment period or relapse during the off-treatment period. In addition, the Sponsor will have regular safety monitoring meetings during the course of the study, and sites will be proactively notified if one of the above rules is triggered. Subjects who experience virologic failure must discontinue all study drugs and return for the follow-up visits as described in (Table 7-1) and (Table 7-2). 5 Population The targeted study population will include adult non-cirrhotic subjects with GT 1 or 3, chronic hepatitis C infection. 5.1 Inclusion/exclusion criteria To participate in the study, subjects must meet all of the inclusion criteria and none of the exclusion criteria. Rescreening of prior screen failures is not permitted. 5.1.1 Inclusion criteria 18 (or the legal age of consent per local regulations, if greater than 18 years) to 65 years of age, inclusive. Female subjects of both childbearing potential and non-childbearing potential may be included, unless the local regulatory authority requires that only females of nonchildbearing potential be included. Non-childbearing potential is defined as one of the following: \u2022 Postmenopausal, defined as amenorrheic for at least 2 years and serum follicle stimulating hormone (FSH) level consistent with postmenopausal status at Screening, OR \u2022 A documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation at least 6 months prior to study initiation. All female subjects must have a negative serum beta-human chorionic gonadotropin (\u03b2-HCG) at Screening and a negative urine pregnancy test prior to the first dose of study medication on Day 1. Women of childbearing potential and men must have agreed to use an acceptable double method of birth control (one of which must be a barrier method) from Screening through at least 7 months after the last dose of study drugs. Male subjects must have agreed not to donate sperm from the first dose through at least 7 months after the last dose of study drugs. QTcF interval \u2264 450 ms at Screening and prior to dosing on Day 1. Documented clinical history compatible with chronic hepatitis C, including any one of the following: \u2022 anti- HCV antibody positive at least 6 months prior to Screening or dosing, OR \u2022 HCV RNA present in plasma by a sensitive and specific assay at least 6 months prior to Screening or dosing, OR \u2022 HCV genotype determined at least 6 months prior to Screening or dosing, OR \u2022 histologic evidence of chronic hepatitis C infection. Plasma HCV RNA positive at Screening with minimal viral load of 4 log 10 IU/mL. HCV GT 1 or 3 by HCV genotyping performed at Screening ( Note : Mixed subtypes are not acceptable for GT 1 ). Documented absence of cirrhosis within 36 months of Screening or dosing (histology or non-invasive equivalent, according to local standard of care). Note: A score of F4 on any test is exclusionary. Must not have received prior approved or investigational antiviral treatment for HCV infection (Note: Non-cirrhotic, Peg-IFN/RBV-na\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3month washout period).  Subject is, in the opinion of the investigator, willing and able to comply with the protocol and all other study requirements. Subject has provided written informed consent to participate in the study. 5.1.2 Exclusion criteria Female subjects who are pregnant or breastfeeding. Body Mass Index (BMI) > 36 kg/m 2 . Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen (HBsAg) positive) and/or human immunodeficiency virus (HIV). History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC. History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency. One or more known primary or secondary causes of liver disease, other than hepatitis C (e.g., alcoholism, autoimmune hepatitis, nonalcoholic steatohepatitis, drug-related liver disease, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson Disease, Dubin-Johnson syndrome, other congenital or metabolic conditions affecting the liver (with the exception of Gilbert\u2019s syndrome), etc.). Steatosis is allowed, if clinically asymptomatic. History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, nonHCV viral hepatitis, gallstones or other etiologies. Active, clinically significant (per judgment of the Principal Investigator) disease including: \u2022 Acute or chronic kidney disease, \u2022 Malignant disease or suspicion or history of malignant disease within previous 5 years (except for adequately treated basal cell carcinoma or other localized, non-metastatic cancer), \u2022 Uncontrolled depressive illness, \u2022 Uncontrolled thyroid disease; thyroid stimulating hormone (TSH) must be normal at Screening, \u2022 Uncontrolled hypertension, \u2022 Poorly controlled diabetes mellitus as evidenced by hemoglobin A 1c \u2265 8.5% or equivalent at Screening, \u2022 Neurological disease, \u2022 Acute or chronic pancreatitis, \u2022 Infections (e.g., tuberculosis), \u2022 Intestinal malabsorption (e.g., structural defects, digestive failure, enzyme deficiencies with the exception of lactose intolerance, etc.), \u2022 Pulmonary disease associated with ongoing functional impairment, \u2022 Cardiac disease, clinically significant arrhythmia, family history of congenital heart disease, family history of prolonged QT, or family history of sudden death of unknown etiology, OR \u2022 Any other condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results. Donated blood or had significant blood loss 30 days prior to dosing. Use of alcohol and/or drugs that could interfere with adherence to study requirements as judged by the investigator. Concomitant use of any major inhibitors or inducers of CYP3A (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Concomitant use of any major inhibitors, inducers or substrates of permeability glycoprotein (P-gp) transporter (see Section 6.6.6). A washout period of at least 5 halflives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Based on limited in vitro metabolic results, the concomitant use of other drugs is prohibited until further information is available to guide their use (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Concomitant use of drugs contraindicated in the RBV product label. A washout period of at least 5 half-lives of the contraindicated drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Subjects who require frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions); required use for greater than 5 days should be discussed with the Sponsor during Screening ( Note : Topical or inhaled corticosteroids are permitted) . Concomitant use of antacids or acid blockers. For acid blockers, a washout period of at least 5 half-lives must be observed prior to study drug dosing, if the Principal Investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Concomitant use of herbal medications (e.g., St. John\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements. Concomitant use of opioid substitution drugs (e.g., buprenorphine and methadone). Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study. Subject with known allergy/hypersensitivity/intolerance to any of the study drugs, or any of their components. 21. Clinically significant abnormal ECG at Screening or prior to dosing on Day 1. Abnormal values at Screening: \u2022 hemoglobin (Hgb) < 10.0 g/dL \u2022 absolute neutrophil count (ANC) < 1.0 x 10 9 /L \u2022 platelets < 120 x 10 9 /L \u2022 ALT or AST > 5 x ULN \u2022 total bilirubin > 1.1 x ULN (subjects with history of Gilbert\u2019s syndrome > 2 x ULN) \u2022 serum albumin < 3.5 g/dL \u2022 alkaline phosphatase > 1.25 x ULN \u2022 serum creatinine > 1.1 x ULN \u2022 pancreatic amylase > 1.5 x ULN Any other laboratory abnormalities > Grade 1, as defined in (Appendix 2), considered clinically significant by the investigators. Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study. 5.2 Premature subject withdrawal Subjects may voluntarily withdraw from the study, or be removed from the study at the discretion of the investigator or Sponsor at any time. The investigator may withdraw a subject at any time if it is determined that continuing the study would result in a safety risk to the subject. If such withdrawal occurs, or if the subject fails to return for visits, the investigator should determine the primary reason for a subject\u2019s premature withdrawal from the study and record the reason in the respective subject\u2019s study records. Premature withdrawal may occur for any of the following reasons: \u2022 Noncompliance with the protocol requirements \u2022 Pregnancy \u2022 Death \u2022 Adverse event (AE) \u2022 Lack of efficacy \u2022 Subject request \u2022 Investigator request \u2022 Sponsor request All subjects who prematurely discontinue their assigned study drug treatment should have an EOT visit and return for all of the post-EOT follow-up visits, as described in Table 7-1. Subjects who have received at least one dose of samatasvir or IDX21437 will then be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2). Those subjects who fail investigational treatment and start another HCV treatment will not be followed in the extended observational follow-on phase of the study. For subjects who are lost to follow-up (i.e., those subjects whose status is unclear because they fail to appear for study visits without stating an intention to withdraw), the investigator should show due diligence by documenting in the source documents all steps taken to contact the subject, e.g., dates of telephone calls, registered letters, etc. Subjects who prematurely withdraw from the study for reasons other than safety or efficacy may be replaced by an equal number of newly enrolled subjects at the Sponsor\u2019s discretion. 6 Treatment 6.1 Subject numbering At Screening, each subject will receive a unique subject number. If a subject fails to be randomized, the reason for not being randomized should be documented in the source documents. 6.2 Investigational and control drugs IDX21437 will be supplied as 150 mg tablets. IDX21437 storage conditions will be included on the label. Samatasvir will be supplied as 50 mg tablets. Storage conditions of samatasvir will be included on the label. Ribavirin will be supplied as 200 mg tablets in its commercial packaging and should be stored according to the approved product label. 6.3 Treatment arms Eligible subjects will be assigned to treatment via a computer-generated randomization/enrollment list to one of the treatment groups specified in Table 4-1 and as described in Section 4, Study Design. 6.4 Treatment assignment Randomization schedules will be prepared across all investigators by the Sponsor\u2019s biostatistician (or designee). Once screening eligibility data are available, including laboratory results, and it has been determined that the subject is eligible for randomization, the subject must be contacted by telephone to confirm that he/she is still willing to participate in the study. Through a centralized randomization process, the subject will then be randomized by the site personnel to a treatment assignment and a randomization number assigned. Randomization will occur prior to dosing and will define the subject\u2019s entry into the study, which must be documented in the source documents and case report form (CRF). If a subject is randomized but does not receive study drug for any reason, the reason should be documented in the source documents and the Sponsor should be notified immediately. 6.5 Treatment blinding This study is not blinded to treatment. 6.6 Treating the subject 6.6.1 Dispensing the study drug Study drugs will be dispensed to the subjects by the study center personnel, under the supervision of the investigator. 6.6.2 Instructions for prescribing and taking the study drug For all study drugs, the investigator should communicate the importance of compliance and timing of dose to the subject. The subject should be instructed to take their study drugs at approximately the same time each day, and to contact the investigator if he/she is unable to take the study drug as prescribed. All dosages prescribed and dispensed to the subject during the study must be recorded in the source documents. Administration of the first dose of study drugs (Day 1) must occur in the clinic . Samatasvir, IDX21437 and the morning dose of RBV (if applicable) will be administered at the same time with a standard breakfast (approximately 400-500 calories: 20 g fat, 25 g protein, and 50 g carbohydrate). For those subjects participating in the optional predose PK sampling on Day 2 and/or the intensive PK sampling on Day 15 the morning doses of study drug must also be taken while  in the clinic with a standard breakfast.  Note: The predose PK sample on Day 2 should occur no later than 28 h after the Day 1 dose.  On the morning of all other dosing days, samatasvir and IDX21437 may be administered with the morning dose of RBV (if applicable), which must be administered with food. IDX21437 IDX21437 300 mg QD will be administered once daily as 2 x 150 mg tablets. Samatasvir Samatasvir 50 mg QD will be administered once daily as 1 x 50 mg tablet. Samatasvir 100 mg QD will be administered once daily as 2 x 50 mg tablets. See Section 6.6.6 for special dosing instructions for subjects taking acid blockers or antacids. Ribavirin Starting on Day 1, for those subjects assigned to receive RBV, the bodyweight-dependent dose of RBV will be divided into a morning and evening dose for the duration of the study (Table 6-1). The RBV doses should be taken with food, and at approximately the same times each day. Table 6-1 Ribavirin dosing schedule Body weight Time of dose Ribavirin dose < 75 kg AM 2 x 200 mg tablets with food  PM 3 x 200 mg tablets with food \u2265 75 kg AM 3 x 200 mg tablets with food  PM 3 x 200 mg tablets with food 6.6.3 Permitted study drug dose modifications or interruptions Study drug dose adjustments and interruptions are not permitted for IDX21437 or samatasvir without prior discussion with the Sponsor. Dose modifications for RBV, if applicable, are permitted per the approved product label. 6.6.4 Study drug discontinuation If any of the investigational DAA drugs (e.g., samatasvir or IDX21437) must be discontinued for any reason, all study drugs should be permanently discontinued at the same time and subjects asked to complete an EOT visit and return for all of the post-EOT follow-up visits, as described in Table 7-1. Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will then be followed in the observational follow-on phase (Table 7-2). Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase. 6.6.5 Concomitant medications Concomitant medications should be administered only as medically necessary during the study. Any concomitant medications should be initiated with caution, since they may increase the possibility of AEs. The investigator should instruct the subject to notify the study site about any new medications he/she takes during the course of the study. Relevant drug-drug interaction studies with samatasvir or IDX21437 have not been conducted to date; therefore, the potential for drug interactions is unpredictable at this stage of clinical development. Concomitant medications should be recorded in the site\u2019s study records and entered into the appropriate CRF page, per the schedule of assessments in Table 7-1. 6.6.6 Prohibited medications Use of the following medications is prohibited during the study: \u2022 All investigational drugs other than samatasvir and IDX21437. \u2022 All other treatments for HCV. \u2022 Pharmaceutical agents associated with significant renal or hepatic toxicity. \u2022 Drugs which are major inhibitors, inducers or substrates of P-gp. \u2022 Drugs which are major inducers or inhibitors of CYP3A. o  CYP3A4 inducers, such as: \u2212  The anti-epileptics: carbamazepine, phenytoin and phenobarbital. \u2212  The anti-tuberculosis drugs: rifabutin, rifampin. \u2212  Systemic dexamethasone. \u2212  Miscellaneous: products containing Hypericum perforatum (e.g., St. John\u2019s Wort). o  CYP3A4 inhibitors, such as: \u2212  The antifungals (systemic): ketoconazole, itraconazole, posaconazole, voriconazole. \u2212  The macrolide antibiotics: clarithromycin, erythromycin, telithromycin (azithromycin is the preferred option). \u2022 Concomitant use of acid blockers (proton pump inhibitors, e.g., omeprazole, or H2 blockers, e.g., cimetidine). Antacids (stomach acid neutralizers such as calcium carbonate or aluminum hydroxide-based products) will be allowed during the study, except \u00b1 4 h of dosing. \u2022 All herbal medications (e.g., St. John\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements. \u2022 Concomitant use of the following medications:  amlodipine, aripiprazole, atorvastatin, carvedilol, diazepam, diltiazem, fluoxetine, isradipine, perphenazine, procainamide, simvastatin, thioridazine or verapamil. \u2022 Concomitant use of opioid substitution drugs (e.g., buprenorphine and methadone). \u2022 Drugs that are contraindicated in the product label for RBV. The list of disallowed concomitant medication is not exhaustive; any questions regarding the concomitant use of a medication should be directed to the Sponsor to determine whether the drug can be allowed. 6.6.7 Emergency unblinding of treatment assignment This study is not blinded to treatment. 7 Visit schedule and assessments Table 7-1 lists the study assessments with an \u201cX\u201d indicating when the assessments are performed. Table 7-2 lists the study assessments for the extended observational follow-on phase to assess durability of SVR or monitoring of resistance. Table 7-3 displays the schedule of PK assessments. All subjects who prematurely discontinue their assigned study drugs should have an EOT visit and return for all of the post-EOT follow-up visits, as described in Table 7-1. Subjects who have received at least one dose of samatasvir or IDX21437 will then be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2). Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.   Idenix Pharmaceuticals, Inc.  Confidential  Page 30 Clinical Study Protocol (Original) \u2013 08-May-2014   Study No. IDX-04B-004  Table 7-1  Schedule of assessments  SCR Pre-TX     Treatment Period    Post EOT Follow-up STUDY DAY \u21d2  ASSESSMENT \u21d3  -75 to  -7 -6 to -1 1 2 (opt) 4\u00b11 8\u00b11 W1 11\u00b11 15\u00b11 W2 22\u00b13 W3 29\u00b13 W4 43\u00b13 W6 57\u00b13 W8 (EOT) 10  85\u00b13 W12 (EOT) 11  28\u00b17 Days Post EOT (SVR 4 ) 56\u00b17 Days Post EOT (SVR 8 ) 84\u00b17 Days Post EOT (SVR 12 ) 168\u00b17 Days Post EOT (SVR 24 ) Informed Consent X                 IWR (drug assignment/shipment) X (Day -14 to Day -1)        X  X 11       Inclusion/Exclusion Criteria & Medical History X                Study Drug Dosing   X 7  X 7  X X X X 7  X X X X 11       HIV-1 and HIV-2 Ab, HBsAg, Hemoglobin A1c X                 FSH (females of nonchildbearing potential only) X                 Height 1 & Weight & BMI 1 X X X  X X X X X X X X X X    Vital Signs (excluding temperature) X X X 2   X X X X X X X X X X    Complete Physical Exam X X          X 10  X     Adverse Events  (with targeted physical exam) 3  SAE only SAE only X X X X X X X X X X X X SAE only Concomitant Medications X X X X X X X X X X X X X X X X X Echocardiogram 4  X                12-Lead ECG 5 X X X 2       X  X 10  X X    HCV RNA Quantitation X X X 2, 6  X X X X X X X X X X X X X X HCV Genotyping X                 Host IL28B   X               PK Sample Collection 7   X X X X X X X X X X X X    Hematology, Clinical Chemistry, GFR, Coagulation  X X X 2   X X X X X  X X X X X    FibroTest X                 TSH X                  Idenix Pharmaceuticals, Inc.  Confidential  Page 31  Clinical Study Protocol (Original) \u2013 08-May-2014   Study No. IDX-04B-004   SCR Pre-TX     Treatment Period    Post EOT Follow-up STUDY DAY \u21d2  ASSESSMENT \u21d3  -75 to  -7 -6 to -1 1 2 (opt) 4\u00b11 8\u00b11 W1 11\u00b11 15\u00b11 W2 22\u00b13 W3 29\u00b13 W4 43\u00b13 W6 57\u00b13 W8 (EOT) 10  85\u00b13 W12 (EOT) 11  28\u00b17 Days Post EOT (SVR 4 ) 56\u00b17 Days Post EOT (SVR 8 ) 84\u00b17 Days Post EOT (SVR 12 ) 168\u00b17 Days Post EOT (SVR 24 ) Pregnancy Test 8 X  X 2        X  X 10  X    X Plasma and/or Serum Stored Samples 9  X X X 2  X X X X X X X X X X X X X X Urinalysis X X X 2   X X X X X X X X X X    SCR=Screening Period; Pre-TX=Pre-Treatment Period; W=Week; opt=optional; EOT=End of Treatment; SVR=Sustained Virologic Response; IWR=Interactive Web Response; FSH=Follicle Stimulating Hormone; BMI=Body Mass Index; IL28B=interleukin-28B; GFR= Glomerular Filtration Rate 1. Height will be measured at Screening only. BMI will be calculated at Screening only. Predose 3. SAEs will be reported from time of informed consent through 168 days post EOT visit. Nonserious AEs will be recorded from time of first dose of study drug through 28 days post EOT visit. 4. Echocardiogram to be scheduled during Screening period but not performed until subject qualifies for entry into the study. 5. Three consecutive ECG determinations collected within 5 minutes apart from each other at each scheduled time point. 6. If optional intensive PK assessments are performed on Day 1, HCV RNA determinations will be time-matched up to and including the 8 h PK timepoint. 7. Refer to Table 7-3 for PK schedule. Study drugs must be taken while in the clinic on Day 1 for all subjects, and on Days 2 and 15 for those subjects who elect to participate in the optional PK  sampling timepoints (Table 7-3). 7. Pregnancy tests should be performed at the indicated visits; however, additional tests should be done if required by the local standard of care.   A serum pregnancy test will be conducted during  Screening, and a urine pregnancy test will be conducted on Day 1, prior to dosing.  In addition, per the local standard of care, male subjects may be queried at each visit to ensure their female  partners have not become pregnant. 9. Stored plasma samples will be dedicated for HCV antiviral resistance testing. In addition, stored plasma or serum samples may be used for testing safety or PK parameters. 10. Applies to Groups A and C only. Last dose of study drugs for Groups A and C is Day 56. Subjects in these groups will enter the post-EOT follow-up phase after the Week 8 visit. Applies to Groups B, D, E and F only. Last dose of study drugs for Groups B, D, E and F is Day 84. Subjects in these groups will enter the post-EOT follow-up phase after the Week 12 visit.  Table 7-2  Schedule of assessments \u2013 Extended observational follow-on phase STUDY DAY \u21d2  ASSESSMENT \u21d3  252\u00b114 Days Post EOT 336\u00b114 Days Post EOT (48 Weeks Post EOT) 420\u00b114 Days Post EOT 504\u00b114 Days Post EOT (72 Weeks Post EOT) 588\u00b114 Days Post EOT 672\u00b114 Days Post EOT (96 Weeks Post EOT) HCV RNA Quantitation X X X X X X Stored Plasma Samples X X X X X X Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.  Table 7-3  Schedule of PK assessments Visit Mandatory PK schedule 1  Optional PK schedule 1, 2  Day 1 Predose (0 h) and at least 1 h post dose prior to leaving clinic Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h   (HCV RNA timepoints to be timematched to PK timepoints) 3  Day 2  Predose (0 h) to be obtained no later than 28 h after the Day 1 dose Day 4 Any time during visit 4   Day 8 (Week 1) Any time during visit 4   Day 11 Any time during visit 4   Day 15 (Week 2) Any time during visit 4, 5  Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h Day 22 (Week 3) Any time during visit 4   Day 29 (Week 4) Any time during visit 4   Day 43 (Week 6) Any time during visit 4   Day 57 (Week 8) Any time during visit 4   Day 85 (Week 12) Any time during visit 4, 6   28-Day Post EOT Any time during visit 4   Timepoints are relative to the last study drug dosing. Optional schedule, open to all subjects, will assess one or all of the following: predose (trough) on  Day 2, and/or intensive PK on Days 1 and/or 15. HCV RNA samples should be obtained within 10 min following the PK sample. Time of PK sampling, time of last dose, and time of last meal will be recorded. A single sample at any time during the Day 15 visit will be obtained from subjects not participating  in the intensive PK sampling. Day 85 (Week 12) visit applies only to Groups B, D, E and F. For plasma PK samples, all predose timepoints must be drawn within 30 minutes prior to dosing. For intensive PK sampling, blood samples will be collected within a \u00b15 min window for timepoints \u2264 4 h and a window of \u00b110 min for time points > 4h. 7.1 Information to be collected on screening failures All subjects who provide informed consent for the study will undergo the Screening evaluations described in Table 7-1. The investigator will retain a subject file including the original signed informed consent forms and all the Screening data generated on the subject. 7.2 Subject demographics/other baseline characteristics The following demographic and baseline characteristics will be collected during Screening: \u2022 subject initials \u2022 age \u2022 gender \u2022 race/ethnicity \u2022 height \u2022 weight \u2022 BMI \u2022 current medications \u2022 medical/surgical history 7.3 Treatment exposure and compliance Study drug dosing will occur as described in Section 6. Subjects should bring used or partially used IDX21437 and samatasvir study drug kits and RBV bottle with them to each study visit, in order for study personnel at study sites to assess subject compliance. Subjects will be asked to return all unused study drugs at the end of the study. Complete and accurate records of receipt and disposition of all study drugs must be kept. Drug accountability will be noted by the study monitor during site visits and at the completion of the trial. The key a 7.4 Antiviral activity The key antiviral activity endpoints are: \u2022 Proportion of subjects with plasma HCV RNA <LLOQ o  Primary: \u2212  SVR 12 :  12 weeks after the end of treatment o  Secondary \u2212  Week 4 during treatment \u2212  End of treatment  \u2212  SVR 4 :  4 weeks after the end of treatment  \u2212  SVR 8 :  8 weeks after the end of treatment  \u2212  SVR 24 :  24 weeks after the end of treatment \u2022 Emergence of resistance mutations \u2022 Durability of SVR and the kinetics of antiviral resistant HCV Plasma HCV RNA determinations will be performed at a central laboratory through use of a validated commercial assay. HCV resistance testing will be performed to monitor HCV variants present at the timepoints indicated in the Schedule of Assessments. Plasma samples for viral sequencing and the determination of HCV RNA will be collected at visits specified in Table 7-1 and Table 7-2. 7.5 Safety 7.5.1 Adverse events Adverse event: An AE is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and that does not necessarily have a causal relationship with the study drug(s). An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drug(s). All serious adverse events (SAEs) will be recorded from the time the subject signs the informed consent form (ICF) until completion of the post-EOT follow-up phase of the study. All nonserious AEs will be recorded from first dose of study drug until the 28-day post-EOT visits (Table 7-1). The occurrence of AEs should be sought by nondirective questioning of the subject at each visit during the study. Adverse events also may be detected when they are volunteered by the subject during or between visits or through physical examination, laboratory test, or other assessments. All AEs must be recorded in the site\u2019s study records and transcribed onto the Adverse Event CRF with the following information: Intensity grade: Grade 1, Grade 2, Grade 3, Grade 4, Grade 5 Note :  The intensity of each AE is to be assessed by the investigator according to the criteria in Appendix 2. The terms above are used to describe the intensity of an AE and should not be confused with whether an AE should be considered serious. Seriousness (not intensity) serves as a guide for defining regulatory obligations and the definition of SAEs is provided below. For example, a severe (grade 3) headache is not necessarily serious, unless it meets the definition of an SAE (described below). Relationship to the study drug: Reasonably or possibly related applies to those AEs that, after careful medical consideration at the time they are evaluated, are considered by the investigator (or other qualified designee) to have at least a possible relationship to study drug. Not reasonably or not possibly related applies to those AEs that, after careful medical consideration at the time they are evaluated, are considered by the investigator (or other qualified designee) to have no relationship, or no reasonable possibility of a relationship, to study drug.  Duration: start and end dates or if continuing Treatment required Whether it constitutes a SAE, per definition below Outcome: recovered/resolved, recovering/resolving, recovered/resolved with sequelae, not recovered/not resolved, fatal, or unknown (only for cases in which subjects are lost to follow-up) Note :  The recovered/resolved with sequelae option should only be used in cases where an event may be considered resolved by clinical standards, however, the subject continues to have residual effects or sequelae which may be considered chronic and stable by the investigator. For example, \u201crecovered/ resolved with sequelae\u201d may be checked for a subject who has experienced a cardiovascular accident (resolved), but may have partial paralysis in the limbs or speech impairment (sequelae). The investigator should attempt to establish a diagnosis of the AE based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis, and not the individual signs/symptoms or laboratory abnormalities, should be documented in the subject\u2019s source documentation and CRF, unless the etiology of the event is unknown. Serious adverse event: Any untoward medical occurrence that at any dose: \u2022 Results in death:  This includes deaths that appear to be completely unrelated to study drug (e.g., car accident). If a subject dies during the study and an autopsy is performed, autopsy results will become part of the subject\u2019s record/chart. \u2022 Is life-threatening:  A life-threatening adverse event is any AE that places the subject, in the view of the investigator, of immediate risk of death from the reaction as it occurred. It does not include a reaction that, had it occurred in a more severe form, might have caused death. \u2022 Requires inpatient hospitalization or prolongation of existing hospitalization:  Exceptions would be hospitalizations for a) elective or preplanned treatment for a pre-existing condition that is unrelated to the indication under study and has not worsened since the start of study drug or b) treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE and not resulting in hospital admission. \u2022 Results in persistent or significant disability/incapacity:  A persistent or significantly disabling AE is any AE that results in a substantial disruption of a person\u2019s ability to conduct normal life functions. \u2022 Is a congenital anomaly/birth defect. \u2022 Is an important medical event:  An event that may not result in death, be life-threatening, or require hospitalization may be considered a SAE when, based upon appropriate medical judgment, it may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependence or drug abuse. Unlike routine safety assessments, SAEs are monitored continuously and have special reporting requirements; see Section 8.1. All AEs should be treated appropriately. Treatment may include one or more of the following: no action taken (i.e., further observation only); concomitant medication given or other nondrug therapy given. The action taken with study drug, if any, should be recorded on the AE CRF and could include one of the following: no action taken or study drug withdrawn. An assessment should be made at each visit (or more frequently, if necessary) of any changes in intensity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome. 7.5.2 Management of anemia Anemia is a common side effect of RBV. Management of anemia should be consistent with guidelines in the prescribing information of RBV. 7.5.3 Physical examination Complete physical examinations will be performed by a medically qualified and licensed individual as scheduled in Table 7-1. On study days not requiring a complete physical examination, a symptom-targeted physical exam should be done, if medically indicated. 7.5.4 Vital signs Routine vital sign measurements will include pulse and sitting blood pressure (after 3 minutes of rest), as specified in Table 7-1. 7.5.5 Laboratory evaluations Laboratory evaluations to be performed according to Table 7-1 are as follows: \u2022 Hematology:  hematocrit, Hgb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), platelet count, red cell count, white blood cell (WBC) count and differential. \u2022 Hemoglobin A 1c (Screening only). \u2022 Clinical chemistry:  calcium, sodium, potassium, chloride, magnesium, bicarbonate, phosphate, albumin, total bilirubin, direct bilirubin, indirect bilirubin, ALT, AST, triglycerides, cholesterol, blood glucose, blood urea nitrogen (BUN), alkaline phosphatase, serum creatinine, creatine kinase (CK) and serum amylase. o Elevations in serum amylase will trigger analysis of pancreatic amylase. Elevations in CK will trigger analysis of CK isoenzymes (CK-MM, CK-MB, CK-BB). o The anion gap will be calculated and reported. \u2022 Thyroid stimulating hormone (TSH) (Screening only). \u2022 Coagulation:  prothrombin time (PT) and International Normalized Ratio (INR). \u2022 FSH (females of non-childbearing potential at Screening only). \u2022 Urinalysis:  specific gravity, pH, protein, glucose, ketones, occult blood, bilirubin, urobilinogen, leukocyte esterase, and nitrite. Microscopy (identification of cells, casts and crystals) will be done if the urinalysis is abnormal. \u2022 HIV antibody screen:  HIV-1 and HIV-2. \u2022 Hepatitis B surface antigen screen. \u2022 HCV RNA genotype (Screening only). \u2022 FibroTest (Screening only):  FibroTest results, as well as each of the additional individual serum markers (alpha 2-macroglobulin, haptoglobin, apolipoprotein A1 and gammaglutamyl transpeptidase (GGT)) which contribute to the FibroTest score, will be reported. At each visit, a plasma and/or a serum sample will be collected and stored for testing of laboratory or PK parameters (if needed), with one sample dedicated for possible resistance analysis to determine potential mutations in the HCV genome. A buccal or blood sample (or other, depending on laboratory process) will also be collected at Baseline (predose on Day 1) for interleukin-28B (IL28B) polymorphism determination. 7.5.5.1 Pregnancy tests Serum and urine \u03b2-HCG pregnancy tests will be performed as specified in Table 7-1; however, additional tests should be done if required by the local standard of care. 7.5.5.2 Renal function Renal function will be assessed as specified in Table 7-1 using the abbreviated Modification of Diet in Renal Disease (MDRD) study equation to estimate GFR. 7.5.6 12-lead electrocardiogram (ECG) Twelve-lead ECGs will be performed as specified in Table 7-1. ECGs will be collected after subjects are supine for 5 minutes. Three consecutive determinations, collected no more than 5 minutes apart from each other, will be performed at each scheduled time point. The individual details of each tracing, as well as their average, will be reported. The average QTcF value from the three determinations will be used to include subjects (inclusion criterion #6). 7.5.7 Echocardiogram A baseline echocardiogram will be performed during the Screening period on all subjects who qualify for entry into the study. 7.6 Pharmacokinetics Blood samples will be collected at the time points specified in Table 7-3. Time of PK sample, time of last dose prior to each sample, and time of last meal prior to PK sample will be recorded only on study visit days. On days of intensive PK assessments, PK sampling shall always take precedence over other concurrent assessments (such as ECG and vital sign measurements) unless otherwise instructed by the Principal Investigator or his or her designee. HCV RNA timepoints will be time-matched to the PK timepoints for subjects participating in the optional Day 1 intensive PK sampling. HCV RNA samples should be obtained within 10 min following the PK sample. The following plasma PK parameters will be obtained using noncompartmental analysis: \u2022 C max :  Observed maximum plasma drug concentration. \u2022 T max :  Time to maximum concentration. \u2022 AUC 0-t :  Area under the drug concentration-time curve calculated using trapezoidal summation from time zero to last measurable concentration. \u2022 C 24h or C trough :  Plasma concentration 24 h after dosing or the predose trough plasma concentration following multiple dosing. Concentration data from intensive and sparse sampling will also be analyzed using appropriate modeling techniques. Plasma concentrations of samatasvir, IDX21437 and/or their metabolites, as appropriate, will be quantitated using validated liquid chromatographic methods with mass-spectrometric detection (LC/MS/MS). 7.6.1 Pharmacokinetic blood sampling and processing Blood samples will be collected at the timepoints specified in Table 7-3. The processing of blood samples for PK analysis will be provided in a separate instruction to the investigational site. 7.7 Pharmacodynamics Exploratory pharmacodynamic analyses may include, but are not limited to, evaluating the relationships between plasma concentrations of samatasvir, IDX21437 and/or their metabolites and HCV RNA viral load. 8 Safety monitoring 8.1 Serious adverse event (SAE) reporting To ensure subject safety, every SAE, regardless of suspected causality, occurring after the subject has provided informed consent and through the end of the study must be reported to Idenix Pharmaceuticals, Inc. or their designee by phone and fax (or email) within 24 hours of learning of its occurrence. At a minimum, a description of the event and the investigator\u2019s judgment of causality must be provided at the time of the initial report. These preliminary reports will be followed by detailed descriptions that will include copies of hospital case reports, autopsy reports, and other documents when requested and applicable. Complications or progression of an initial SAE must be reported as a follow-up SAE Report to the original SAE, regardless of when the follow-up information is received by the investigator. A follow-up SAE Report must be submitted within 24 hours of the investigator receiving the follow-up information. A SAE that is considered completely unrelated to a previously reported one should be reported separately as a new SAE. The procedures for reporting SAEs are as follows: \u2022 Complete the \u201cSerious Adverse Event Report Form\u201d in English. \u2022 Fax or email the Serious Adverse Event Report Form to the attention of the Idenix Medical Monitor (below) within 24 hours of the investigator\u2019s knowledge of the event. \u2022 Confirm the occurrence of the SAE by phone by contacting the Idenix Medical Monitor (contact information listed below). Contact information for SAE Reporting is as follows:  John Z. Sullivan-B\u00f3lyai, MD, MPH (Idenix Medical Monitor) Vice President, Clinical Research Idenix Pharmaceuticals, Inc. 320 Bent Street Cambridge, MA 02141, USA Telephone:  +1 (617) 224-4473  Mobile:  +1 (617) 584-8011 Fax:  +1 (617) 995-9940 E-mail:  sae@idenix.com The original copy of the SAE Report Form and the fax confirmation sheet must be kept with the source documentation at the study site. Follow-up information should be communicated the same way, using a new SAE Report Form stating that it is a follow-up to the previously reported SAE and giving the date of the original report. The follow-up information should describe whether the event has resolved or continues, if and how it was treated, and whether the subject continued or withdrew from study participation. If the SAE was not previously documented in the Investigator\u2019s Brochure and is thought to be related to study drug(s), Idenix Pharmaceuticals, Inc. or their designee may urgently require further information from the investigator for regulatory authority reporting. Idenix may need to issue an Investigator Notification Letter to inform all investigators involved in any study with the same drug(s) that this SAE has been reported. The investigator and study personnel should institute any supplemental investigations of SAEs based on their clinical judgment of likely causative factors. This may include clinical laboratory tests not specified in the protocol, histopathologic examinations, or consultations with specialists. Idenix Pharmaceuticals, Inc. or their designee may also request the investigator to conduct supplemental assessments. The investigator should notify the Idenix Medical Monitor of any death or SAE occurring after a subject has withdrawn from the study when such a death or SAE may reasonably be related to the study medication(s). However, the investigator is not obligated to actively seek AEs in former study participants. 8.2 Follow-up of adverse events All SAEs will be recorded from the time the subject signs the ICF until completion of the post-EOT follow-up phase of the study. All nonserious AEs will be recorded from first dose of study drug until the 28-day post-EOT visit (Table 7-1). All SAEs, Grade 3/4 clinical AEs, Grade 3/4 laboratory abnormalities (other than asymptomatic triglyceride or cholesterol) or any other AEs/laboratory abnormalities resulting in premature discontinuation will be followed until they have resolved, returned to baseline, or are determined to be chronic or stable by the investigator. 8.3 Reporting safety information to the IRB/EC The investigator is responsible for following all local regulations for the reporting of safety information, including the reporting of SAEs to the Institutional Review Board (IRB)/Ethics Committee (EC). The investigator must promptly report to his or her IRB/EC all unanticipated problems involving risks to subjects. This includes death from any cause and all SAEs reasonably or possibly associated with the use of study drug(s). It is recommended that all SAEs occurring at a site, regardless of causality, be reported to the site\u2019s IRB/EC in accordance with the IRB/EC\u2019s requirements. A SAE may require safety reports to be filed to regulatory agencies if the SAE is attributable to the study drug(s) and is unexpected based upon the current Investigator\u2019s Brochure(s). In this case, the investigator will receive a copy of the safety report as submitted to the regulatory agencies. The investigator is responsible for submitting the safety report (initial and follow-up) or other safety information (e.g., revised Investigator\u2019s Brochure(s)) to the IRB/EC in accordance with the IRB/EC\u2019s requirements and keep a copy in the study files. 8.4 Pregnancies To ensure subject safety, any pregnancy in a subject must be reported to the medical monitor within 24 hours of learning of its occurrence. Subjects who become pregnant will be withdrawn from study drug(s). The pregnancy should be followed to determine outcome, including spontaneous or voluntary termination, details of the birth including the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. Pregnancy should be recorded on a subject\u2019s source documents and a Pregnancy Notification and Outcome Form and reported by the investigator to Idenix Pharmaceuticals, Inc. (or designee) using the same procedure for reporting SAEs in Section 8.1. Pregnancy follow-up should also be recorded and should include an assessment of the possible relationship to the study drug(s) of any pregnancy outcome. Any pregnancy-related SAE (e.g., spontaneous abortion) or any other SAE experienced during pregnancy must be recorded on a separate SAE Report Form and reported to the Sponsor per SAE reporting procedures in Section 8.1. Pregnancy outcomes must be collected for the female partners of any males who took study drug(s) in this study. Consent to report information regarding these pregnancy outcomes should be obtained from the mother. Ribavirin Pregnancy Registry As described in the product label, a Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies of female patients and female partners of male patients exposed to ribavirin during treatment and for 7 months following cessation of treatment. Healthcare providers and patients are encouraged to report such cases. Contact information is provided in the product label. 9 Data review and database management 9.1 Site monitoring Before study initiation, at a site initiation visit or teleconference, representatives of Idenix Pharmaceuticals or designee will review the protocol and CRF with the investigators and their staff.  The study monitor will visit the site to check the completeness of subject records, the accuracy of entries on the CRFs, the adherence to the protocol and to Good Clinical Practice (GCP), and to ensure that study drug is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the study monitor. The investigator must maintain source documents for each subject in the study, consisting of case and visit notes (hospital or clinic medical records). All information on CRFs must be traceable to these source documents in the subject's file. The investigator must also keep the original signed informed consent form (a signed copy is given to the subject). The investigator must give the study monitor access to all relevant source documents to confirm their consistency with the CRF entries. 9.2 Data collection Investigational sites will be supplied with instructions on accessing the web-based electronic data capture (EDC) system via secure web portal. Representatives of Idenix Pharmaceuticals, Inc. (or designee) will train designated site staff on the EDC system. Investigational site staff will not be given access to the EDC system until the required training is completed and documented. Designated site staff will enter the data required by the protocol into the CRFs. Automatic validation programs check for data discrepancies in the CRFs and, by generating appropriate error messages, allow modification or verification of the entered data by the site staff.  After database lock, the investigator will receive a compact disc-read only memory (CD-ROM) or digital video disc (DVD) of the subject data for archiving at the investigational site. 9.3 Database management and quality control Idenix Pharmaceuticals, Inc. representatives (or designee) will review the CRFs entered by investigational site staff for completeness and accuracy and instruct the investigational site staff to make any required corrections or additions. Queries will be sent to the investigational site using an electronic data query within the EDC system. Designated investigational site staff will be required to respond to the query and make any necessary changes to the data. Concomitant medications entered into the database will be coded using the WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. Laboratory samples will be processed through a central laboratory and the results will be sent electronically to Idenix. After the above actions have been completed and the database has been declared to be complete and accurate, it will be locked for data analysis. Any changes to the database after that time can only be made with the approval of Senior Management of Idenix Pharmaceuticals, Inc. 9.4 Archival of study records Essential documents should be retained for a minimum of two years after the last approval of a marketing application in an International Conference on Harmonisation (ICH) region and until there are no pending or contemplated marketing applications in an ICH region or at least two years have elapsed since the formal discontinuation of clinical development of the investigational product. However, these documents should be retained for a longer period if required by the applicable local requirements. 10 Statistical analyses Details of the statistical analyses will be provided in the Statistical Analysis Plan (SAP). 10.1 Populations for analysis The safety population will include all subjects who receive at least one dose of study drug(s). Other analysis populations will be defined in the SAP. 10.1.1 Protocol deviations Departures from the protocol should be avoided, unless required for the safety of the subject. The following is a list of significant protocol deviations which may exclude subjects from the efficacy analysis: \u2022 Subject does not have chronic HCV Genotype 1 or 3 infection. \u2022 Subject received another antiviral treatment for HCV during the study. \u2022 Subject had previously received antiviral treatment for hepatitis C infection.  Note: Noncirrhotic, Peg-IFN/RBV-na\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3-month washout period.  \u2022 Subject had poor compliance with study drug regimen, as defined in the SAP. Other protocol deviations which may affect subject safety or demonstrate noncompliance with the protocol include: \u2022 Informed consent issues (for example, study-specific procedures occurred before informed consent form was signed). \u2022 Inclusion/exclusion criteria not met. \u2022 Randomization error. \u2022 Prohibited concomitant medication use. \u2022 Missed safety or laboratory assessment. \u2022 AE, SAE or pregnancy reporting procedures not followed. \u2022 Assessments or procedures performed by site personnel who were not appropriately qualified or trained. 10.2 Subject demographics/other baseline characteristics Demographic and baseline characteristics will be summarized using descriptive statistics. 10.3 Analysis of the primary objective(s) 10.3.1 Safety parameters The safety endpoints of this study are: \u2022 Proportion of subjects experiencing SAEs \u2022 Proportion of subjects experiencing AEs \u2022 Proportion of subjects experiencing Grade 1-4 laboratory abnormalities The proportions of subjects experiencing the above safety endpoints will be tabulated and summarized with descriptive statistics. Laboratory abnormalities will be graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS (2004), Clarification August 2009). 10.3.2 Antiviral activity The key antiviral activity endpoints are: \u2022  Proportion of subjects with plasma HCV RNA <LLOQ o  Primary: \u2212  SVR 12 :  12 weeks after the end of treatment o  Secondary \u2212  Week 4 during treatment \u2212  End of treatment  \u2212  SVR 4 :  4 weeks after the end of treatment  \u2212  SVR 8 :  8 weeks after the end of treatment  \u2212  SVR 24 :  24 weeks after the end of treatment Details of the antiviral activity and efficacy analyses will be provided in the SAP. 10.4 Analysis of secondary objective(s) 10.4.1 Pharmacokinetic parameters Pharmacokinetic parameters will be summarized using descriptive statistics (arithmetic mean, geometric mean, median, standard deviation (SD), standard error of the mean (SEM), coefficient of variation (CV) %, sample size, minimum and maximum, where applicable). 10.4.2 Pharmacokinetic/pharmacodynamic relationships PK/PD analyses will be described in the SAP. 10.4.3 Emergence of resistance mutations The analysis of resistance will be provided in a separate report. 10.4.4 Durability of SVR and the kinetics of antiviral resistant HCV The proportion of subjects with sustained SVR, defined as the absence of detectable plasma HCV RNA after SVR 24 will be descriptively evaluated over the extended observational follow-on phase (Table 7-2). The proportion of subjects with detectable resistance mutations with population sequencing will be descriptively evaluated over the extended observational follow-on phase (Table 7-2). 10.5 Missing, unused and spurious data Handling of missing, unused and spurious data will be described in the SAP. All available safety and PK data will be included in data listings. 10.6 Ongoing data analysis For this early phase study, the Sponsor may perform interim data reviews during the course of the study. 10.7 Sample size consideration The primary antiviral activity endpoint is the proportion of subjects with undetectable levels of HCV RNA at 12 weeks after the end of treatment (SVR 12 ). Table 10-1 displays the levels of detection based on the difference in the primary efficacy endpoint vs. the reference (SOVALDI\u2122 (2013)), with 80% power at a two-sided significance level of \u03b1=0.05. Table 10-1 Levels of detection \u2013 primary efficacy endpoint vs. the reference (SOVALDI\u2122) HCV  genotype Sample size SVR 12 observed Reference Difference in SVR 12  Power 1 60 76% 89% a  13% 82% 3 40 77% 56% b  21% 80% a Response rate for Genotype 1 in NEUTRINO study (SOVALDI\u2122 +Peg-IFN + RBV x 12 weeks) b Response rate for Genotype 3 in FISSION study (SOVALDI\u2122 + RBV x 12 weeks)  11 References [Division of AIDS (2004), Clarification August 2009] Table for Grading the Severity of Adult and Pediatric Adverse Events. [Ribavirin Tablets (2013)] [package insert]. Pennington, NJ: Zydus Pharmaceuticals USA, Inc. [Lawitz E, et al. (2013)] A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Na\u00efve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies. Presented at HEP DART, December 8\u201312, 2013, Big Island, HI, USA. [SOVALDI\u2122 (2013)]: [package insert]. Foster City, CA: Gilead Sciences, Inc. [World Health Organization (2013)] Hepatitis C. World Health Organization Updated July 2013.  Appendix 1:  Administrative procedures Regulatory and ethical compliance This clinical study was designed and shall be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki. Responsibilities of the investigator and IRB/IEC/REB The protocol and the proposed informed consent form must be reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board (IRB/IEC/REB) before study start. A signed and dated statement that the protocol and informed consent have been approved by the IRB/IEC/REB must be given to Idenix Pharmaceuticals, Inc. or its designated representative(s) before study initiation. Prior to study start, the investigator is required to sign the investigator statement page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol. In addition, the investigator agrees to give access to all relevant data and records to Idenix Pharmaceuticals, Inc. monitors, auditors, quality assurance representatives, designated agents of Idenix Pharmaceuticals, Inc., IRBs/IECs/REBs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform Idenix Pharmaceuticals, Inc. immediately that this request has been made. The investigator may delegate trial-related duties to qualified members of his or her staff.  Per ICH GCP, the investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions. The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties. Informed consent Eligible subjects may only be included in the study after providing written (witnessed, where required by law or regulation), IRB/IEC/REB-approved informed consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable representative of the subject. In cases where the subject\u2019s representative gives consent, the subject should be informed about the study to the extent possible given his/her understanding. If the subject is capable of doing so, he/she should indicate assent by personally signing and dating the written informed consent form or a separate assent form. Informed consent must be obtained before conducting any study-specific procedures (i.e., all of the procedures described in the protocol). The process of obtaining informed consent should be documented in the subject source documents. Each investigator must retain the original signed and dated informed consent form. A copy of the signed and dated informed consent form will be given to the subject. Idenix Pharmaceuticals, Inc. or its designated representative(s) will provide to investigators in a separate document a proposed informed consent form that complies with the ICH GCP guideline and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by the investigator must be agreed to by Idenix Pharmaceuticals, Inc. or its designated representative(s) before submission to the IRB/IEC/REB, and a copy of the approved version must be provided to the Idenix Pharmaceuticals, Inc. monitor or designated representative(s) after IRB/IEC/REB approval. Amendments to the protocol To alter the protocol, amendments must be written by Idenix Pharmaceuticals, Inc., and receive approvals from all parties that approved the original protocol (IRB/IEC/REB, and if applicable, the local regulatory authorities) before implementation. However, in cases where an amendment is required for subject safety, an amendment may be implemented prior to IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any subject included in this study, even if this action represents a deviation from the protocol. Idenix Pharmaceuticals, Inc. may make administrative changes (i.e., changes that do not significantly affect subject safety, the study\u2019s scope or scientific quality) without a formal protocol amendment. Discontinuation of the study Idenix Pharmaceuticals, Inc. reserves the right to discontinue this study at any time under any condition. Study drug supply, storage and tracking Study drugs must be received by a designated person at the study site, handled and stored safely and properly, and kept in a secured location to which only the investigator and designated assistants have access. Upon receipt, all study drugs should be stored according to the instructions specified on the drug labels. Drug labels will be in the local language and comply with the legal requirements of each country. Clinical supplies are to be dispensed only in accordance with the protocol. Subjects will be asked to return all unused study drug and packaging at the end of the study or at the time of study drug discontinuation. All empty, partially used containers and unused supplies may be destroyed at the site, retrieved by the study monitor or shipped to a designated facility identified by Idenix Pharmaceuticals, Inc. according to governmental regulations at the conclusion of this study (or as appropriate during the course of the study), per the instructions of the Sponsor. The investigator will keep an accurate accounting of all study medication dispensed, destroyed or returned. Monitoring of drug accountability will be performed by the monitor during site visits and at the completion of the trial. Confidentiality All study findings and documents will be regarded as confidential. The investigator and other study personnel must not disclose such information without prior written approval from Idenix Pharmaceuticals, Inc. Subject confidentiality will be strictly maintained to the extent possible under the law. Subject names must not be disclosed. Subjects will be identified on the CRFs and other documents submitted to Idenix Pharmaceuticals, Inc., or its designated representative, by their initials and/or assigned subject number. Documents that identify the subject (e.g., the signed informed consent form) should not be submitted to Idenix Pharmaceuticals, Inc., or its designated representative, and must be maintained in confidence by the investigator. Publication policy Any formal presentation or publication of data collected as a direct or indirect result of this Study may be considered as a joint presentation or publication by the investigators and the Sponsor. As is customary for multicenter trials, publication by individual Study sites or investigator/institution will not be allowed prior to the publication of the principal Study abstract(s) and manuscript(s), without the explicit written permission of Sponsor. Sponsor will determine authorship of the principal Study manuscript(s) in conjunction with the investigators. All investigators contributing at least one evaluable subject to the Study may be considered as co-authors for the principal Study manuscript(s). For such manuscript(s), masthead roles for investigators will be determined based on subject enrollment and scientific contributions to the Study. Subsequent to publication of the principal Study manuscript(s) and abstract(s), institution and investigator may, consistent with academic and scientific standards, publish or present the results of work performed in accordance with the Study, provided that any proposed publication, presentation, abstract, submission or disclosure (collectively hereinafter \u201cProposed Publication\u201d) is first reviewed and commented upon by Sponsor prior to submission for publication or presentation. Institution and investigator will submit any Proposed Publication to Sponsor for review and comment at least sixty (60) days prior to submission to a third party. If Sponsor believes in good faith that any Proposed Publication contains any proprietary or Confidential Information, Sponsor shall have the right to remove such references to such Confidential Information. At the request of Sponsor, each of the institution and investigator agree to withhold submission of a Proposed Publication for an additional period of up to ninety (90) days after receipt of Sponsor\u2019s comments, in order to allow filing of patent application(s) relating to an invention or otherwise seek protection of information to be published or otherwise disclosed. Financing and insurance In the event of injury resulting from participation in this study, any medical treatment deemed necessary will be provided to subjects to assist in recovery from the injury. Subjects will not be charged for this care beyond that covered by the subject\u2019s health insurance. This agreement to provide free medical treatment does not include treatment for illnesses experienced during the study if the illness is not proven to be the direct result of study participation. No compensation other than free medical treatment will be provided for an injury resulting from participation in this study. To the extent subjects are to be compensated for their participation in the study, such compensation will be set forth in the informed consent form.  Appendix 2:  Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004, Clarification August 2009)                                                            ", "uploadDate": "20211108104415", "SourceFileName": "Protocol-2014-05-08-DOD-V1---000001.pdf", "documentPath": "\\\\quintiles.net\\enterprise\\Services\\protdigtest\\pilot_iqvxml\\0ce056ac-4360-4920-9443-4396b9c2c391", "is_active": 1, "ProtocolNo": "FEED_TEST2_Summary", "MoleculeDevice": "test", "SponsorName": "(CKD)Chong Kun Dang Pharm", "DocumentStatus": "final", "VersionNumber": "08nov modified 1", "UserId": "1061485", "UserModified": "", "ProjectId": "123456", "IsAmendment": "N", "Indication": "ABCC6 deficiency", "TimeCreated": "20211110073204", "TimeUpdated": "20211110073204", "Environment": "", "SourceSystem": "", "StudyStatus": "", "DraftVersion": "", "qcStatus": "QC_NOT_STARTED", "QC_Flag": false, "ProtocolTitle": "08nov modified A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection", "ShortTitle": "08nov modified", "AmendmentNumber": "08nov modified", "phase": "08nov modified", "SponsorAddress": "08nov modified", "Drug": "08nov modified", "approval_date": "", "VersionDate": "08nov modified", "Blinding": "08nov modified", "Compound": "08nov modified", "Control": "08nov modified", "Investigator": "08nov modified", "StudyId": "08nov modified", "NumberOfSubjects": "08nov modified 240", "ParticipantAge": "08nov modified 65y", "ParticipantSex": "08nov modified MALE", "ExclusionSection": "08nov modified Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.", "InclusionSection": "08nov modified Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.", "ObjectivesSection": "08nov modified \u2022 Emergence of resistance mutations during treatment and in the post-treatment period", "Population": "08nov modified patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..", "EntitiesInAssessments": "", "SoaEpochs": "", "SoaFootnote": "", "summary_entities": "{\"ProtocolTitle\": [{\"start_idx\": 86, \"end_idx\": 95, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 86, \"end_idx\": 95, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 86, \"end_idx\": 95, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 101, \"end_idx\": 108, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 101, \"end_idx\": 108, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 101, \"end_idx\": 108, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}]}", "ProtocolName": "", "Activity_Status": "", "Completeness_of_digitization": "", "Digitized_Confidence_interval": "", "toc": "{\"index\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456], \"columns\": [\"section_level\", \"CPT_section\", \"type\", \"content\", \"font_info\", \"level_1_CPT_section\", \"file_section\", \"file_section_num\", \"file_section_level\", \"seq_num\", \"qc_change_type\"], \"data\": [[\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a3523639-512a-400a-803b-ba91e2485e70\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"TITLE\", \"\", 1, 1, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"526759f2-dba5-46ea-986e-b0bb3bed8dae\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"TITLE\", \"\", 1, 2, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bea28b7b-08c6-4f2e-84e5-cd962d6adf09\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"TITLE\", \"\", 1, 3, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8fa43949-0880-45df-b300-088e16b18346\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"TITLE\", \"\", 1, 4, \"\"], [\"\", \"Unmapped\", \"text\", \"08nov modified Study drugs: Samatasvir (IDX719) and IDX21437\", {\"IsBold\": false, \"font_size\": 32, \"font_style\": \"\", \"entity\": [{\"start_idx\": 28, \"end_idx\": 37, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 28, \"end_idx\": 37, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 28, \"end_idx\": 37, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 40, \"end_idx\": 45, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 40, \"end_idx\": 45, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 40, \"end_idx\": 45, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 40, \"end_idx\": 45, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 52, \"end_idx\": 59, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 52, \"end_idx\": 59, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"c8fe9ded-ed40-4d15-851f-9570accf5b88\", \"childbox\": \"5c907c68-1d61-403e-b95f-770009172e7d\", \"subtext\": \"9e906826-b4b8-4ed2-a9d8-338e7d095a63\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 32, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 5, \"\"], [\"\", \"Unmapped\", \"text\", \"08nov deleted Protocol number: IDX-04B-004\", {\"IsBold\": false, \"font_size\": 28, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d7e555f-57c8-453b-a1c0-7a40dc12bbc2\", \"childbox\": \"60f8d62e-57e3-4d26-bf1c-270f00a81a24\", \"subtext\": \"c6488923-3590-4c53-964e-bc0e77b55137\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 28, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 6, \"\"], [\"\", \"Unmapped\", \"text\", \"08nov deleted Protocol number: IDX-04B-004\", {\"IsBold\": false, \"font_size\": 28, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe36fdc6-2fde-448c-a577-f7498449ad2a\", \"childbox\": \"8cf867bc-7e97-4e3b-9815-c7bcaa6a2195\", \"subtext\": \"c6488923-3590-4c53-964e-bc0e77b55137\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 28, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 7, \"\"], [\"\", \"Unmapped\", \"text\", \"A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in\", {\"IsBold\": true, \"font_size\": 32, \"font_style\": \"\", \"entity\": [{\"start_idx\": 71, \"end_idx\": 80, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 71, \"end_idx\": 80, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 71, \"end_idx\": 80, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 86, \"end_idx\": 93, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 86, \"end_idx\": 93, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 86, \"end_idx\": 93, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"9385ffc2-dbfb-48bb-b2f3-c59fe95af8b7\", \"childbox\": \"de889600-fcab-4745-a469-735bfc22f1a9\", \"subtext\": \"0da75517-ee65-46d2-8ce2-11d034f15272\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 32, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 8, \"\"], [\"\", \"Unmapped\", \"text\", \"Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", {\"IsBold\": true, \"font_size\": 32, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fff4ab8f-80ec-4dd1-a414-69b8b81599fe\", \"childbox\": \"2db96efe-89ac-43d0-a481-6f62078630d6\", \"subtext\": \"386b3ba9-63d6-4bb8-b57e-d81faacd6987\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 32, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 9, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>08nov modified Author(s):</td>\\n      <td>Frank D, Zhou XJ, Sullivan-B\\u00f3lyai JZ</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>08nov added Author(s):</td>\\n      <td>Frank D, Zhou XJ, Sullivan-Bu00f3lyai JZ</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td></td>\\n      <td>Idenix Pharmaceuticals, Inc. 320 Bent Street</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Eudract Number:</td>\\n      <td>2014-001378-33</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>Document type:</td>\\n      <td>Protocol</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>Development phase:</td>\\n      <td>II</td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>Version date:</td>\\n      <td>08-May-2014</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"08nov modified Author(s):\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"ae04c1a3-16bd-45a5-8062-40eb8ebb0ec9\\\",\\\"column_roi_id\\\":\\\"31ae5083-6dfa-435f-9302-046b8cf8d13a\\\",\\\"datacell_roi_id\\\":\\\"6506d19e-95ce-4dd3-a860-5d028cdb0b92\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":6,\\\"standard_entity_name\\\":\\\"OTHER: Person Name\\\",\\\"subcategory\\\":\\\"OTHER: Person Name\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Frank D\\\"},{\\\"start_idx\\\":9,\\\"end_idx\\\":15,\\\"standard_entity_name\\\":\\\"OTHER: Person Name\\\",\\\"subcategory\\\":\\\"OTHER: Person Name\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Zhou XJ\\\"},{\\\"start_idx\\\":18,\\\"end_idx\\\":35,\\\"standard_entity_name\\\":\\\"OTHER: Person Name\\\",\\\"subcategory\\\":\\\"OTHER: Person Name\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Sullivan-B\\\\u00f3lyai JZ\\\"}],\\\"content\\\":\\\"Frank D, Zhou XJ, Sullivan-B\\\\u00f3lyai JZ\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"ae04c1a3-16bd-45a5-8062-40eb8ebb0ec9\\\",\\\"column_roi_id\\\":\\\"4b8544a6-1a38-4aa1-afca-746eaa4144ac\\\",\\\"datacell_roi_id\\\":\\\"4eb90375-d04d-47f9-ac8d-19b1c34b1a97\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"08nov added Author(s):\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"05d69e52-7a87-4794-82c8-2e03c61a0939\\\",\\\"column_roi_id\\\":\\\"88fac83e-9ea0-4d3d-9c5d-50034b51aefc\\\",\\\"datacell_roi_id\\\":\\\"ba1fbd22-8273-4d81-8bae-b6fb1b82ec37\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Frank D, Zhou XJ, Sullivan-Bu00f3lyai JZ\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"05d69e52-7a87-4794-82c8-2e03c61a0939\\\",\\\"column_roi_id\\\":\\\"f6cf02e5-fd1b-4a82-967a-1fdee2ed7ce7\\\",\\\"datacell_roi_id\\\":\\\"5b83ae57-13b6-4180-9548-4b5a3ccd0252\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":29,\\\"end_idx\\\":43,\\\"standard_entity_name\\\":\\\"ANY: Address\\\",\\\"subcategory\\\":\\\"ANY: Address\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"320 Bent Street\\\"},{\\\"start_idx\\\":29,\\\"end_idx\\\":43,\\\"standard_entity_name\\\":\\\"OTHER: Address\\\",\\\"subcategory\\\":\\\"OTHER: Address\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"320 Bent Street\\\"}],\\\"content\\\":\\\"Idenix Pharmaceuticals, Inc. 320 Bent Street\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"269f7fd3-58eb-417c-b025-830c8cb32112\\\",\\\"column_roi_id\\\":\\\"45d5fae8-d464-4ffe-8fce-512df8918314\\\",\\\"datacell_roi_id\\\":\\\"9b46cd8c-d17e-41ad-964e-c05433e2936b\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Eudract Number:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"a51231ed-0ec0-4487-9934-3ffb46429724\\\",\\\"column_roi_id\\\":\\\"522f6c68-5073-4170-a8aa-47e66c97d278\\\",\\\"datacell_roi_id\\\":\\\"0c72fd10-68db-41b7-bbff-c5302e1d201d\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"2014-001378-33\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"a51231ed-0ec0-4487-9934-3ffb46429724\\\",\\\"column_roi_id\\\":\\\"d9201f3d-d3ef-4f12-ac5f-c63f0f9f4122\\\",\\\"datacell_roi_id\\\":\\\"b6557c56-a9d7-469c-984c-59572a2ed4b5\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Document type:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"4fb7482e-ece1-4f2f-b974-c5ba25a1965e\\\",\\\"column_roi_id\\\":\\\"3ab49f9b-c21a-41fd-b40f-b8754d4ee4ad\\\",\\\"datacell_roi_id\\\":\\\"ebf8e0f6-8b00-4393-b7d6-f47aa449963e\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Protocol\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"4fb7482e-ece1-4f2f-b974-c5ba25a1965e\\\",\\\"column_roi_id\\\":\\\"0a1e4690-823c-434a-9577-53fd725cf238\\\",\\\"datacell_roi_id\\\":\\\"d115c894-2799-41d9-9a88-b6f96b2e44db\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Development phase:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"a3708d8a-1693-43db-9e91-0d16d9500a2d\\\",\\\"column_roi_id\\\":\\\"a2c06fe6-35f3-4b96-8d96-64cd79b362ab\\\",\\\"datacell_roi_id\\\":\\\"81841a5f-1117-4666-aaab-bfa1e7ce9e2b\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"II\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"a3708d8a-1693-43db-9e91-0d16d9500a2d\\\",\\\"column_roi_id\\\":\\\"3e0b66e3-d054-4d79-adbf-86d113dd4a2a\\\",\\\"datacell_roi_id\\\":\\\"d915c3e9-5306-4d7c-99e0-f2f2df2b27c1\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Version date:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"ea7f0d9f-cbaf-4520-875e-a3ab7621d689\\\",\\\"column_roi_id\\\":\\\"23082150-946e-4fe7-9f6e-ab00cd4e0424\\\",\\\"datacell_roi_id\\\":\\\"80d530f7-fdd9-4dc7-876d-62e818ec357e\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"08-May-2014\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4d5dc787-0da8-4f4d-8f3e-964d9784bf54\\\",\\\"row_roi_id\\\":\\\"ea7f0d9f-cbaf-4520-875e-a3ab7621d689\\\",\\\"column_roi_id\\\":\\\"ff4f19fc-81a2-4b64-beda-0ed6badfa606\\\",\\\"datacell_roi_id\\\":\\\"56f7ea80-87a6-4421-9b7d-d8f41664ab8e\\\"},\\\"table_index\\\":0.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"0\", \"TableIndex\": \"1.0\", \"TableName\": \"\", \"Header\": []}, {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6506d19e-95ce-4dd3-a860-5d028cdb0b92\", \"childbox\": \"c2335d9d-7db6-4fc8-bac8-56460d282b6e\", \"subtext\": \"8eb8e8e0-2fe9-4532-a9ed-8692a5153a08\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 10, \"\"], [\"\", \"Unmapped\", \"text\", \"Property of Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 12, \"end_idx\": 39, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 12, \"end_idx\": 39, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"662c00ce-58b8-4642-9d2a-cedb6ed5fc80\", \"childbox\": \"c7ea1374-9c89-43be-b8f2-c10a0b86e8ba\", \"subtext\": \"1d727d7f-e275-4150-bec0-53e8c450c9db\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 11, \"\"], [\"\", \"Unmapped\", \"text\", \"Confidential\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e70fece3-7260-4496-8238-4fb1497080f2\", \"childbox\": \"440b3389-5259-43a6-bfe7-97bd231dc53d\", \"subtext\": \"d28b12d4-16cc-48e7-a8f6-446a588b634d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 12, \"\"], [\"\", \"Unmapped\", \"text\", \"May not be used, divulged, published, or otherwise disclosed without the consent of Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 84, \"end_idx\": 111, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 84, \"end_idx\": 111, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"16057ae8-384a-495f-a01d-3532de61b15c\", \"childbox\": \"70b5f8f9-b3d6-43ad-9fa1-a6c54c4856ef\", \"subtext\": \"71301ca3-1d76-48ae-84bd-0f0addeaf8ee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 13, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"96ebe0f4-c30b-4cab-8100-0bcab8b06575\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"TITLE\", \"\", 1, 14, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b198a188-c1df-4d4c-b97a-ddd9c1545232\", \"childbox\": \"b70dd8c5-5670-4726-aef3-ebfe2bb44b96\", \"subtext\": \"18eb4621-1b40-4a4f-b306-6ee127172db0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"TITLE\", \"\", 1, 15, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c281946c-e7ab-4291-b5b4-9cf351c9d6d6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"TITLE\", \"\", 1, 16, \"\"], [\"\", \"Unmapped\", \"text\", \"Investigator statement\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c55c2b00-5ce2-42a7-a7e8-7bf72295f818\", \"childbox\": \"4cb0c534-db6a-45ac-ba8b-9d83d2d987b5\", \"subtext\": \"5affd2d7-5c36-44b4-b32c-9d180490c7a5\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigator statement\", \"\", \"1\", 17, \"\"], [\"\", \"Unmapped\", \"text\", \"Protocol Number:\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93bd9859-f54b-41cc-8344-5630a31e48ee\", \"childbox\": \"1c8459f3-f22b-45fa-af74-b4ff90e9dbfe\", \"subtext\": \"715695ff-cf25-484c-ba41-c8b31c81e26d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigator statement\", \"\", \"1\", 18, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93bd9859-f54b-41cc-8344-5630a31e48ee\", \"childbox\": \"7bfef902-16af-4747-8548-7c40451e4da1\", \"subtext\": \"bd7a9cf7-8126-41b9-b7d6-77d2f92cb35d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigator statement\", \"\", \"1\", 19, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX-04B-004\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93bd9859-f54b-41cc-8344-5630a31e48ee\", \"childbox\": \"2b8018c6-2195-4ee2-93fd-4f0770d412ea\", \"subtext\": \"bd7a9cf7-8126-41b9-b7d6-77d2f92cb35d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigator statement\", \"\", \"1\", 20, \"\"], [\"\", \"Unmapped\", \"text\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 87, \"end_idx\": 96, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 87, \"end_idx\": 96, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 87, \"end_idx\": 96, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 102, \"end_idx\": 109, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 102, \"end_idx\": 109, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 102, \"end_idx\": 109, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"78dc349e-035b-424f-af1f-de184618a0cf\", \"childbox\": \"31f9d10b-4f1d-49b9-9c68-17aa4dfe3f39\", \"subtext\": \"ae050a35-8256-4c7c-8de2-c9e72db54a88\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 21, \"\"], [\"\", \"Unmapped\", \"text\", \"I understand that all documentation provided to me by Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 54, \"end_idx\": 81, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 54, \"end_idx\": 81, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"f1948f3b-5a6e-4dbe-8cc6-e46ed2f0ca29\", \"childbox\": \"c0ba616a-7b77-4da0-8b75-222fe36a7a62\", \"subtext\": \"39ac602b-cfc1-4daf-94d8-ec56dff9cf32\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 22, \"\"], [\"\", \"Unmapped\", \"text\", \"or its designated representative(s) concerning this study that has not been published previously will be kept in the strictest confidence.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f1948f3b-5a6e-4dbe-8cc6-e46ed2f0ca29\", \"childbox\": \"4c5b8a76-496d-45a7-933e-2b5ddf0fc1a0\", \"subtext\": \"c4a2f71a-7082-40fe-ac53-ef1b115d6349\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 23, \"\"], [\"\", \"Unmapped\", \"text\", \"This documentation includes the study protocol, Investigator\\u2019s Brochure, case report forms, and other scientific data.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f1948f3b-5a6e-4dbe-8cc6-e46ed2f0ca29\", \"childbox\": \"0293fc0f-671e-45c8-a283-287c580bb589\", \"subtext\": \"c4a2f71a-7082-40fe-ac53-ef1b115d6349\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 24, \"\"], [\"\", \"Unmapped\", \"text\", \"This study will not commence without the prior written approval of a properly constituted Institutional Review Board or Ethics Committee.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"af4b35e7-c6be-46b6-b136-cf6437eb9bd5\", \"childbox\": \"9ce2d629-43c0-4742-820c-63d198a5b72b\", \"subtext\": \"d002703f-4ff9-4a94-b939-e886d0a5e257\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 25, \"\"], [\"\", \"Unmapped\", \"text\", \"No changes will be made to the study protocol without the prior written approval of Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 84, \"end_idx\": 111, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 84, \"end_idx\": 111, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"af4b35e7-c6be-46b6-b136-cf6437eb9bd5\", \"childbox\": \"94e0bb13-5aa5-455f-97cb-16fdf590853a\", \"subtext\": \"d002703f-4ff9-4a94-b939-e886d0a5e257\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 26, \"\"], [\"\", \"Unmapped\", \"text\", \"and the Institutional Review Board/Ethics Committee, except where necessary to eliminate an immediate hazard to the subject.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"af4b35e7-c6be-46b6-b136-cf6437eb9bd5\", \"childbox\": \"232f6586-07ed-4392-bf4d-2cde8200ce52\", \"subtext\": \"c18151e0-1f9a-4ed3-a12f-1d725d1ad6e7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 27, \"\"], [\"\", \"Unmapped\", \"text\", \"All subjects will provide a written informed consent prior to participation.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"af4b35e7-c6be-46b6-b136-cf6437eb9bd5\", \"childbox\": \"443c9ed0-38bc-45b7-9013-0c5fb2d3fffa\", \"subtext\": \"c18151e0-1f9a-4ed3-a12f-1d725d1ad6e7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 28, \"\"], [\"\", \"Unmapped\", \"text\", \"I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c40b779e-d516-43a1-804d-895540e3c467\", \"childbox\": \"8fd010d3-1450-4d34-b15c-901bef0632d6\", \"subtext\": \"a56369b5-7826-4c35-9e20-7637f9ef8cef\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 29, \"\"], [\"\", \"Unmapped\", \"text\", \"I have read, understood, and agree to abide by all the conditions and instructions contained in this protocol, and in compliance with ICH, GCP and other applicable regulatory requirements.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c40b779e-d516-43a1-804d-895540e3c467\", \"childbox\": \"4f661b55-cf2a-4156-97d6-9e2cefa4b209\", \"subtext\": \"c5cdac6d-6724-4745-afde-e132ffab0df4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 30, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a085ce76-df80-4975-87f1-eb09c1aef948\", \"childbox\": \"3490ca8e-f118-4d4b-a5d6-d570fef01a9a\", \"subtext\": \"e4767eae-aa1d-419d-a01a-3028ac8efe8b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 31, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a085ce76-df80-4975-87f1-eb09c1aef948\", \"childbox\": \"14089606-2a5e-457a-9ab2-6c0cba99a794\", \"subtext\": \"da195463-c9cd-4b4e-86c5-874ff1a55e28\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 32, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a085ce76-df80-4975-87f1-eb09c1aef948\", \"childbox\": \"124adf80-e27c-4a23-ba67-4cabbb899c9c\", \"subtext\": \"349d80e1-4307-4868-bae3-b30413c9cf55\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 33, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1d8b81fb-eb27-4f28-9644-408cbbcccee6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 34, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"908a927d-9906-4f75-9c87-c723599e9a82\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 35, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"228f914f-af56-4046-9db0-9ca29308d66b\", \"childbox\": \"ea461f91-5687-4b72-932d-bce6960b144e\", \"subtext\": \"2b23ad9c-dce3-487c-9604-226a0b7ad2cc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 36, \"\"], [\"\", \"Unmapped\", \"text\", \"Investigator Signature\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"228f914f-af56-4046-9db0-9ca29308d66b\", \"childbox\": \"c515627c-5c14-452e-9b06-0184e503654c\", \"subtext\": \"2b23ad9c-dce3-487c-9604-226a0b7ad2cc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 37, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"228f914f-af56-4046-9db0-9ca29308d66b\", \"childbox\": \"b7408bed-1b91-4d51-b214-ab6da42ea53d\", \"subtext\": \"f8aef384-6f85-4b31-8566-de2617b0c8bb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 38, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"228f914f-af56-4046-9db0-9ca29308d66b\", \"childbox\": \"90d79042-0d80-446f-85c9-42941b023004\", \"subtext\": \"2fcb89f2-3abf-4a4c-af91-968c3aeb27a2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 39, \"\"], [\"\", \"Unmapped\", \"text\", \"Date\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"228f914f-af56-4046-9db0-9ca29308d66b\", \"childbox\": \"f7184e39-ec40-44fb-92b5-a0dacd64cff8\", \"subtext\": \"2fcb89f2-3abf-4a4c-af91-968c3aeb27a2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 40, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8918a40-6696-4632-8b0e-f926b2e15964\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 41, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aeeb7a26-77e8-4d1e-bc63-18b6364e1af0\", \"childbox\": \"e6a0f2a9-046a-4faf-b494-775c116e2816\", \"subtext\": \"f97cb4f0-1512-44d0-9b65-de515b07b015\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 42, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aeeb7a26-77e8-4d1e-bc63-18b6364e1af0\", \"childbox\": \"dfbdae5e-3a3d-41cd-8d5b-86cdd58a2214\", \"subtext\": \"7e99e30f-4dc0-4059-bc3f-a3ecf3560f04\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 43, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aeeb7a26-77e8-4d1e-bc63-18b6364e1af0\", \"childbox\": \"685a2a25-a36e-4513-8926-4ae8cb8409bc\", \"subtext\": \"4fd6d327-8bdc-4cc0-a1d1-c74cb7b950df\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 44, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"89b34c3b-d80d-4380-a7f4-1c5f93fd507f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 45, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3160f82f-e1eb-4837-bb0f-508f8af8b021\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 46, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"61f4e66e-448e-4336-b041-6e1e88b12f0f\", \"childbox\": \"f1870cf0-265a-411b-aa23-2a80e2bba492\", \"subtext\": \"ee062344-8796-47bc-9ec0-ee0169f86f3e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 47, \"\"], [\"\", \"Unmapped\", \"text\", \"Investigator Name (Printed)\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"61f4e66e-448e-4336-b041-6e1e88b12f0f\", \"childbox\": \"c9f7518e-2b37-435b-8122-f34685416270\", \"subtext\": \"ee062344-8796-47bc-9ec0-ee0169f86f3e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 48, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"61f4e66e-448e-4336-b041-6e1e88b12f0f\", \"childbox\": \"81c64cb8-3a2a-4639-a4ce-00a583706cea\", \"subtext\": \"b6186c6f-c722-477d-b19b-ec64b14ccb9d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 49, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"61f4e66e-448e-4336-b041-6e1e88b12f0f\", \"childbox\": \"78f96aba-0247-44d5-b835-3c3880a619b8\", \"subtext\": \"46570383-c047-4ef3-b64a-115ec3eb7717\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 50, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ab0ddc08-4bae-4694-8593-cc472546a562\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol Title: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"\", \"1\", 51, \"\"], [\"\", \"Unmapped\", \"text\", \"Table of contents\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f8d52ab7-1d7b-435d-81bd-4a534aa814a3\", \"childbox\": \"776a3b5d-a9ac-4c56-aa4c-cedab7d9b177\", \"subtext\": \"5f02613e-b5de-4ab6-bac1-ab98429682b2\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 52, \"\"], [\"\", \"Unmapped\", \"text\", \"List of tables 6\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7825f46-a464-4f16-b67f-deab6d834faa\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 53, \"\"], [\"\", \"Unmapped\", \"text\", \"List of abbreviations 7\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"557fbc76-63d1-47c3-be8e-c4e9dbf97324\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 54, \"\"], [\"\", \"Unmapped\", \"text\", \"Protocol synopsis 9\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"787c1b81-ac64-41b8-8015-b4133d7addf2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 55, \"\"], [\"\", \"Unmapped\", \"text\", \"1 Background 14\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"09bda743-935c-496b-8b7c-967eee6c27ca\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 56, \"\"], [\"\", \"Unmapped\", \"text\", \"1.1 Justification of selected doses 15\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"50af1e74-7c49-40b0-a2f2-669ed6ca8fa2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 57, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2 Ri sk/benefit assessment 15\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6d94b1a9-69a1-43b2-b5c6-a1404dd50f28\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 58, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2.1 Known Benefits 15\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"66dc4a39-58da-4db8-9be2-d26f10567fca\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 59, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2.2 Potential Benefits 16\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c973fe68-ca93-474a-88c2-c0dd391ef564\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 60, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2.3 Known Risk s 16\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7e41cdb3-a776-418f-881a-8aefc0589578\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 61, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2.4 Potential Risks 16\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"231dbc96-c1db-48aa-849f-abf5e33cdf64\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 62, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2.5 Risk mitigation 17\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"73d6d725-2bfd-4703-8807-6ce6eaf22de5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 63, \"\"], [\"\", \"Unmapped\", \"text\", \"1.2.6 Overall benefit/risk assessment 17\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"24cfe122-5f93-49f1-ba04-d95213632a14\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 64, \"\"], [\"\", \"Unmapped\", \"text\", \"2 Study purpose 18\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d3358af2-59e3-46ec-acae-057de94139d0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 65, \"\"], [\"\", \"Unmapped\", \"text\", \"3 Objectives 18\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ca5f273-0897-4f20-80f9-e12baad5d5cf\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 66, \"\"], [\"\", \"Unmapped\", \"text\", \"3.1 Primary objectives 18\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"de0480bd-865f-44d7-b2a5-595686704e8b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 67, \"\"], [\"\", \"Unmapped\", \"text\", \"3.2 Secondary objectiv es 18\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bb0bfbdb-5a70-404d-895d-d919e786519a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 68, \"\"], [\"\", \"Unmapped\", \"text\", \"4 Study design 18\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cf903d08-0f2a-4c66-b39d-9abbb71bd353\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 69, \"\"], [\"\", \"Unmapped\", \"text\", \"4.1 Data Safety Monitoring Board 19\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c5bb24f3-9399-4b01-9a93-85267583803b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 70, \"\"], [\"\", \"Unmapped\", \"text\", \"4.2 Stop ping rules 19\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aaae531f-09bc-4c27-b2f2-7c65e674e383\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 71, \"\"], [\"\", \"Unmapped\", \"text\", \"4.2.1 Study safety stopping rules 19\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7f187692-d811-4c35-8d42-ca6ef59dea75\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 72, \"\"], [\"\", \"Unmapped\", \"text\", \"4.2.2 Futility rules (criteria for closing a treatment arm due to inadequate\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"de2d7b47-51fb-4e59-80cc-3beadbec7126\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 73, \"\"], [\"\", \"Unmapped\", \"text\", \"antiviral response) 20\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"00bee688-3753-4a89-9f4f-7c3c9e47c298\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 74, \"\"], [\"\", \"Unmapped\", \"text\", \"4.2.3 Individual subject stopping rules 20\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"049206bf-2a3b-43d8-a8c8-af2289f8e91e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 75, \"\"], [\"\", \"Unmapped\", \"text\", \"4.2.4 Virologic failure 21\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fd7a59dd-2be4-4675-87cc-68bba74e82a4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 76, \"\"], [\"\", \"Unmapped\", \"text\", \"5 Population 21\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7b5dc821-c057-4823-a582-3821c3e7ab11\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 77, \"\"], [\"\", \"Unmapped\", \"text\", \"5.1 Inclusion/exclusion criteria 21\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"158f2482-a9f3-4627-a9f6-ae2e2d3c74d8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 78, \"\"], [\"\", \"Unmapped\", \"text\", \"5.1.1 Inclusion criteria 21\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b9763c28-98bd-4b8b-9990-99e10f5b9bfd\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 79, \"\"], [\"\", \"Unmapped\", \"text\", \"5.1.2 Exclusion criteria 22\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5e0e0938-29d7-413d-8b2e-c26b389cc34e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 80, \"\"], [\"\", \"Unmapped\", \"text\", \"5.2 Prematur e subject withdrawal 25\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1a3266b0-f83d-4ff9-aff7-48249f56a233\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 81, \"\"], [\"\", \"Unmapped\", \"text\", \"6 Treatment 25\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f8267c9b-e1aa-4c3e-a38d-7aa9ee90487a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 82, \"\"], [\"\", \"Unmapped\", \"text\", \"6.1 Subject numbering 25\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bed10f9a-5299-49cc-ba0d-6a88aa4fcba5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 83, \"\"], [\"\", \"Unmapped\", \"text\", \"6.2 Investigational and control drugs 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"baba7528-01f8-4535-84b2-6a2fdbfc976e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 84, \"\"], [\"\", \"Unmapped\", \"text\", \"6.3 Treatment arms 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8d2c0cba-ad62-4212-acd1-a1afe6d50ce7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 85, \"\"], [\"\", \"Unmapped\", \"text\", \"6.4 Treatment assignment 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aaec10ad-2812-448d-81f0-bb0515b01b83\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 86, \"\"], [\"\", \"Unmapped\", \"text\", \"6.5 Treatment bl inding 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"66bd5ecf-15c5-45a3-ab64-8c0010cd6c7e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 87, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6 Treating the subject 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27bd093d-8f80-40b5-9a32-76b9bd036446\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 88, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.1 Dispensing the study drug 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"daa5524d-1aca-4dfe-93c7-98318427a736\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 89, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.2 Instructions for prescribing and taking the study drug 26\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e656f8f2-4e2d-4033-9ae1-950c6aea487c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 90, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.3 Permitted study drug dose modifications or interruptions 27\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"045d4d54-e39b-4476-855a-2e8debf43a4f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 91, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.4 Study drug discontinuation 27\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d98f2ed5-2584-4a12-b3c0-10ece1dd2bc0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 92, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.5 Concomitant medications 28\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e0d33b41-ee61-4219-9de0-34d4a971c0b0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 93, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.6 Prohibited medications 28\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"949d7bc2-efec-483f-afbc-ee1d98d1e04d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 94, \"\"], [\"\", \"Unmapped\", \"text\", \"6.6.7 Emergency unblinding of treatment assignment 29\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"49677522-f595-4097-9f51-e49eba852246\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 95, \"\"], [\"\", \"Unmapped\", \"text\", \"7 Visit schedule and assessments 29\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b1e93844-523d-4c7b-8d6b-029d2c881796\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"of contents\", \"Table\", \"1\", 96, \"\"], [\"\", \"Unmapped\", \"text\", \"7.1 Information to be collected on screening failures 32\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"41ea98b2-77c5-4883-9d3d-ea71dc8c0ba1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Information to be collected on screening failures 32\", \"7.1\", \"2\", 97, \"\"], [\"\", \"Unmapped\", \"text\", \"7.2 Subject demographics/other baseline characteristics 33\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98d895d5-8f1a-4742-96f4-7d93213734d5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Information to be collected on screening failures 32\", \"7.1\", \"2\", 98, \"\"], [\"\", \"Unmapped\", \"text\", \"7.3 Treatment exposure and compliance 33\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"73c52031-4818-4ffa-89f5-4e9054799fa5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Treatment exposure and compliance 33\", \"7.3\", \"2\", 99, \"\"], [\"\", \"Unmapped\", \"text\", \"7.4 Antiviral activity 33\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e9b01bd0-2820-48b9-92dd-122e5b400f6c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Treatment exposure and compliance 33\", \"7.3\", \"2\", 100, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5 Safety 34\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"02646526-856e-4e86-aa1f-6aad4e49a5ac\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Treatment exposure and compliance 33\", \"7.3\", \"2\", 101, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.1 Adverse events 34\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4cdb7bcf-f705-4b23-a4e6-0f187a14f16e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Adverse events 34\", \"7.5.1\", \"3\", 102, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.2 Management of anemia 36\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7efd5f00-5c11-4a5e-a0ae-360732726cee\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Management of anemia 36\", \"7.5.2\", \"3\", 103, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.3 Physical examination 36\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"97ef9cc5-d766-497d-a2f3-1aaa58cd93a3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Physical examination 36\", \"7.5.3\", \"3\", 104, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.4 Vital signs 36\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2be72a48-ce3f-4714-accd-49efc2d70fc1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Vital signs 36\", \"7.5.4\", \"3\", 105, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.5 Laboratory evaluations 36\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"61ddb9a4-81bd-4cd6-8e3f-47e32db97ff8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Laboratory evaluations 36\", \"7.5.5\", \"3\", 106, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.6 12-lead electrocardiogram (ECG) 37\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bccd2a1c-3de5-45a3-b965-4b3202543c64\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-lead electrocardiogram (ECG) 37\", \"7.5.6  12\", \"3\", 107, \"\"], [\"\", \"Unmapped\", \"text\", \"7.5.7 Echocardiogram 37\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"57bfc199-24d5-4bc6-af12-6e3c312aa628\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-lead electrocardiogram (ECG) 37\", \"7.5.6  12\", \"3\", 108, \"\"], [\"\", \"Unmapped\", \"text\", \"7.6 Pharmacokinetics 37\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e5b78425-9a5e-4b2b-a7c6-471b68e62b63\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-lead electrocardiogram (ECG) 37\", \"7.5.6  12\", \"3\", 109, \"\"], [\"\", \"Unmapped\", \"text\", \"7.6.1 Pharmacokinetic blood sampling and processing 38\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"76816b57-f7ed-4c72-a599-3309342d42d3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetic blood sampling and processing 38\", \"7.6.1\", \"3\", 110, \"\"], [\"\", \"Unmapped\", \"text\", \"7.7 Pharmacodynamics 38\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ea03afe5-6c21-44b8-85f3-fe82971421fb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetic blood sampling and processing 38\", \"7.6.1\", \"3\", 111, \"\"], [\"\", \"Unmapped\", \"text\", \"8 Safety monitoring 38\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ad397c5-cb62-44c9-adae-c819b0c01f8a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Safety monitoring 38\", \"8\", \"1\", 112, \"\"], [\"\", \"Unmapped\", \"text\", \"8.1 Serious adverse event (SAE) reporting 38\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"362c399a-f9b1-40ab-9f92-f5e110a86224\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Serious adverse event (SAE) reporting 38\", \"8.1\", \"2\", 113, \"\"], [\"\", \"Unmapped\", \"text\", \"8 .2 Follow-up of adverse events 39\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"46bf9711-2f45-46fb-b4a3-bb427928c59f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Serious adverse event (SAE) reporting 38\", \"8.1\", \"2\", 114, \"\"], [\"\", \"Unmapped\", \"text\", \"8.3 Reporting safety information to the IRB/EC 40\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fa84b81f-1e2c-423d-bfd2-6f4132fdcce2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Reporting safety information to the IRB/EC 40\", \"8.3\", \"2\", 115, \"\"], [\"\", \"Unmapped\", \"text\", \"8.4 Pregnancies 40\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"103ef7fa-f17d-4ecf-ae3a-0c3ac4e76ae4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pregnancies 40\", \"8.4\", \"2\", 116, \"\"], [\"\", \"Unmapped\", \"text\", \"9 Data review and database management 41\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"03b4d077-b4e4-4144-94cd-8a507add14ff\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Data review and database management 41\", \"9\", \"1\", 117, \"\"], [\"\", \"Unmapped\", \"text\", \"9.1 Site monitoring 41\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a3e685ce-2a48-4919-9a6c-dd431c1bde38\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Site monitoring 41\", \"9.1\", \"2\", 118, \"\"], [\"\", \"Unmapped\", \"text\", \"9.2 Data collection 41\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6601d6c9-8f4a-4da4-8c31-73de2978ebf9\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Data collection 41\", \"9.2\", \"2\", 119, \"\"], [\"\", \"Unmapped\", \"text\", \"9.3 Database management and quality control 41\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1fc68bb9-1138-4122-8e4b-21851ec35853\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Database management and quality control 41\", \"9.3\", \"2\", 120, \"\"], [\"\", \"Unmapped\", \"text\", \"9.4 Archival of study records 42\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b95fe6fd-0548-4a9b-9863-810dd24e530c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Archival of study records 42\", \"9.4\", \"2\", 121, \"\"], [\"\", \"Unmapped\", \"text\", \"10 Statistical analyses 42\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f15ecbab-1bfa-4f24-8541-c7d08764d0fc\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Statistical analyses 42\", \"10\", \"1\", 122, \"\"], [\"\", \"Unmapped\", \"text\", \"10.1 Populations for analysis 42\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2a61a74b-410e-4f34-b5e8-6a093352d81c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Populations for analysis 42\", \"10.1\", \"2\", 123, \"\"], [\"\", \"Unmapped\", \"text\", \"10.1.1 Protocol deviations 42\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d95d1ac9-81af-4273-9afe-d2910554d848\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol deviations 42\", \"10.1.1\", \"3\", 124, \"\"], [\"\", \"Unmapped\", \"text\", \"10.2 Subject demographics/other baseline characteristics 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4d263e38-bad7-4207-a27a-38e81986d0c5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Subject demographics/other baseline characteristics 43\", \"10.2\", \"2\", 125, \"\"], [\"\", \"Unmapped\", \"text\", \"10.3 Analysis of the primary objective(s) 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90f9e848-d1c1-4f14-b8ec-38cad17138e6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Analysis of the primary objective(s) 43\", \"10.3\", \"2\", 126, \"\"], [\"\", \"Unmapped\", \"text\", \"10.3.1 Safety para meters 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"36c3cab1-1123-42b0-a140-d2948c9df520\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Analysis of the primary objective(s) 43\", \"10.3\", \"2\", 127, \"\"], [\"\", \"Unmapped\", \"text\", \"7.4 10.3.2 Antiviral activity 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c44d3843-eaf8-4e0e-925a-d5e596388f30\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Antiviral activity 43\", \"10.3.2\", \"2\", 128, \"\"], [\"\", \"Unmapped\", \"text\", \"10.4 Analysis of secondary objective(s) 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ae1ac1fc-4aaa-4589-a3d8-86f75bfd21b8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Analysis of secondary objective(s) 43\", \"10.4\", \"2\", 129, \"\"], [\"\", \"Unmapped\", \"text\", \"10. 4.1 Pharmacokinetic parameters 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"62f375d1-f93f-4eec-a8c9-ffb25f7a0a47\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Analysis of secondary objective(s) 43\", \"10.4\", \"2\", 130, \"\"], [\"\", \"Unmapped\", \"text\", \"10.4.2 Pharmacokinetic/pharmacodynamic relationships 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"12a06fc1-3c45-4ac8-89a9-c3b3eb108a2e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetic/pharmacodynamic relationships 43\", \"10.4.2\", \"3\", 131, \"\"], [\"\", \"Unmapped\", \"text\", \"10.4.3 Emergence of resistance mutations 43\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"802db118-32b6-4574-ae5c-b78bf8ee4294\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetic/pharmacodynamic relationships 43\", \"10.4.2\", \"3\", 132, \"\"], [\"\", \"Unmapped\", \"text\", \"10.4.4 Durability of SVR and the kinetics of antiviral resistant HCV 44\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1a838a5e-0c07-41c4-b8fe-175413980283\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetic/pharmacodynamic relationships 43\", \"10.4.2\", \"3\", 133, \"\"], [\"\", \"Unmapped\", \"text\", \"10.5 Missing, unused and spurious data 44\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"86aedb53-4949-4448-ab5b-84b070a34373\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Missing, unused and spurious data 44\", \"10.5\", \"2\", 134, \"\"], [\"\", \"Unmapped\", \"text\", \"10.6 Ongoing data analysis 44\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c99a494b-3d4f-49ba-ae41-c74e9f16a7fa\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Ongoing data analysis 44\", \"10.6\", \"2\", 135, \"\"], [\"\", \"Unmapped\", \"text\", \"10.7 Sample size consideration 44\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"95441755-81f3-407c-99bf-0adeb1522cec\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Sample size consideration 44\", \"10.7\", \"2\", 136, \"\"], [\"\", \"Unmapped\", \"text\", \"11 Referenc es 45\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb43fc23-2511-49eb-974f-b07b1a4319a1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Sample size consideration 44\", \"10.7\", \"2\", 137, \"\"], [\"\", \"Unmapped\", \"text\", \"Appendix 1:  Administrative procedures 46\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"23788794-1ecc-49e6-9766-a9c923307c6e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Administrative procedures 46\", \"Appendix 1:\", \"1\", 138, \"\"], [\"\", \"Unmapped\", \"text\", \"Appendix 2:  Division of AIDS Table for Grading the Severity of Adult and\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 13, \"end_idx\": 34, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Division of AIDS Table\"}], \"roi_id\": {\"para\": \"a99d49a5-f0d5-46c2-b62f-f0011d418a7b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Administrative procedures 46\", \"Appendix 1:\", \"1\", 139, \"\"], [\"\", \"Unmapped\", \"text\", \"Pediatric Adverse Events (December 2004, Clarification August 2009) 49\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 41, \"end_idx\": 60, \"standard_entity_name\": \"OTHER: Person Name\", \"subcategory\": \"OTHER: Person Name\", \"confidence\": 100.0, \"text\": \"Clarification August\"}], \"roi_id\": {\"para\": \"0c26d319-f5e5-45cd-a9b4-0cdb7591c138\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Administrative procedures 46\", \"Appendix 1:\", \"1\", 140, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4698aa5d-7d2e-4d8d-9c35-d169561d0fbc\", \"childbox\": \"3e521920-66a1-4ef0-aed2-7845be327430\", \"subtext\": \"4effe7c3-4797-4e8d-88ab-3396ee1d005b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Administrative procedures 46\", \"Appendix 1:\", \"1\", 141, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85778871-724b-4ee9-af4a-15bf6416ab37\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Administrative procedures 46\", \"Appendix 1:\", \"1\", 142, \"\"], [\"\", \"Unmapped\", \"header\", \"List of tables\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"c48d29e8-c3da-4f7d-88fb-0c785b17c5bf\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 143, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 4-1\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"770bd2a2-224e-47af-99ce-09f88523678d\", \"childbox\": \"c56af21d-d119-4b7b-a103-7a54322cae37\", \"subtext\": \"349a8079-6086-4f8b-97c4-06ea990424d4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 144, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"770bd2a2-224e-47af-99ce-09f88523678d\", \"childbox\": \"c56af21d-d119-4b7b-a103-7a54322cae37\", \"subtext\": \"da4b465b-425d-43a4-af49-193513bc47eb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 145, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"770bd2a2-224e-47af-99ce-09f88523678d\", \"childbox\": \"a33cfa5d-06f1-4e47-aa9d-435b23a61309\", \"subtext\": \"19711176-c29c-4b66-9b10-cba1bdbfa2d1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 146, \"\"], [\"\", \"Unmapped\", \"text\", \"Study design..........................................................................................19\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"770bd2a2-224e-47af-99ce-09f88523678d\", \"childbox\": \"c66d531f-5ab4-4923-9718-eccef3863662\", \"subtext\": \"987c930e-750c-4b1a-87bb-91fed4237a8a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 147, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"770bd2a2-224e-47af-99ce-09f88523678d\", \"childbox\": \"c66d531f-5ab4-4923-9718-eccef3863662\", \"subtext\": \"6b259a55-030f-4133-bb68-82216d48d6ec\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 148, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 6-1\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b0964fb-9f32-4455-8343-b80c146b8650\", \"childbox\": \"2218b87f-343e-4c4d-af4b-7b6348aec533\", \"subtext\": \"e403385d-9382-44a8-9c6e-06a88744997c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 149, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b0964fb-9f32-4455-8343-b80c146b8650\", \"childbox\": \"2218b87f-343e-4c4d-af4b-7b6348aec533\", \"subtext\": \"c08b3d34-b921-48d4-9de2-e242321d024d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 150, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b0964fb-9f32-4455-8343-b80c146b8650\", \"childbox\": \"586be57e-8d5d-499c-aa0e-aabb1a74ac6d\", \"subtext\": \"b9063c77-b4ca-4a63-9097-f4a2c220e8f4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 151, \"\"], [\"\", \"Unmapped\", \"text\", \"Ribavirin dosing schedule.....................................................................27\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b0964fb-9f32-4455-8343-b80c146b8650\", \"childbox\": \"4d48f40c-fd7a-4fca-98c4-f4c5aaf251de\", \"subtext\": \"ed128186-35f7-459c-86b7-69202145f69d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 152, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b0964fb-9f32-4455-8343-b80c146b8650\", \"childbox\": \"4d48f40c-fd7a-4fca-98c4-f4c5aaf251de\", \"subtext\": \"bcdfb7f0-e96d-42fb-97ac-8224eecd6455\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 153, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-1\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1214d407-5018-4562-853b-014e3d0546b1\", \"childbox\": \"7b01a5a1-3f1f-449e-a14e-d8f119cda6e1\", \"subtext\": \"efd16366-c9b9-4b80-bad3-c7b23ce51957\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 154, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1214d407-5018-4562-853b-014e3d0546b1\", \"childbox\": \"7b01a5a1-3f1f-449e-a14e-d8f119cda6e1\", \"subtext\": \"7f8c7677-6264-4843-b253-c9f961c9228c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 155, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1214d407-5018-4562-853b-014e3d0546b1\", \"childbox\": \"d5c565eb-7110-44f2-96a0-b97d6310dbdb\", \"subtext\": \"cd5784d7-cc14-413f-a209-a0d1945f4fa4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 156, \"\"], [\"\", \"Unmapped\", \"text\", \"Schedule of assessments .......................................................................30\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1214d407-5018-4562-853b-014e3d0546b1\", \"childbox\": \"1950f600-4388-4640-838c-14b27f1d0025\", \"subtext\": \"c1f9d603-9bc0-4b50-89da-055663969eb0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 157, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1214d407-5018-4562-853b-014e3d0546b1\", \"childbox\": \"1950f600-4388-4640-838c-14b27f1d0025\", \"subtext\": \"179d891a-c5a9-46c3-9eb6-a117677e8e25\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 158, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-2\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42148d28-f1be-4601-bca8-8cd9eb83afc7\", \"childbox\": \"ae4501e8-dea9-4d69-bfaa-e699a51f6b06\", \"subtext\": \"90b274ca-5f68-413c-8a7a-993d86cbb289\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 159, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42148d28-f1be-4601-bca8-8cd9eb83afc7\", \"childbox\": \"ae4501e8-dea9-4d69-bfaa-e699a51f6b06\", \"subtext\": \"3d801175-fe51-4cd8-b830-791011a93120\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 160, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42148d28-f1be-4601-bca8-8cd9eb83afc7\", \"childbox\": \"1b7a5053-4cf9-4567-8970-b8b25c5d8221\", \"subtext\": \"43ef21e1-a4d4-42b3-ad90-dbe986eb234d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 161, \"\"], [\"\", \"Unmapped\", \"text\", \"Schedule of assessments \\u2013 Extended observational follow-on phase...31\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42148d28-f1be-4601-bca8-8cd9eb83afc7\", \"childbox\": \"71f497f3-6e5a-4b34-bacb-90b6f14e8863\", \"subtext\": \"c86cd57c-e211-492c-ba4f-dc3d8776dd2b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 162, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42148d28-f1be-4601-bca8-8cd9eb83afc7\", \"childbox\": \"71f497f3-6e5a-4b34-bacb-90b6f14e8863\", \"subtext\": \"fa56c956-0d42-48e2-b920-bd3b4c0a61a1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 163, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-3\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04536d55-be0e-468e-8d2e-b9a9cdbed73d\", \"childbox\": \"81472cc6-24c5-4ff8-993f-568b0c220324\", \"subtext\": \"4aea2d14-83e7-4ada-bc62-331d41265033\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 164, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04536d55-be0e-468e-8d2e-b9a9cdbed73d\", \"childbox\": \"81472cc6-24c5-4ff8-993f-568b0c220324\", \"subtext\": \"cc9b2edc-4c8a-4c17-ac24-a47d3d72d18f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 165, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04536d55-be0e-468e-8d2e-b9a9cdbed73d\", \"childbox\": \"072a22c0-a94a-4511-ab00-841d1c7939f3\", \"subtext\": \"5093d909-88a3-4db9-b6e7-e0fad425cb5d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 166, \"\"], [\"\", \"Unmapped\", \"text\", \"Schedule of PK assessments .................................................................32\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04536d55-be0e-468e-8d2e-b9a9cdbed73d\", \"childbox\": \"ddd92e3a-8cca-4291-a73a-95e8ff30a98d\", \"subtext\": \"c9f0970b-7197-4951-8f27-1eaa4ee4b968\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 167, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04536d55-be0e-468e-8d2e-b9a9cdbed73d\", \"childbox\": \"ddd92e3a-8cca-4291-a73a-95e8ff30a98d\", \"subtext\": \"ce2a3f3a-84d5-49a7-9b1b-0743a767d3c6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 168, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 10-1\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e97a12a2-e0cc-4e2e-bd14-bbb01a2fa28b\", \"childbox\": \"0af35ccd-470d-43bc-a82a-390da49b4b89\", \"subtext\": \"f79f3eb9-dfe4-42ee-b5d0-cff927b57273\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 169, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e97a12a2-e0cc-4e2e-bd14-bbb01a2fa28b\", \"childbox\": \"0af35ccd-470d-43bc-a82a-390da49b4b89\", \"subtext\": \"65cf8617-6c3e-4de5-9840-d7b8e4a29698\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 170, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e97a12a2-e0cc-4e2e-bd14-bbb01a2fa28b\", \"childbox\": \"47411379-1ffe-4dc3-a039-61f4e483923a\", \"subtext\": \"56397898-b1ad-4a6f-9d76-fe94e6c7c8fe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 171, \"\"], [\"\", \"Unmapped\", \"text\", \"Levels of detection \\u2013 primary efficacy endpoint vs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e97a12a2-e0cc-4e2e-bd14-bbb01a2fa28b\", \"childbox\": \"bfc86f7c-eaa0-4800-aa91-9b0b3a9245d7\", \"subtext\": \"2b4a9b25-be33-4558-aa62-8656f6d8e994\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 172, \"\"], [\"\", \"Unmapped\", \"text\", \"the reference\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e97a12a2-e0cc-4e2e-bd14-bbb01a2fa28b\", \"childbox\": \"54187478-356c-4282-8fc6-f475dc4782db\", \"subtext\": \"2b4a9b25-be33-4558-aa62-8656f6d8e994\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 173, \"\"], [\"\", \"Unmapped\", \"text\", \"(SOVALDI\\u2122).......................................................................................44\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9410fab4-87d0-4b7f-8946-ee8251c76668\", \"childbox\": \"0409c326-0d6a-4a16-a29b-bf9d8a779fc0\", \"subtext\": \"c2602465-9fda-42df-be47-5853c770e0b4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 174, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9410fab4-87d0-4b7f-8946-ee8251c76668\", \"childbox\": \"0409c326-0d6a-4a16-a29b-bf9d8a779fc0\", \"subtext\": \"2d1e2a81-80ac-404b-bddf-a564c5b987be\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of tables\", \"\", \"1\", 175, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ec1d03a8-9455-45e4-8005-d2e7f189ceb0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"List of tables\", \"\", \"1\", 176, \"\"], [\"\", \"Unmapped\", \"header\", \"List of abbreviations\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"a7b20aab-83f9-4470-9248-4085f7aef41d\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of abbreviations\", \"\", \"1\", 177, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>\\u03b2-HCG</td>\\n      <td>Beta-human chorionic gonadotropin</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>AE</td>\\n      <td>Adverse event</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>ALT</td>\\n      <td>Alanine aminotransferase</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>AST</td>\\n      <td>Aspartate aminotransferase</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>AUC 0-t</td>\\n      <td>Area under the concentration-time curve from time zero to t</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>BID</td>\\n      <td>Bis in die or twice a day</td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>BMI</td>\\n      <td>Body mass index</td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>C 24h</td>\\n      <td>Drug concentration 24 h after dosing or the predose trough drug concentration following multiple dosing</td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td>CK</td>\\n      <td>Creatine kinase</td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>C max</td>\\n      <td>Maximum observed drug concentration</td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>CRF</td>\\n      <td>Case report form</td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td>C trough</td>\\n      <td>Trough drug concentration</td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>CYP3A4</td>\\n      <td>Cytochrome P450 3A4</td>\\n    </tr>\\n    <tr>\\n      <th>13</th>\\n      <td>DAA</td>\\n      <td>Direct-acting antiviral</td>\\n    </tr>\\n    <tr>\\n      <th>14</th>\\n      <td>DAIDS</td>\\n      <td>Division of AIDS</td>\\n    </tr>\\n    <tr>\\n      <th>15</th>\\n      <td>DSMB</td>\\n      <td>Data safety monitoring board</td>\\n    </tr>\\n    <tr>\\n      <th>16</th>\\n      <td>EC</td>\\n      <td>Ethics committee</td>\\n    </tr>\\n    <tr>\\n      <th>17</th>\\n      <td>ECG</td>\\n      <td>Electrocardiogram</td>\\n    </tr>\\n    <tr>\\n      <th>18</th>\\n      <td>EDC</td>\\n      <td>Electronic data capture</td>\\n    </tr>\\n    <tr>\\n      <th>19</th>\\n      <td>EOT</td>\\n      <td>End of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>20</th>\\n      <td>FSH</td>\\n      <td>Follicle stimulating hormone</td>\\n    </tr>\\n    <tr>\\n      <th>21</th>\\n      <td>GCP</td>\\n      <td>Good clinical practices</td>\\n    </tr>\\n    <tr>\\n      <th>22</th>\\n      <td>GFR</td>\\n      <td>Glomerular filtration rate</td>\\n    </tr>\\n    <tr>\\n      <th>23</th>\\n      <td>GT</td>\\n      <td>genotype</td>\\n    </tr>\\n    <tr>\\n      <th>24</th>\\n      <td>h or hr</td>\\n      <td>hour(s)</td>\\n    </tr>\\n    <tr>\\n      <th>25</th>\\n      <td>HBsAg</td>\\n      <td>Hepatitis B surface antigen</td>\\n    </tr>\\n    <tr>\\n      <th>26</th>\\n      <td>HBV</td>\\n      <td>Hepatitis B virus</td>\\n    </tr>\\n    <tr>\\n      <th>27</th>\\n      <td>HCC</td>\\n      <td>Hepatocellular carcinoma</td>\\n    </tr>\\n    <tr>\\n      <th>28</th>\\n      <td>HCV</td>\\n      <td>Hepatitis C virus</td>\\n    </tr>\\n    <tr>\\n      <th>29</th>\\n      <td>HCV RNA</td>\\n      <td>Hepatitis C virus ribonucleic acid</td>\\n    </tr>\\n    <tr>\\n      <th>30</th>\\n      <td>Hgb</td>\\n      <td>Hemoglobin</td>\\n    </tr>\\n    <tr>\\n      <th>31</th>\\n      <td>HIV</td>\\n      <td>Human immunodeficiency virus</td>\\n    </tr>\\n    <tr>\\n      <th>32</th>\\n      <td>ICF</td>\\n      <td>Informed consent form</td>\\n    </tr>\\n    <tr>\\n      <th>33</th>\\n      <td>ICH</td>\\n      <td>International Conference on Harmonisation</td>\\n    </tr>\\n    <tr>\\n      <th>34</th>\\n      <td>IEC</td>\\n      <td>Independent Ethics Committee</td>\\n    </tr>\\n    <tr>\\n      <th>35</th>\\n      <td>IRB</td>\\n      <td>Institutional review board</td>\\n    </tr>\\n    <tr>\\n      <th>36</th>\\n      <td>IU</td>\\n      <td>International units</td>\\n    </tr>\\n    <tr>\\n      <th>37</th>\\n      <td>IWR</td>\\n      <td>Interactive Web Response</td>\\n    </tr>\\n    <tr>\\n      <th>38</th>\\n      <td>kg</td>\\n      <td>kilogram</td>\\n    </tr>\\n    <tr>\\n      <th>39</th>\\n      <td>LLOQ</td>\\n      <td>Lower limit of quantitation</td>\\n    </tr>\\n    <tr>\\n      <th>40</th>\\n      <td>MDRD</td>\\n      <td>Modification of Diet in Renal Disease</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u03b2-HCG\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"79a0e4cf-525d-4dd6-9975-a638efe5163d\\\",\\\"column_roi_id\\\":\\\"98c8b01e-437e-4965-8a42-20248cffacf4\\\",\\\"datacell_roi_id\\\":\\\"912bb3af-3023-40ae-ac56-2d0de8ca00f1\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Beta-human chorionic gonadotropin\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"79a0e4cf-525d-4dd6-9975-a638efe5163d\\\",\\\"column_roi_id\\\":\\\"1856f173-3d12-4064-8df8-e6d27eae4da2\\\",\\\"datacell_roi_id\\\":\\\"db564472-8a2d-43e6-ad38-03085e426720\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AE\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"291eb93d-7939-42f5-857a-c7d2a330a7aa\\\",\\\"column_roi_id\\\":\\\"70f18906-2dfb-487b-b88e-da821be3621d\\\",\\\"datacell_roi_id\\\":\\\"eb8d20e6-2493-4cf9-8871-8dd106c14b5e\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Adverse event\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"291eb93d-7939-42f5-857a-c7d2a330a7aa\\\",\\\"column_roi_id\\\":\\\"76243ea4-bae0-4e60-920a-1bfea849375e\\\",\\\"datacell_roi_id\\\":\\\"94b3a9d4-0710-442b-ac8f-062eea2839c6\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ALT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"f949cc36-9b3e-479c-9f0f-f2b696062e0d\\\",\\\"column_roi_id\\\":\\\"0d53bd02-ef66-4fd5-8d82-10f6921ea6e2\\\",\\\"datacell_roi_id\\\":\\\"4e7becaa-aca4-4a58-8d5f-29cb323b8a9f\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Alanine aminotransferase\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"f949cc36-9b3e-479c-9f0f-f2b696062e0d\\\",\\\"column_roi_id\\\":\\\"50005d0f-feab-4003-a944-5438f937006c\\\",\\\"datacell_roi_id\\\":\\\"0c317e00-86d9-4be4-bdaf-262651deaf0c\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AST\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"e8b43d01-c385-4449-880f-534c2b5b6341\\\",\\\"column_roi_id\\\":\\\"ccd5262a-e425-4d71-a3e3-2169f171ca21\\\",\\\"datacell_roi_id\\\":\\\"a578ffe2-66dc-45ab-afb9-f469f4bed16c\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Aspartate aminotransferase\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"e8b43d01-c385-4449-880f-534c2b5b6341\\\",\\\"column_roi_id\\\":\\\"66723892-ab23-4936-9cc2-8ba87a768959\\\",\\\"datacell_roi_id\\\":\\\"2961f18a-b4ef-4e22-a1e3-03dc670b6def\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AUC 0-t \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"dec9a868-2b71-46c0-a986-705ae1ebe465\\\",\\\"column_roi_id\\\":\\\"8226f884-e89f-4d39-968f-48776656fea3\\\",\\\"datacell_roi_id\\\":\\\"582d1598-2f59-4b46-a30d-d3cdcb5f8d84\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Area under the concentration-time curve from time zero to t\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"dec9a868-2b71-46c0-a986-705ae1ebe465\\\",\\\"column_roi_id\\\":\\\"19f842fb-0e80-47f9-9ae4-b3f2d87ea377\\\",\\\"datacell_roi_id\\\":\\\"31ce54fb-6e74-4e1a-abb3-524e8d94107a\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"BID\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"3fb0dc55-89af-40e2-97fd-f351ac7fbca2\\\",\\\"column_roi_id\\\":\\\"89943da7-cb68-4854-a4a9-caeb866371e4\\\",\\\"datacell_roi_id\\\":\\\"37875e3f-da94-4947-ac55-9c7869fe5709\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Bis in die or twice a day\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"3fb0dc55-89af-40e2-97fd-f351ac7fbca2\\\",\\\"column_roi_id\\\":\\\"be21b702-891e-4951-a0e7-fdbffdbfebef\\\",\\\"datacell_roi_id\\\":\\\"9e1316b1-4cbb-4ded-a6a4-5b9f5acc97e8\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"BMI\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"f32613fc-a7af-4651-8f8c-dd0322923bd6\\\",\\\"column_roi_id\\\":\\\"49cc6334-283b-41e6-8d39-b6982bcc34a2\\\",\\\"datacell_roi_id\\\":\\\"6e0cf3b3-18eb-4cea-9174-da7737b6c037\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Body mass index\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"f32613fc-a7af-4651-8f8c-dd0322923bd6\\\",\\\"column_roi_id\\\":\\\"e804821b-f209-4e5d-9b40-7def63f0580e\\\",\\\"datacell_roi_id\\\":\\\"335f083f-423d-4d2a-90d2-6c50032848e4\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"C 24h \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"48c7caee-8ade-4e80-a844-3931ca72676e\\\",\\\"column_roi_id\\\":\\\"7f95c862-50ae-4047-beca-5004df1f3c34\\\",\\\"datacell_roi_id\\\":\\\"dd076cea-5edf-4b03-829a-51f82f52d2da\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Drug concentration 24 h after dosing or the predose trough drug concentration following multiple dosing\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"48c7caee-8ade-4e80-a844-3931ca72676e\\\",\\\"column_roi_id\\\":\\\"55aa0fce-5653-43d8-8c5c-d9b1f8a33914\\\",\\\"datacell_roi_id\\\":\\\"68f32ffe-fef0-483e-8fea-03558fdc9eda\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"CK\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"10846bb5-2b2a-410d-bade-410b6713ed47\\\",\\\"column_roi_id\\\":\\\"0c66ef24-89b3-4668-850a-69a440420888\\\",\\\"datacell_roi_id\\\":\\\"ce3fb23b-c4f4-4a27-b719-a36f5ce37276\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Creatine kinase\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"10846bb5-2b2a-410d-bade-410b6713ed47\\\",\\\"column_roi_id\\\":\\\"c8121f76-86ea-4336-a551-de56d0f7bbe8\\\",\\\"datacell_roi_id\\\":\\\"635581c2-6c5b-4187-a112-e57087981015\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"C max \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"64fbe0fe-549e-46ca-ab88-cc466e3a7a80\\\",\\\"column_roi_id\\\":\\\"705bc9f4-0b39-4411-83e8-a4a7e8de94f3\\\",\\\"datacell_roi_id\\\":\\\"2e44b51b-79d0-4112-82db-b0b5b3750c6e\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Maximum observed drug concentration\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"64fbe0fe-549e-46ca-ab88-cc466e3a7a80\\\",\\\"column_roi_id\\\":\\\"1c7d9543-3087-4e5d-b4fe-6d2d7cae5321\\\",\\\"datacell_roi_id\\\":\\\"250f741a-c60f-42a0-aa07-8f1e80b4cf6a\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"CRF\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"d303dccb-00c4-4f67-9cec-c75f24f3b8ec\\\",\\\"column_roi_id\\\":\\\"27d8f404-87ff-4789-9b3f-564f95786d3a\\\",\\\"datacell_roi_id\\\":\\\"51538ab1-94d9-4205-8048-68161a8134f9\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Case report form\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"d303dccb-00c4-4f67-9cec-c75f24f3b8ec\\\",\\\"column_roi_id\\\":\\\"42d02525-988c-4be7-8ad1-a3a7c621b21f\\\",\\\"datacell_roi_id\\\":\\\"720403c5-8e89-4e26-8594-b5416efceadb\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"C trough \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"8fe02553-3312-492f-b277-7b31b6e5a7ee\\\",\\\"column_roi_id\\\":\\\"3f8b2462-68f4-41aa-bf9d-9e395c3cc0af\\\",\\\"datacell_roi_id\\\":\\\"74e5a947-41b0-4aa0-8c0b-0ebb9a70d18a\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Trough drug concentration\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"8fe02553-3312-492f-b277-7b31b6e5a7ee\\\",\\\"column_roi_id\\\":\\\"947c862c-d2f1-4c68-b048-57584bdf3635\\\",\\\"datacell_roi_id\\\":\\\"7338e41a-f01f-4870-8671-c658a304bda5\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"CYP3A4 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"adf0198d-fb00-481b-b202-4772089ab8a0\\\",\\\"column_roi_id\\\":\\\"0acb9c5f-888d-4d6d-b969-a7a2df0742d8\\\",\\\"datacell_roi_id\\\":\\\"3c3f6b41-d669-4598-b698-b9d5e01a1a63\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Cytochrome P450 3A4\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"adf0198d-fb00-481b-b202-4772089ab8a0\\\",\\\"column_roi_id\\\":\\\"cb1304c5-22f8-4c9a-9b31-55cdd8ecf11a\\\",\\\"datacell_roi_id\\\":\\\"26a348fc-3cdc-45c6-8811-7df63846454d\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"DAA\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"306be6d1-5172-4185-b7d6-c0dfbc947039\\\",\\\"column_roi_id\\\":\\\"f28015e5-8a9b-44ec-a573-8e142f54ac73\\\",\\\"datacell_roi_id\\\":\\\"9213d5b6-b76d-4d80-b1fb-475cb5562bcc\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Direct-acting antiviral\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"306be6d1-5172-4185-b7d6-c0dfbc947039\\\",\\\"column_roi_id\\\":\\\"66a91371-1c14-4924-ae2e-d88674557abc\\\",\\\"datacell_roi_id\\\":\\\"5d0c783e-636b-47ad-9a77-f4bd02857e04\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"DAIDS\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"553a252b-83b5-4aed-8b11-d6e236e0a0d3\\\",\\\"column_roi_id\\\":\\\"d3c802ce-627f-4180-aae5-740ddad3b4a4\\\",\\\"datacell_roi_id\\\":\\\"a50074ab-6644-4c12-9b45-c12681cb8648\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":15,\\\"standard_entity_name\\\":\\\"ANY: Organization\\\",\\\"subcategory\\\":\\\"ANY: Organization\\\",\\\"confidence\\\":87.0,\\\"text\\\":\\\"Division of AIDS\\\"}],\\\"content\\\":\\\"Division of AIDS\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"553a252b-83b5-4aed-8b11-d6e236e0a0d3\\\",\\\"column_roi_id\\\":\\\"d9c95198-2ed9-4d5e-ab6d-eb4e7184251c\\\",\\\"datacell_roi_id\\\":\\\"16049f18-1cd9-4cdf-9b2a-ba9770e79bdd\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"DSMB\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"7067a536-4562-41be-9368-bc8c91a8ee90\\\",\\\"column_roi_id\\\":\\\"0880b647-caf3-4a1c-a7ca-190c5dd699c3\\\",\\\"datacell_roi_id\\\":\\\"e9de188b-daf2-4302-9afb-1718c5b73531\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Data safety monitoring board\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"7067a536-4562-41be-9368-bc8c91a8ee90\\\",\\\"column_roi_id\\\":\\\"a8f3807d-bafc-47b9-9142-4072fb05242a\\\",\\\"datacell_roi_id\\\":\\\"4644bde4-d71c-433d-a97d-1be738b37fc5\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"EC\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"19789739-5c9a-4ab6-b786-76f9ccadaef7\\\",\\\"column_roi_id\\\":\\\"4e0761a4-4792-4872-a032-bf3b46079817\\\",\\\"datacell_roi_id\\\":\\\"76a3d976-2317-4f9d-a6e2-eb3ca6051896\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Ethics committee\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"19789739-5c9a-4ab6-b786-76f9ccadaef7\\\",\\\"column_roi_id\\\":\\\"1d15dae7-7bf1-4c7e-9769-54d3109738f1\\\",\\\"datacell_roi_id\\\":\\\"8dea64f1-825c-4263-9036-9f2e4aa7f6e4\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ECG\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"3c9f960a-448a-47ae-98d2-27535641fee1\\\",\\\"column_roi_id\\\":\\\"1ff1e6db-b3c5-4b4a-9dcd-d290b54852be\\\",\\\"datacell_roi_id\\\":\\\"b971c3cd-9fad-41b7-abae-2afc1f4cfdec\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Electrocardiogram\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"3c9f960a-448a-47ae-98d2-27535641fee1\\\",\\\"column_roi_id\\\":\\\"c18dbcce-c700-4c96-9d98-c4468be0bbb6\\\",\\\"datacell_roi_id\\\":\\\"2361f7fc-76db-44f6-b160-702a78c388f7\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"EDC\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"6a1ff99e-f5c8-4753-a05c-a097444cf542\\\",\\\"column_roi_id\\\":\\\"135ebf75-ce61-4383-8f27-dc4534d39d85\\\",\\\"datacell_roi_id\\\":\\\"00046ad4-7cc0-40a9-9ad3-6a1400a93dc3\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Electronic data capture\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"6a1ff99e-f5c8-4753-a05c-a097444cf542\\\",\\\"column_roi_id\\\":\\\"3dca56a3-2896-430f-a745-c1f397117816\\\",\\\"datacell_roi_id\\\":\\\"ae810e55-c2b2-4afe-8913-1e76866f7e2b\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"8e7e8eed-1b16-47f9-8913-c1c32d00c083\\\",\\\"column_roi_id\\\":\\\"fc252338-0e9b-4add-9796-2e1c1ad10572\\\",\\\"datacell_roi_id\\\":\\\"73937c69-9a69-4a52-abb6-fb3ad337492c\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"End of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"8e7e8eed-1b16-47f9-8913-c1c32d00c083\\\",\\\"column_roi_id\\\":\\\"d79cdbc9-8db1-4511-80a8-268bb9be5d88\\\",\\\"datacell_roi_id\\\":\\\"0084203b-2d33-41eb-8805-77ea9b6ce60d\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"FSH\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"317da73c-016d-4f99-a974-05ce16b8ec39\\\",\\\"column_roi_id\\\":\\\"12a49c58-4375-4634-aa1c-5c771e53078b\\\",\\\"datacell_roi_id\\\":\\\"26bf4644-e12d-437b-add2-c6d854daa857\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Follicle stimulating hormone\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"317da73c-016d-4f99-a974-05ce16b8ec39\\\",\\\"column_roi_id\\\":\\\"6549a618-532b-4deb-afc9-ee89fa762f91\\\",\\\"datacell_roi_id\\\":\\\"3ec602a4-2f98-4de4-a2f3-68b1ab66dd39\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"GCP\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"0cea4778-6211-4f96-b83c-d0a49fbbbecb\\\",\\\"column_roi_id\\\":\\\"e61a1fae-280e-434e-9147-993d672bebe1\\\",\\\"datacell_roi_id\\\":\\\"9f150db4-3419-4077-a455-eb4549e7ce15\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Good clinical practices\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"0cea4778-6211-4f96-b83c-d0a49fbbbecb\\\",\\\"column_roi_id\\\":\\\"28e20a24-3fa7-4b6f-839f-753e71aadda1\\\",\\\"datacell_roi_id\\\":\\\"4a53747b-f9b4-4577-b1f4-318fd8e8fc8e\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"GFR\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"01d0b928-5576-4561-ac5e-fc72a9981970\\\",\\\"column_roi_id\\\":\\\"42aab8ba-e54b-4d48-b005-43e5c3ff243f\\\",\\\"datacell_roi_id\\\":\\\"b4a36769-87c1-4251-92de-e21e44c19ef1\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Glomerular filtration rate\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"01d0b928-5576-4561-ac5e-fc72a9981970\\\",\\\"column_roi_id\\\":\\\"51c0d58b-39d1-4132-9224-2337c4992189\\\",\\\"datacell_roi_id\\\":\\\"180da885-0141-4586-bad2-c9bc1d69f3db\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"GT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"b18ef370-f31f-4387-808b-29330c4068ff\\\",\\\"column_roi_id\\\":\\\"afa8306b-5d82-4d30-b3d4-f8fe34a4d750\\\",\\\"datacell_roi_id\\\":\\\"3d2b144c-4e31-415c-9dae-764b1c9a01f2\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"genotype\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"b18ef370-f31f-4387-808b-29330c4068ff\\\",\\\"column_roi_id\\\":\\\"d4597d2d-a749-47b9-8dce-b374e29bc6d8\\\",\\\"datacell_roi_id\\\":\\\"b0eb1aab-b1d1-4b6d-aa44-301a44f70fe2\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"h or hr\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"e63ef847-345e-49ca-819f-9f199f362f2d\\\",\\\"column_roi_id\\\":\\\"abf0f1de-accd-44ba-8a8f-29ea16b685cf\\\",\\\"datacell_roi_id\\\":\\\"f9eade74-8333-4841-8c1d-0dafaca8afbf\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"hour(s)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"e63ef847-345e-49ca-819f-9f199f362f2d\\\",\\\"column_roi_id\\\":\\\"6ec190ff-3499-424b-8081-92c544cf165d\\\",\\\"datacell_roi_id\\\":\\\"b43b8565-01ed-4e5b-83b5-1f8c6c6c1c17\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HBsAg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"9ce6c5ea-2b54-4ee9-bd74-5a0ddecd7b77\\\",\\\"column_roi_id\\\":\\\"1a2f9e72-fa15-4894-b332-6aa708d9b5d7\\\",\\\"datacell_roi_id\\\":\\\"7106b691-ff63-45bd-a9d0-51a741686136\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hepatitis B surface antigen\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"9ce6c5ea-2b54-4ee9-bd74-5a0ddecd7b77\\\",\\\"column_roi_id\\\":\\\"044e5749-3809-4818-a857-345179731ca8\\\",\\\"datacell_roi_id\\\":\\\"21fc67eb-193e-4b72-a8d0-6043f398d33a\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HBV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"61aee765-a8f6-4368-9f1f-2db60d179702\\\",\\\"column_roi_id\\\":\\\"1a4661aa-78ab-42b3-b81f-63d039b681bd\\\",\\\"datacell_roi_id\\\":\\\"406722a8-8b99-4692-8505-a3a07704f754\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hepatitis B virus\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"61aee765-a8f6-4368-9f1f-2db60d179702\\\",\\\"column_roi_id\\\":\\\"28a50faa-7020-468b-a4b5-5b82c5da26c0\\\",\\\"datacell_roi_id\\\":\\\"5f83a540-f4e9-479b-925e-03a29c858a1d\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCC\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"be7ddea8-6c88-425c-a5f8-a5220340fb7e\\\",\\\"column_roi_id\\\":\\\"db1e617a-b4d3-4d88-b624-d1f4c699ef0b\\\",\\\"datacell_roi_id\\\":\\\"5a62d1e6-78b4-4d2a-86b2-6a598bd60359\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hepatocellular carcinoma\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"be7ddea8-6c88-425c-a5f8-a5220340fb7e\\\",\\\"column_roi_id\\\":\\\"7faccf49-edd9-4fb2-82b7-6d473342f30c\\\",\\\"datacell_roi_id\\\":\\\"5596dd1b-386b-4ece-adf7-2e679b0a1bd2\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"5a1c2442-c710-43eb-8386-f0e852f059ca\\\",\\\"column_roi_id\\\":\\\"5a3a787d-99af-48f4-948e-60aa1c10c127\\\",\\\"datacell_roi_id\\\":\\\"cf890b2e-525d-4413-9c7f-0294bdb1468e\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hepatitis C virus\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"5a1c2442-c710-43eb-8386-f0e852f059ca\\\",\\\"column_roi_id\\\":\\\"352b1c3d-a822-444d-92a3-a2dc006d2adb\\\",\\\"datacell_roi_id\\\":\\\"7e86c153-255f-4fde-b3fa-df5cefd9300b\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV RNA\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"b63be572-359c-4428-a234-532ee7781ffd\\\",\\\"column_roi_id\\\":\\\"12222fa8-99bb-4817-a4fd-d12a89562e49\\\",\\\"datacell_roi_id\\\":\\\"4aec0c17-bd20-45c5-bef0-aa7e25e315e1\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hepatitis C virus ribonucleic acid\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"b63be572-359c-4428-a234-532ee7781ffd\\\",\\\"column_roi_id\\\":\\\"dd55719b-eae1-4fee-badd-578232643eaa\\\",\\\"datacell_roi_id\\\":\\\"5ef7e290-5aa7-433d-bf5f-7215d931efc6\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hgb\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"cced7a51-50aa-4ec2-8875-69a79e0859d5\\\",\\\"column_roi_id\\\":\\\"f1e5f9d7-5def-4c71-99fc-44197ebde10e\\\",\\\"datacell_roi_id\\\":\\\"b225e52e-80d9-455e-987c-e2be8e4710dc\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hemoglobin\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"cced7a51-50aa-4ec2-8875-69a79e0859d5\\\",\\\"column_roi_id\\\":\\\"c7960345-3736-4c04-80ec-fbb7d3945dfc\\\",\\\"datacell_roi_id\\\":\\\"8ec11302-13c2-41f9-bcb9-2610144fcd20\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HIV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"bceaab4e-8297-4f09-add8-69982834613a\\\",\\\"column_roi_id\\\":\\\"9ebbf818-2131-449d-b458-a040b320edcd\\\",\\\"datacell_roi_id\\\":\\\"84367e79-d02f-4d5d-b64d-51e2cf73c4d3\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Human immunodeficiency virus\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"bceaab4e-8297-4f09-add8-69982834613a\\\",\\\"column_roi_id\\\":\\\"0d5a1f0f-3c9c-475f-886e-1f7a2579d6a2\\\",\\\"datacell_roi_id\\\":\\\"b8207ac4-b3f2-4326-9a55-a699c25a4dfe\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ICF\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"4a2ade4e-7c04-4d83-9de7-acedb0cdb1c3\\\",\\\"column_roi_id\\\":\\\"1af6b898-9065-4958-9608-7525180546c4\\\",\\\"datacell_roi_id\\\":\\\"892e6e41-88e1-471f-8ec8-66e07efc3468\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Informed consent form\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"4a2ade4e-7c04-4d83-9de7-acedb0cdb1c3\\\",\\\"column_roi_id\\\":\\\"dc02440e-703b-4f7c-8b6f-518b5a021263\\\",\\\"datacell_roi_id\\\":\\\"41046361-0912-495a-a621-4c51eb6dee5f\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ICH\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"33e7078d-f5f5-4d15-b8d6-33842d1c4900\\\",\\\"column_roi_id\\\":\\\"04ade669-f4ff-4096-aec3-aabf55a907a6\\\",\\\"datacell_roi_id\\\":\\\"39fb33a7-65d8-4be4-b14e-eac5c0522589\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"International Conference on Harmonisation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"33e7078d-f5f5-4d15-b8d6-33842d1c4900\\\",\\\"column_roi_id\\\":\\\"3cd06400-f816-415b-87af-d695465e71c4\\\",\\\"datacell_roi_id\\\":\\\"364212f7-4a44-495c-9d97-079cefe1e884\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IEC \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"b89b6b4f-a2bd-4826-bd04-de36981977de\\\",\\\"column_roi_id\\\":\\\"dad71149-977b-4d57-9bae-75eb0c27e921\\\",\\\"datacell_roi_id\\\":\\\"7165af37-45a6-4269-96b9-8687415c0750\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Independent Ethics Committee\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"b89b6b4f-a2bd-4826-bd04-de36981977de\\\",\\\"column_roi_id\\\":\\\"5b3b9d83-fb69-4258-a9d6-c07cb685e6d1\\\",\\\"datacell_roi_id\\\":\\\"04e4c3e0-8faf-4e92-a8b2-570d8c29f8f4\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IRB\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"9db1509f-cc80-4b48-a7ca-7b404146e158\\\",\\\"column_roi_id\\\":\\\"a7066d0e-aa0a-46c9-b5d1-4741cf3ffcd5\\\",\\\"datacell_roi_id\\\":\\\"c27df8ce-bf3b-4c8f-9b0a-d18475fac69c\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Institutional review board\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"9db1509f-cc80-4b48-a7ca-7b404146e158\\\",\\\"column_roi_id\\\":\\\"2ac65c83-8fe0-455a-8c44-adef3d064725\\\",\\\"datacell_roi_id\\\":\\\"2dde3cc7-d08a-4599-aa44-dd884198cc83\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IU\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"19bac5e8-768f-470a-b19b-106cb5acd41d\\\",\\\"column_roi_id\\\":\\\"16bbb12f-bf5b-401f-8918-880555540447\\\",\\\"datacell_roi_id\\\":\\\"ec3ae1dc-4374-4057-972a-7232ff6cb5b4\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"International units\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"19bac5e8-768f-470a-b19b-106cb5acd41d\\\",\\\"column_roi_id\\\":\\\"e954ef1f-8841-4c56-a149-359722e9c903\\\",\\\"datacell_roi_id\\\":\\\"a0424083-9214-4383-89f9-cc636c970284\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IWR\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"cb8717ce-d54d-4930-8f49-f41cd8dd7eaa\\\",\\\"column_roi_id\\\":\\\"a86440fe-ac28-49d5-858e-fed5a650e330\\\",\\\"datacell_roi_id\\\":\\\"6e10c810-142a-4083-baed-2a66c503e8c0\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Interactive Web Response\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"cb8717ce-d54d-4930-8f49-f41cd8dd7eaa\\\",\\\"column_roi_id\\\":\\\"b7183c5c-6ea5-4893-93d4-1c1381dc3a72\\\",\\\"datacell_roi_id\\\":\\\"8954c4fd-dce3-4a68-aaff-9b962eeb2430\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"kg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"35364411-ff3d-4ddf-a227-7f9b5e3abcee\\\",\\\"column_roi_id\\\":\\\"dd758713-8e08-4aae-9d27-30e382c61653\\\",\\\"datacell_roi_id\\\":\\\"c773247e-2825-4ef6-b6ea-8e1191fdddd6\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"kilogram\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"35364411-ff3d-4ddf-a227-7f9b5e3abcee\\\",\\\"column_roi_id\\\":\\\"3cf2d9dc-1034-4783-bd5f-5027e7927d4f\\\",\\\"datacell_roi_id\\\":\\\"ff47c387-624f-47f7-a0ce-89d7de4af18a\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"LLOQ\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"99e98645-22e4-4e81-b77a-68e56c30e621\\\",\\\"column_roi_id\\\":\\\"ca294055-23b4-43c5-8133-1c5b2c6224a2\\\",\\\"datacell_roi_id\\\":\\\"26fb30ff-3b1f-4227-98ee-0076acd6ec6a\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Lower limit of quantitation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"99e98645-22e4-4e81-b77a-68e56c30e621\\\",\\\"column_roi_id\\\":\\\"32af5fcd-96b1-4514-a7a5-940ea144a100\\\",\\\"datacell_roi_id\\\":\\\"5ba36d0e-7b55-4c30-8675-67bf02bfb99e\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"MDRD\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"1c3fcea4-206d-453a-bc94-c2695470c737\\\",\\\"column_roi_id\\\":\\\"e42a84f7-0853-4084-af88-86c606039b16\\\",\\\"datacell_roi_id\\\":\\\"b9555023-e863-48a9-a8a7-5f25953119e2\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Modification of Diet in Renal Disease\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"21e6da0c-d979-43a0-9fe1-1f425742e558\\\",\\\"row_roi_id\\\":\\\"1c3fcea4-206d-453a-bc94-c2695470c737\\\",\\\"column_roi_id\\\":\\\"2edabd93-f60f-4869-bfa8-cbdbdb5ea2f6\\\",\\\"datacell_roi_id\\\":\\\"9bccef0d-9a80-43c4-aa32-db8a18afd18e\\\"},\\\"table_index\\\":1.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"6\", \"TableIndex\": \"2.0\", \"TableName\": \"List of abbreviations\", \"Header\": []}, {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"912bb3af-3023-40ae-ac56-2d0de8ca00f1\", \"childbox\": \"6d241209-b7e1-429c-ab8f-6e98eb979c30\", \"subtext\": \"7f851303-3783-47bf-b364-10d63cccc6a6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of abbreviations\", \"\", \"1\", 178, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"365cdf03-c802-4778-b5d3-d5c4bd8398db\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"List of abbreviations\", \"\", \"1\", 179, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>MedDRA</td>\\n      <td>Medical Dictionary for Regulatory Activities</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>mg</td>\\n      <td>milligram</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>min</td>\\n      <td>minute(s)</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>mL</td>\\n      <td>milliliter</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>ms</td>\\n      <td>millisecond</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>NS5A</td>\\n      <td>Nonstructural protein 5A</td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>PD</td>\\n      <td>Pharmacodynamics</td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>Peg-IFN</td>\\n      <td>Pegylated interferon</td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td>P-gp</td>\\n      <td>permeability glycoprotein (transporter)</td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>pH</td>\\n      <td>Measure of acidity or basicity of an aqueous solution</td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>PK</td>\\n      <td>Pharmacokinetic(s)</td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td>QD</td>\\n      <td>Quaque die or once a day</td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>QT</td>\\n      <td>QT interval</td>\\n    </tr>\\n    <tr>\\n      <th>13</th>\\n      <td>QTcF</td>\\n      <td>QT interval corrected for heart rate using Fridericia's formula</td>\\n    </tr>\\n    <tr>\\n      <th>14</th>\\n      <td>RBV</td>\\n      <td>Ribavirin</td>\\n    </tr>\\n    <tr>\\n      <th>15</th>\\n      <td>REB</td>\\n      <td>Research ethics board</td>\\n    </tr>\\n    <tr>\\n      <th>16</th>\\n      <td>RNA</td>\\n      <td>Ribonucleic acid</td>\\n    </tr>\\n    <tr>\\n      <th>17</th>\\n      <td>SAE</td>\\n      <td>Serious adverse event</td>\\n    </tr>\\n    <tr>\\n      <th>18</th>\\n      <td>Samatasvir</td>\\n      <td>IDX719</td>\\n    </tr>\\n    <tr>\\n      <th>19</th>\\n      <td>SAP</td>\\n      <td>Statistical analysis plan</td>\\n    </tr>\\n    <tr>\\n      <th>20</th>\\n      <td>SD</td>\\n      <td>Standard deviation</td>\\n    </tr>\\n    <tr>\\n      <th>21</th>\\n      <td>SEM</td>\\n      <td>Standard error of the mean</td>\\n    </tr>\\n    <tr>\\n      <th>22</th>\\n      <td>SVR</td>\\n      <td>Sustained virologic response</td>\\n    </tr>\\n    <tr>\\n      <th>23</th>\\n      <td>T max</td>\\n      <td>Time to maximum drug concentration (C max )</td>\\n    </tr>\\n    <tr>\\n      <th>24</th>\\n      <td>TSH</td>\\n      <td>Thyroid stimulating hormone</td>\\n    </tr>\\n    <tr>\\n      <th>25</th>\\n      <td>ULN</td>\\n      <td>Upper limit of normal</td>\\n    </tr>\\n    <tr>\\n      <th>26</th>\\n      <td>WBC</td>\\n      <td>White blood cell</td>\\n    </tr>\\n    <tr>\\n      <th>27</th>\\n      <td>WHO</td>\\n      <td>World Health Organization</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"MedDRA\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"162a68d8-6a2f-4011-9300-0af57a73c871\\\",\\\"column_roi_id\\\":\\\"1aa60c76-e178-4b0e-b190-500fb4442dbc\\\",\\\"datacell_roi_id\\\":\\\"8c405503-2d85-41d5-bb48-2c8e5986086b\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Medical Dictionary for Regulatory Activities\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"162a68d8-6a2f-4011-9300-0af57a73c871\\\",\\\"column_roi_id\\\":\\\"45e9b313-dc86-4b60-9ff1-c40c152c71e7\\\",\\\"datacell_roi_id\\\":\\\"756b4077-811f-4863-813a-7c7ae8e2fb28\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"mg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"9ef620c6-1ab9-4f74-9287-91e7994f7587\\\",\\\"column_roi_id\\\":\\\"b575f43a-c53d-44a9-a19d-56fcf4f2fa18\\\",\\\"datacell_roi_id\\\":\\\"e885d894-8c91-4390-80e5-1e9ab57495e7\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"milligram\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"9ef620c6-1ab9-4f74-9287-91e7994f7587\\\",\\\"column_roi_id\\\":\\\"f6e2a867-a748-419d-b348-81760b873535\\\",\\\"datacell_roi_id\\\":\\\"d910e907-3599-4381-a3b8-1c0a4f485bde\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"min\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"776e9053-79e1-4d46-9ef9-7ab15e24bd75\\\",\\\"column_roi_id\\\":\\\"c475e6cb-1f6c-4463-aff3-6efce8c052cc\\\",\\\"datacell_roi_id\\\":\\\"e2723752-d815-4629-ac35-66dbd05b9f6a\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"minute(s)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"776e9053-79e1-4d46-9ef9-7ab15e24bd75\\\",\\\"column_roi_id\\\":\\\"296f04b2-841c-49d2-bc4c-a6bdc645cc51\\\",\\\"datacell_roi_id\\\":\\\"276d3988-442c-4be7-9991-9cfc1c76a8e8\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"mL\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"e9fa639f-4747-4932-96e7-d31d4a13da10\\\",\\\"column_roi_id\\\":\\\"0e9917cd-6439-42df-829c-b85d24070ffd\\\",\\\"datacell_roi_id\\\":\\\"e653f2fa-c008-4179-8ae4-9dec5966a61f\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"milliliter\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"e9fa639f-4747-4932-96e7-d31d4a13da10\\\",\\\"column_roi_id\\\":\\\"ccc3aeda-f027-4dae-bd35-ead5633f9bbd\\\",\\\"datacell_roi_id\\\":\\\"84fb7755-a168-4e0a-8e73-5410544f4d20\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ms\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"3f1c59ea-7ce3-458e-8565-81dd9a43a53d\\\",\\\"column_roi_id\\\":\\\"709619f5-7e8d-459f-bd88-2238b22bcef7\\\",\\\"datacell_roi_id\\\":\\\"3776166d-ddb2-4690-9af4-917ecc7a1a20\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"millisecond\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"3f1c59ea-7ce3-458e-8565-81dd9a43a53d\\\",\\\"column_roi_id\\\":\\\"5df38a5c-2370-4821-90b9-69f7a06a2022\\\",\\\"datacell_roi_id\\\":\\\"30d7ada5-6e82-403e-916e-89205321d417\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"NS5A\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"4a1b3721-693b-4b8c-baf5-54c452a3cb2d\\\",\\\"column_roi_id\\\":\\\"4b55c6e3-ae86-4de3-8db1-ae6126bfb381\\\",\\\"datacell_roi_id\\\":\\\"83a859f0-c287-4c88-bc11-cacc3b8ac1e1\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Nonstructural protein 5A\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"4a1b3721-693b-4b8c-baf5-54c452a3cb2d\\\",\\\"column_roi_id\\\":\\\"55c403d7-8475-4603-b501-09338caa08ed\\\",\\\"datacell_roi_id\\\":\\\"524e7d3f-0714-4c75-a6ca-350cc69a917e\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"PD\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"4805060d-c59e-4ce7-aafc-17eb6fcb1c3d\\\",\\\"column_roi_id\\\":\\\"abbbfb9d-2ba5-4d13-a973-97cdac80896f\\\",\\\"datacell_roi_id\\\":\\\"e45853a3-a6e4-42c3-8a0a-d08a5efb67cd\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pharmacodynamics\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"4805060d-c59e-4ce7-aafc-17eb6fcb1c3d\\\",\\\"column_roi_id\\\":\\\"d66a1518-c73b-41c5-8bbb-bdb383c0ee18\\\",\\\"datacell_roi_id\\\":\\\"9e56b7af-27ad-4bbf-a312-7c829b0efcd0\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Peg-IFN\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"71a125cf-2611-46db-8f19-cd2d22bd74d9\\\",\\\"column_roi_id\\\":\\\"a1d00366-8226-4828-8cc8-73242f5865f4\\\",\\\"datacell_roi_id\\\":\\\"219edc51-3b69-456d-bd5d-ffac29beff34\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pegylated interferon\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"71a125cf-2611-46db-8f19-cd2d22bd74d9\\\",\\\"column_roi_id\\\":\\\"59a90df4-7191-479c-954c-da9805181f31\\\",\\\"datacell_roi_id\\\":\\\"837be3d1-e87f-4983-b7d0-7a632adeb16b\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"P-gp\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"e33200cf-dd97-4002-8208-e82a04120139\\\",\\\"column_roi_id\\\":\\\"b203ba47-0fa0-4e27-b19f-e80918cd7ea5\\\",\\\"datacell_roi_id\\\":\\\"2da0cc3e-1de4-408b-b18a-4c7e0cf566ca\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"permeability glycoprotein (transporter)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"e33200cf-dd97-4002-8208-e82a04120139\\\",\\\"column_roi_id\\\":\\\"a704b17f-6cd6-458b-bc5c-9d5ed6feca7b\\\",\\\"datacell_roi_id\\\":\\\"035038af-7ff8-44c2-99e9-0b8145e77579\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"pH\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"d5756270-8512-4117-aec5-2500186da07b\\\",\\\"column_roi_id\\\":\\\"b3b03b72-e05d-4ba8-ac35-117b9cdb0d78\\\",\\\"datacell_roi_id\\\":\\\"7d491cc8-3eea-43b6-bec1-dee579ca799a\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Measure of acidity or basicity of an aqueous solution\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"d5756270-8512-4117-aec5-2500186da07b\\\",\\\"column_roi_id\\\":\\\"de6cbc87-ca00-4f36-9c4d-f05f21a649d8\\\",\\\"datacell_roi_id\\\":\\\"907b4f7c-7fe4-4150-985a-f787fc203c37\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"PK\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"b9ea1dd0-a018-47fc-9a8b-67e13d32af0e\\\",\\\"column_roi_id\\\":\\\"2a40ee3e-dda2-4143-a62c-ef52a945ae0b\\\",\\\"datacell_roi_id\\\":\\\"ae1d5cde-b5f9-46e0-89fe-83762197f518\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pharmacokinetic(s)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"b9ea1dd0-a018-47fc-9a8b-67e13d32af0e\\\",\\\"column_roi_id\\\":\\\"7a49fec7-a93c-49d0-92a9-fbde689055d7\\\",\\\"datacell_roi_id\\\":\\\"cc062fa9-a08d-4e70-9f83-c965693d3266\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"QD\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"45470159-26bd-434f-9a62-1e30f17a6b53\\\",\\\"column_roi_id\\\":\\\"a6f9d62f-fd1c-42f9-8bc0-e25c0da3aa67\\\",\\\"datacell_roi_id\\\":\\\"f68b84d4-ff2e-41d1-b6a3-c752714f28e4\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Quaque die or once a day\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"45470159-26bd-434f-9a62-1e30f17a6b53\\\",\\\"column_roi_id\\\":\\\"01f9c1b8-812d-4546-bd4d-0aaeaba7bad8\\\",\\\"datacell_roi_id\\\":\\\"e27d681b-6303-4734-8a38-15a0fd71028c\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"QT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"3ec25440-bef0-4bd5-be74-cd85614a26b1\\\",\\\"column_roi_id\\\":\\\"075dc83e-2816-452a-ac6b-9f1fd6c81f46\\\",\\\"datacell_roi_id\\\":\\\"76a1ebda-72c3-4976-917f-227b8040bd95\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"QT interval\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"3ec25440-bef0-4bd5-be74-cd85614a26b1\\\",\\\"column_roi_id\\\":\\\"aa8868fb-136b-4397-9a12-00d05ca92695\\\",\\\"datacell_roi_id\\\":\\\"d50ca0dd-724c-49aa-91c4-6fae2ded80a1\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"QTcF\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"9870cb7c-e9c8-47be-923e-9c76d382bb73\\\",\\\"column_roi_id\\\":\\\"bd2c74ff-8017-4909-9cac-4f6f001474ba\\\",\\\"datacell_roi_id\\\":\\\"061f46e5-0fde-4e25-a1f2-a6e47f70a77c\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"QT interval corrected for heart rate using Fridericia's formula\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"9870cb7c-e9c8-47be-923e-9c76d382bb73\\\",\\\"column_roi_id\\\":\\\"6494a906-4128-4200-afe9-1b4d60c1a2ea\\\",\\\"datacell_roi_id\\\":\\\"e0ed8d96-5c59-4782-b0dd-ea1bb7429a0d\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"RBV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"226183e9-0150-4efe-8adf-c7f886fefa37\\\",\\\"column_roi_id\\\":\\\"92e922d6-f636-441c-8067-2e8dc3901515\\\",\\\"datacell_roi_id\\\":\\\"242c4cf0-7344-4471-ac6c-1eb1ef611932\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Ribavirin\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"226183e9-0150-4efe-8adf-c7f886fefa37\\\",\\\"column_roi_id\\\":\\\"4a39a039-7244-418d-956a-589e7631369e\\\",\\\"datacell_roi_id\\\":\\\"449d05c7-cd9e-442c-8672-4df40b8346aa\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"REB\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"b21f0513-a726-4d83-98f9-b25f66250f00\\\",\\\"column_roi_id\\\":\\\"f6d3e8a0-84d2-4c6e-a7e6-2def9e962978\\\",\\\"datacell_roi_id\\\":\\\"cc3aa6e3-4b0c-4f1d-a788-84749e725652\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Research ethics board\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"b21f0513-a726-4d83-98f9-b25f66250f00\\\",\\\"column_roi_id\\\":\\\"4180ae99-e034-4e95-a9e6-55fd3f50bb35\\\",\\\"datacell_roi_id\\\":\\\"75878103-2f03-4cb9-a781-94bbf750e67b\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"RNA\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"815564e7-19fe-4c6f-80b4-56b28ac23d5c\\\",\\\"column_roi_id\\\":\\\"162f9e86-7e5e-4572-9bd2-04e3a26b83be\\\",\\\"datacell_roi_id\\\":\\\"18001def-3e79-4868-8bbc-c51356511f02\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Ribonucleic acid\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"815564e7-19fe-4c6f-80b4-56b28ac23d5c\\\",\\\"column_roi_id\\\":\\\"186dc5db-1ded-45c8-b7e4-d3daeed98e7b\\\",\\\"datacell_roi_id\\\":\\\"be6dd24f-d4e8-4c7d-98c7-b898c4bf18d6\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"343f995b-e3b4-4492-8aed-758bc81a2c0b\\\",\\\"column_roi_id\\\":\\\"09d989b7-a608-4d02-adf6-112e1f152bf8\\\",\\\"datacell_roi_id\\\":\\\"fa381612-15bc-4d6c-8e3e-e0df75587cdf\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Serious adverse event\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"343f995b-e3b4-4492-8aed-758bc81a2c0b\\\",\\\"column_roi_id\\\":\\\"5a2ba40e-af1c-41b2-be89-25758a570e55\\\",\\\"datacell_roi_id\\\":\\\"7a92407e-b7fc-41bb-b38e-976b01113561\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"}],\\\"content\\\":\\\"Samatasvir\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"ca6ab858-7e3b-49bd-9bed-0cd577fbaa6d\\\",\\\"column_roi_id\\\":\\\"4454db11-93da-4af4-baf6-2e5406e7ddca\\\",\\\"datacell_roi_id\\\":\\\"be97d2ba-1e00-4e0c-9588-18f976435011\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":5,\\\"standard_entity_name\\\":\\\"IDX719\\\",\\\"subcategory\\\":\\\"IDX719\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX719\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":5,\\\"standard_entity_name\\\":\\\"IDX719\\\",\\\"subcategory\\\":\\\"IDX719\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX719\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":5,\\\"standard_entity_name\\\":\\\"IDX719\\\",\\\"subcategory\\\":\\\"IDX719\\\",\\\"confidence\\\":87.0,\\\"text\\\":\\\"IDX719\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":5,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":87.0,\\\"text\\\":\\\"IDX719\\\"}],\\\"content\\\":\\\"IDX719\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"ca6ab858-7e3b-49bd-9bed-0cd577fbaa6d\\\",\\\"column_roi_id\\\":\\\"4fb5453c-58d7-4f34-98bb-8798718df2d0\\\",\\\"datacell_roi_id\\\":\\\"87516147-1ab6-4af5-8bb3-badd90759f9c\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAP\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"029328bf-c18c-48c0-8e24-4f1fe19fd361\\\",\\\"column_roi_id\\\":\\\"940eefb5-5cff-4a99-81e9-14a332f78313\\\",\\\"datacell_roi_id\\\":\\\"6c784ba7-a387-4268-b5c8-264830ebb2d5\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Statistical analysis plan\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"029328bf-c18c-48c0-8e24-4f1fe19fd361\\\",\\\"column_roi_id\\\":\\\"37407525-33ba-4b4b-b8de-1c7abceccc22\\\",\\\"datacell_roi_id\\\":\\\"4baac622-acd0-4db1-812b-3ae4baf40574\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SD\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"c4740eaa-e72c-4ceb-97fc-a21ac8500268\\\",\\\"column_roi_id\\\":\\\"741652c3-33ef-4903-8e2f-309e39aa58db\\\",\\\"datacell_roi_id\\\":\\\"796b432b-82cc-4fe6-88cf-c5320716dec7\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Standard deviation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"c4740eaa-e72c-4ceb-97fc-a21ac8500268\\\",\\\"column_roi_id\\\":\\\"c558d7a8-a70e-4481-8243-20875aaee797\\\",\\\"datacell_roi_id\\\":\\\"50805816-06f4-47c9-b0ee-441528cbeaad\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SEM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"d3c82096-fa7c-48d9-9e16-8efa1867ac4a\\\",\\\"column_roi_id\\\":\\\"5979dcef-d424-433f-9bcf-742c857e92c8\\\",\\\"datacell_roi_id\\\":\\\"54c23549-ceae-4ee1-b530-6de629de6944\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Standard error of the mean\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"d3c82096-fa7c-48d9-9e16-8efa1867ac4a\\\",\\\"column_roi_id\\\":\\\"5e88434f-9c0a-4a2f-94ce-2fa7b64a18e2\\\",\\\"datacell_roi_id\\\":\\\"a9c1b61d-3929-4c7c-a1f3-851557ff84a6\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SVR\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"813de3e8-af83-4cec-96be-7f67e6f5b2a3\\\",\\\"column_roi_id\\\":\\\"0277e31b-e0f8-4025-a12a-126f9116a80a\\\",\\\"datacell_roi_id\\\":\\\"db7b2a8a-0d97-4f1d-8aab-484c4974aa7a\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Sustained virologic response\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"813de3e8-af83-4cec-96be-7f67e6f5b2a3\\\",\\\"column_roi_id\\\":\\\"260ae328-5b94-4bb1-a136-a314525dd584\\\",\\\"datacell_roi_id\\\":\\\"7d3a8837-ab6a-4afb-bda7-bf898fb0d0ff\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"T max \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"6b727215-4037-4042-8e39-2be5c4ef2f72\\\",\\\"column_roi_id\\\":\\\"88d8559a-b068-4ab3-bd74-a79585696e65\\\",\\\"datacell_roi_id\\\":\\\"82e3e4ed-1e95-4e12-9e5b-a30cda67f7ad\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Time to maximum drug concentration (C max )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"6b727215-4037-4042-8e39-2be5c4ef2f72\\\",\\\"column_roi_id\\\":\\\"9a732a96-24c5-4980-8bf1-8f9b402913e9\\\",\\\"datacell_roi_id\\\":\\\"62814663-9a80-4ed7-83f6-c0fd8fb64d91\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"TSH\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"8dc1eeee-ca39-478e-8278-8f795f85b65d\\\",\\\"column_roi_id\\\":\\\"96632b32-4e0d-4a0c-8fb3-1435477e6b2f\\\",\\\"datacell_roi_id\\\":\\\"c31988e7-206d-4e18-a253-76f6a80b4d7a\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Thyroid stimulating hormone\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"8dc1eeee-ca39-478e-8278-8f795f85b65d\\\",\\\"column_roi_id\\\":\\\"e2586019-716d-4425-b469-4580f23bc270\\\",\\\"datacell_roi_id\\\":\\\"c20968aa-d55d-4bb5-895f-159efff8e659\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ULN\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"a4c827af-7e7e-4ae6-91ef-848184eb0ab9\\\",\\\"column_roi_id\\\":\\\"14a56111-67b6-40c6-a566-a4b5ed4a512b\\\",\\\"datacell_roi_id\\\":\\\"efbbe9d2-0602-4db6-9ba9-205828617a2a\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Upper limit of normal\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"a4c827af-7e7e-4ae6-91ef-848184eb0ab9\\\",\\\"column_roi_id\\\":\\\"ffcc8f12-8b63-45a5-b718-084e2785dd8f\\\",\\\"datacell_roi_id\\\":\\\"8215747c-eaad-4432-b850-c09ee3364401\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"WBC\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"36edd682-85bf-4294-aab5-c6bae7d3833e\\\",\\\"column_roi_id\\\":\\\"e3ac4f3b-5f36-43b5-be66-099fd8e73e59\\\",\\\"datacell_roi_id\\\":\\\"77f5b19a-304e-4bf2-aeca-bac1c4c9d23b\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"White blood cell\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"36edd682-85bf-4294-aab5-c6bae7d3833e\\\",\\\"column_roi_id\\\":\\\"04fce02f-ee27-415d-9de7-e2a3f17a5720\\\",\\\"datacell_roi_id\\\":\\\"423e2658-bb6d-40c7-a562-744104a1ea6f\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"WHO\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"7b12cc9a-12de-4644-9e81-2fe2f3a55206\\\",\\\"column_roi_id\\\":\\\"361b5bce-52aa-4a4c-adbb-d05bd03e4b56\\\",\\\"datacell_roi_id\\\":\\\"346e819a-01c9-4c53-8c97-7add60b6bc68\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":24,\\\"standard_entity_name\\\":\\\"ANY: Organization\\\",\\\"subcategory\\\":\\\"ANY: Organization\\\",\\\"confidence\\\":62.0,\\\"text\\\":\\\"World Health Organization\\\"}],\\\"content\\\":\\\"World Health Organization\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"995b85fe-78c1-4f10-9b2a-6d4abf3a6860\\\",\\\"row_roi_id\\\":\\\"7b12cc9a-12de-4644-9e81-2fe2f3a55206\\\",\\\"column_roi_id\\\":\\\"cabb1b9d-59b4-4bb8-a25e-e1bde4760ef1\\\",\\\"datacell_roi_id\\\":\\\"5a778e7c-5fb6-40aa-8601-b6b37371baa7\\\"},\\\"table_index\\\":2.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"6\", \"TableIndex\": \"3.0\", \"TableName\": \"List of abbreviations\", \"Header\": []}, {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c405503-2d85-41d5-bb48-2c8e5986086b\", \"childbox\": \"4a3e3095-7560-4cee-850d-6a03efd25010\", \"subtext\": \"05f4ff04-ecbf-4dd0-bc39-25404793fa2e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"List of abbreviations\", \"\", \"1\", 180, \"\"], [\"\", \"Unmapped\", \"header\", \"Protocol synopsis\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"d2e16ba1-1df9-4803-8f0d-4c0a950fa57c\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 181, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Protocol Title:</td>\\n      <td>A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection</td>\\n      <td>A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection</td>\\n      <td>A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Protocol Number:</td>\\n      <td>IDX-04B-004</td>\\n      <td>IDX-04B-004</td>\\n      <td>IDX-04B-004</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Clinical Phase:</td>\\n      <td>II</td>\\n      <td>II</td>\\n      <td>II</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Principal Investigator & Study Site:</td>\\n      <td>Site specific information provided on separate site contact list</td>\\n      <td>Site specific information provided on separate site contact list</td>\\n      <td>Site specific information provided on separate site contact list</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>Objectives:</td>\\n      <td>Primary : Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : Treatment duration Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites PK/Pharmacodynamics (PK/PD) of samatasvir, IDX21437 and their metabolites Emergence of resistance mutations during treatment and in the post-treatment period</td>\\n      <td>Primary : Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : Treatment duration Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites PK/Pharmacodynamics (PK/PD) of samatasvir, IDX21437 and their metabolites Emergence of resistance mutations during treatment and in the post-treatment period</td>\\n      <td>Primary : Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : Treatment duration Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites PK/Pharmacodynamics (PK/PD) of samatasvir, IDX21437 and their metabolites Emergence of resistance mutations during treatment and in the post-treatment period</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>Key Safety Parameters:</td>\\n      <td>Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests</td>\\n      <td>Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests</td>\\n      <td>Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests</td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>Key Antiviral Activity Parameters:</td>\\n      <td>\\u2022 lower limit o o</td>\\n      <td>Proportion of subjects with plasma hepatitis C virus (HCV) RNA below the f quantitation (<LLOQ)  Primary:  \\u2212   SVR 12 :  12 weeks after the end of treatment</td>\\n      <td>Proportion of subjects with plasma hepatitis C virus (HCV) RNA below the f quantitation (<LLOQ)  Primary:  \\u2212   SVR 12 :  12 weeks after the end of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td></td>\\n      <td>o</td>\\n      <td>Second \\u2212</td>\\n      <td>ary Week 4 during treatment</td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td></td>\\n      <td></td>\\n      <td>\\u2212</td>\\n      <td>End of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td></td>\\n      <td></td>\\n      <td>\\u2212</td>\\n      <td>SVR 4 :  4 weeks after the end of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td></td>\\n      <td></td>\\n      <td>\\u2212</td>\\n      <td>SVR 8: :  8 weeks after the end of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td></td>\\n      <td></td>\\n      <td>\\u2212</td>\\n      <td>SVR 24 :  24 weeks after the end of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td></td>\\n      <td>Emergence of resistance mutations Durability of SVR and the kinetics of antiviral resistant HCV</td>\\n      <td>Emergence of resistance mutations Durability of SVR and the kinetics of antiviral resistant HCV</td>\\n      <td>Emergence of resistance mutations Durability of SVR and the kinetics of antiviral resistant HCV</td>\\n    </tr>\\n    <tr>\\n      <th>13</th>\\n      <td>Key Pharmacokinetic Parameters:</td>\\n      <td>Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable</td>\\n      <td>Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable</td>\\n      <td>Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable</td>\\n    </tr>\\n    <tr>\\n      <th>14</th>\\n      <td>Study Design:</td>\\n      <td>Treatment-na\\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-</td>\\n      <td>Treatment-na\\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-</td>\\n      <td>Treatment-na\\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Protocol Title:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"3c48357b-10dd-4c5a-8f62-b4a668d246ce\\\",\\\"column_roi_id\\\":\\\"44528a2d-5222-42e3-99d6-97660171c4bc\\\",\\\"datacell_roi_id\\\":\\\"f0651b13-2f8e-4a24-a51c-0d2768d13a60\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"3c48357b-10dd-4c5a-8f62-b4a668d246ce\\\",\\\"column_roi_id\\\":\\\"1f5777a8-ac6d-4eed-adb0-b927c9c2a21a\\\",\\\"datacell_roi_id\\\":\\\"3ccf095f-1e2e-4494-91db-e15227497e90\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"3c48357b-10dd-4c5a-8f62-b4a668d246ce\\\",\\\"column_roi_id\\\":\\\"1f5777a8-ac6d-4eed-adb0-b927c9c2a21a\\\",\\\"datacell_roi_id\\\":\\\"3ccf095f-1e2e-4494-91db-e15227497e90\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":71,\\\"end_idx\\\":80,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":86,\\\"end_idx\\\":93,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"3c48357b-10dd-4c5a-8f62-b4a668d246ce\\\",\\\"column_roi_id\\\":\\\"1f5777a8-ac6d-4eed-adb0-b927c9c2a21a\\\",\\\"datacell_roi_id\\\":\\\"3ccf095f-1e2e-4494-91db-e15227497e90\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Protocol Number:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"47c6a830-e1c4-4fdb-b0df-e894130bbc81\\\",\\\"column_roi_id\\\":\\\"c402657c-291c-4e9f-94e4-22321ef5315d\\\",\\\"datacell_roi_id\\\":\\\"42d7ca12-d070-4f68-966b-9b4bc421b92b\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IDX-04B-004\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"47c6a830-e1c4-4fdb-b0df-e894130bbc81\\\",\\\"column_roi_id\\\":\\\"c287e7cc-c585-4f3b-ae48-67f2bb89013a\\\",\\\"datacell_roi_id\\\":\\\"0035b338-c10d-47c0-a0fb-af677ce138bd\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IDX-04B-004\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"47c6a830-e1c4-4fdb-b0df-e894130bbc81\\\",\\\"column_roi_id\\\":\\\"c287e7cc-c585-4f3b-ae48-67f2bb89013a\\\",\\\"datacell_roi_id\\\":\\\"0035b338-c10d-47c0-a0fb-af677ce138bd\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IDX-04B-004\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"47c6a830-e1c4-4fdb-b0df-e894130bbc81\\\",\\\"column_roi_id\\\":\\\"c287e7cc-c585-4f3b-ae48-67f2bb89013a\\\",\\\"datacell_roi_id\\\":\\\"0035b338-c10d-47c0-a0fb-af677ce138bd\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Clinical Phase:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a2d81efc-15a6-40d1-8809-51965d859553\\\",\\\"column_roi_id\\\":\\\"8e0c8257-55db-4b2c-b9cb-24aa125ddf2b\\\",\\\"datacell_roi_id\\\":\\\"b61448b4-0b7e-4455-8448-fade5eac4eff\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"II\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a2d81efc-15a6-40d1-8809-51965d859553\\\",\\\"column_roi_id\\\":\\\"e23c57be-7842-4bf7-96ee-356ed5ded01b\\\",\\\"datacell_roi_id\\\":\\\"841a974e-b29b-44c7-9c1a-bccd125b4e7d\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"II\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a2d81efc-15a6-40d1-8809-51965d859553\\\",\\\"column_roi_id\\\":\\\"e23c57be-7842-4bf7-96ee-356ed5ded01b\\\",\\\"datacell_roi_id\\\":\\\"841a974e-b29b-44c7-9c1a-bccd125b4e7d\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"II\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a2d81efc-15a6-40d1-8809-51965d859553\\\",\\\"column_roi_id\\\":\\\"e23c57be-7842-4bf7-96ee-356ed5ded01b\\\",\\\"datacell_roi_id\\\":\\\"841a974e-b29b-44c7-9c1a-bccd125b4e7d\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Principal Investigator & Study Site:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a805d2d5-d0a1-4931-b9da-4c7bf3c69bf6\\\",\\\"column_roi_id\\\":\\\"89fbb5ba-e781-4a72-b1ad-b7c923794ef9\\\",\\\"datacell_roi_id\\\":\\\"fecd515f-d90d-4618-8bb2-0d076eea62c0\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Site specific information provided on separate site contact list\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a805d2d5-d0a1-4931-b9da-4c7bf3c69bf6\\\",\\\"column_roi_id\\\":\\\"08a54a31-f6ac-4111-a158-b1f1cb0d7886\\\",\\\"datacell_roi_id\\\":\\\"cdba7cf6-bbca-4169-8ee9-6d7ca8a70fb6\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Site specific information provided on separate site contact list\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a805d2d5-d0a1-4931-b9da-4c7bf3c69bf6\\\",\\\"column_roi_id\\\":\\\"08a54a31-f6ac-4111-a158-b1f1cb0d7886\\\",\\\"datacell_roi_id\\\":\\\"cdba7cf6-bbca-4169-8ee9-6d7ca8a70fb6\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Site specific information provided on separate site contact list\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"a805d2d5-d0a1-4931-b9da-4c7bf3c69bf6\\\",\\\"column_roi_id\\\":\\\"08a54a31-f6ac-4111-a158-b1f1cb0d7886\\\",\\\"datacell_roi_id\\\":\\\"cdba7cf6-bbca-4169-8ee9-6d7ca8a70fb6\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Objectives:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"f4dfdf75-0f35-4975-aa4f-c8c6f8076abc\\\",\\\"column_roi_id\\\":\\\"6bdf6d82-8a91-4f6d-8d98-61f7f6091018\\\",\\\"datacell_roi_id\\\":\\\"ba34127e-e913-4c40-a571-fb48210181b3\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Primary : Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : Treatment duration Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites PK\\\\/Pharmacodynamics (PK\\\\/PD) of samatasvir, IDX21437 and their metabolites Emergence of resistance mutations during treatment and in the post-treatment period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"f4dfdf75-0f35-4975-aa4f-c8c6f8076abc\\\",\\\"column_roi_id\\\":\\\"daa2f74a-7544-4df9-b81a-e0e8958c67cb\\\",\\\"datacell_roi_id\\\":\\\"4d860ac0-e83a-4a1a-912f-88b7b8bbfb3c\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Primary : Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : Treatment duration Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites PK\\\\/Pharmacodynamics (PK\\\\/PD) of samatasvir, IDX21437 and their metabolites Emergence of resistance mutations during treatment and in the post-treatment period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"f4dfdf75-0f35-4975-aa4f-c8c6f8076abc\\\",\\\"column_roi_id\\\":\\\"daa2f74a-7544-4df9-b81a-e0e8958c67cb\\\",\\\"datacell_roi_id\\\":\\\"4d860ac0-e83a-4a1a-912f-88b7b8bbfb3c\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Primary : Safety of samatasvir plus IDX21437 with and without ribavirin (RBV) Efficacy of samatasvir plus IDX21437 with and without RBV Secondary : Treatment duration Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites PK\\\\/Pharmacodynamics (PK\\\\/PD) of samatasvir, IDX21437 and their metabolites Emergence of resistance mutations during treatment and in the post-treatment period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"f4dfdf75-0f35-4975-aa4f-c8c6f8076abc\\\",\\\"column_roi_id\\\":\\\"daa2f74a-7544-4df9-b81a-e0e8958c67cb\\\",\\\"datacell_roi_id\\\":\\\"4d860ac0-e83a-4a1a-912f-88b7b8bbfb3c\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Key Safety Parameters:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"1b3dd99a-22d1-4c0c-80dc-cd97ac590a46\\\",\\\"column_roi_id\\\":\\\"890d388d-4327-4f76-ba4c-18a3ad292de5\\\",\\\"datacell_roi_id\\\":\\\"f14e441c-d65c-41c0-be43-c0247f79146b\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"1b3dd99a-22d1-4c0c-80dc-cd97ac590a46\\\",\\\"column_roi_id\\\":\\\"8701f887-7933-4e81-b2dc-3f50a69fca87\\\",\\\"datacell_roi_id\\\":\\\"b890f15a-a4e7-4143-bfb8-31160590e1be\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"1b3dd99a-22d1-4c0c-80dc-cd97ac590a46\\\",\\\"column_roi_id\\\":\\\"8701f887-7933-4e81-b2dc-3f50a69fca87\\\",\\\"datacell_roi_id\\\":\\\"b890f15a-a4e7-4143-bfb8-31160590e1be\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Adverse events (AEs), physical examination, vital signs, 12-lead electrocardiogram (ECG) and standard safety laboratory tests\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"1b3dd99a-22d1-4c0c-80dc-cd97ac590a46\\\",\\\"column_roi_id\\\":\\\"8701f887-7933-4e81-b2dc-3f50a69fca87\\\",\\\"datacell_roi_id\\\":\\\"b890f15a-a4e7-4143-bfb8-31160590e1be\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Key Antiviral Activity Parameters: \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"54d9f671-c528-4718-8b09-657bd73d0ec8\\\",\\\"column_roi_id\\\":\\\"74478095-e963-4df4-b19e-7d22ca496d84\\\",\\\"datacell_roi_id\\\":\\\"b0e4929f-454e-42b1-9fda-4a31fccf4d54\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2022 lower limit o o \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"54d9f671-c528-4718-8b09-657bd73d0ec8\\\",\\\"column_roi_id\\\":\\\"2619e6b3-7e68-4a79-85de-7235dc150273\\\",\\\"datacell_roi_id\\\":\\\"9423fa8a-6a7f-4c6d-a91e-d6dc6e854517\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Proportion of subjects with plasma hepatitis C virus (HCV) RNA below the f quantitation (<LLOQ)  Primary:  \\\\u2212   SVR 12 :  12 weeks after the end of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"54d9f671-c528-4718-8b09-657bd73d0ec8\\\",\\\"column_roi_id\\\":\\\"734baf1e-3c65-4266-a049-2c4c8824b2c7\\\",\\\"datacell_roi_id\\\":\\\"b4ea2e04-6afe-4311-be41-46ae191a347a\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Proportion of subjects with plasma hepatitis C virus (HCV) RNA below the f quantitation (<LLOQ)  Primary:  \\\\u2212   SVR 12 :  12 weeks after the end of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"54d9f671-c528-4718-8b09-657bd73d0ec8\\\",\\\"column_roi_id\\\":\\\"734baf1e-3c65-4266-a049-2c4c8824b2c7\\\",\\\"datacell_roi_id\\\":\\\"b4ea2e04-6afe-4311-be41-46ae191a347a\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"o \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"b5def54c-a90a-43ae-82d2-8e37979a3a04\\\",\\\"column_roi_id\\\":\\\"5561c3b7-1c1e-4824-aa98-31511103165c\\\",\\\"datacell_roi_id\\\":\\\"3942deaa-b57a-48aa-8b1f-e29ee6c0dcb4\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Second \\\\u2212 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"b5def54c-a90a-43ae-82d2-8e37979a3a04\\\",\\\"column_roi_id\\\":\\\"c5fbbfcd-82e8-4be8-a880-abfb57f8d7e1\\\",\\\"datacell_roi_id\\\":\\\"2b225881-812d-4582-b66f-a12073bf9d87\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"ary Week 4 during treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"b5def54c-a90a-43ae-82d2-8e37979a3a04\\\",\\\"column_roi_id\\\":\\\"ad93580c-01c9-476e-ae7e-ffd7beaf0653\\\",\\\"datacell_roi_id\\\":\\\"6ce1ad46-c2e5-4c1f-b4a2-8542b0bf2024\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2212 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"8145d1a9-64eb-46aa-b9d7-2fdf47338bec\\\",\\\"column_roi_id\\\":\\\"aa962654-36ee-41b6-90d8-266c7ffd7d56\\\",\\\"datacell_roi_id\\\":\\\"6f24a8fd-cf1d-493e-8f52-64891e656067\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"End of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"8145d1a9-64eb-46aa-b9d7-2fdf47338bec\\\",\\\"column_roi_id\\\":\\\"4e5a229b-7139-456c-9733-a7bd08c108da\\\",\\\"datacell_roi_id\\\":\\\"d64e4bec-1475-46f1-93c0-b5f68c09d3f4\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2212 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"08c52207-9fe4-4c03-a8c3-1a3649044ed2\\\",\\\"column_roi_id\\\":\\\"8aedc5b0-beef-4042-8a5c-144266846ef4\\\",\\\"datacell_roi_id\\\":\\\"8e1a61b2-0199-4635-8f86-539612991d5f\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SVR 4 :  4 weeks after the end of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"08c52207-9fe4-4c03-a8c3-1a3649044ed2\\\",\\\"column_roi_id\\\":\\\"4872bb0f-5623-42dd-bfc0-14eb33c088a7\\\",\\\"datacell_roi_id\\\":\\\"7d0eb663-6d91-4a8c-846e-86f0af9ef64e\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2212 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"c7b7759f-e742-41dc-90de-b441b17472c0\\\",\\\"column_roi_id\\\":\\\"025c631c-5a7a-4218-98a5-6ef098f436b5\\\",\\\"datacell_roi_id\\\":\\\"f7ca3db1-2f6b-48e9-9a63-4ce9a191f393\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SVR 8: :  8 weeks after the end of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"c7b7759f-e742-41dc-90de-b441b17472c0\\\",\\\"column_roi_id\\\":\\\"4b94b5c3-d76f-498c-b834-3ebb092994d4\\\",\\\"datacell_roi_id\\\":\\\"413825e1-84b0-4397-a245-c388dc33c2ed\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2212 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"5f43a2a2-c4fb-46c3-97ce-5b11d4399c0b\\\",\\\"column_roi_id\\\":\\\"37df8608-e9c4-4525-8366-d1da7a5dfb3e\\\",\\\"datacell_roi_id\\\":\\\"8dbd7be0-5f3c-4448-8cab-362a1fecd3ff\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SVR 24 :  24 weeks after the end of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"5f43a2a2-c4fb-46c3-97ce-5b11d4399c0b\\\",\\\"column_roi_id\\\":\\\"6b055965-3456-4e95-961f-309b3d1cd357\\\",\\\"datacell_roi_id\\\":\\\"a56ad4e9-78c1-4638-b1cd-9ce5a2116cf3\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Emergence of resistance mutations Durability of SVR and the kinetics of antiviral resistant HCV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"58cfde08-8104-4b54-8d5e-178cf86806e9\\\",\\\"column_roi_id\\\":\\\"a9dd0566-4882-49ca-b3aa-7565a5654dd9\\\",\\\"datacell_roi_id\\\":\\\"8c977ff0-7442-46d7-88e0-7f57956a8ea6\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Emergence of resistance mutations Durability of SVR and the kinetics of antiviral resistant HCV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"58cfde08-8104-4b54-8d5e-178cf86806e9\\\",\\\"column_roi_id\\\":\\\"a9dd0566-4882-49ca-b3aa-7565a5654dd9\\\",\\\"datacell_roi_id\\\":\\\"8c977ff0-7442-46d7-88e0-7f57956a8ea6\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Emergence of resistance mutations Durability of SVR and the kinetics of antiviral resistant HCV\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"58cfde08-8104-4b54-8d5e-178cf86806e9\\\",\\\"column_roi_id\\\":\\\"a9dd0566-4882-49ca-b3aa-7565a5654dd9\\\",\\\"datacell_roi_id\\\":\\\"8c977ff0-7442-46d7-88e0-7f57956a8ea6\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Key Pharmacokinetic Parameters:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"2e1e04a9-ae62-4285-8b51-999a0516679c\\\",\\\"column_roi_id\\\":\\\"e746f74d-5cd5-4c54-9169-11cbbae9f3ba\\\",\\\"datacell_roi_id\\\":\\\"9141e0b3-054f-4573-9522-c08fbfb5ebae\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"2e1e04a9-ae62-4285-8b51-999a0516679c\\\",\\\"column_roi_id\\\":\\\"9bc155f7-2a04-4c72-b31c-a40037144f39\\\",\\\"datacell_roi_id\\\":\\\"919de6db-1162-4e5a-811d-2f89f2deb540\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"2e1e04a9-ae62-4285-8b51-999a0516679c\\\",\\\"column_roi_id\\\":\\\"9bc155f7-2a04-4c72-b31c-a40037144f39\\\",\\\"datacell_roi_id\\\":\\\"919de6db-1162-4e5a-811d-2f89f2deb540\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":82,\\\"end_idx\\\":91,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"samatasvir\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":94,\\\"end_idx\\\":101,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"Pharmacokinetic measures of plasma drug exposure (AUC 0-t C max and C trough ) of samatasvir, IDX21437 and their metabolites, as applicable\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"2e1e04a9-ae62-4285-8b51-999a0516679c\\\",\\\"column_roi_id\\\":\\\"9bc155f7-2a04-4c72-b31c-a40037144f39\\\",\\\"datacell_roi_id\\\":\\\"919de6db-1162-4e5a-811d-2f89f2deb540\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Study Design:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"da78c096-98d0-431e-b8ce-a4394bc331ad\\\",\\\"column_roi_id\\\":\\\"fc07988d-4f58-4122-90f1-b146b34d209a\\\",\\\"datacell_roi_id\\\":\\\"0e737f10-5da5-4e1d-ab86-38ae28579984\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment-na\\\\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"da78c096-98d0-431e-b8ce-a4394bc331ad\\\",\\\"column_roi_id\\\":\\\"e8ae8089-f53a-4246-afe6-48452da7d72c\\\",\\\"datacell_roi_id\\\":\\\"1885f959-32c0-4a42-803d-576a1713baa0\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment-na\\\\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"da78c096-98d0-431e-b8ce-a4394bc331ad\\\",\\\"column_roi_id\\\":\\\"e8ae8089-f53a-4246-afe6-48452da7d72c\\\",\\\"datacell_roi_id\\\":\\\"1885f959-32c0-4a42-803d-576a1713baa0\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment-na\\\\u00efve, Genotypes 1 and 3, chronic HCV-infected subjects Open-label, randomized design o   Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data. The safety, antiviral activity and available PK data from the first 40 subjects who have completed 4 weeks of treatment will be reviewed by an independent Data Safety Monitoring Board (DSMB). Pharmacokinetics:  o   All subjects: one sample per visit through the 28-day post End-of-\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ee5b64a8-c9d3-4aef-b7b5-9c423f2f1e94\\\",\\\"row_roi_id\\\":\\\"da78c096-98d0-431e-b8ce-a4394bc331ad\\\",\\\"column_roi_id\\\":\\\"e8ae8089-f53a-4246-afe6-48452da7d72c\\\",\\\"datacell_roi_id\\\":\\\"1885f959-32c0-4a42-803d-576a1713baa0\\\"},\\\"table_index\\\":3.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"8\", \"TableIndex\": \"4.0\", \"TableName\": \"Protocol synopsis\", \"Header\": [0, 1, 2, 3]}, {\"IsBold\": true, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f0651b13-2f8e-4a24-a51c-0d2768d13a60\", \"childbox\": \"9236b857-2fb5-422e-8c4e-29dcca205b8c\", \"subtext\": \"a816d34d-b12e-4cc0-aa74-def49892a9cf\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 182, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8a3c8193-1f32-40d3-a6b8-3803884da8dd\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 183, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aac26975-87e4-482d-b9fa-fe58c0dc9e2a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 184, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"462a885a-bd48-4040-979f-c29fba1798d6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 185, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"56fc8223-502a-4b01-b210-17df8a0f9905\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 186, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fa2159fb-2c78-42ec-bbdb-86cd3f974103\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 187, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d4b397ec-395f-4bd4-8202-a5b09be08d7a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 188, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1890f896-0072-44f6-94cb-4293631f8c95\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 189, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"276e93e1-031a-42ca-a1cf-09678ee1eb05\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 190, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a21a7421-8c3a-48f3-a722-e41d17e7b4cd\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 191, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d687e3cd-7e0d-4caa-a061-769bb0f1ce9a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 192, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1629f4fd-b7e6-4f9b-af66-37cdc721988c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Protocol synopsis\", \"\", \"1\", 193, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d53b134b-e267-43ca-956a-14e919d36871\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetics:\", \"7.6\", \"2\", 194, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb137a16-cd42-4ea4-8287-01d13515cc98\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetics:\", \"7.6\", \"2\", 195, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td></td>\\n      <td>Treatment (EOT) visit for monitoring of study drug concentrations.  o   Intensive PK/PD on Day 1 and Day 15, and a single blood sample on Day 2, will be optional for all subjects (see Table 7-3).  GT Group N=240 Samatasvir (mg QD) IDX21437 (mg QD) RBV 1 Weeks of treatment 1 A 20 50 300 No 8 1 B 20 50 300 No 12 1 C 60 100 300 No 8 1 D 60 100 300 No 12 3 E 40 100 300 Yes 12 3 F 40 100 300 No 12 1 RBV dosing weight-based, according to product label The occurrence of one of the following rules will constitute virologic failure: HCV RNA above LLOQ for two consecutive measurements (second measurement to be collected as soon as possible) in a subject in whom HCV RNA was below LLOQ, OR >1 log 10 increase in HCV RNA above nadir for two consecutive measurements. Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2). Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Duration:</td>\\n      <td>Up to 832 days, including Screening, Treatment, Post EOT follow-up and the Extended observational follow-on phase.</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Number of Subjects:</td>\\n      <td>Approximately 240 randomized and treated</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Inclusion Criteria:</td>\\n      <td>18 (or the legal age of consent per local regulations, if greater than 18 years) to 65 years of age, inclusive. Female subjects of both childbearing potential and non-childbearing potential may be included, unless the local regulatory authority requires that only females of non-childbearing potential be included. Non-childbearing potential is defined as one of the following: Postmenopausal, defined as amenorrheic for at least 2 years and serum follicle stimulating hormone (FSH) level consistent with postmenopausal status at Screening, or A documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation at least 6 months prior to study initiation. All female subjects must have a negative serum beta-human chorionic gonadotropin (\\u03b2-HCG) at Screening and a negative urine pregnancy test prior to the first dose of study medication on Day 1. Women of childbearing potential and men must have agreed to use an acceptable double method of birth control (one of which must be a barrier method) from Screening through at least 7 months after the last dose of study drugs. Male subjects must have agreed not to donate sperm from the first dose through at least 7 months after the last dose of study drugs.</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment (EOT) visit for monitoring of study drug concentrations.  o   Intensive PK\\\\/PD on Day 1 and Day 15, and a single blood sample on Day 2, will be optional for all subjects (see Table 7-3).  GT Group N=240 Samatasvir (mg QD) IDX21437 (mg QD) RBV 1 Weeks of treatment 1 A 20 50 300 No 8 1 B 20 50 300 No 12 1 C 60 100 300 No 8 1 D 60 100 300 No 12 3 E 40 100 300 Yes 12 3 F 40 100 300 No 12 1 RBV dosing weight-based, according to product label The occurrence of one of the following rules will constitute virologic failure: HCV RNA above LLOQ for two consecutive measurements (second measurement to be collected as soon as possible) in a subject in whom HCV RNA was below LLOQ, OR >1 log 10 increase in HCV RNA above nadir for two consecutive measurements. Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2). Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"94be6677-4b14-4bfa-8e39-bd15314cc8ca\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Duration:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"7964fda3-c080-4c63-870b-0a611d387eb9\\\",\\\"column_roi_id\\\":\\\"867a4ff4-ca9e-43aa-9c1f-2a71e0c512a8\\\",\\\"datacell_roi_id\\\":\\\"aa7e8bf3-3d9a-4a37-8620-f3cda4fc36c8\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Up to 832 days, including Screening, Treatment, Post EOT follow-up and the Extended observational follow-on phase.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"7964fda3-c080-4c63-870b-0a611d387eb9\\\",\\\"column_roi_id\\\":\\\"f1a51085-4bba-4ce7-939d-3c668f593de4\\\",\\\"datacell_roi_id\\\":\\\"a1c36d20-21b2-4132-b377-0b6714055b59\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Number of Subjects:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"30fda7b0-53ff-415d-9495-c867a6c7c932\\\",\\\"column_roi_id\\\":\\\"8e2912e0-67dd-4f8d-8046-c31bac998516\\\",\\\"datacell_roi_id\\\":\\\"0f7b464b-8795-4998-be92-5e56f79e1f48\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Approximately 240 randomized and treated\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"30fda7b0-53ff-415d-9495-c867a6c7c932\\\",\\\"column_roi_id\\\":\\\"5ae31d7b-5917-4587-ae9d-9362c6dc321c\\\",\\\"datacell_roi_id\\\":\\\"ec95ff30-0229-4e69-b810-7c9e92131bc6\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Inclusion Criteria:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"21e23d79-3c9f-4cdf-b75b-b933c8de5f23\\\",\\\"column_roi_id\\\":\\\"dc714f61-65b5-4034-930a-0769a8ef84f0\\\",\\\"datacell_roi_id\\\":\\\"8235bddd-4f96-4c7b-88b6-e391af027f8d\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"18 (or the legal age of consent per local regulations, if greater than 18 years) to 65 years of age, inclusive. Female subjects of both childbearing potential and non-childbearing potential may be included, unless the local regulatory authority requires that only females of non-childbearing potential be included. Non-childbearing potential is defined as one of the following: Postmenopausal, defined as amenorrheic for at least 2 years and serum follicle stimulating hormone (FSH) level consistent with postmenopausal status at Screening, or A documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation at least 6 months prior to study initiation. All female subjects must have a negative serum beta-human chorionic gonadotropin (\\\\u03b2-HCG) at Screening and a negative urine pregnancy test prior to the first dose of study medication on Day 1. Women of childbearing potential and men must have agreed to use an acceptable double method of birth control (one of which must be a barrier method) from Screening through at least 7 months after the last dose of study drugs. Male subjects must have agreed not to donate sperm from the first dose through at least 7 months after the last dose of study drugs.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"21e23d79-3c9f-4cdf-b75b-b933c8de5f23\\\",\\\"column_roi_id\\\":\\\"253930f7-0af8-4438-b911-7d8253b66963\\\",\\\"datacell_roi_id\\\":\\\"1b75dac1-1430-4a6c-9795-eb3ac3b9f62b\\\"},\\\"table_index\\\":4.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"36\", \"TableIndex\": \"5.0\", \"TableName\": \"7.6 Pharmacokinetics\", \"Header\": [0, 1, 2, 3]}, {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ed1a540c-8a62-447a-b16a-5ef77e05670a\", \"childbox\": \"4960da4d-02a9-429d-bc4c-d8db4ac75342\", \"subtext\": \"9ade8776-6e5c-4296-8deb-f769fdd52c41\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetics:\", \"7.6\", \"2\", 196, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c6a7a6ac-39be-47f5-bab0-d8ab4c6f6eea\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetics:\", \"7.6\", \"2\", 197, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b36362b4-0f0a-430c-9a47-a7b74bb932f8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Pharmacokinetics:\", \"7.6\", \"2\", 198, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n      <th>7.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>GT</td>\\n      <td>RBV 1</td>\\n      <td>N=240</td>\\n      <td>Samatasvir (mg QD)</td>\\n      <td>IDX21437 (mg QD)</td>\\n      <td></td>\\n      <td>Weeks of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>1</td>\\n      <td>8</td>\\n      <td>20</td>\\n      <td>50</td>\\n      <td>300</td>\\n      <td>No</td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>1</td>\\n      <td>12</td>\\n      <td>20</td>\\n      <td></td>\\n      <td>300</td>\\n      <td>No</td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td></td>\\n      <td>No</td>\\n      <td>60</td>\\n      <td>100</td>\\n      <td>300</td>\\n      <td></td>\\n      <td>8</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>3</td>\\n      <td>100</td>\\n      <td></td>\\n      <td></td>\\n      <td>300</td>\\n      <td>Yes</td>\\n      <td>12</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>3</td>\\n      <td>300</td>\\n      <td>40</td>\\n      <td>100</td>\\n      <td></td>\\n      <td>No</td>\\n      <td>12</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"GT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"07ac4e38-94c5-416d-98c0-d473ecbadbdb\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"RBV 1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"11438a1a-1e7f-4884-b263-488fe68e8889\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"N=240\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"6b392a66-49f0-41c1-af4e-6d2520398915\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"}],\\\"content\\\":\\\"Samatasvir (mg QD)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"a4be6852-7871-4b16-9e1a-4dbd3891460b\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":7,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":7,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":7,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"IDX21437 (mg QD)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"d27abccb-6eb0-4c28-b3a2-297a9af9cae9\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Weeks of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"1d3a5727-7748-445c-929f-0c4ac80637aa\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"ffc19d70-31dc-4f69-9392-5968c6f7c2fc\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"8\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"0d79db8e-844f-464b-ba45-0ea8382884a7\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"20\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"8240d975-94ed-4dc7-8614-ff503b8f52f6\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"50\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"87002c6b-2a5f-4016-bba0-7a43398e2018\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"42ea72c2-44d6-43bb-b1f8-57ca723311ce\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"6b687ee5-52cf-4522-962e-19d696cc6e61\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"8debed86-ae0e-40bc-8140-085dd93dfffb\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"9bfd66d7-137e-4afc-a761-7003b52a414d\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"20\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"ae702292-3eb8-4dc5-be5f-f65a1f7dde56\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"f734bb7c-928e-40fe-9069-c1194b0eeea5\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"e4309edf-d0e1-453c-b600-9d01a4bcbc02\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":\\\"\\\"},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"40091f05-14cb-4848-9cbd-08f0c93f532b\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"60\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"b80023bf-e5de-4d01-ba20-4bded7f713e5\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"100\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"d670a5e7-012c-46a7-aaea-7111e6f2ce41\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"fc0b728d-8b84-436c-b8ec-a8ace525a29d\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"8\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"d2ec265a-5d1a-424d-b347-7e052aa45968\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"d77ae242-1948-4eb0-a517-2c3e74ccaa5e\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"100\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"22ac131e-3705-42c7-8fc9-02aaf34c9c78\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"b68f88ce-77b4-482f-a39b-8fdbd54b179d\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Yes\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"e267c8c6-2b7c-4412-bca3-809a82ca43c6\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"db50fad2-a291-4571-b712-be17b24b016a\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"6efa625e-f58e-4231-8e3c-4735587ec79a\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"9301013a-3423-43a0-ae34-e423c0a49baf\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"40\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"d0187d20-d3da-4c7a-b7d7-263b303510f6\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"100\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"0ad934ff-2073-414d-94d9-f9b0e616cc35\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"ae7548ef-3f52-4ea6-9d6b-36551a968b48\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"ba0ae46b-c0ac-4996-b5db-5dfc981fa4f2\\\",\\\"row_roi_id\\\":\\\"72c5d41d-dbf6-4d96-9eb9-acc7444b2be2\\\",\\\"column_roi_id\\\":\\\"44a78192-97c9-46b1-9108-28134de28b85\\\",\\\"datacell_roi_id\\\":\\\"7f0aaaf3-31f3-434e-a6c1-b8b0a49c62d7\\\"},\\\"table_index\\\":5.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"36\", \"TableIndex\": \"6.0\", \"TableName\": \"7.6 Pharmacokinetics\", \"Header\": [0]}, {\"IsBold\": true, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"07ac4e38-94c5-416d-98c0-d473ecbadbdb\", \"childbox\": \"98096d87-c352-41ab-a0f0-9a9c5ed1b007\", \"subtext\": \"819eecaa-f9d9-48ab-9b3b-49448d008a8a\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetics:\", \"7.6\", \"2\", 199, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f69633a4-b23e-4a0a-957b-82e7b67d3c46\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Inclusion Criteria:\", \"5.1.1\", \"3\", 200, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"36f5e6df-670e-4df6-bb50-7fde06faa067\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Inclusion Criteria:\", \"5.1.1\", \"3\", 201, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td></td>\\n      <td>QTcF interval \\u2264 450 ms at Screening and prior to dosing on Day 1. Documented clinical history compatible with chronic hepatitis C, including any one of the following: anti-HCV antibody positive at least 6 months prior to Screening or dosing, OR HCV RNA present in plasma by a sensitive and specific assay at least 6 months prior to Screening or dosing, OR HCV genotype determined at least 6 months prior to Screening or dosing, OR Histologic evidence of chronic hepatitis C infection. Plasma HCV RNA positive at Screening with minimal viral load of 4 log 10 IU/mL. HCV GT 1 or 3 by HCV genotyping performed at Screening ( Note : Mixed subtypes are not acceptable for GT 1 ). Documented absence of cirrhosis within 36 months of Screening or dosing (histology or non-invasive equivalent, according to local standard of care). Note: A score of F4 on any test is exclusionary.  Must not have received prior approved or investigational antiviral treatment for HCV infection (Note: Non-cirrhotic, pegylated interferon/RBV-na\\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3-month washout period) . Subject is, in the opinion of the investigator, willing and able to comply with the protocol and all other study requirements. Subject has provided written informed consent to participate in the study.</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Exclusion Criteria:</td>\\n      <td>Female subjects who are pregnant or breastfeeding. Body Mass Index (BMI) > 36 kg/m <sup>2</sup> . Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen (HBsAg) positive) and/or human immunodeficiency virus (HIV). History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC. History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency. One or more known primary or secondary causes of liver disease, other than hepatitis C (e.g., alcoholism, autoimmune hepatitis, nonalcoholic steatohepatitis, drug-related liver disease, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson Disease, Dubin-Johnson syndrome, other congenital or metabolic conditions affecting the liver (with the exception of Gilbert\\u2019s syndrome), etc.). Steatosis is allowed, if clinically asymptomatic. History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, non-HCV viral hepatitis, gallstones or other etiologies. Active, clinically significant (per judgment of the Principal Investigator) disease including: Acute or chronic kidney disease, Malignant disease or suspicion or history of malignant disease within previous 5 years (except for adequately treated basal cell carcinoma or other localized, non-metastatic cancer),</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"QTcF interval \\\\u2264 450 ms at Screening and prior to dosing on Day 1. Documented clinical history compatible with chronic hepatitis C, including any one of the following: anti-HCV antibody positive at least 6 months prior to Screening or dosing, OR HCV RNA present in plasma by a sensitive and specific assay at least 6 months prior to Screening or dosing, OR HCV genotype determined at least 6 months prior to Screening or dosing, OR Histologic evidence of chronic hepatitis C infection. Plasma HCV RNA positive at Screening with minimal viral load of 4 log 10 IU\\\\/mL. HCV GT 1 or 3 by HCV genotyping performed at Screening ( Note : Mixed subtypes are not acceptable for GT 1 ). Documented absence of cirrhosis within 36 months of Screening or dosing (histology or non-invasive equivalent, according to local standard of care). Note: A score of F4 on any test is exclusionary.  Must not have received prior approved or investigational antiviral treatment for HCV infection (Note: Non-cirrhotic, pegylated interferon\\\\/RBV-na\\\\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3-month washout period) . Subject is, in the opinion of the investigator, willing and able to comply with the protocol and all other study requirements. Subject has provided written informed consent to participate in the study.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"a9092948-464b-420d-968a-8ddc8d07f770\\\",\\\"row_roi_id\\\":\\\"4718071c-c7af-45fb-bf79-c467a1d3cd35\\\",\\\"column_roi_id\\\":\\\"e41738ab-a28f-42f1-93c2-3327bc27cc0c\\\",\\\"datacell_roi_id\\\":\\\"6744fbdc-b6b2-4f49-a495-3f84c4058d19\\\"},\\\"table_index\\\":6.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Exclusion Criteria:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"a9092948-464b-420d-968a-8ddc8d07f770\\\",\\\"row_roi_id\\\":\\\"b5e8bf31-89a9-4da6-8b98-ca80c97b6030\\\",\\\"column_roi_id\\\":\\\"13ab9415-c46b-4266-b659-f416bd99db2b\\\",\\\"datacell_roi_id\\\":\\\"e0e17ef2-1ba9-4af5-a0e8-55229e058e9a\\\"},\\\"table_index\\\":6.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Female subjects who are pregnant or breastfeeding. Body Mass Index (BMI) > 36 kg\\\\/m <sup>2<\\\\/sup> . Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen (HBsAg) positive) and\\\\/or human immunodeficiency virus (HIV). History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC. History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency. One or more known primary or secondary causes of liver disease, other than hepatitis C (e.g., alcoholism, autoimmune hepatitis, nonalcoholic steatohepatitis, drug-related liver disease, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson Disease, Dubin-Johnson syndrome, other congenital or metabolic conditions affecting the liver (with the exception of Gilbert\\\\u2019s syndrome), etc.). Steatosis is allowed, if clinically asymptomatic. History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, non-HCV viral hepatitis, gallstones or other etiologies. Active, clinically significant (per judgment of the Principal Investigator) disease including: Acute or chronic kidney disease, Malignant disease or suspicion or history of malignant disease within previous 5 years (except for adequately treated basal cell carcinoma or other localized, non-metastatic cancer),\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"a9092948-464b-420d-968a-8ddc8d07f770\\\",\\\"row_roi_id\\\":\\\"b5e8bf31-89a9-4da6-8b98-ca80c97b6030\\\",\\\"column_roi_id\\\":\\\"eed5d59a-6911-4a28-bfb1-0b9daf24fb02\\\",\\\"datacell_roi_id\\\":\\\"e24f283b-bc20-4f6d-a24f-5260707b81dc\\\"},\\\"table_index\\\":6.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"20\", \"TableIndex\": \"7.0\", \"TableName\": \"5.1.1 Inclusion criteria\", \"Header\": [1]}, {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5cdc117c-75cc-44a5-b081-c626b42644de\", \"childbox\": \"a4c9ece0-115e-4fda-a0cd-2c1208097a65\", \"subtext\": \"7a389ce3-e2c6-4c09-bbf1-0abaccc06617\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion Criteria:\", \"5.1.1\", \"3\", 202, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2782627b-bb2b-48c4-8433-c3f60a889658\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Exclusion Criteria:\", \"5.1.2\", \"3\", 203, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"396c5df0-40fe-448c-896f-553f01bd3a08\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Exclusion Criteria:\", \"5.1.2\", \"3\", 204, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Uncontrolled depressive illness, Uncontrolled thyroid disease; thyroid stimulating hormone (TSH) must be normal at Screening, Uncontrolled hypertension, Poorly controlled diabetes mellitus as evidenced by hemoglobin A 1c \\u2265 8.5% or equivalent at Screening, Neurological disease, Acute or chronic pancreatitis, Infections (e.g., tuberculosis), Intestinal malabsorption (e.g., structural defects, digestive failure, enzyme deficiencies with the exception of lactose intolerance, etc.), Pulmonary disease associated with ongoing functional impairment, Cardiac disease, clinically significant arrhythmia, family history of congenital heart disease, family history of prolonged QT, or family history of sudden death of unknown etiology, OR Any other condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results. Donated blood or had significant blood loss 30 days prior to dosing. Use of alcohol and/or drugs that could interfere with adherence to study requirements as judged by the investigator. Concomitant use of any major inhibitors or inducers of CYP3A (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Concomitant use of any major inhibitors, inducers or substrates of permeability glycoprotein (P-gp) transporter (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Based on limited in vitro metabolic results, the concomitant use of other drugs is prohibited until further information is available to guide their use (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Concomitant use of drugs contraindicated in the RBV product label. A washout period of at least 5 half-lives of the contraindicated drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Subjects who require frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions); required use for greater than 5 days should be discussed with the Sponsor during Screening ( Note : Topical or inhaled corticosteroids are permitted).  Concomitant use of antacids or acid blockers. For acid blockers, a washout period of at least 5 half-lives must be observed prior to study drug dosing, if the Principal Investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Concomitant use of herbal medications (e.g., St. John\\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements. Concomitant use of opioid substitution drugs (e.g., buprenorphine and</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Uncontrolled depressive illness, Uncontrolled thyroid disease; thyroid stimulating hormone (TSH) must be normal at Screening, Uncontrolled hypertension, Poorly controlled diabetes mellitus as evidenced by hemoglobin A 1c \\\\u2265 8.5% or equivalent at Screening, Neurological disease, Acute or chronic pancreatitis, Infections (e.g., tuberculosis), Intestinal malabsorption (e.g., structural defects, digestive failure, enzyme deficiencies with the exception of lactose intolerance, etc.), Pulmonary disease associated with ongoing functional impairment, Cardiac disease, clinically significant arrhythmia, family history of congenital heart disease, family history of prolonged QT, or family history of sudden death of unknown etiology, OR Any other condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results. Donated blood or had significant blood loss 30 days prior to dosing. Use of alcohol and\\\\/or drugs that could interfere with adherence to study requirements as judged by the investigator. Concomitant use of any major inhibitors or inducers of CYP3A (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Concomitant use of any major inhibitors, inducers or substrates of permeability glycoprotein (P-gp) transporter (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Based on limited in vitro metabolic results, the concomitant use of other drugs is prohibited until further information is available to guide their use (as described in Section 6.6.6). A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study. Concomitant use of drugs contraindicated in the RBV product label. A washout period of at least 5 half-lives of the contraindicated drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Subjects who require frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions); required use for greater than 5 days should be discussed with the Sponsor during Screening ( Note : Topical or inhaled corticosteroids are permitted).  Concomitant use of antacids or acid blockers. For acid blockers, a washout period of at least 5 half-lives must be observed prior to study drug dosing, if the Principal Investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Concomitant use of herbal medications (e.g., St. John\\\\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements. Concomitant use of opioid substitution drugs (e.g., buprenorphine and\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"dd38de05-e266-4057-89bb-6d18c74471cb\\\",\\\"row_roi_id\\\":\\\"a194f54c-56b1-4537-8771-9206bbaa73fe\\\",\\\"column_roi_id\\\":\\\"4ba8d320-9ad6-4dfb-871f-7d4b950f5a5b\\\",\\\"datacell_roi_id\\\":\\\"f3d2f8b7-3c2c-4637-be18-645b39bb3009\\\"},\\\"table_index\\\":7.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"21\", \"TableIndex\": \"8.0\", \"TableName\": \"5.1.2 Exclusion criteria\", \"Header\": []}, {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5847068e-339b-4d75-bad1-269e2cd14e2a\", \"childbox\": \"5a9ea58e-eb7b-48e1-9dbd-fd7187b95bb4\", \"subtext\": \"01cf4060-b181-41e1-b897-d3fa15490653\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Exclusion Criteria:\", \"5.1.2\", \"3\", 205, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3625c692-7b22-43ff-9d87-2776b012ec61\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Exclusion Criteria:\", \"5.1.2\", \"3\", 206, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d9531368-56c3-48a0-944f-135a6482c00e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Exclusion Criteria:\", \"5.1.2\", \"3\", 207, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td></td>\\n      <td>methadone). Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study. Subject with known allergy/hypersensitivity/intolerance to any of the study drugs, or any of their components. Clinically significant abnormal ECG at Screening or prior to dosing on Day 1. Abnormal values at Screening: hemoglobin (Hgb) < 10.0 g/dL absolute neutrophil count (ANC) < 1.0 x 10 <sup>9</sup> /L platelets < 120 x 10 <sup>9</sup> /L ALT or AST > 5 x upper limit of normal (ULN) total bilirubin > 1.1 x ULN (subjects with history of Gilbert\\u2019s syndrome > 2 x ULN) serum albumin < 3.5 g/dL alkaline phosphatase > 1.25 x ULN serum creatinine > 1.1 x ULN pancreatic amylase > 1.5 x ULN Any other laboratory abnormalities > Grade 1, as defined in (Appendix 2), considered clinically significant by the investigators.</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Test Product:</td>\\n      <td>Samatasvir:  50 mg tablets IDX21437:  150 mg tablets Ribavirin:  200 mg tablets</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Dose and Mode of Administration:</td>\\n      <td>Study drug dosing is described in the Study Design Section. RBV will be administered orally with food starting on Day 1 per RBV label (for 12 weeks) as per Table 4-1. \\uf0be 1,000-1,200 mg/day in two divided doses (weight based) <75 kg = 1,000 mg/day \\u226575 kg = 1,200 mg/day Samatasvir, IDX21437 dose modifications are not allowed without prior discussion with the Sponsor. RBV dose modifications are allowed per RBV product label.</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Statistical Methods:</td>\\n      <td>Data will be summarized using descriptive statistics.</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"methadone). Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study. Subject with known allergy\\\\/hypersensitivity\\\\/intolerance to any of the study drugs, or any of their components. Clinically significant abnormal ECG at Screening or prior to dosing on Day 1. Abnormal values at Screening: hemoglobin (Hgb) < 10.0 g\\\\/dL absolute neutrophil count (ANC) < 1.0 x 10 <sup>9<\\\\/sup> \\\\/L platelets < 120 x 10 <sup>9<\\\\/sup> \\\\/L ALT or AST > 5 x upper limit of normal (ULN) total bilirubin > 1.1 x ULN (subjects with history of Gilbert\\\\u2019s syndrome > 2 x ULN) serum albumin < 3.5 g\\\\/dL alkaline phosphatase > 1.25 x ULN serum creatinine > 1.1 x ULN pancreatic amylase > 1.5 x ULN Any other laboratory abnormalities > Grade 1, as defined in (Appendix 2), considered clinically significant by the investigators.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"3c12ba87-45bc-49a9-b685-c9b6dc3bfddc\\\",\\\"column_roi_id\\\":\\\"02a2b588-bb2f-4a29-ae33-4ceae61864ce\\\",\\\"datacell_roi_id\\\":\\\"8a836f2f-f2e5-4dce-a162-5af6b5656422\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Test Product:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"25a50e19-759a-4c88-85d7-17cba6cc3521\\\",\\\"column_roi_id\\\":\\\"d79fb4e8-3542-4b9e-b99c-2b0bb2a6b5cc\\\",\\\"datacell_roi_id\\\":\\\"46d8ccbf-6475-46ae-be56-f85279f9ea34\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Samatasvir:  50 mg tablets IDX21437:  150 mg tablets Ribavirin:  200 mg tablets\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"25a50e19-759a-4c88-85d7-17cba6cc3521\\\",\\\"column_roi_id\\\":\\\"f6ec14d6-f93f-4b09-afd7-c4ea76541167\\\",\\\"datacell_roi_id\\\":\\\"473edab0-5b3f-48c1-867b-adac85407c0a\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Dose and Mode of Administration:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"2913c7c6-f224-46c8-883d-a20658fe51bf\\\",\\\"column_roi_id\\\":\\\"69234f26-c0c3-4865-bb86-e59b2c172ddd\\\",\\\"datacell_roi_id\\\":\\\"3ff36b02-7beb-4b6f-9133-bb4551e0c33c\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Study drug dosing is described in the Study Design Section. RBV will be administered orally with food starting on Day 1 per RBV label (for 12 weeks) as per Table 4-1. \\\\uf0be 1,000-1,200 mg\\\\/day in two divided doses (weight based) <75 kg = 1,000 mg\\\\/day \\\\u226575 kg = 1,200 mg\\\\/day Samatasvir, IDX21437 dose modifications are not allowed without prior discussion with the Sponsor. RBV dose modifications are allowed per RBV product label.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"2913c7c6-f224-46c8-883d-a20658fe51bf\\\",\\\"column_roi_id\\\":\\\"6b65238c-f64f-408c-8124-b4bdab6d4361\\\",\\\"datacell_roi_id\\\":\\\"726a0faf-e207-488e-916d-7529ff1c391d\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Statistical Methods:\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"bc3312c3-3157-4f56-988a-db3e613e4c70\\\",\\\"column_roi_id\\\":\\\"e305a6e6-2638-410b-8f26-36d4976d49a1\\\",\\\"datacell_roi_id\\\":\\\"e3b93ae5-51ad-4ff4-95ec-11b52ddc6211\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Data will be summarized using descriptive statistics.\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"b7e69e96-7d3f-4a05-b3d1-695ee9e0dbf9\\\",\\\"row_roi_id\\\":\\\"bc3312c3-3157-4f56-988a-db3e613e4c70\\\",\\\"column_roi_id\\\":\\\"e851c450-8cb8-472a-836a-9894a5072277\\\",\\\"datacell_roi_id\\\":\\\"94d9145e-740d-4b45-8c6b-68ee8081ed1a\\\"},\\\"table_index\\\":8.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"21\", \"TableIndex\": \"9.0\", \"TableName\": \"5.1.2 Exclusion criteria\", \"Header\": [1, 2, 3]}, {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a417bdcd-05cf-465b-ae64-5a7c6b5b7c96\", \"childbox\": \"e4b233b5-4140-428b-8eb2-2300ccf11bc7\", \"subtext\": \"1f55f63c-18dd-499e-94c4-72797fa169b8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Exclusion Criteria:\", \"5.1.2\", \"3\", 208, \"\"], [\"\", \"Unmapped\", \"header\", \"1 Background\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"7031e351-beb6-474d-9a37-082bd4323fc1\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 209, \"\"], [\"\", \"Unmapped\", \"text\", \"Hepatitis C virus (HCV) infection is a global public health problem.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"962babdd-2140-4255-adcc-49211a26ffbc\", \"childbox\": \"8d602153-10e9-4f2b-abeb-440d5a4802a6\", \"subtext\": \"00746e31-6e2a-47ea-b228-a72f4c8a0fee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 210, \"\"], [\"\", \"Unmapped\", \"text\", \"The global prevalence of chronic hepatitis C infection is estimated to be approximately 150 million people.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"962babdd-2140-4255-adcc-49211a26ffbc\", \"childbox\": \"dc95447d-edb8-48cd-9a60-6c35ab1225d2\", \"subtext\": \"00746e31-6e2a-47ea-b228-a72f4c8a0fee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 211, \"\"], [\"\", \"Unmapped\", \"text\", \"An estimated 20-50% of patients with chronic HCV infection are at risk for developing such long-term complications as cirrhosis and hepatocellular carcinoma (HCC) (World Health Organization (WHO) (2013)).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 164, \"end_idx\": 188, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"World Health Organization\"}], \"roi_id\": {\"para\": \"962babdd-2140-4255-adcc-49211a26ffbc\", \"childbox\": \"23f98e5b-59d7-482a-bece-0ac28ca73c99\", \"subtext\": \"00746e31-6e2a-47ea-b228-a72f4c8a0fee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 212, \"\"], [\"\", \"Unmapped\", \"text\", \"It is anticipated that combinations of all oral, direct-acting antivirals (DAAs) will soon become the treatment of choice for chronic HCV infection for both treatment-na\\u00efve and -experienced subjects across multiple genotypes.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"962babdd-2140-4255-adcc-49211a26ffbc\", \"childbox\": \"5f776c6c-b2e3-41da-a1ae-dc03199d6e28\", \"subtext\": \"74ebaea0-f862-4eed-a4ae-801d38039660\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 213, \"\"], [\"\", \"Unmapped\", \"text\", \"The standard duration of treatment in multiple ongoing and completed Phase II, III and IV studies of HCV DAAs is 12 weeks or less.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b92ce42e-6569-4136-9207-137526b5ce7b\", \"childbox\": \"417cf759-89b6-453a-bef8-2597b3d5143c\", \"subtext\": \"d9b3e199-89bb-4748-b8d0-75c8354494b1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 214, \"\"], [\"\", \"Unmapped\", \"text\", \"Similarly, the same studies are testing whether ribavirin (RBV) is a necessary component of treatment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b92ce42e-6569-4136-9207-137526b5ce7b\", \"childbox\": \"102d0488-1c5b-4f7c-a0c1-5014b2ef86fd\", \"subtext\": \"d13991a8-7098-4085-b693-7bdc7b35d3e1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 215, \"\"], [\"\", \"Unmapped\", \"text\", \"Sofosbuvir (SOVALDI\\u2122 (2013)), a licensed uridine nucleotide prodrug, in combination with a second DAA, has been demonstrated to be efficacious without RBV for the treatment of HCV Genotype (GT) 1 infection (Lawitz E, et al.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 207, \"end_idx\": 214, \"standard_entity_name\": \"OTHER: Person Name\", \"subcategory\": \"OTHER: Person Name\", \"confidence\": 100.0, \"text\": \"Lawitz E\"}], \"roi_id\": {\"para\": \"b92ce42e-6569-4136-9207-137526b5ce7b\", \"childbox\": \"0851225d-963a-49cc-87e9-e49cffe7fa78\", \"subtext\": \"d13991a8-7098-4085-b693-7bdc7b35d3e1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 216, \"\"], [\"\", \"Unmapped\", \"text\", \"(2013)).  Sofosbuvir, with and without RBV, has been less effective against GT 3 (SOVALDI\\u2122 (2013)).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b92ce42e-6569-4136-9207-137526b5ce7b\", \"childbox\": \"fd1ae93d-6d37-4a97-b9c1-9c10f41a5e0e\", \"subtext\": \"fb147d47-3230-4644-a375-d449db5241b3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 217, \"\"], [\"\", \"Unmapped\", \"text\", \"The present study has been designed to explore whether samatasvir and IDX21437, with or without RBV, can achieve comparable results.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 55, \"end_idx\": 64, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 70, \"end_idx\": 77, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"b92ce42e-6569-4136-9207-137526b5ce7b\", \"childbox\": \"8021069a-5f6c-423e-97b3-08131d12a961\", \"subtext\": \"4e4a3f07-5146-4668-afa6-8df9ccd8bfb9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 218, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"3869fd71-a41a-4cda-98e9-6519f47397ce\", \"childbox\": \"d61ca8e9-409d-4372-960d-94c289da30f2\", \"subtext\": \"ecb8c219-de4b-4e4b-9ffb-81ebf5784af5\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 219, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals is developing IDX21437, a novel uridine nucleotide analog prodrug.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 21, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 75.0, \"text\": \"Idenix Pharmaceuticals\"}, {\"start_idx\": 37, \"end_idx\": 44, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 37, \"end_idx\": 44, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 37, \"end_idx\": 44, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 21, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 75.0, \"text\": \"Idenix Pharmaceuticals\"}], \"roi_id\": {\"para\": \"bcab4344-e0cc-4a06-a7e0-bc0ccf3f4d79\", \"childbox\": \"c786a55e-6090-4b77-89dc-24e80cc31d6a\", \"subtext\": \"f867a133-1348-4cd9-8e95-d6b4f3cf94be\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 220, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 is designed to generate high levels of the active uridine analog triphosphate in the liver, the site of HCV replication.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"bcab4344-e0cc-4a06-a7e0-bc0ccf3f4d79\", \"childbox\": \"2c92e2d2-ff4c-4840-9fbf-512d226cd8ab\", \"subtext\": \"f867a133-1348-4cd9-8e95-d6b4f3cf94be\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 221, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 is anticipated to have pan-genotypic activity and to exhibit a high barrier to resistance.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"bcab4344-e0cc-4a06-a7e0-bc0ccf3f4d79\", \"childbox\": \"fc17c7c1-0ae2-4ff6-9bfa-00c3becb78ba\", \"subtext\": \"1213b363-f147-4c6d-b34a-9b781c179714\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 222, \"\"], [\"\", \"Unmapped\", \"text\", \"Summaries of nonclinical studies conducted are described in the [IDX21437 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 65, \"end_idx\": 72, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"bcab4344-e0cc-4a06-a7e0-bc0ccf3f4d79\", \"childbox\": \"bf5a88c0-fe01-4356-a17b-8b0f834b40a2\", \"subtext\": \"1213b363-f147-4c6d-b34a-9b781c179714\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 223, \"\"], [\"\", \"Unmapped\", \"text\", \"In an ongoing, first-in-human IDX21437 study [IDX-04B-001], multiple doses up to a total daily dose of 300 mg IDX21437 for 7 days were found to be safe and well tolerated in healthy and HCV-infected subjects.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 110, \"end_idx\": 117, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 110, \"end_idx\": 117, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 110, \"end_idx\": 117, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"0e67b535-a1cf-4826-8893-6e754bd2419b\", \"childbox\": \"cec181cb-8a4a-4754-a7da-1d518f778c02\", \"subtext\": \"c16a1c4c-fe83-486f-8138-ec1167c9432d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 224, \"\"], [\"\", \"Unmapped\", \"text\", \"There were no treatment-emergent serious adverse events (SAEs) or safety related discontinuations ([IDX-04B-001], data on file).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0e67b535-a1cf-4826-8893-6e754bd2419b\", \"childbox\": \"99fa6705-e39f-4f6b-bf49-3a569bc44b90\", \"subtext\": \"81c8ae0b-19e4-4310-a225-34edc15a957b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 225, \"\"], [\"\", \"Unmapped\", \"text\", \"Samatasvir\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}], \"roi_id\": {\"para\": \"d0f5da4a-6276-4410-a313-7db20f57b7bd\", \"childbox\": \"03653264-1520-4a48-a6a2-95b2b0737f80\", \"subtext\": \"b316cd7f-76f3-4dc3-82de-4b6cfa0e20d6\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 226, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals is also developing samatasvir (IDX719), a novel HCV nonstructural protein 5A (NS5A) inhibitor agent for the therapy of chronic hepatitis C.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 21, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 75.0, \"text\": \"Idenix Pharmaceuticals\"}, {\"start_idx\": 42, \"end_idx\": 51, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 42, \"end_idx\": 51, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 42, \"end_idx\": 51, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 54, \"end_idx\": 59, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 54, \"end_idx\": 59, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 54, \"end_idx\": 59, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 54, \"end_idx\": 59, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 0, \"end_idx\": 21, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 75.0, \"text\": \"Idenix Pharmaceuticals\"}], \"roi_id\": {\"para\": \"0eaa0178-07e6-42b4-8556-3000f7812bb6\", \"childbox\": \"c8d5d4ee-b132-4aca-943b-048f9ec3e333\", \"subtext\": \"bb64dd7f-cd7e-443f-a9a1-35ed77302ea1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 227, \"\"], [\"\", \"Unmapped\", \"text\", \"Multiple doses up to a total daily dose of samatasvir 150 mg were found to be safe and well tolerated in healthy subjects when administered for up to 14 days ([IDX-06A-004], data on file) and in HCV-infected subjects when administered for up to 12 weeks ([IDX-06A-005], data on file).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 43, \"end_idx\": 52, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 43, \"end_idx\": 52, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 43, \"end_idx\": 52, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"c854d885-c08f-4145-adf2-6ad1ba075501\", \"childbox\": \"bd6a0743-3b6b-4c07-92ef-d1f92d36ce24\", \"subtext\": \"21aa85b6-54cf-43d6-bb49-ff923cade0f3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 228, \"\"], [\"\", \"Unmapped\", \"text\", \"In treatment-naive HCV-infected subjects, administration of samatasvir QD or BID for 3 days at a total daily dose of 100 mg resulted in mean maximal viral load reductions of 3.5, 2.0, 3.4 and 3.9 log\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 60, \"end_idx\": 69, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"c854d885-c08f-4145-adf2-6ad1ba075501\", \"childbox\": \"47bf3a17-3b05-430a-80dc-688af7b2e40d\", \"subtext\": \"7c943fce-e19a-4645-bfe4-a05b79b0707b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 229, \"\"], [\"\", \"Unmapped\", \"text\", \"10\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c854d885-c08f-4145-adf2-6ad1ba075501\", \"childbox\": \"47bf3a17-3b05-430a-80dc-688af7b2e40d\", \"subtext\": \"d212d77e-1d8e-417d-bedc-1afff641b024\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 230, \"\"], [\"\", \"Unmapped\", \"text\", \"IU/mL in GT 1, 2, 3 and 4 HCV infections, respectively ([IDX06A-001] [IDX719 Investigator\\u2019s Brochure]).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 70, \"end_idx\": 75, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"c854d885-c08f-4145-adf2-6ad1ba075501\", \"childbox\": \"47bf3a17-3b05-430a-80dc-688af7b2e40d\", \"subtext\": \"91223153-4590-4e0f-948f-b6b01a2b0d8e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 231, \"\"], [\"\", \"Unmapped\", \"text\", \"Interim analyses of safety and antiviral activity data from the ongoing 12-week study of samatasvir (25 mg, 50 mg, 100 mg or 150 mg) in combination with simeprevir and RBV have shown the combination to be safe and well tolerated and have demonstrated antiviral activity against HCV GT 1b and 4 ([IDX-06A-005],  data on file).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 89, \"end_idx\": 98, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"c854d885-c08f-4145-adf2-6ad1ba075501\", \"childbox\": \"5ce68bf2-5fc5-4991-a127-77424aff31d9\", \"subtext\": \"8e51890a-c5cf-45a6-897a-b58fed03542c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 232, \"\"], [\"\", \"Unmapped\", \"text\", \"Results of\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"821f0d15-be46-4fe5-be25-2220d390d8e1\", \"childbox\": \"6ed54db5-9ad7-41a1-a281-382aee05c900\", \"subtext\": \"f0f857af-4ae7-445b-b2b8-42a04ccd4e2b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 233, \"\"], [\"\", \"Unmapped\", \"text\", \"in vitro\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"821f0d15-be46-4fe5-be25-2220d390d8e1\", \"childbox\": \"6ed54db5-9ad7-41a1-a281-382aee05c900\", \"subtext\": \"a273f53c-ace8-4a5b-8e2c-f192b5429752\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 234, \"\"], [\"\", \"Unmapped\", \"text\", \"studies suggest samatasvir has a limited potential for drug-drug interactions, making it possible to test samatasvir with various combinations of other DAAs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 16, \"end_idx\": 25, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 106, \"end_idx\": 115, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 16, \"end_idx\": 25, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 106, \"end_idx\": 115, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 16, \"end_idx\": 25, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 106, \"end_idx\": 115, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"821f0d15-be46-4fe5-be25-2220d390d8e1\", \"childbox\": \"6ed54db5-9ad7-41a1-a281-382aee05c900\", \"subtext\": \"8b3cbfbe-b1a6-4f0b-bde8-aa9a0c203046\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 235, \"\"], [\"\", \"Unmapped\", \"text\", \"Summaries of nonclinical studies conducted are described in the [IDX719 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 65, \"end_idx\": 70, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"821f0d15-be46-4fe5-be25-2220d390d8e1\", \"childbox\": \"fb4ed1ef-8721-4407-b295-d42ddf771772\", \"subtext\": \"8b3cbfbe-b1a6-4f0b-bde8-aa9a0c203046\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Background\", \"1\", \"1\", 236, \"\"], [\"\", \"Unmapped\", \"header\", \"1.1 Justification of selected doses\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"2d55d27d-a4c9-4018-a968-5e54cb7ae495\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 237, \"\"], [\"\", \"Unmapped\", \"header\", \"IDX21437\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"098ef40e-92a4-490e-b5e0-c4dc26984970\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 238, \"\"], [\"\", \"Unmapped\", \"text\", \"The selected IDX21437 dose for this study, 300 mg QD, is supported by 3-month repeat-dose toxicology studies in the rat and monkey.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 13, \"end_idx\": 20, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 13, \"end_idx\": 20, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 13, \"end_idx\": 20, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"675bb51e-b6f0-4e71-89d2-de235ed63ee9\", \"childbox\": \"7a05f89a-cfb7-4d61-a57e-1cb2e70296df\", \"subtext\": \"2198bfb4-7f42-4ed2-b2ef-c5a1f0e4daa7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 239, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 was well tolerated up to 1000 mg/kg/day in the rat and monkey [IDX21437 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 72, \"end_idx\": 79, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"675bb51e-b6f0-4e71-89d2-de235ed63ee9\", \"childbox\": \"c2d7929e-1f80-451c-8c01-cfd0e66284cf\", \"subtext\": \"2198bfb4-7f42-4ed2-b2ef-c5a1f0e4daa7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 240, \"\"], [\"\", \"Unmapped\", \"text\", \"In an ongoing, first-in-human IDX21437 study [IDX-04B-001], multiple doses up to a total daily dose of 300 mg IDX21437 for 7 days were found to be safe and well tolerated in healthy subjects.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 110, \"end_idx\": 117, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 110, \"end_idx\": 117, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 110, \"end_idx\": 117, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"d4f03f88-7be9-4ee8-87ba-32a4e50167ec\", \"childbox\": \"dc7cb62c-60fc-4fe7-b657-cc379f44e99a\", \"subtext\": \"263885bf-320e-427a-b6af-96ed24e42cac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 241, \"\"], [\"\", \"Unmapped\", \"text\", \"There were no treatment-emergent serious adverse events (SAEs) or safety related discontinuations.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d4f03f88-7be9-4ee8-87ba-32a4e50167ec\", \"childbox\": \"614bb02e-117f-4c4e-beeb-72ea1859d34e\", \"subtext\": \"722199eb-52ca-4c69-948a-aaf8ffde3a00\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 242, \"\"], [\"\", \"Unmapped\", \"text\", \"Single doses from 10 to 300 mg administered to HCV-infected subjects demonstrated antiviral activity ([IDX-04B-001], data on file).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d4f03f88-7be9-4ee8-87ba-32a4e50167ec\", \"childbox\": \"48f9100e-b125-4c01-bfe7-fd82642a495d\", \"subtext\": \"3906ea98-4cab-4c16-ab8e-6deaa04b93fc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 243, \"\"], [\"\", \"Unmapped\", \"text\", \"Testing of daily doses ranging from 50 to 300 mg for 7 days in approximately 35 GT 1-3, HCV-infected subjects has demonstrated that 300 mg QD is the most active dose producing mean maximal viral load reductions of >4 log\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d4f03f88-7be9-4ee8-87ba-32a4e50167ec\", \"childbox\": \"9ebb0dea-ccc8-42c9-aa94-1149457a822d\", \"subtext\": \"f7e59584-c4d2-4f4b-bdde-c8984fc14c8b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 244, \"\"], [\"\", \"Unmapped\", \"text\", \"10\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d4f03f88-7be9-4ee8-87ba-32a4e50167ec\", \"childbox\": \"9ebb0dea-ccc8-42c9-aa94-1149457a822d\", \"subtext\": \"37631959-4553-42a6-bf08-90b27938c098\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 245, \"\"], [\"\", \"Unmapped\", \"text\", \"IU/mL, and is safe and well tolerated [IDX21437 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 39, \"end_idx\": 46, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"d4f03f88-7be9-4ee8-87ba-32a4e50167ec\", \"childbox\": \"9ebb0dea-ccc8-42c9-aa94-1149457a822d\", \"subtext\": \"026b9163-1bf8-4c7e-bd6d-6709a593d7e0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 246, \"\"], [\"\", \"Unmapped\", \"header\", \"Samatasvir\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}], \"roi_id\": {\"para\": \"dd1ad1cc-235e-46d0-bb1b-1f61aa589966\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 247, \"\"], [\"\", \"Unmapped\", \"text\", \"The selected samatasvir doses for this study, 50 or 100 mg QD for 8 or 12 weeks, are supported by the repeat-dose toxicology studies with durations of up to 13 weeks at doses up to 250 mg/kg/day [IDX719 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 13, \"end_idx\": 22, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 13, \"end_idx\": 22, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 13, \"end_idx\": 22, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 196, \"end_idx\": 201, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 196, \"end_idx\": 201, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 196, \"end_idx\": 201, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 196, \"end_idx\": 201, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"862f59c5-2a2d-4568-b1b9-5e99bb51a528\", \"childbox\": \"f4becf8b-7f84-4bf2-8ca7-72fd41a97054\", \"subtext\": \"d8430b05-bfed-4ceb-bb06-811072ceab4c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 248, \"\"], [\"\", \"Unmapped\", \"text\", \"The antiviral activity of samatasvir has been demonstrated by 3 days of monotherapy in the proof-of-concept study [IDX-06A-001].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 26, \"end_idx\": 35, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"862f59c5-2a2d-4568-b1b9-5e99bb51a528\", \"childbox\": \"301149bf-18d5-4577-a3c1-d84921ab59d7\", \"subtext\": \"1b5dfbee-df10-4b7a-8787-80b5510cac73\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 249, \"\"], [\"\", \"Unmapped\", \"text\", \"At a total daily dose of 50 or 100 mg x 3 days, mean HCV RNA reductions were similar in GT 1 HCV-infected subjects [IDX719 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 116, \"end_idx\": 121, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"862f59c5-2a2d-4568-b1b9-5e99bb51a528\", \"childbox\": \"e005b6ed-56df-48d6-b175-05836ab75bd4\", \"subtext\": \"3b515e41-72a1-4ccc-8d8d-10b61d674c05\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 250, \"\"], [\"\", \"Unmapped\", \"text\", \"Interim analyses of safety and antiviral activity data from the ongoing study of samatasvir 25 mg, 50 mg, 100 mg or 150 mg, in combination with simeprevir and RBV [IDX-06A-005], also support the use of samatasvir 50 mg QD and 100 mg QD [IDX719 Investigator\\u2019s Brochure] in the current study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 81, \"end_idx\": 90, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 202, \"end_idx\": 211, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 81, \"end_idx\": 90, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 202, \"end_idx\": 211, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 81, \"end_idx\": 90, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 202, \"end_idx\": 211, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 237, \"end_idx\": 242, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 237, \"end_idx\": 242, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 237, \"end_idx\": 242, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 237, \"end_idx\": 242, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"e6dc2a61-c54d-4373-94e7-7ba4db7694be\", \"childbox\": \"f8fc734f-2883-43e8-8911-acb9c325d301\", \"subtext\": \"b8933b21-8eb8-471e-893a-4c16ded437d4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Justification of selected doses\", \"1.1\", \"2\", 251, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2 Risk/benefit assessment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"3dd7224b-5f7f-4713-b4f1-7fa099576988\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk/benefit assessment\", \"1.2\", \"2\", 252, \"\"], [\"\", \"Unmapped\", \"text\", \"Phase II combination studies of DAAs for the treatment of chronic HCV infection have been promising at demonstrating rapid and early viral response without pegylated interferon (PegIFN).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1608e268-fca8-49d4-afb3-88035051af9a\", \"childbox\": \"c97c7d90-4358-4bc6-a0cb-6ad6456d6d3e\", \"subtext\": \"4e792adf-5e7b-463d-8578-ba11709f890d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk/benefit assessment\", \"1.2\", \"2\", 253, \"\"], [\"\", \"Unmapped\", \"text\", \"While additional trials are required to confirm that these results translate into clinical benefit, combinations of DAAs with different modes of action and complementary resistance profiles likely represent the future of HCV care.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1608e268-fca8-49d4-afb3-88035051af9a\", \"childbox\": \"aaa65579-b9a2-4b7c-83cf-7f959d77c770\", \"subtext\": \"4e792adf-5e7b-463d-8578-ba11709f890d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk/benefit assessment\", \"1.2\", \"2\", 254, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2.1 Known Benefits\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"05edfc2d-af47-417d-839c-a96651fc32a1\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Benefits\", \"1.2.1\", \"3\", 255, \"\"], [\"\", \"Unmapped\", \"text\", \"There is no known benefit for participants in this study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c650f46e-70ae-4c9e-82e6-be2949ce43a0\", \"childbox\": \"83246e7f-18fb-44c3-850c-0513d08e22b6\", \"subtext\": \"539329f7-0670-4b71-8ef7-6a107ecc6294\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Benefits\", \"1.2.1\", \"3\", 256, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2.2 Potential Benefits\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"ecf537f3-aefb-495d-bfee-3442ff18ca16\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Benefits\", \"1.2.2\", \"3\", 257, \"\"], [\"\", \"Unmapped\", \"text\", \"The potential benefit for participants in this study is in achieving a cure from HCV infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a2dc9be4-25e2-444a-ba67-494e3bea8d7d\", \"childbox\": \"5d053411-a4ce-4617-9c81-b39db1267bf0\", \"subtext\": \"e1d013ae-d1d9-46d7-b25f-a9bdbba0012b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Benefits\", \"1.2.2\", \"3\", 258, \"\"], [\"\", \"Unmapped\", \"text\", \"The results may be useful in developing new therapies and treatment strategies for individuals with HCV infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a2dc9be4-25e2-444a-ba67-494e3bea8d7d\", \"childbox\": \"a1d186bb-a488-4042-b7a0-8c17309ad6f4\", \"subtext\": \"e1d013ae-d1d9-46d7-b25f-a9bdbba0012b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Benefits\", \"1.2.2\", \"3\", 259, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2.3 Known Risks\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"a2091ad0-0998-432a-8d6c-807fe5ef43aa\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 260, \"\"], [\"\", \"Unmapped\", \"text\", \"Every medication can have\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a721d83f-f82f-414d-b836-da75d9d82076\", \"childbox\": \"6d122ab7-d846-4695-bbc5-21f534fb3a0e\", \"subtext\": \"ea34a429-71d1-49f5-8ae1-c6c6486ff179\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 261, \"\"], [\"\", \"Unmapped\", \"text\", \"undesirable effects\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a721d83f-f82f-414d-b836-da75d9d82076\", \"childbox\": \"6d122ab7-d846-4695-bbc5-21f534fb3a0e\", \"subtext\": \"afa97fe1-bf12-4ff2-8fae-dfca8c82f4c4\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 262, \"\"], [\"\", \"Unmapped\", \"text\", \".\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a721d83f-f82f-414d-b836-da75d9d82076\", \"childbox\": \"6d122ab7-d846-4695-bbc5-21f534fb3a0e\", \"subtext\": \"d5570670-3c93-47e6-b45c-1b578e774c73\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 263, \"\"], [\"\", \"Unmapped\", \"header\", \"Adverse events for IDX21437\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [{\"start_idx\": 19, \"end_idx\": 26, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 19, \"end_idx\": 26, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 19, \"end_idx\": 26, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"66667994-af9a-4d4f-a972-df5ae1128075\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 264, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 has been safe and well tolerated in a limited number of healthy and HCV-infected subjects up to doses of 300 mg QD x 7 days (Section 1.1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"f99ed80a-0493-4d0e-837d-a7a5e7f59c94\", \"childbox\": \"3c7a2cca-f573-498f-bfaa-5edd547c9d98\", \"subtext\": \"92ffb68c-f58a-4d5a-b3fc-3ed927575f19\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 265, \"\"], [\"\", \"Unmapped\", \"text\", \"To date, there is no observed doserelated or other pattern in the clinical or laboratory data.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f99ed80a-0493-4d0e-837d-a7a5e7f59c94\", \"childbox\": \"0ae01d27-5fc0-4812-97a4-c5e5452aeb1e\", \"subtext\": \"03ce1e69-6253-407f-bea2-e78db17b3d59\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 266, \"\"], [\"\", \"Unmapped\", \"text\", \"Studies in rats and monkeys administered up to 1000 mg/kg/day for 3 months indicate that the kidney and liver are potential target organs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e9dea66-1603-4be4-8f2b-81ccc8d961dc\", \"childbox\": \"6be56e6f-86e2-458b-9386-9d7a7b35da68\", \"subtext\": \"8b4036e0-3de3-4280-8e56-544ab6fb0110\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 267, \"\"], [\"\", \"Unmapped\", \"text\", \"While\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8de9b90d-7db9-44d9-953a-7384c5805328\", \"childbox\": \"bc00d3c6-2f2f-450b-9112-259170d153cf\", \"subtext\": \"430184a9-95e1-4004-9124-3b25a70b0812\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 268, \"\"], [\"\", \"Unmapped\", \"text\", \"in vitro\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8de9b90d-7db9-44d9-953a-7384c5805328\", \"childbox\": \"bc00d3c6-2f2f-450b-9112-259170d153cf\", \"subtext\": \"6505d544-4462-4aa3-9c3f-8dd1b2ac9276\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 269, \"\"], [\"\", \"Unmapped\", \"text\", \"and animal toxicology data are consistent with IDX21437 having a low potential for cardiac or mitochondrial toxicity, nucleoside analogues as a class have been associated with mitochondrial toxicity, resulting in symptoms such as pancreatitis, lactic acidosis, severe hepatomegaly, peripheral neuropathy, and myopathy, including cardiomyopathy.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 47, \"end_idx\": 54, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 47, \"end_idx\": 54, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 47, \"end_idx\": 54, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"8de9b90d-7db9-44d9-953a-7384c5805328\", \"childbox\": \"bc00d3c6-2f2f-450b-9112-259170d153cf\", \"subtext\": \"8687b40a-e801-403c-84db-b0036fe9ca00\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 270, \"\"], [\"\", \"Unmapped\", \"header\", \"Adverse events for samatasvir (IDX719)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [{\"start_idx\": 19, \"end_idx\": 28, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 19, \"end_idx\": 28, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 19, \"end_idx\": 28, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 31, \"end_idx\": 36, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 31, \"end_idx\": 36, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 31, \"end_idx\": 36, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 31, \"end_idx\": 36, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"046589f4-d3a9-4d37-bb7d-13117f76bdfe\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 271, \"\"], [\"\", \"Unmapped\", \"text\", \"Approximately 200 healthy subjects have received samatasvir from 5 mg to 200 mg per day, for up to 14 days.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 49, \"end_idx\": 58, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 49, \"end_idx\": 58, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 87.0, \"text\": \"samatasvir\"}, {\"start_idx\": 49, \"end_idx\": 58, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"6d9cdebd-3f1f-4503-979a-85e7f9dce550\", \"childbox\": \"c4050c04-8027-4684-bc18-ef81a785c9f2\", \"subtext\": \"c2ac66c5-eb6e-4992-ae2f-209850049539\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 272, \"\"], [\"\", \"Unmapped\", \"text\", \"In an ongoing phase II study, approximately 100 HCV-infected subjects have received samatasvir, ranging from 50 to 150 mg QD, + simeprevir + RBV for 12 weeks.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 84, \"end_idx\": 93, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"6d9cdebd-3f1f-4503-979a-85e7f9dce550\", \"childbox\": \"932484c6-93ea-40a4-b3d1-3a5bb7f0d89f\", \"subtext\": \"c2ac66c5-eb6e-4992-ae2f-209850049539\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 273, \"\"], [\"\", \"Unmapped\", \"text\", \"An additional 44 subjects received samatasvir in combination with simeprevir, TMC647055, ritonavir and RBV.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 35, \"end_idx\": 44, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"6d9cdebd-3f1f-4503-979a-85e7f9dce550\", \"childbox\": \"d471da02-db9b-46c2-be04-2e311368a100\", \"subtext\": \"50470fcb-cdf2-422b-83a1-99ec473b19fa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 274, \"\"], [\"\", \"Unmapped\", \"text\", \"The safety profile of samatasvir has been consistent with the known safety profile of the same combinations without samatasvir.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 22, \"end_idx\": 31, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 116, \"end_idx\": 125, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"6d9cdebd-3f1f-4503-979a-85e7f9dce550\", \"childbox\": \"fb500c1e-158b-486d-a6ba-b44bb154a61f\", \"subtext\": \"50470fcb-cdf2-422b-83a1-99ec473b19fa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 275, \"\"], [\"\", \"Unmapped\", \"text\", \"When samatasvir was administered alone, there was no observed dose-related or other pattern in the clinical or laboratory data.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 5, \"end_idx\": 14, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 5, \"end_idx\": 14, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 5, \"end_idx\": 14, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"b1cd3693-6108-4bf6-a595-6621b0f253df\", \"childbox\": \"e5f969fc-ce95-4505-bae7-a39d4ab2c342\", \"subtext\": \"3e196d40-89ce-4bb9-8f6c-a0fcf84203e1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 276, \"\"], [\"\", \"Unmapped\", \"text\", \"The majority of observed adverse events have been mild or moderate.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b1cd3693-6108-4bf6-a595-6621b0f253df\", \"childbox\": \"fb017c8e-433f-4fc8-908f-29310ce6ec6f\", \"subtext\": \"3e196d40-89ce-4bb9-8f6c-a0fcf84203e1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 277, \"\"], [\"\", \"Unmapped\", \"header\", \"Ribavirin\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"8dda78af-367d-4be1-ba9f-745a2dccf79d\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 278, \"\"], [\"\", \"Unmapped\", \"text\", \"Refer to the U.S.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5dd1cbac-edd5-4464-a63c-5621659b2eee\", \"childbox\": \"2b7dc459-5ae1-4a81-9d01-9bb597a76fa8\", \"subtext\": \"a7ee78bb-ad0d-43f4-b600-9c5cf8c05cb2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 279, \"\"], [\"\", \"Unmapped\", \"text\", \"summary of product information (package insert) for RBV (Ribavirin Tablets (2013)), and/or to the local country summary of product information, as applicable, for the associated risks of taking RBV.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5dd1cbac-edd5-4464-a63c-5621659b2eee\", \"childbox\": \"355d081d-4ec5-4850-a18c-3c0b2ea80308\", \"subtext\": \"a7ee78bb-ad0d-43f4-b600-9c5cf8c05cb2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Known Risks\", \"1.2.3\", \"3\", 280, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2.4 Potential Risks\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"151178cf-341f-4fa6-897b-a3ac9cabc485\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 281, \"\"], [\"\", \"Unmapped\", \"text\", \"Reproductive risk\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d914414c-709b-48ee-ab7e-776b12f517d2\", \"childbox\": \"8420f1ea-1584-40c3-bd1f-06d3c603560b\", \"subtext\": \"be1c29a1-a6df-4807-aa9c-a0a8ce7f8ac9\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 282, \"\"], [\"\", \"Unmapped\", \"text\", \"It is not known at this time whether samatasvir or IDX21437 has any impact on reproductive function.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 37, \"end_idx\": 46, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 37, \"end_idx\": 46, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 37, \"end_idx\": 46, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 51, \"end_idx\": 58, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 51, \"end_idx\": 58, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 51, \"end_idx\": 58, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"0338c5a7-5905-448a-a026-9a7f283a25f8\", \"childbox\": \"bca1e7c1-f994-470c-a89b-46b19d737726\", \"subtext\": \"bffe1eaa-4e76-4791-8cf6-45c96add688f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 283, \"\"], [\"\", \"Unmapped\", \"text\", \"Pregnant subjects must not be included in this study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0338c5a7-5905-448a-a026-9a7f283a25f8\", \"childbox\": \"d6a508da-fbfb-4337-970d-33ebc6f55bd8\", \"subtext\": \"bffe1eaa-4e76-4791-8cf6-45c96add688f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 284, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects of child-bearing potential must be informed to use a double-method of birth control (one of which must be a barrier) while participating in this study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0338c5a7-5905-448a-a026-9a7f283a25f8\", \"childbox\": \"49003856-4951-4fec-87be-43842ee0826b\", \"subtext\": \"bffe1eaa-4e76-4791-8cf6-45c96add688f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 285, \"\"], [\"\", \"Unmapped\", \"text\", \"It is not known whether samatasvir or IDX21437 is excreted in human milk.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 24, \"end_idx\": 33, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 24, \"end_idx\": 33, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 24, \"end_idx\": 33, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 38, \"end_idx\": 45, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 38, \"end_idx\": 45, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 38, \"end_idx\": 45, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"5d81d332-948e-4ce4-b855-7450e5558eeb\", \"childbox\": \"a658e90c-a5a6-4ec6-88a0-61e3da91d9c6\", \"subtext\": \"0e5b68ab-7eeb-4c33-9992-7ac2232190fb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 286, \"\"], [\"\", \"Unmapped\", \"text\", \"Nursing mothers must not be included in clinical trials with samatasvir or IDX21437.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 61, \"end_idx\": 70, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 75, \"end_idx\": 82, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"5d81d332-948e-4ce4-b855-7450e5558eeb\", \"childbox\": \"c1d0b70b-b234-4b78-893d-001cd63ec0b3\", \"subtext\": \"0e5b68ab-7eeb-4c33-9992-7ac2232190fb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 287, \"\"], [\"\", \"Unmapped\", \"header\", \"Potential genotoxicity\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"192e236b-bd32-40a8-ac19-1998c4d552c3\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 288, \"\"], [\"\", \"Unmapped\", \"text\", \"Samatasvir and IDX21437 are non-genotoxic compounds [IDX719 Investigator\\u2019s Brochure] [IDX21437 Investigator\\u2019s Brochure].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 15, \"end_idx\": 22, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 86, \"end_idx\": 93, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 15, \"end_idx\": 22, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 86, \"end_idx\": 93, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 15, \"end_idx\": 22, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 86, \"end_idx\": 93, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 53, \"end_idx\": 58, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 87.0, \"text\": \"IDX719\"}, {\"start_idx\": 53, \"end_idx\": 58, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 53, \"end_idx\": 58, \"standard_entity_name\": \"IDX719\", \"subcategory\": \"IDX719\", \"confidence\": 100.0, \"text\": \"IDX719\"}, {\"start_idx\": 53, \"end_idx\": 58, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"IDX719\"}], \"roi_id\": {\"para\": \"5ede9feb-14fe-4446-9894-2876acec6aff\", \"childbox\": \"74672a4b-9fab-431f-8275-b97695c0fe65\", \"subtext\": \"c165ba8f-fe90-42af-83ef-ba0d74de1182\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 289, \"\"], [\"\", \"Unmapped\", \"header\", \"QT prolongation\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"fdab65db-4837-4b6a-99e5-644c85422a81\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 290, \"\"], [\"\", \"Unmapped\", \"text\", \"The available data indicate that samatasvir and IDX21437 have very limited potential for QT prolongation at clinical exposures.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 33, \"end_idx\": 42, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 33, \"end_idx\": 42, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 33, \"end_idx\": 42, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 48, \"end_idx\": 55, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 48, \"end_idx\": 55, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 48, \"end_idx\": 55, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"1951bf7c-c842-4afe-b10b-566eb62ca2f2\", \"childbox\": \"859cc12e-687d-4b7b-aa5c-0fd64362411b\", \"subtext\": \"835c46f4-cb4a-4bf9-a75b-09cf485a6213\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Potential Risks\", \"1.2.4\", \"3\", 291, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2.5 Risk mitigation\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"5378e68d-7ae1-4139-a61a-573fafc4d01b\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 292, \"\"], [\"\", \"Unmapped\", \"text\", \"Liver and renal function laboratory parameters will be monitored (Table 7-1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"68399aed-46b6-4228-9039-01550e2bbf59\", \"subtext\": \"056d2c30-c6bf-49f5-a779-cc3cd6919ee7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 293, \"\"], [\"\", \"Unmapped\", \"text\", \"These will include the clinical chemistry parameters defined in Section 7.5.5 Cardiac parameters, including ECGs and creatine kinase (CK) isoenzyme levels will be monitored, although these investigational modalities have not been shown to fully predict the presence of human cardiac injury.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"3728bfdd-c76b-4f5e-b456-f7c2baf88164\", \"subtext\": \"7568886a-4d6b-4698-b10d-86563be23a99\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 294, \"\"], [\"\", \"Unmapped\", \"text\", \"While\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"2f9ff298-3991-4863-886c-9d4bf1ffd098\", \"subtext\": \"1c3ac04c-175f-4012-84f1-51096559d86b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 295, \"\"], [\"\", \"Unmapped\", \"text\", \"in vitro\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"2f9ff298-3991-4863-886c-9d4bf1ffd098\", \"subtext\": \"3cfcc884-4907-4ef2-91e5-77565848fb64\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 296, \"\"], [\"\", \"Unmapped\", \"text\", \"and animal toxicology data are consistent with IDX21437 having a low potential for cardiac or mitochondrial toxicity, nucleoside analogues as a class have been associated with mitochondrial toxicity, resulting in symptoms such as pancreatitis, lactic acidosis, severe hepatomegaly, peripheral neuropathy, and myopathy, including cardiomyopathy.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 47, \"end_idx\": 54, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"2f9ff298-3991-4863-886c-9d4bf1ffd098\", \"subtext\": \"52c1bd4d-2f37-4d44-b5ba-d7c31e5c2302\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 297, \"\"], [\"\", \"Unmapped\", \"text\", \"Amylase and anion gap will be monitored.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"be9fa762-3b8f-46cb-92da-3e2c5f59b52e\", \"subtext\": \"b86c229c-cf0f-4e95-98e5-f521a9d4d5e6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 298, \"\"], [\"\", \"Unmapped\", \"text\", \"In addition, standard serum chemistries, complete blood counts (CBC) with differentials and clinical adverse events will be monitored.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"d6d50929-da38-4995-a199-2bcbef63c7cb\", \"subtext\": \"d73a088d-4328-43ab-aa8a-a3f84af3d0b1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 299, \"\"], [\"\", \"Unmapped\", \"text\", \"A baseline echocardiogram will be performed and archived, as a contingency, for comparisons to unplanned evaluations after study drug exposure, should such comparisons be needed.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8ade8f0c-d097-43a9-a6d3-c69df1d78468\", \"childbox\": \"c5f1dc0a-4505-4ef7-9513-92ad021df596\", \"subtext\": \"d73a088d-4328-43ab-aa8a-a3f84af3d0b1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Risk mitigation\", \"1.2.5\", \"3\", 300, \"\"], [\"\", \"Unmapped\", \"header\", \"1.2.6 Overall benefit/risk assessment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"8f1670d0-06a8-43a1-8f77-3ef213447828\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 301, \"\"], [\"\", \"Unmapped\", \"text\", \"Based on the available data and proposed safety measures, the overall risk/benefit assessment for this clinical study in HCV-infected subjects is acceptable for the following reasons:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f15e72a-a45d-4d73-b207-6b98a0203d67\", \"childbox\": \"f25ee798-8299-4fe1-9ace-8a548374183f\", \"subtext\": \"fd25606e-553f-420e-a174-59b10d454021\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 302, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 There is a high unmet medical need for new therapies for the treatment of chronic HCV infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"41f5038f-2ec0-4c6a-8586-31a7e9f5a925\", \"childbox\": \"1c2a0811-f0ae-4f50-ac6f-4578abef3f5c\", \"subtext\": \"ace08aab-553f-47af-b156-5abf650c4637\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 303, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Samatasvir and IDX21437 have demonstrated clinical antiviral activity against HCV genotypes 1 and 3.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 2, \"end_idx\": 11, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 2, \"end_idx\": 11, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 2, \"end_idx\": 11, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 17, \"end_idx\": 24, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 17, \"end_idx\": 24, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 17, \"end_idx\": 24, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"561d6a76-a540-437d-b3aa-2329fc707d49\", \"childbox\": \"99bef44a-b139-46fa-b3fc-79ab5dccd8b1\", \"subtext\": \"16d187b3-e1e1-4975-abd6-8796d6cb4fe9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 304, \"\"], [\"\", \"Unmapped\", \"text\", \"Each compound has a favorable safety profile in preclinical and clinical studies, to date.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"561d6a76-a540-437d-b3aa-2329fc707d49\", \"childbox\": \"1c8d69b1-1e75-4d10-97be-276e44498705\", \"subtext\": \"16d187b3-e1e1-4975-abd6-8796d6cb4fe9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 305, \"\"], [\"\", \"Unmapped\", \"text\", \"5.1.2 \\u2022 Only subjects who meet all of the inclusion criteria and none of the exclusion criteria (as specified in the protocol) will be allowed to participate in this study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f511c41c-8340-4dd9-9c11-5f9aab2d1e48\", \"childbox\": \"9d93a48c-27c7-43f0-a1e9-2a1ec521ad30\", \"subtext\": \"df491fac-f940-4cdf-a4f8-9dc4d725981e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 306, \"\"], [\"\", \"Unmapped\", \"text\", \"The selection criteria include adequate provisions to minimize the risk and protect the well-being of subjects in the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f511c41c-8340-4dd9-9c11-5f9aab2d1e48\", \"childbox\": \"13246f04-0137-4c11-9f4b-1d9e56146a3e\", \"subtext\": \"8a9f0462-c8d3-49f3-bc58-61a3ee9997d0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 307, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Safety will be closely monitored by the investigator throughout the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04c03284-24b8-489a-9172-209349c392a7\", \"childbox\": \"f4196bfb-a7db-4a6c-8cbc-fc8c74e645e3\", \"subtext\": \"ca9590d8-cc29-4399-bdf4-90c3ddaf5955\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 308, \"\"], [\"\", \"Unmapped\", \"text\", \"Safety and tolerability assessments (including clinical laboratory tests, ECG, vital signs, physical examination) will be performed at scheduled visits throughout the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04c03284-24b8-489a-9172-209349c392a7\", \"childbox\": \"98d140f4-c6df-40d9-946f-5564f43edda8\", \"subtext\": \"a60c3875-0f7b-4328-be08-439e538b5b97\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 309, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 The study is being conducted under Data Safety Monitoring Board (DSMB) supervision (Section 4.1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"11964466-1c1a-42af-917b-9a466707d4f0\", \"childbox\": \"2c12368a-31c2-4420-9a62-4dc654e7be6a\", \"subtext\": \"6fbbf62e-63f5-441a-93a7-7150e434427c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 310, \"\"], [\"\", \"Unmapped\", \"text\", \"Study and individual safety stopping rules and futility rules have been included in the protocol (Section 4.2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"11964466-1c1a-42af-917b-9a466707d4f0\", \"childbox\": \"be8b9c21-f6b3-48a6-bbe0-2af52f4a562f\", \"subtext\": \"32fc9cbb-7ed7-4267-8c36-76963865bea3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 311, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Any clinically significant abnormalities persisting at the end of the study/early withdrawal will be followed by the investigator until resolution or until a clinically stable endpoint is reached.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"60c74e8b-d78f-4274-8520-e062eb9e7b38\", \"childbox\": \"6b2cb68d-1d6b-4514-b298-4fd7ae3859a6\", \"subtext\": \"18e18d60-c86d-43a3-b6ec-bb397d2ab3e5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Overall benefit/risk assessment\", \"1.2.6\", \"3\", 312, \"\"], [\"\", \"Unmapped\", \"header\", \"2 Study purpose\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"fb14ec7b-a66a-4425-a09d-7abf0dabc7c6\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study purpose\", \"2\", \"1\", 313, \"\"], [\"\", \"Unmapped\", \"text\", \"The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and IDX21437 when administered in combination with and without RBV for 8 or 12 weeks in treatment-na\\u00efve, GT 1 or 3 HCV-infected subjects.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 108, \"end_idx\": 117, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 108, \"end_idx\": 117, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 108, \"end_idx\": 117, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 123, \"end_idx\": 130, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 123, \"end_idx\": 130, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 123, \"end_idx\": 130, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"79678359-f7c6-40c9-851c-d2eda3fb1085\", \"childbox\": \"2df5edc1-d308-48a7-84d5-eb26a016cad5\", \"subtext\": \"1bb320f8-3b2e-457d-94b3-d3400b4474ee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study purpose\", \"2\", \"1\", 314, \"\"], [\"\", \"Unmapped\", \"header\", \"3 Objectives\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"25137a8c-109e-490d-912d-bad6c7d4de5e\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Objectives\", \"3\", \"1\", 315, \"\"], [\"\", \"Unmapped\", \"header\", \"3.1 Primary objectives\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"a478c533-4b52-4d15-bcd4-5b058b84f9a4\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Primary objectives\", \"3.1\", \"2\", 316, \"\"], [\"\", \"Unmapped\", \"text\", \"The primary objectives are to evaluate the:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6eac2f37-9e26-4707-af44-18219f510312\", \"childbox\": \"fda4962e-06e4-4546-93ae-e40d1796b830\", \"subtext\": \"62a1fd8a-69cb-43f8-880d-26809d267652\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Primary objectives\", \"3.1\", \"2\", 317, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Safety of samatasvir plus IDX21437 with and without RBV\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 12, \"end_idx\": 21, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 12, \"end_idx\": 21, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 12, \"end_idx\": 21, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 28, \"end_idx\": 35, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 28, \"end_idx\": 35, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 28, \"end_idx\": 35, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"6c28ca45-f9da-4efc-aabf-7cfc269300b5\", \"childbox\": \"8662d7ab-151b-48e0-963a-cdd4aa77a8f1\", \"subtext\": \"a67204f8-5f76-479c-9994-c91be118848f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Primary objectives\", \"3.1\", \"2\", 318, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Efficacy of samatasvir plus IDX21437 with and without RBV\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 14, \"end_idx\": 23, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 14, \"end_idx\": 23, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 14, \"end_idx\": 23, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 30, \"end_idx\": 37, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"dcde9a15-20a7-4bca-be35-2bed91bcf318\", \"childbox\": \"9977a907-70f7-4b1c-abe3-649730207265\", \"subtext\": \"e487b463-32fa-43a7-847f-9f548e4139e1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Primary objectives\", \"3.1\", \"2\", 319, \"\"], [\"\", \"Unmapped\", \"header\", \"3.2 Secondary objectives\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"aafb21e2-4fb4-4468-8064-c147c6ba496a\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Secondary objectives\", \"3.2\", \"2\", 320, \"\"], [\"\", \"Unmapped\", \"text\", \"The secondary objectives are to evaluate the:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d9dc3432-2210-49c6-bc51-59e7865b7293\", \"childbox\": \"3a1f7df0-ccf1-4153-aabe-114a544c1c60\", \"subtext\": \"c1ef3c01-7779-4b63-acd1-18af027561e6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Secondary objectives\", \"3.2\", \"2\", 321, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Treatment duration\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c3953786-6a52-4bcf-b891-85099bc2ef3e\", \"childbox\": \"309fd9d0-c4e5-43e4-b4b2-d49284c0e4af\", \"subtext\": \"c4f725f5-b1b1-4597-a143-ef817f8434a7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Secondary objectives\", \"3.2\", \"2\", 322, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Pharmacokinetics (PK) of samatasvir, IDX21437 and their metabolites\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 27, \"end_idx\": 36, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 27, \"end_idx\": 36, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 27, \"end_idx\": 36, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 39, \"end_idx\": 46, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 39, \"end_idx\": 46, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 39, \"end_idx\": 46, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"49134c80-c42e-4676-b40b-0e988e619288\", \"childbox\": \"afa8e44d-a041-4017-aa0d-3fedb7c62fba\", \"subtext\": \"4984e207-671c-4edf-9753-9193dbcc7393\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Secondary objectives\", \"3.2\", \"2\", 323, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 PK/Pharmacodynamics (PK/PD) of samatasvir, IDX21437 and their metabolites\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 33, \"end_idx\": 42, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 33, \"end_idx\": 42, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 33, \"end_idx\": 42, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 45, \"end_idx\": 52, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 45, \"end_idx\": 52, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 45, \"end_idx\": 52, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"67504e5c-e6b5-4645-8ba0-45bde358b1a9\", \"childbox\": \"21956609-7925-46cc-af7a-610f1b558035\", \"subtext\": \"abdf6489-6e02-44df-a898-42d8f159662e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Secondary objectives\", \"3.2\", \"2\", 324, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Emergence of resistance mutations during treatment and in the post-treatment period\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2e934001-3828-441b-9442-48d0ced05c21\", \"childbox\": \"acd067ae-ffea-4ce5-99ed-51308ad0eb8d\", \"subtext\": \"184c26dd-d654-4230-b3c1-0e411f07ca37\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Secondary objectives\", \"3.2\", \"2\", 325, \"\"], [\"\", \"Unmapped\", \"header\", \"4 Study design\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"330ee314-9457-4460-bdaa-e8c1e6b3ff95\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study design\", \"4\", \"1\", 326, \"\"], [\"\", \"Unmapped\", \"text\", \"This will be an open-label, randomized study in treatment-na\\u00efve, GT 1 and 3 HCV-infected subjects.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"08d77c64-3bf8-43ba-b032-b49f469fd89e\", \"childbox\": \"6e1a5ae2-e44f-44f4-a5fa-23677ec1e7cb\", \"subtext\": \"dac3bcbd-72e6-40a9-826b-43972f0fb2a0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study design\", \"4\", \"1\", 327, \"\"], [\"\", \"Unmapped\", \"text\", \"Each subject will receive the study drugs with or without RBV for 8 or 12 weeks, as shown in Table 4-1, followed by a 24-week follow-up to determine sustained virologic response (SVR).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"08d77c64-3bf8-43ba-b032-b49f469fd89e\", \"childbox\": \"cfd9fded-ee53-44fd-8e33-ec7ec9bded50\", \"subtext\": \"0d3b9a91-c0d8-4cb9-957b-2bfc864b3c25\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study design\", \"4\", \"1\", 328, \"\"], [\"\", \"Unmapped\", \"text\", \"Enrollment will commence either with enrollment into Groups A and B (50 mg arms) or enrollment into all groups in parallel based on review of data from the ongoing clinical drug-drug interaction study [IDX-04B-002] and preclinical data.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"08d77c64-3bf8-43ba-b032-b49f469fd89e\", \"childbox\": \"0788a57d-a1a9-4cd5-83da-6ff945a92963\", \"subtext\": \"9a8a25db-e56e-4193-9e66-b62bf8c0d920\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study design\", \"4\", \"1\", 329, \"\"], [\"\", \"Unmapped\", \"text\", \"An independent DSMB will review the PK, safety and antiviral activity data of the first 40 subjects after they have completed 4 weeks of treatment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6a447c1b-ab7a-408f-8549-bc55783b649f\", \"childbox\": \"20b523ad-d681-49a8-b815-e0d6eca37116\", \"subtext\": \"a6466d9b-105a-4b88-96d2-aa7bdac07481\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study design\", \"4\", \"1\", 330, \"\"], [\"\", \"Unmapped\", \"text\", \"Screening and dosing of new subjects will not pause during the DSMB review.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6a447c1b-ab7a-408f-8549-bc55783b649f\", \"childbox\": \"4cbfefeb-9b7a-4ad5-b3d0-d3c45592877b\", \"subtext\": \"a6466d9b-105a-4b88-96d2-aa7bdac07481\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study design\", \"4\", \"1\", 331, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 4-1\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5da91cb5-b41a-47d2-b35c-ee588f78fb5c\", \"childbox\": \"6ecca74b-53b9-4905-aa5e-2e60d26ce93d\", \"subtext\": \"08d9b6a7-5368-44f4-871d-544bb08d9a6c\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 332, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5da91cb5-b41a-47d2-b35c-ee588f78fb5c\", \"childbox\": \"7cf7629c-213f-409a-ad06-df262f2992d7\", \"subtext\": \"3699eff8-f71f-4ee5-b8db-e3dd27b0ec58\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 333, \"\"], [\"\", \"Unmapped\", \"text\", \"Study design\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5da91cb5-b41a-47d2-b35c-ee588f78fb5c\", \"childbox\": \"338ee321-0c9f-4ee5-abbf-82127c33296b\", \"subtext\": \"3699eff8-f71f-4ee5-b8db-e3dd27b0ec58\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 334, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n      <th>7.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>GT</td>\\n      <td>Group</td>\\n      <td>N=240</td>\\n      <td>Samatasvir (mg QD)</td>\\n      <td>IDX21437 (mg QD)</td>\\n      <td>RBV 1</td>\\n      <td>Weeks of treatment</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>1</td>\\n      <td>A</td>\\n      <td>20</td>\\n      <td>50</td>\\n      <td>300</td>\\n      <td>No</td>\\n      <td>8</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>1</td>\\n      <td>B</td>\\n      <td>20</td>\\n      <td>50</td>\\n      <td>300</td>\\n      <td>No</td>\\n      <td>12</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>1</td>\\n      <td>C</td>\\n      <td>60</td>\\n      <td>100</td>\\n      <td>300</td>\\n      <td>No</td>\\n      <td>8</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>3</td>\\n      <td>E</td>\\n      <td>40</td>\\n      <td>100</td>\\n      <td>300</td>\\n      <td>Yes</td>\\n      <td>12</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>3</td>\\n      <td>F</td>\\n      <td>40</td>\\n      <td>100</td>\\n      <td>300</td>\\n      <td>No</td>\\n      <td>12</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"GT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"406c597c-2cc1-410a-a6c8-e9ad10ea3b96\\\",\\\"datacell_roi_id\\\":\\\"1066db91-4192-4f10-b321-a843dd8d5074\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Group\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"67eaa1ce-03e6-4ea0-b3fa-91f11b2e3187\\\",\\\"datacell_roi_id\\\":\\\"853b2eeb-f333-4190-a60c-a8b0cdb3d071\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"N=240\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"47729be5-96c4-46f6-b42b-18fec53538ca\\\",\\\"datacell_roi_id\\\":\\\"9e2c9b36-e7f0-435b-a32b-9e20b387d674\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"SAMATASVIR\\\",\\\"subcategory\\\":\\\"SAMATASVIR\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":9,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":75.0,\\\"text\\\":\\\"Samatasvir\\\"}],\\\"content\\\":\\\"Samatasvir (mg QD)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"c0bd7b30-27fd-4bf3-9b3c-374993c095d0\\\",\\\"datacell_roi_id\\\":\\\"67e5425c-0a07-46d1-8daa-8842b4dfe937\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[{\\\"start_idx\\\":0,\\\"end_idx\\\":7,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":7,\\\"standard_entity_name\\\":\\\"IDX21437\\\",\\\"subcategory\\\":\\\"IDX21437\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"},{\\\"start_idx\\\":0,\\\"end_idx\\\":7,\\\"standard_entity_name\\\":\\\"Molecule\\\",\\\"subcategory\\\":\\\"Molecule\\\",\\\"confidence\\\":100.0,\\\"text\\\":\\\"IDX21437\\\"}],\\\"content\\\":\\\"IDX21437 (mg QD)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"ef1b2c90-10c2-46da-b2cd-9dca5f1b87bb\\\",\\\"datacell_roi_id\\\":\\\"6d386bf7-af17-49b6-b64a-ca0897cc7bbe\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"RBV 1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"bf619ff2-e8d5-4b7e-ba33-9900be2fa773\\\",\\\"datacell_roi_id\\\":\\\"419c65d2-eea3-4ea0-8d7b-df0858cb0a00\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Weeks of treatment\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"dfa49060-d9b8-4632-9464-ccb4f673f007\\\",\\\"column_roi_id\\\":\\\"a84767c6-5c00-43ac-a5ff-029a87bd8c26\\\",\\\"datacell_roi_id\\\":\\\"010ab6b0-7c7f-430e-99b1-28664eb0be7c\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"e841f4c2-a31c-4aa3-af47-af0dc34edecd\\\",\\\"datacell_roi_id\\\":\\\"e3e7bbf2-34dd-46b2-a735-7e06fdbf7768\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"A\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"30e4efa2-fb7a-4e28-baab-85f2d5568d5b\\\",\\\"datacell_roi_id\\\":\\\"94b1f75a-16f8-438e-a7c0-943e551cae7c\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"20\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"0bd1e5ce-b643-489b-bdbb-33d9359b4ad8\\\",\\\"datacell_roi_id\\\":\\\"b5cb42b6-b7ff-47a0-b1cf-a97538883f54\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"50\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"f84c1cf5-53a6-44d8-ba7a-7c861358ba79\\\",\\\"datacell_roi_id\\\":\\\"36970c0d-411c-43c0-be8e-82bd22e59681\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"2ac25f6d-4eb7-4743-ac87-46d55a18beeb\\\",\\\"datacell_roi_id\\\":\\\"789cd11a-d62b-4602-b988-52834cf6dfc1\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"84a7ae45-5845-46bf-a217-b2cdcb19f759\\\",\\\"datacell_roi_id\\\":\\\"eb7fe928-2110-4c0e-a9a2-ebead3213409\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"8\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"90ec3353-82b2-46a8-bc68-fb0330eaf2d9\\\",\\\"column_roi_id\\\":\\\"06ff35ed-d791-447f-bbd1-928fe3cf20d2\\\",\\\"datacell_roi_id\\\":\\\"3c7ee96f-6fd0-4ee9-8f8f-4a960edc2f7a\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"2d0b9f0c-a972-4696-8cac-adbf3e6191b9\\\",\\\"datacell_roi_id\\\":\\\"f274dddc-f2aa-4982-9ea4-f078f2e4c89d\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"B\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"83895e6c-22e2-4857-a8c3-58d20fa0bc47\\\",\\\"datacell_roi_id\\\":\\\"f2eb98a7-fe12-4fab-96ba-86efe13faaf2\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"20\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"e57efabc-5f38-4c4a-80fc-383ac37bff9a\\\",\\\"datacell_roi_id\\\":\\\"0568db75-e527-4422-9117-330990df41ef\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"50\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"a56013ac-3751-419a-8e8a-b6d79fe93531\\\",\\\"datacell_roi_id\\\":\\\"ab02a44f-236b-461c-8505-7a8fe3270869\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"165d08db-a79c-4b9c-9d10-fa713d29d38d\\\",\\\"datacell_roi_id\\\":\\\"57c9f27f-2f23-49b9-aed5-0c18763411e6\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"59deb236-1112-4a1f-b3dc-c0578b854e3c\\\",\\\"datacell_roi_id\\\":\\\"276b7cef-7414-4986-8a76-384a06d7593a\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"d6570c06-0ae1-4c54-8ff1-b1eeac5a70c0\\\",\\\"column_roi_id\\\":\\\"cd796103-ae01-4d6a-962c-b7c9df7742ce\\\",\\\"datacell_roi_id\\\":\\\"fa38db1a-358d-42c1-b5ef-87b36681e347\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"1d00c15c-7594-40fb-8a76-b908c4cc4dc8\\\",\\\"datacell_roi_id\\\":\\\"60ec25e7-254e-437f-a23e-e6a107f8cfb8\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"C\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"ebf4de2f-3922-4ee0-9514-15d2d50a65e1\\\",\\\"datacell_roi_id\\\":\\\"1aa65c6e-2b2a-4596-9199-dc368ef10597\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"60\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"895ce2f4-a730-4562-a80d-2ec35aa8955c\\\",\\\"datacell_roi_id\\\":\\\"289c558f-380b-4f23-ab44-040e890fe304\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"100\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"d5c0fb01-0b4c-4359-9b98-4b7c7bbe1f28\\\",\\\"datacell_roi_id\\\":\\\"efb598e2-7124-43b1-b64f-cf3de70aa54c\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"4f58f8b4-89b5-469b-848a-953f13c1a3f4\\\",\\\"datacell_roi_id\\\":\\\"395756bd-9823-4e0f-8afb-607b147def4d\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"715616a4-564e-4bab-9768-3f58c78ac831\\\",\\\"datacell_roi_id\\\":\\\"a1f1e5cb-cd20-408a-be31-7250cc77e190\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"8\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"c158a8ed-79f6-48a7-8242-63363879ffe2\\\",\\\"column_roi_id\\\":\\\"2e99ea98-9c58-4a29-8252-9cdc42cc2acd\\\",\\\"datacell_roi_id\\\":\\\"39d9e2dd-6cb9-41fd-b2ef-765af99db029\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"82c59002-0a4a-4194-94be-b6eba2bd4034\\\",\\\"datacell_roi_id\\\":\\\"c8fb99db-c73f-4672-91bb-0d74556bc335\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"E\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"d2d04c2f-ebd5-4b15-8653-79cf8e5380c5\\\",\\\"datacell_roi_id\\\":\\\"0fabade7-59a7-498a-8e92-4c61fe1e5c21\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"40\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"fa0d8e6d-a01a-428c-839c-d816feec55a4\\\",\\\"datacell_roi_id\\\":\\\"d2feb402-3c58-431f-a4d1-344ad8ebbabb\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"100\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"9793467e-32af-4756-89ae-532b429a3f13\\\",\\\"datacell_roi_id\\\":\\\"f6f7a968-5666-400c-a8ca-9341b14d6b18\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"4d81633c-d860-43fc-a005-4e0a62110a23\\\",\\\"datacell_roi_id\\\":\\\"b81886cb-81f2-44af-9822-5a77129eceb5\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Yes\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"3424f880-fe75-4fad-8b8c-a1ddb0f38f41\\\",\\\"datacell_roi_id\\\":\\\"4096f104-3c7c-4ef6-bb80-707bd938b8e8\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"e1a45f6c-a10a-42f8-b8b1-f2615e66249a\\\",\\\"column_roi_id\\\":\\\"286dc8d0-65ca-4e82-a623-27bf70d8c72e\\\",\\\"datacell_roi_id\\\":\\\"94481f54-8f22-4c17-9495-0b11f85750ed\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"c5b5773b-bf79-4172-a262-4f0b9e645843\\\",\\\"datacell_roi_id\\\":\\\"dc76df7c-999a-4387-b096-0efbc05a8892\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"F\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"77d49cba-af67-4374-a787-04bd8b42afc0\\\",\\\"datacell_roi_id\\\":\\\"41985d88-979f-44c5-9a38-02b19d38db43\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"40\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"f1aa9254-3587-46dc-809f-4bfc7e8c60f6\\\",\\\"datacell_roi_id\\\":\\\"508fc0b9-8107-4a2f-88c9-310020b022be\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"100\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"7a8d1920-9c60-4d63-8e6a-18c14c9ce74e\\\",\\\"datacell_roi_id\\\":\\\"6f2ca71a-56c7-4c22-b678-a213fc70d97a\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"300\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"ebddcb01-9287-468b-8e98-223fb99f10c8\\\",\\\"datacell_roi_id\\\":\\\"da8755d1-fe98-47d0-8272-c239dda5d5a6\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"No\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"ae936dca-9bfb-446b-913f-a9dffd82f6d8\\\",\\\"datacell_roi_id\\\":\\\"0b1b7f45-c992-433b-8d22-3355917dff7b\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"89ec356c-d680-4072-812c-eeface867b0b\\\",\\\"row_roi_id\\\":\\\"2f122a61-74a2-4af1-b0c0-3585b76afaf2\\\",\\\"column_roi_id\\\":\\\"3c50a859-484e-4412-bb0f-fefcab26fe94\\\",\\\"datacell_roi_id\\\":\\\"0712b258-742d-4d52-af1b-159ff18fe767\\\"},\\\"table_index\\\":9.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"18\", \"TableIndex\": \"10.0\", \"TableName\": \"Table 4-1 Study design\", \"Header\": [0]}, {\"IsBold\": true, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1066db91-4192-4f10-b321-a843dd8d5074\", \"childbox\": \"12e9d292-b9c3-4339-90d8-12b9951d4ccb\", \"subtext\": \"d3e7bca6-4b57-4fb2-80ce-bca80f2b9f7d\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 335, \"\"], [\"\", \"Unmapped\", \"text\", \"1\", {\"IsBold\": false, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"48d543cb-c60d-4d27-a065-b389c404809b\", \"childbox\": \"0614bd3a-441c-4269-b65f-2d3e6e27a584\", \"subtext\": \"2420155d-ba26-49ca-b6d2-600a5739329a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"superscript\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 336, \"\"], [\"\", \"Unmapped\", \"text\", \"RBV dosing weight-based, according to product label\", {\"IsBold\": false, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"48d543cb-c60d-4d27-a065-b389c404809b\", \"childbox\": \"0614bd3a-441c-4269-b65f-2d3e6e27a584\", \"subtext\": \"12dc8b23-f281-40c5-a8ef-18e09a743ed4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 337, \"\"], [\"\", \"Unmapped\", \"text\", \"A single blood sample per visit will be collected postdose on Day 1 through the 28-day post End-of-Treatment (EOT) visit from all subjects to monitor study drug concentrations.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"487e88e9-24f6-4475-9a64-2aa821ce0988\", \"childbox\": \"1d7c1b63-9c99-4b6a-a84c-89a40dabca7f\", \"subtext\": \"f5246496-56e8-49b7-8f10-58b39fe83cb3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 338, \"\"], [\"\", \"Unmapped\", \"text\", \"Intensive PK sampling on Day 1 and Day 15, and a single blood sample on Day 2, as detailed in Table 7-3, will be optional for all study subjects.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"487e88e9-24f6-4475-9a64-2aa821ce0988\", \"childbox\": \"2adbd034-d177-423d-b929-37166cf322ec\", \"subtext\": \"f5246496-56e8-49b7-8f10-58b39fe83cb3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 339, \"\"], [\"\", \"Unmapped\", \"text\", \"HCV RNA timepoints will be timematched to the PK timepoints for subjects participating in the optional Day 1 intensive PK sampling.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"487e88e9-24f6-4475-9a64-2aa821ce0988\", \"childbox\": \"a8ac56b9-cb99-4913-a90c-131af6443132\", \"subtext\": \"6e43ab9f-ebc3-4465-80e0-53cbd33906ea\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 340, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will be followed in the extended observational follow-on phase in which a blood sample is collected every 12 weeks to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"cc6951ca-9b8b-4be5-8439-490e594c679f\", \"childbox\": \"3808d67d-c05b-4081-bbbe-9a09b17486eb\", \"subtext\": \"650c4bb0-1226-40e9-9b03-8e2e8cee8f2f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 341, \"\"], [\"\", \"Unmapped\", \"text\", \"If another antiviral treatment for HCV is initiated, participation in the observational follow-on phase will be terminated.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cc6951ca-9b8b-4be5-8439-490e594c679f\", \"childbox\": \"b06652fb-a794-47c1-acf6-e3343d0e8c51\", \"subtext\": \"d0dfef2b-1d86-4d27-974c-4bb2c519ab5d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Study design\", \"Table 4\", \"2\", 342, \"\"], [\"\", \"Unmapped\", \"header\", \"4.1 Data Safety Monitoring Board\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"206fe3cd-c6fe-424c-afc5-bf7bcde791eb\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Data Safety Monitoring Board\", \"4.1\", \"2\", 343, \"\"], [\"\", \"Unmapped\", \"text\", \"An independent DSMB, constituted according to applicable international and local regulations, will review the available PK, safety and antiviral activity data after the first 40 subjects have completed 4 weeks of treatment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e028d315-eb12-4c07-adc6-c7997b5813b9\", \"childbox\": \"e54e2eed-c99c-41cc-a125-b4cce8118812\", \"subtext\": \"e418586a-05ad-43e8-a4f0-2833bd31fa73\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Data Safety Monitoring Board\", \"4.1\", \"2\", 344, \"\"], [\"\", \"Unmapped\", \"text\", \"Screening and dosing of new subjects will not pause during the DSMB reviews.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e028d315-eb12-4c07-adc6-c7997b5813b9\", \"childbox\": \"cca7c81f-3686-4454-acb6-69bf96a0d07c\", \"subtext\": \"e418586a-05ad-43e8-a4f0-2833bd31fa73\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Data Safety Monitoring Board\", \"4.1\", \"2\", 345, \"\"], [\"\", \"Unmapped\", \"text\", \"Subsequent DSMB meetings will occur approximately every 2 months to review the available PK, safety and antiviral activity data or, as needed, when triggered by the study stopping rules (Section 4.2.1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"426057bb-2ef6-44a8-ba7e-d617cac6b423\", \"childbox\": \"b9a0e968-5a81-4039-95bf-506dfe616554\", \"subtext\": \"17188f9f-6478-40e6-b1dc-fc8bf8c463b1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Data Safety Monitoring Board\", \"4.1\", \"2\", 346, \"\"], [\"\", \"Unmapped\", \"header\", \"4.2 Stopping rules\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"96af62a6-9351-4b62-8eaf-d58396a59a2b\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Stopping rules\", \"4.2\", \"2\", 347, \"\"], [\"\", \"Unmapped\", \"header\", \"4.2.1 Study safety stopping rules\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"6d5a5432-b7a9-449f-97ce-a8df8d4fe13e\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 348, \"\"], [\"\", \"Unmapped\", \"text\", \"If any of the following rules are triggered, the cases will be immediately reviewed with the DSMB Chairperson.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f0791c62-9594-49b1-b912-4d47565a6f7e\", \"childbox\": \"2cfef74f-15d4-4767-b902-0be4d70e4cad\", \"subtext\": \"0165f58f-d8c7-4400-a1da-7ba5f91b1667\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 349, \"\"], [\"\", \"Unmapped\", \"text\", \"If the DSMB Chairperson feels there is a possible relationship with IDX21437, samatasvir, or any combination of these drugs, the Chairperson will call an\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 68, \"end_idx\": 75, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 78, \"end_idx\": 87, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"f0791c62-9594-49b1-b912-4d47565a6f7e\", \"childbox\": \"adf6ea40-b825-4b78-bf14-e4d0ba62d285\", \"subtext\": \"0165f58f-d8c7-4400-a1da-7ba5f91b1667\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 350, \"\"], [\"\", \"Unmapped\", \"text\", \"ad hoc\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f0791c62-9594-49b1-b912-4d47565a6f7e\", \"childbox\": \"adf6ea40-b825-4b78-bf14-e4d0ba62d285\", \"subtext\": \"2384b601-1234-42be-aa42-749598590760\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 351, \"\"], [\"\", \"Unmapped\", \"text\", \"DSMB meeting to review the data with the full DSMB.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f0791c62-9594-49b1-b912-4d47565a6f7e\", \"childbox\": \"adf6ea40-b825-4b78-bf14-e4d0ba62d285\", \"subtext\": \"cd78e5dc-013c-4dac-a92c-c09d3559fc53\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 352, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Any single subject who has a confirmed alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x baseline and total bilirubin > 2x upper limit of normal (ULN), without any reason to explain a concurrent increase of ALT/AST and total bilirubin  (\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b719c17a-d661-447f-9933-f8288f001bc1\", \"childbox\": \"e814bffb-2023-4cc5-a60f-535755f894ff\", \"subtext\": \"ac0a6850-7835-42be-b7ea-cc7c079b3251\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 353, \"\"], [\"\", \"Unmapped\", \"text\", \"Note\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b719c17a-d661-447f-9933-f8288f001bc1\", \"childbox\": \"e814bffb-2023-4cc5-a60f-535755f894ff\", \"subtext\": \"92e2359c-798c-40c4-b95e-3b86536e0fef\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 354, \"\"], [\"\", \"Unmapped\", \"text\", \":  If ALT or AST are in the normal range at study entry, \\u201cbaseline\\u201d will be considered the upper limit of normal), OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b719c17a-d661-447f-9933-f8288f001bc1\", \"childbox\": \"e814bffb-2023-4cc5-a60f-535755f894ff\", \"subtext\": \"84c36ee6-c08a-414e-b271-e5f35ecaa8c5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 355, \"\"], [\"\", \"Unmapped\", \"text\", \"For the first 40 subjects:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dcbf2393-f5fa-4a43-b943-05fa22c195e3\", \"childbox\": \"a7c1a919-3256-4fee-93de-8b492cf03ebe\", \"subtext\": \"6ddb656d-6576-497a-90d3-0529d3c4617d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 356, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 If  \\u2265 2 subjects experience a similar unexpected and treatment-related SAE, OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"daef6589-2c8b-4523-a7ef-f627fe3701f1\", \"childbox\": \"e61e8d32-3df8-4c82-a1df-75b100ddd933\", \"subtext\": \"c7b45285-a620-453b-8ffc-6450299a9a55\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 357, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"daef6589-2c8b-4523-a7ef-f627fe3701f1\", \"childbox\": \"e61e8d32-3df8-4c82-a1df-75b100ddd933\", \"subtext\": \"be1af924-5f0a-4e26-8226-992049d60eb4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 358, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"daef6589-2c8b-4523-a7ef-f627fe3701f1\", \"childbox\": \"e61e8d32-3df8-4c82-a1df-75b100ddd933\", \"subtext\": \"d6d29aa9-4890-4afa-9c83-776584724acb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 359, \"\"], [\"\", \"Unmapped\", \"text\", \"If 25% (10/40) of subjects experience:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"daef6589-2c8b-4523-a7ef-f627fe3701f1\", \"childbox\": \"e61e8d32-3df8-4c82-a1df-75b100ddd933\", \"subtext\": \"e0ccea26-c98b-4163-9b1a-ca369ca39fbc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 360, \"\"], [\"\", \"Unmapped\", \"text\", \"o Grade 3/4 AE or confirmed Grade 3/4 laboratory abnormality affecting the same organ system, with the exception of asymptomatic increases in cholesterol and triglyceride.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6583aa11-47a0-4d1e-a1df-3a2bbc1f739a\", \"childbox\": \"b3f25200-7b00-4dca-9700-8fed3868bd68\", \"subtext\": \"e1ad3640-c555-43dc-a1be-bf28d02d6096\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 361, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ba2a677-78db-4d29-a1f3-9e7910335560\", \"childbox\": \"a5da39ad-cb26-426a-ae37-0ff57fd8252e\", \"subtext\": \"1be7b812-cce5-4622-8d96-67ac4be480cd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 362, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ba2a677-78db-4d29-a1f3-9e7910335560\", \"childbox\": \"a5da39ad-cb26-426a-ae37-0ff57fd8252e\", \"subtext\": \"ebaa0658-a62a-4a9f-9103-86e721a1abaf\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 363, \"\"], [\"\", \"Unmapped\", \"text\", \"Exception for ALT/AST: Because HCV-infected subjects are likely to have improved ALT or AST parameters on-treatment, a two-grade shift from ontreatment nadir levels for either ALT or AST, as opposed to an absolute Grade 3/4 level, will trigger the rule above.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ba2a677-78db-4d29-a1f3-9e7910335560\", \"childbox\": \"a5da39ad-cb26-426a-ae37-0ff57fd8252e\", \"subtext\": \"317643f6-d656-49d6-a400-adc108a718a2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 364, \"\"], [\"\", \"Unmapped\", \"text\", \"The rule does not apply to ALT/AST rebound in the case of treatment failure.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ba2a677-78db-4d29-a1f3-9e7910335560\", \"childbox\": \"1ed52ea6-9bbe-45b7-bb69-a0f539dffb51\", \"subtext\": \"1259bc06-b81a-478b-a7b5-56a9a0c62ca2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 365, \"\"], [\"\", \"Unmapped\", \"text\", \"o Any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"59581dc8-3f37-40e5-91d1-21c8fec1758e\", \"childbox\": \"527eaed6-12a2-404f-85ac-8b82560711be\", \"subtext\": \"a35b4806-7cc6-4b3c-9ac5-9a68c4e3d843\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 366, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"59581dc8-3f37-40e5-91d1-21c8fec1758e\", \"childbox\": \"715348ac-d168-495d-a0bd-98b7097059fc\", \"subtext\": \"ea974779-70f4-4d47-ae2a-af8864b10897\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 367, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"59581dc8-3f37-40e5-91d1-21c8fec1758e\", \"childbox\": \"715348ac-d168-495d-a0bd-98b7097059fc\", \"subtext\": \"d6bfe17a-e5cd-414e-8536-cacd4a188637\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 368, \"\"], [\"\", \"Unmapped\", \"text\", \"Any confirmed serum creatinine of \\u2265 Grade 2.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"59581dc8-3f37-40e5-91d1-21c8fec1758e\", \"childbox\": \"715348ac-d168-495d-a0bd-98b7097059fc\", \"subtext\": \"cdabafe6-f96b-43d6-81f3-59a86a16e37a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 369, \"\"], [\"\", \"Unmapped\", \"text\", \"For the criteria above, \\u201cconfirmed\\u201d is defined as an equivalent or higher grade value on a second, sequential determination.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"17737efe-7a97-42c6-a369-f04b9410fd10\", \"childbox\": \"4d842ec2-3a0d-4f20-97fc-183495a4583b\", \"subtext\": \"d7d2dbf8-99d9-437b-ba34-7e4a5056b086\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 370, \"\"], [\"\", \"Unmapped\", \"text\", \"All laboratory abnormalities meeting the above criteria must be repeated as soon as possible, preferably within 24-48 hours of the results being available to the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"17737efe-7a97-42c6-a369-f04b9410fd10\", \"childbox\": \"426f6575-be89-4ccb-b372-136eb55bb393\", \"subtext\": \"0282e16e-e5e5-4fd2-8d48-6d6c1af2692d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study safety stopping rules\", \"4.2.1\", \"3\", 371, \"\"], [\"\", \"Unmapped\", \"header\", \"4.2.2 Futility rules (criteria for closing a treatment arm due to inadequate\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"e8fabca5-0f8f-4c4e-87e1-2b66a5ff6ea0\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 372, \"\"], [\"\", \"Unmapped\", \"header\", \"antiviral response)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading4\", \"entity\": [], \"roi_id\": {\"para\": \"8e4be4aa-4823-4c92-828c-cf62764d820c\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 373, \"\"], [\"\", \"Unmapped\", \"text\", \"If > 33% of subjects within any given treatment arm that has enrolled at least 10 subjects experience virologic failure (as defined in Section 4.2.4), including failure to respond to treatment, on-treatment virologic breakthrough, or post-treatment virologic relapse, the arm will be closed to enrollment, and an\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 217, \"end_idx\": 228, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 75.0, \"text\": \"breakthrough\"}], \"roi_id\": {\"para\": \"e11ef142-875f-4ada-8a5a-2555eb0b3efc\", \"childbox\": \"6ee538ff-2c51-43ba-8611-b8d595eec4fd\", \"subtext\": \"69069d6a-a0e9-4df0-a9c2-362fc3b16128\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 374, \"\"], [\"\", \"Unmapped\", \"text\", \"ad hoc\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e11ef142-875f-4ada-8a5a-2555eb0b3efc\", \"childbox\": \"6ee538ff-2c51-43ba-8611-b8d595eec4fd\", \"subtext\": \"78334930-f79b-4256-884a-71fcf2b00f23\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 375, \"\"], [\"\", \"Unmapped\", \"text\", \"DSMB meeting will be called to review the data.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e11ef142-875f-4ada-8a5a-2555eb0b3efc\", \"childbox\": \"6ee538ff-2c51-43ba-8611-b8d595eec4fd\", \"subtext\": \"79181d4a-12fe-4c57-9bc1-3fb5a1a3d0c9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 376, \"\"], [\"\", \"Unmapped\", \"text\", \"Continued treatment of subjects in the closed treatment arm who are still receiving treatment and who have not experienced virologic failure will be determined after discussion with the\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e11ef142-875f-4ada-8a5a-2555eb0b3efc\", \"childbox\": \"4a9e03de-d352-4e3f-83bf-272409f57933\", \"subtext\": \"79181d4a-12fe-4c57-9bc1-3fb5a1a3d0c9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 377, \"\"], [\"\", \"Unmapped\", \"text\", \"DSMB.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"30c20c08-ea67-4bb4-8dfc-b6bd27da7147\", \"childbox\": \"95ae6f1a-d6f7-4d7d-8f2b-969f77a208c3\", \"subtext\": \"3d76b6b9-3c2c-4489-a1e9-384908994744\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Futility rules (criteria for closing a treatment arm due to inadequate\", \"4.2.2\", \"3\", 378, \"\"], [\"\", \"Unmapped\", \"header\", \"4.2.3 Individual subject stopping rules\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"b9de2b23-41f6-4358-8e6c-7758a883f737\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 379, \"\"], [\"\", \"Unmapped\", \"text\", \"A subject\\u2019s study treatment should be discontinued if:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ea4cef4b-11b5-49c6-b75a-9fe721959c0e\", \"childbox\": \"00004182-40a8-4bbd-866e-834a54479eea\", \"subtext\": \"a9e6fd05-35e8-428a-9e23-704af4d471df\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 380, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 The subject has a confirmed ALT or AST > 3x baseline and total bilirubin > 2x upper limit of normal (ULN), without any reason to explain a concurrent increase of ALT/AST and total bilirubin.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"89f255ec-34ac-4246-a2d3-b02039060034\", \"childbox\": \"708e2c5d-42ad-41d0-8a1e-445aa01b69e7\", \"subtext\": \"2d47d8ec-8c08-4227-bd19-5a1cdbc36545\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 381, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"89f255ec-34ac-4246-a2d3-b02039060034\", \"childbox\": \"03676fb4-6993-40cd-b1e9-07f5d1f653e8\", \"subtext\": \"bd49f370-6e80-4e59-bcff-fba8d455d886\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 382, \"\"], [\"\", \"Unmapped\", \"text\", \"Note\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"89f255ec-34ac-4246-a2d3-b02039060034\", \"childbox\": \"03676fb4-6993-40cd-b1e9-07f5d1f653e8\", \"subtext\": \"11e885d7-cfce-4fc7-81b4-b391e6ac43c3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 383, \"\"], [\"\", \"Unmapped\", \"text\", \":  If ALT or AST are in the normal range at study entry, \\u201cbaseline\\u201d will be considered the upper limit of normal.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"89f255ec-34ac-4246-a2d3-b02039060034\", \"childbox\": \"03676fb4-6993-40cd-b1e9-07f5d1f653e8\", \"subtext\": \"e72e8e42-61e8-46a0-bfd8-035cb37d1498\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 384, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 If the subject has any Grade 3/4 AE or confirmed Grade 3/4 laboratory abnormality which is felt to be at least reasonably or possibly related to study drug and clinically significant by the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3921bc51-582e-4e59-8cf4-b4579af6e20b\", \"childbox\": \"2b18482a-ea90-4c55-bef3-6a5c19aa0024\", \"subtext\": \"288d2c29-b9b3-4a0f-8308-472402f2f681\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 385, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7791b3b9-bdea-4621-8aca-a692bada777c\", \"childbox\": \"28b3d314-e7a7-45d2-80c2-ffe922cb9557\", \"subtext\": \"85314f24-82a7-4635-9f32-a76aa6854d7e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 386, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7791b3b9-bdea-4621-8aca-a692bada777c\", \"childbox\": \"28b3d314-e7a7-45d2-80c2-ffe922cb9557\", \"subtext\": \"2e62a6f4-0e5e-4489-b69c-afb4479c56c6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 387, \"\"], [\"\", \"Unmapped\", \"text\", \"Exception for ALT/AST: Because HCV-infected subjects are likely to have improved\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7791b3b9-bdea-4621-8aca-a692bada777c\", \"childbox\": \"28b3d314-e7a7-45d2-80c2-ffe922cb9557\", \"subtext\": \"2f16cf85-f365-41e0-8790-296105b42a30\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 388, \"\"], [\"\", \"Unmapped\", \"text\", \"ALT or AST parameters on-treatment, a two-grade shift from on-treatment nadir\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"820478ec-945f-475f-94e3-e986c0499c68\", \"childbox\": \"ca151e50-6408-41c6-adc9-c563ba816553\", \"subtext\": \"89d6c673-bbe4-4dd0-8a37-dd70cb90e228\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 389, \"\"], [\"\", \"Unmapped\", \"text\", \"levels for either ALT or AST, as opposed to an absolute Grade 3/4 level, will trigger the rule above.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85b7479d-3e55-43a8-83de-ff402e79a8d2\", \"childbox\": \"3482070c-ded1-4db9-a577-2c0bc1fecffa\", \"subtext\": \"93734745-fc9b-408e-924d-31dfc559bbf9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 390, \"\"], [\"\", \"Unmapped\", \"text\", \"The rule does not apply to ALT/AST rebound in the case of treatment failure.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85b7479d-3e55-43a8-83de-ff402e79a8d2\", \"childbox\": \"497240f7-c6d3-49ec-9860-53b72127c409\", \"subtext\": \"93734745-fc9b-408e-924d-31dfc559bbf9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 391, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 If the subject has any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fd88947d-5ec6-4ced-95bb-30bfcea206e0\", \"childbox\": \"3fe4e068-653c-4e54-bd6e-624237cb7d36\", \"subtext\": \"38632cc1-ae66-48b8-bd01-110158cedc8f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 392, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 If the subject has a confirmed serum creatinine of \\u2265 Grade 2.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3c2f4a44-7f0a-4cc9-8803-e4438be4fc08\", \"childbox\": \"e41b952f-e5a1-4ecd-a012-d10fd19ac570\", \"subtext\": \"c9c1e9cc-5d3b-4044-8ce0-ad26196141aa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 393, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 If the subject has a confirmed increase in QTcF \\u2265 60 milliseconds (ms) over Baseline or absolute QTcF \\u2265 500 ms.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7643f498-d148-42ee-a6b9-abf608ed624c\", \"childbox\": \"4beed457-4e88-4072-be09-2f19bc69308e\", \"subtext\": \"c5bbbf2e-5de0-45c9-bbf0-41a8add70ab2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 394, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 If the subject becomes pregnant.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c84b9fdf-7d6e-4648-85bb-adce017a00c2\", \"childbox\": \"4b733f31-6fb2-4650-8153-62f4e92fca60\", \"subtext\": \"823b680e-f8bc-4c5a-b452-e1a8219ca818\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 395, \"\"], [\"\", \"Unmapped\", \"text\", \"For the criteria above, \\u201cconfirmed\\u201d is defined as an equivalent or higher grade value on a second, sequential determination.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"135dfbb3-22ef-4641-9c84-9550c5695e0c\", \"childbox\": \"b2a61f15-6d0a-41f3-990a-fb9e9aa74a2f\", \"subtext\": \"8f68e008-5b57-4275-a413-3b7d04ed9493\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 396, \"\"], [\"\", \"Unmapped\", \"text\", \"All laboratory abnormalities meeting the above criteria must be repeated as soon as possible, preferably within 24-48 hours of the results being available to the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"135dfbb3-22ef-4641-9c84-9550c5695e0c\", \"childbox\": \"c85aa43a-83cd-422e-bbf3-6edcd1442892\", \"subtext\": \"8f68e008-5b57-4275-a413-3b7d04ed9493\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Individual subject stopping rules\", \"4.2.3\", \"3\", 397, \"\"], [\"\", \"Unmapped\", \"header\", \"4.2.4 Virologic failure\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"23b7adef-bb8f-4411-82ed-33d646e5b37c\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 398, \"\"], [\"\", \"Unmapped\", \"text\", \"The occurrence of one of the following rules will constitute virologic failure:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ba87bad3-b6b1-47f2-9dbb-0cd777755eac\", \"childbox\": \"32c33429-7a1a-46b9-a9dd-1c128e71f5b2\", \"subtext\": \"bd03f809-e28c-47fa-afe1-a6ce1dda2a63\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 399, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 HCV RNA above LLOQ for two consecutive measurements (second measurement to be collected as soon as possible) in a subject in whom HCV RNA was below LLOQ, OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"477ea7f5-fdf8-495e-bf21-fc9d0bd3e55c\", \"childbox\": \"7bacc538-050e-483d-9004-0ae961b369d7\", \"subtext\": \"4d48c63f-9c7a-4a2a-a4f1-fbc5477b935b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 400, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 > 1 log\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c911b38-ddb5-4748-8588-01902df7fa0c\", \"childbox\": \"007dff7f-35dc-4641-9d21-ea038375c7b5\", \"subtext\": \"d21a02cb-a1c3-43d7-8171-2e492efc8ccd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 401, \"\"], [\"\", \"Unmapped\", \"text\", \"10\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c911b38-ddb5-4748-8588-01902df7fa0c\", \"childbox\": \"007dff7f-35dc-4641-9d21-ea038375c7b5\", \"subtext\": \"6b450df2-e662-420a-849c-83bdaaae4a25\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 402, \"\"], [\"\", \"Unmapped\", \"text\", \"increase in HCV RNA above nadir for two consecutive measurements.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c911b38-ddb5-4748-8588-01902df7fa0c\", \"childbox\": \"007dff7f-35dc-4641-9d21-ea038375c7b5\", \"subtext\": \"b773e009-b838-4d86-8287-d5955cda0f55\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 403, \"\"], [\"\", \"Unmapped\", \"text\", \"HCV RNA levels will be unblinded to the investigators so that he/she can assess in real-time whether subjects fail during the treatment period or relapse during the off-treatment period.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d37e42b3-d77d-44b5-91e6-83e35218b365\", \"childbox\": \"f62901c2-70d8-4e2c-9ccb-06385e3cff83\", \"subtext\": \"0bc6044d-4209-4707-9b6f-1a98c5adae86\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 404, \"\"], [\"\", \"Unmapped\", \"text\", \"In addition, the Sponsor will have regular safety monitoring meetings during the course of the study, and sites will be proactively notified if one of the above rules is triggered.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d37e42b3-d77d-44b5-91e6-83e35218b365\", \"childbox\": \"60024b7e-48d2-4f2c-9ecc-f81d9317fcf0\", \"subtext\": \"b0b2bbe9-3d7b-42a3-9b14-96b74993f8e9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 405, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who experience virologic failure must discontinue all study drugs and return for the follow-up visits as described in (Table 7-1) and (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d25ec5a6-c762-46b9-9a7c-482ea74b5a8b\", \"childbox\": \"a4b9bed2-5d16-4c61-bd67-791956d7e509\", \"subtext\": \"808ee363-c899-4a4e-84de-7102e2ec7b8f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Virologic failure\", \"4.2.4\", \"3\", 406, \"\"], [\"\", \"Unmapped\", \"header\", \"5 Population\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"ee5e1735-e9af-455e-91c5-08c0ba5b98ca\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Population\", \"5\", \"1\", 407, \"\"], [\"\", \"Unmapped\", \"text\", \"The targeted study population will include adult non-cirrhotic subjects with GT 1 or 3, chronic hepatitis C infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"866103d4-e6eb-43d8-a191-aab5e3e7bf77\", \"childbox\": \"0fab415a-53f3-4fbb-bb56-f8fe09301d8e\", \"subtext\": \"5c8f1b32-52d3-4e01-aa69-a321af5edb8a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Population\", \"5\", \"1\", 408, \"\"], [\"\", \"Unmapped\", \"header\", \"5.1 Inclusion/exclusion criteria\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"245e63f4-5406-4430-a938-6023ad006f76\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 409, \"\"], [\"\", \"Unmapped\", \"text\", \"To participate in the study, subjects must meet all of the inclusion criteria and none of the exclusion criteria.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"23b6081a-3ff4-42f1-a40e-1db4047c6356\", \"childbox\": \"d7f29d16-c7bb-40c9-98a5-fdd21818b172\", \"subtext\": \"1e1040a2-affb-44ea-92dd-d81827bbf67c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 410, \"\"], [\"\", \"Unmapped\", \"text\", \"Rescreening of prior screen failures is not permitted.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"23b6081a-3ff4-42f1-a40e-1db4047c6356\", \"childbox\": \"84ed5d28-e2ff-43b3-b915-80b4b9209883\", \"subtext\": \"56fbeeba-1581-41cc-9be5-f55e5eb14692\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 411, \"\"], [\"\", \"Unmapped\", \"header\", \"5.1.1 Inclusion criteria\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"71148993-eaba-40b6-a67c-6056ef53e054\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 412, \"\"], [\"\", \"Unmapped\", \"text\", \"18 (or the legal age of consent per local regulations, if greater than 18 years) to 65 years of age, inclusive.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0635409c-d112-4374-ab91-eef5dec8bf2b\", \"childbox\": \"d8b43972-d1fe-47c2-936e-49d5caf0b948\", \"subtext\": \"316a5cc4-df1e-4c62-a620-a6251ce62efc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 413, \"\"], [\"\", \"Unmapped\", \"text\", \"Female subjects of both childbearing potential and non-childbearing potential may be included, unless the local regulatory authority requires that only females of nonchildbearing potential be included.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db7cae9a-cd8c-4e5c-be94-96a7598e2e69\", \"childbox\": \"18aa66bd-8635-48df-b978-e2d5f15a788d\", \"subtext\": \"ffa5b423-d8d1-4c27-9dd4-46338ad4d7e4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 414, \"\"], [\"\", \"Unmapped\", \"text\", \"Non-childbearing potential is defined as one of the following:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ad592b97-4b89-4735-9680-9c4cb3c5b8d8\", \"childbox\": \"c4736b55-c45e-4f71-9353-1e59f0e262be\", \"subtext\": \"9c8160c6-7b99-4cca-a04e-0c70875bbd17\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 415, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Postmenopausal, defined as amenorrheic for at least 2 years and serum follicle stimulating hormone (FSH) level consistent with postmenopausal status at Screening,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dab229e0-826e-4caa-b398-c9fe9b66dd32\", \"childbox\": \"450f4809-0a0f-4b75-815e-4092dff3ad5a\", \"subtext\": \"a6324491-a9ad-41e5-83e9-59efa4076489\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 416, \"\"], [\"\", \"Unmapped\", \"text\", \"OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2a5b9d53-588f-4b9c-a98e-935d8da93edb\", \"childbox\": \"d4d4b563-44ea-4435-b4cd-78a3139fcd3a\", \"subtext\": \"0a0a4beb-9e19-41c3-8d72-1979156845ab\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 417, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 A documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation at least 6 months prior to study initiation.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1e810ca1-3d67-4238-8105-4aec19568271\", \"childbox\": \"886227fd-7062-4297-8e10-a4bc0b624285\", \"subtext\": \"5d5c14e5-6aa6-405e-9fb9-87d38b162f27\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 418, \"\"], [\"\", \"Unmapped\", \"text\", \"All female subjects must have a negative serum beta-human chorionic gonadotropin (\\u03b2-HCG) at Screening and a negative urine pregnancy test prior to the first dose of study medication on Day 1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d72ff543-369a-4671-a83a-7955bda91221\", \"childbox\": \"0c32031e-ef68-4159-aff7-11c63a0e7d40\", \"subtext\": \"283f2105-fba5-4cc7-8a0a-12d87d572d69\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 419, \"\"], [\"\", \"Unmapped\", \"text\", \"Women of childbearing potential and men must have agreed to use an acceptable double method of birth control (one of which must be a barrier method) from Screening through at least 7 months after the last dose of study drugs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4932b07a-0765-41ff-8316-4aba47c442cf\", \"childbox\": \"31b06922-4374-472b-9568-7cb6fc48b224\", \"subtext\": \"d2320d7e-a8d3-4eb8-b125-9e8a25f0a08a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 420, \"\"], [\"\", \"Unmapped\", \"text\", \"Male subjects must have agreed not to donate sperm from the first dose through at least 7 months after the last dose of study drugs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3032eee7-231e-45d9-9a3d-1e5792779c4a\", \"childbox\": \"f2177136-8815-423a-af68-acb213ebfe7c\", \"subtext\": \"72e08e3e-43fc-4f1e-ae06-cf2012ffe9f1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 421, \"\"], [\"\", \"Unmapped\", \"text\", \"QTcF interval \\u2264 450 ms at Screening and prior to dosing on Day 1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7f32ba7c-cb78-4f80-ac5a-54a2554b2256\", \"childbox\": \"8460cd91-a39f-4fe5-8cf3-7ff533db1bf2\", \"subtext\": \"cc80d422-b334-4105-9c48-8adc84fe58cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 422, \"\"], [\"\", \"Unmapped\", \"text\", \"Documented clinical history compatible with chronic hepatitis C, including any one of the following:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d4ec116c-b17d-4c33-ac58-f3ae5926bab5\", \"childbox\": \"c91c5301-1acb-41f2-ac7b-d66bd36539ad\", \"subtext\": \"cc7d5426-1d8f-4633-bf1d-08fdaf8eb361\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 423, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 anti- HCV antibody positive at least 6 months prior to Screening or dosing, OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a2c5899a-cb39-42a2-b9ff-5f53944abe2a\", \"childbox\": \"3f169552-2c8a-4077-b525-ec2d4f4167f0\", \"subtext\": \"6726adfe-a7eb-4ca0-8e11-b3156c7ea482\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 424, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 HCV RNA present in plasma by a sensitive and specific assay at least 6 months prior to Screening or dosing, OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"332d5d09-9c5f-4443-987e-f4e53e5fb5e3\", \"childbox\": \"fb475d07-3028-4ac9-8c22-b97e7f0187c8\", \"subtext\": \"9bbb5909-d787-4974-bc85-adc8f56e47c0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 425, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 HCV genotype determined at least 6 months prior to Screening or dosing, OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"228afe1e-9dab-418a-96de-75b8fbe6ad7b\", \"childbox\": \"2e9cb56a-20d8-4582-a4c7-b6ba3f202731\", \"subtext\": \"72e3f820-f128-4330-a6d4-7b173a461209\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 426, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 histologic evidence of chronic hepatitis C infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0eb2d7f0-5624-4f36-b34f-8d80883b6ece\", \"childbox\": \"ef67f278-dd9a-4757-b549-354854e8028b\", \"subtext\": \"5404488a-266b-4279-99ed-a7adbdb4ae18\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 427, \"\"], [\"\", \"Unmapped\", \"text\", \"Plasma HCV RNA positive at Screening with minimal viral load of 4 log\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0739b53b-9a82-4c67-a421-af9ac8f43499\", \"childbox\": \"5ceec665-a1fe-4361-996a-10b1fec3f770\", \"subtext\": \"12eac064-8560-4816-a4eb-02402c49efc9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 428, \"\"], [\"\", \"Unmapped\", \"text\", \"10\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0739b53b-9a82-4c67-a421-af9ac8f43499\", \"childbox\": \"5ceec665-a1fe-4361-996a-10b1fec3f770\", \"subtext\": \"787b3583-054e-41c8-9a2a-c94a83c76356\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 429, \"\"], [\"\", \"Unmapped\", \"text\", \"IU/mL.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0739b53b-9a82-4c67-a421-af9ac8f43499\", \"childbox\": \"5ceec665-a1fe-4361-996a-10b1fec3f770\", \"subtext\": \"ae7d30a1-f75b-4022-89a1-d5f0575f4139\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 430, \"\"], [\"\", \"Unmapped\", \"text\", \"HCV GT 1 or 3 by HCV genotyping performed at Screening (\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1246f73a-f667-4701-a17b-1211bae6c52d\", \"childbox\": \"e95792fc-0a4a-4596-b1e6-5815977b6983\", \"subtext\": \"d184bcf5-d5aa-4207-81af-062ff4f9559e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 431, \"\"], [\"\", \"Unmapped\", \"text\", \"Note\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1246f73a-f667-4701-a17b-1211bae6c52d\", \"childbox\": \"e95792fc-0a4a-4596-b1e6-5815977b6983\", \"subtext\": \"399595a8-21da-42ea-b513-dff363134e42\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 432, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1246f73a-f667-4701-a17b-1211bae6c52d\", \"childbox\": \"e95792fc-0a4a-4596-b1e6-5815977b6983\", \"subtext\": \"b2685069-cf04-4412-ab7d-769c71043008\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 433, \"\"], [\"\", \"Unmapped\", \"text\", \"Mixed subtypes are not acceptable for GT 1\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1246f73a-f667-4701-a17b-1211bae6c52d\", \"childbox\": \"e95792fc-0a4a-4596-b1e6-5815977b6983\", \"subtext\": \"0b0dab65-583a-4a3c-9dff-696bc808affe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 434, \"\"], [\"\", \"Unmapped\", \"text\", \").\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1246f73a-f667-4701-a17b-1211bae6c52d\", \"childbox\": \"e95792fc-0a4a-4596-b1e6-5815977b6983\", \"subtext\": \"c8a7b45e-56fe-4927-a8f0-d9c67171ccdc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 435, \"\"], [\"\", \"Unmapped\", \"text\", \"Documented absence of cirrhosis within 36 months of Screening or dosing (histology or non-invasive equivalent, according to local standard of care).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fd4c70e2-e69a-4db8-bdfd-d633aa90beb8\", \"childbox\": \"fe6ca888-a331-4e3f-bbab-626470db058b\", \"subtext\": \"ec77cf56-dea8-40cd-baca-fcb94c39aa2f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 436, \"\"], [\"\", \"Unmapped\", \"text\", \"Note: A score of F4 on any test is exclusionary.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fd4c70e2-e69a-4db8-bdfd-d633aa90beb8\", \"childbox\": \"ef1bc211-7b36-4e26-82cd-1973542d10b1\", \"subtext\": \"ca686650-6ce3-4cbc-b37c-795f77e570d3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 437, \"\"], [\"\", \"Unmapped\", \"text\", \"Must not have received prior approved or investigational antiviral treatment for HCV infection\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ebd312f-a1cb-4a57-adde-b78557ef376e\", \"childbox\": \"0503e433-910e-4efb-badc-86ddac2840ae\", \"subtext\": \"25ee886c-054a-4f27-82b9-171be5145272\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 438, \"\"], [\"\", \"Unmapped\", \"text\", \"(Note: Non-cirrhotic, Peg-IFN/RBV-na\\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3month washout period).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 95, \"end_idx\": 110, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix-sponsored\"}], \"roi_id\": {\"para\": \"2ebd312f-a1cb-4a57-adde-b78557ef376e\", \"childbox\": \"0503e433-910e-4efb-badc-86ddac2840ae\", \"subtext\": \"b84cdd6d-dab8-4d7b-b5ad-c1d13576926e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 439, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ebd312f-a1cb-4a57-adde-b78557ef376e\", \"childbox\": \"0503e433-910e-4efb-badc-86ddac2840ae\", \"subtext\": \"e7a9e3cd-d6cc-4f81-9a7c-14955c7dfbdf\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 440, \"\"], [\"\", \"Unmapped\", \"text\", \"Subject is, in the opinion of the investigator, willing and able to comply with the protocol and all other study requirements.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c282d6b1-2197-41c2-bad0-4594c9277773\", \"childbox\": \"1319111b-7b5a-4fb8-bb17-5456545e3d63\", \"subtext\": \"6176ca06-768c-4c06-b0e2-f8590c98d727\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 441, \"\"], [\"\", \"Unmapped\", \"text\", \"Subject has provided written informed consent to participate in the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2594ec1a-df69-4a1f-bbf3-3af3306ea08c\", \"childbox\": \"2c45f2f7-b4da-4aaf-ab73-e0159149181e\", \"subtext\": \"ce3508aa-ed4e-493e-bf9b-61cd62d2c80d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 442, \"\"], [\"\", \"Unmapped\", \"header\", \"5.1.2 Exclusion criteria\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"f72bb9b4-2f7a-4735-9d24-e125fb6e1749\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 443, \"\"], [\"\", \"Unmapped\", \"text\", \"Female subjects who are pregnant or breastfeeding.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1cced5cf-eeb7-4ac4-b1b0-9081d0729aa4\", \"childbox\": \"f36d7a1a-c6fe-4808-839e-c69e9f1e6a5d\", \"subtext\": \"b9c73449-fec3-47cd-aa13-93c407c5f15e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 444, \"\"], [\"\", \"Unmapped\", \"text\", \"Body Mass Index (BMI) > 36 kg/m\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cc036b26-dcdd-4522-9540-fd07b38acd58\", \"childbox\": \"67365206-e57e-477e-96ba-d35cedf1a26c\", \"subtext\": \"90c98c57-b829-4bc6-930f-d797bb88e087\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 445, \"\"], [\"\", \"Unmapped\", \"text\", \"2\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cc036b26-dcdd-4522-9540-fd07b38acd58\", \"childbox\": \"67365206-e57e-477e-96ba-d35cedf1a26c\", \"subtext\": \"9806641d-552e-4305-a935-32ff73091a28\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"superscript\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 446, \"\"], [\"\", \"Unmapped\", \"text\", \".\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cc036b26-dcdd-4522-9540-fd07b38acd58\", \"childbox\": \"67365206-e57e-477e-96ba-d35cedf1a26c\", \"subtext\": \"00fae36d-c502-499a-9c3d-38d9ce03c560\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 447, \"\"], [\"\", \"Unmapped\", \"text\", \"Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen (HBsAg) positive) and/or human immunodeficiency virus (HIV).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b0e82d27-692f-4f9e-bc72-a028aabddbab\", \"childbox\": \"5db105e4-2a62-4644-9038-759bf10b758e\", \"subtext\": \"99c855b4-70a0-4390-98a1-087395a99e2a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 448, \"\"], [\"\", \"Unmapped\", \"text\", \"History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5157d08f-df3d-4f8c-9c67-6dac6ca8dda9\", \"childbox\": \"5f40de2e-738e-4638-abf5-49ce8d6ebcc6\", \"subtext\": \"0f7820b3-76f4-49f3-9620-44ba98b7317a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 449, \"\"], [\"\", \"Unmapped\", \"text\", \"History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4795e67f-43be-4184-bf28-91dc5f8aced8\", \"childbox\": \"aa03c22c-b2a1-4771-b552-9d0f5d780739\", \"subtext\": \"02fe5b4e-a0c4-4521-8755-0eb787df615f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 450, \"\"], [\"\", \"Unmapped\", \"text\", \"One or more known primary or secondary causes of liver disease, other than hepatitis C (e.g., alcoholism, autoimmune hepatitis, nonalcoholic steatohepatitis, drug-related liver disease, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson Disease, Dubin-Johnson syndrome, other congenital or metabolic conditions affecting the liver (with the exception of Gilbert\\u2019s syndrome), etc.).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"38ba226c-35f5-4e5b-923d-c25fa29bf7a1\", \"childbox\": \"c6fd3459-fc86-4cb8-8ff0-765ce1e6b46f\", \"subtext\": \"e665d5b0-9345-4d19-9e4c-a863466e8200\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 451, \"\"], [\"\", \"Unmapped\", \"text\", \"Steatosis is allowed, if clinically asymptomatic.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"38ba226c-35f5-4e5b-923d-c25fa29bf7a1\", \"childbox\": \"c275c67b-6ab2-4462-94bf-1f7160512958\", \"subtext\": \"dd46c3aa-73e7-42be-9875-61b8c47cd7dc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 452, \"\"], [\"\", \"Unmapped\", \"text\", \"History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, nonHCV viral hepatitis, gallstones or other etiologies.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f7f2a023-75ba-425a-a05b-d40935b3b216\", \"childbox\": \"688106c7-3e7d-4b1c-93b7-799736d8aa62\", \"subtext\": \"2f301726-5f69-442f-ac28-616ee9ef53bf\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 453, \"\"], [\"\", \"Unmapped\", \"text\", \"Active, clinically significant (per judgment of the Principal Investigator) disease including:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a4e714be-37a7-49f3-bb6a-a3dc02cefc6a\", \"childbox\": \"4e1be714-091e-4909-932a-bb9b989b83ce\", \"subtext\": \"d4d76151-5201-43de-84aa-1c294ee17bc0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 454, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Acute or chronic kidney disease,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7f12ef2a-60a2-4d8b-b80b-e6dd56e7e87d\", \"childbox\": \"830fd45d-0b2f-4450-bccd-09ef6eac0e58\", \"subtext\": \"6d296237-e6d5-44a8-98f4-5e426a897cf3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 455, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Malignant disease or suspicion or history of malignant disease within previous 5 years (except for adequately treated basal cell carcinoma or other localized, non-metastatic cancer),\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"688b2c29-cc35-440d-bf44-c787a29e4968\", \"childbox\": \"b99a0ded-3d23-495c-ad92-efc09cd61600\", \"subtext\": \"ea55cdf9-4677-4614-9f2a-1c33f136e4bf\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 456, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Uncontrolled depressive illness,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"25583bcb-0f9e-41a7-b587-d45226c657dc\", \"childbox\": \"136f58ab-7048-4a06-bd7c-9ac8c9ee92ca\", \"subtext\": \"fccda384-7b95-4912-9993-1e90b1e22a7d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 457, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Uncontrolled thyroid disease; thyroid stimulating hormone (TSH) must be normal at Screening,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2cb84026-ffff-4043-97a6-ad36add8d808\", \"childbox\": \"d31d59e4-f4a0-484b-b8f7-31a3ba3aa0ca\", \"subtext\": \"16c6fe65-e6ff-45af-8674-01676b83954b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 458, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Uncontrolled hypertension,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1b47c47c-250f-4592-804b-f000c039ffd6\", \"childbox\": \"1f3e45f3-58e5-4706-bb00-f52250373ed8\", \"subtext\": \"5d4ef303-ac7d-423b-91df-600a49fb815e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 459, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Poorly controlled diabetes mellitus as evidenced by hemoglobin A\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ec42f063-62b4-4a93-8b76-7afe8d9349b0\", \"childbox\": \"0edf6467-ef1e-4c0d-9363-46609f45c50c\", \"subtext\": \"6818cb8f-6922-433b-94bd-c8908230ed32\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 460, \"\"], [\"\", \"Unmapped\", \"text\", \"1c\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ec42f063-62b4-4a93-8b76-7afe8d9349b0\", \"childbox\": \"0edf6467-ef1e-4c0d-9363-46609f45c50c\", \"subtext\": \"298cf00b-addb-405e-9f5b-d69a57c51353\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 461, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2265 8.5% or equivalent at Screening,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ec42f063-62b4-4a93-8b76-7afe8d9349b0\", \"childbox\": \"0edf6467-ef1e-4c0d-9363-46609f45c50c\", \"subtext\": \"7c057ddf-c613-4961-ae44-9cbda5dc8609\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 462, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Neurological disease,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8b2fe3b2-995b-4fbe-b25b-6342ede4e52a\", \"childbox\": \"16448342-1bb0-4285-9345-388b5c00c1cf\", \"subtext\": \"18dd426c-819b-43a9-9ef0-5a9bcb9a3c17\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 463, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Acute or chronic pancreatitis,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"69e096c5-6e8a-4056-b6be-ec333a0fad66\", \"childbox\": \"db3d25fa-1fcc-4faf-986d-28f1e96669a7\", \"subtext\": \"0988d915-13c7-4c19-8214-7fbd71a7d3fe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 464, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Infections (e.g., tuberculosis),\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4270fe39-de0a-49b4-894a-ed2559b34d6a\", \"childbox\": \"716b2257-8dd6-48c0-b62d-0971c04e5f22\", \"subtext\": \"125077e8-9b70-45ce-ba00-14ef6b25d101\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 465, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Intestinal malabsorption (e.g., structural defects, digestive failure, enzyme deficiencies with the exception of lactose intolerance, etc.),\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3020d450-8103-4295-941e-ccfe352cd38b\", \"childbox\": \"73e9d7a2-51fe-4b96-ba92-c8c2c5d538e2\", \"subtext\": \"e330651a-08aa-468b-b407-bb7e56c18865\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 466, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Pulmonary disease associated with ongoing functional impairment,\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ff5d0266-4b73-4744-b2f5-8d9b04589cba\", \"childbox\": \"a5dab2a4-fb6a-48af-9ea2-6ec93680027a\", \"subtext\": \"af79c62e-983f-4b83-a291-05d1f2b24887\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 467, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Cardiac disease, clinically significant arrhythmia, family history of congenital heart disease, family history of prolonged QT, or family history of sudden death of unknown etiology, OR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"26a18c85-2d07-49a6-9bb3-26c3a1ea27ef\", \"childbox\": \"b81b35da-fd56-4731-8074-888933a56427\", \"subtext\": \"c8b21646-69b2-4ea6-8cf9-4aa47c5ab61d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 468, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Any other condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"57159c72-cf47-4ca0-80d6-201f4e1d065b\", \"childbox\": \"77f4dd99-484c-4a47-927a-6d87aa00682a\", \"subtext\": \"e3dce901-76d2-485b-ab0f-8faf366d23f3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 469, \"\"], [\"\", \"Unmapped\", \"text\", \"Donated blood or had significant blood loss 30 days prior to dosing.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d2f6f6c3-523b-4974-8b92-380e7ce8ef93\", \"childbox\": \"1d6e9972-fc5c-480e-b45c-70130fd83242\", \"subtext\": \"8e2f9984-99e5-4896-82c1-daaf31f8f325\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 470, \"\"], [\"\", \"Unmapped\", \"text\", \"Use of alcohol and/or drugs that could interfere with adherence to study requirements as judged by the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dde3ab5d-ce42-44b8-a2d4-9ed149a7442a\", \"childbox\": \"2156d8e3-0735-4845-8d88-cf1b10d7cb09\", \"subtext\": \"1f44334c-246e-49f7-b9fc-479870776d25\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 471, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant use of any major inhibitors or inducers of CYP3A (as described in Section 6.6.6).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0940976b-33a6-497b-be44-de2094a7f849\", \"childbox\": \"930ebe75-4853-4da6-842d-7b49c414c462\", \"subtext\": \"c2242540-81fc-4fb4-ad63-e8a16a512d65\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 472, \"\"], [\"\", \"Unmapped\", \"text\", \"A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0940976b-33a6-497b-be44-de2094a7f849\", \"childbox\": \"151c68b3-4f70-40e7-b801-497f3668e0ef\", \"subtext\": \"06e04c1d-b3a8-442c-aa0b-d017e8559a92\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 473, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant use of any major inhibitors, inducers or substrates of permeability glycoprotein (P-gp) transporter (see Section 6.6.6).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e1152a7d-8a16-4489-aeb7-32c779fdee3f\", \"childbox\": \"7ed0f992-bb6d-41b8-94fd-f359748e0db9\", \"subtext\": \"685d3112-b53b-41ef-a436-3be386d71c31\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 474, \"\"], [\"\", \"Unmapped\", \"text\", \"A washout period of at least 5 halflives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e1152a7d-8a16-4489-aeb7-32c779fdee3f\", \"childbox\": \"2db08b34-56c4-41ff-94b5-447d94e8eac2\", \"subtext\": \"23a7d0b1-ae81-4fd6-bfc5-91a0c301cd8d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 475, \"\"], [\"\", \"Unmapped\", \"text\", \"Based on limited\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d8376177-158c-4aac-8549-2ed9a645168e\", \"childbox\": \"f3ea9106-46ba-4312-915f-546b0fa6ee95\", \"subtext\": \"515ad231-d8b0-4b16-8535-403390ead4c7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 476, \"\"], [\"\", \"Unmapped\", \"text\", \"in vitro\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d8376177-158c-4aac-8549-2ed9a645168e\", \"childbox\": \"f3ea9106-46ba-4312-915f-546b0fa6ee95\", \"subtext\": \"101eff97-0a9b-434d-92a7-db4f6bdc4645\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 477, \"\"], [\"\", \"Unmapped\", \"text\", \"metabolic results, the concomitant use of other drugs is prohibited until further information is available to guide their use (as described in Section 6.6.6).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d8376177-158c-4aac-8549-2ed9a645168e\", \"childbox\": \"f3ea9106-46ba-4312-915f-546b0fa6ee95\", \"subtext\": \"3392d183-bd14-47fd-8191-9c1c69fd2b52\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 478, \"\"], [\"\", \"Unmapped\", \"text\", \"A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that it can be safely discontinued or substituted for the duration of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d8376177-158c-4aac-8549-2ed9a645168e\", \"childbox\": \"9a216df3-1b9b-462c-a9d3-6094426ab09a\", \"subtext\": \"1c30d71a-6ed2-4b26-8f83-a079a743a8e4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 479, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant use of drugs contraindicated in the RBV product label.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8b6b8e8b-c8de-49b1-aede-d2f524794e7e\", \"childbox\": \"58ef7342-f2b0-449b-8c5e-173b2ca79b57\", \"subtext\": \"ef8b1cac-ee6b-4733-a039-9e1eb5a1d395\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 480, \"\"], [\"\", \"Unmapped\", \"text\", \"A washout period of at least 5 half-lives of the contraindicated drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8b6b8e8b-c8de-49b1-aede-d2f524794e7e\", \"childbox\": \"7fa43434-a622-4f4d-8042-36556971ddc2\", \"subtext\": \"ef8b1cac-ee6b-4733-a039-9e1eb5a1d395\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 481, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who require frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions); required use for greater than 5 days should be discussed with the Sponsor during Screening (\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ef98507d-76a9-48a8-8e8f-4d2468ffdc4b\", \"childbox\": \"9d26632c-839e-4133-84eb-72502d659d03\", \"subtext\": \"2382af31-9a82-43ac-a280-38b3150c1ddd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 482, \"\"], [\"\", \"Unmapped\", \"text\", \"Note\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ef98507d-76a9-48a8-8e8f-4d2468ffdc4b\", \"childbox\": \"9d26632c-839e-4133-84eb-72502d659d03\", \"subtext\": \"eddf9e84-6648-4e89-af73-62df164ac94a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 483, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ef98507d-76a9-48a8-8e8f-4d2468ffdc4b\", \"childbox\": \"9d26632c-839e-4133-84eb-72502d659d03\", \"subtext\": \"54b65345-ad92-46a1-a1b4-7d2dae00b6ce\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 484, \"\"], [\"\", \"Unmapped\", \"text\", \"Topical or inhaled corticosteroids are permitted)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ef98507d-76a9-48a8-8e8f-4d2468ffdc4b\", \"childbox\": \"9d26632c-839e-4133-84eb-72502d659d03\", \"subtext\": \"595789e3-592b-4896-81fb-e9c6bca11f6b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 485, \"\"], [\"\", \"Unmapped\", \"text\", \".\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ef98507d-76a9-48a8-8e8f-4d2468ffdc4b\", \"childbox\": \"9d26632c-839e-4133-84eb-72502d659d03\", \"subtext\": \"4bec7ed7-76ae-45c4-af5a-22329c662ef1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 486, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant use of antacids or acid blockers.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a8e8d5a9-130e-4cc3-8bfa-c53e51756682\", \"childbox\": \"05b0ab20-01a8-4e4c-a82d-4b1f417b045f\", \"subtext\": \"724d171d-8217-44dc-ab88-b85bec120aff\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 487, \"\"], [\"\", \"Unmapped\", \"text\", \"For acid blockers, a washout period of at least 5 half-lives must be observed prior to study drug dosing, if the Principal Investigator feels that the drug can be safely discontinued or substituted for the duration of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a8e8d5a9-130e-4cc3-8bfa-c53e51756682\", \"childbox\": \"b90f071d-344f-4a0a-80ab-ea378648fdd2\", \"subtext\": \"724d171d-8217-44dc-ab88-b85bec120aff\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 488, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant use of herbal medications (e.g., St. John\\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"120e56ae-de75-4fd1-9c6a-4ae30f1f41c1\", \"childbox\": \"7cf690e5-ca85-4069-a1a9-ff8d5d2ff0da\", \"subtext\": \"556dc941-2b08-49bf-9ebb-16b9882ccfa0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 489, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant use of opioid substitution drugs (e.g., buprenorphine and methadone).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0609dd69-9f4d-4ffd-954d-d0a0af3757e1\", \"childbox\": \"b3519f67-52d6-44a5-a1c6-62ad644dead0\", \"subtext\": \"02f830fb-4641-4bae-9c51-5bbc481399be\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 490, \"\"], [\"\", \"Unmapped\", \"text\", \"Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ad6b82ef-f1c9-419f-a2c7-1c2e380872bf\", \"childbox\": \"296fafe5-397d-4ccb-96d6-4115bf314c26\", \"subtext\": \"5641dbec-bc9d-4bcf-93d8-fe51f93a5462\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 491, \"\"], [\"\", \"Unmapped\", \"text\", \"Subject with known allergy/hypersensitivity/intolerance to any of the study drugs, or any of their components.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"472d3836-41d2-4b45-91f9-31de92e5ffec\", \"childbox\": \"13e7c028-db6c-4e7c-bf4a-ce801fde3476\", \"subtext\": \"094da37f-5171-476b-be91-8288a56795c3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 492, \"\"], [\"\", \"Unmapped\", \"text\", \"21. Clinically significant abnormal ECG at Screening or prior to dosing on Day 1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"54f32bb0-72e2-4a63-a529-2e9f879d0764\", \"childbox\": \"56134467-acd1-4570-ba27-bedd226d13b8\", \"subtext\": \"687fcfe7-2c85-4707-87c5-2410fa114030\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 493, \"\"], [\"\", \"Unmapped\", \"text\", \"Abnormal values at Screening:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7df274af-e812-4b4f-b15f-f72d9e55aaa3\", \"childbox\": \"df646eb8-3337-4635-9619-7ca6012dfa63\", \"subtext\": \"d453d656-e960-4b70-b694-d781c3720373\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 494, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 hemoglobin (Hgb) < 10.0 g/dL\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c0c8e434-84b8-4e98-be2e-5c2501e2b0ad\", \"childbox\": \"fc46f0c7-6ab5-4841-a6f9-b948947419bd\", \"subtext\": \"707e5a02-9f5e-434b-a0a4-1638811e43d5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 495, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 absolute neutrophil count (ANC) < 1.0 x 10\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ac14ecde-002d-4fc9-beed-db77c5bf6210\", \"childbox\": \"67b8987d-7952-434d-96ba-92f673cd1744\", \"subtext\": \"b45a193c-ee21-4687-9fc0-e4d1f9cb5847\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 496, \"\"], [\"\", \"Unmapped\", \"text\", \"9\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ac14ecde-002d-4fc9-beed-db77c5bf6210\", \"childbox\": \"67b8987d-7952-434d-96ba-92f673cd1744\", \"subtext\": \"6ad388d1-9fc0-4476-949b-3302f80d3b5d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"superscript\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 497, \"\"], [\"\", \"Unmapped\", \"text\", \"/L\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ac14ecde-002d-4fc9-beed-db77c5bf6210\", \"childbox\": \"67b8987d-7952-434d-96ba-92f673cd1744\", \"subtext\": \"029ca93d-2119-4f63-a7a9-80129b545d6d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 498, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 platelets < 120 x 10\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d975d6f0-db0a-473d-8876-69b2da96dc01\", \"childbox\": \"6fdda56c-e5b6-4226-9bb1-b7c5b3b3eea6\", \"subtext\": \"6ee268bf-f3b0-41b8-b4f7-212459e2de26\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 499, \"\"], [\"\", \"Unmapped\", \"text\", \"9\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d975d6f0-db0a-473d-8876-69b2da96dc01\", \"childbox\": \"6fdda56c-e5b6-4226-9bb1-b7c5b3b3eea6\", \"subtext\": \"5e69b46e-d5ff-40d0-8991-b1741d11f6ac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"superscript\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 500, \"\"], [\"\", \"Unmapped\", \"text\", \"/L\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d975d6f0-db0a-473d-8876-69b2da96dc01\", \"childbox\": \"6fdda56c-e5b6-4226-9bb1-b7c5b3b3eea6\", \"subtext\": \"5a83f880-9eb6-4b0f-92cd-4714965e073b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 501, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 ALT or AST > 5 x ULN\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"55e45005-24ec-49ca-b566-ff307de0100c\", \"childbox\": \"82d31db8-bdf5-4e66-93e8-97f4a103df9a\", \"subtext\": \"b9542b2f-822f-4e23-b32d-c2748e935e66\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 502, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 total bilirubin > 1.1 x ULN (subjects with history of Gilbert\\u2019s syndrome > 2 x ULN)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b6cba95b-8c75-4071-b4dd-7fb2c5a94d34\", \"childbox\": \"ae8ec91b-4793-41f4-b253-17e8f2127fec\", \"subtext\": \"fe26e722-9715-47e9-b046-95c2a685aefc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 503, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 serum albumin < 3.5 g/dL\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e83530d-92bb-4de9-81ba-fa8cd57a0540\", \"childbox\": \"9fe70b77-b293-4735-a0e1-ab9c689cd23c\", \"subtext\": \"2d197836-d00b-4717-8128-a3b2697b939a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 504, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 alkaline phosphatase > 1.25 x ULN\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8996997b-35c3-43a1-9e67-af0f87cad038\", \"childbox\": \"798fef9b-38ea-4e43-a794-1ecd403126da\", \"subtext\": \"28256df8-2992-4fda-b81f-93b4a1b00054\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 505, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 serum creatinine > 1.1 x ULN\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8188b54e-3f30-478a-86b6-06416ee30527\", \"childbox\": \"694e656c-a9ad-4bbc-9c44-156aac28959e\", \"subtext\": \"53fdddba-29ec-4994-8224-cab15f476314\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 506, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 pancreatic amylase > 1.5 x ULN\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0fc9590a-d8d6-438e-a8b4-08e619416846\", \"childbox\": \"e1afdfce-ba4d-44c5-8659-40dd7a662ff0\", \"subtext\": \"057269a7-d65b-4697-a3d8-534f9b3f8fcd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 507, \"\"], [\"\", \"Unmapped\", \"text\", \"Any other laboratory abnormalities > Grade 1, as defined in (Appendix 2), considered clinically significant by the investigators.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e610df9d-b702-4a15-8099-d68a7148a88b\", \"childbox\": \"083d31d9-050a-4c41-a2d5-139db900de96\", \"subtext\": \"c1d32027-874a-4cc5-af4f-59028d71f0b4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 508, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\\u2019s historical values.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9db0524b-a0cc-4035-9bbf-ccb2fd619a2b\", \"childbox\": \"c0276c38-80f1-4724-817b-c349ea544600\", \"subtext\": \"b00f1160-6a46-47e7-b5da-3240ade0d148\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 509, \"\"], [\"\", \"Unmapped\", \"text\", \"If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9db0524b-a0cc-4035-9bbf-ccb2fd619a2b\", \"childbox\": \"69a9698a-6db5-40bd-a052-5ba3540b9dfe\", \"subtext\": \"7d3a53f2-5f18-4380-8e06-982006d5dd93\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Inclusion/exclusion criteria\", \"5.1\", \"2\", 510, \"\"], [\"\", \"Unmapped\", \"header\", \"5.2 Premature subject withdrawal\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"be92bb25-6c74-4904-9a30-9dea9aedcee9\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 511, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects may voluntarily withdraw from the study, or be removed from the study at the discretion of the investigator or Sponsor at any time.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27517815-2c4c-41f9-aa8e-b2b9d4bd6676\", \"childbox\": \"198a8544-541d-40d6-ba07-3f9290ec8bac\", \"subtext\": \"e4ea77d3-2fdc-4d98-bf4f-09a1f4876495\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 512, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator may withdraw a subject at any time if it is determined that continuing the study would result in a safety risk to the subject.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27517815-2c4c-41f9-aa8e-b2b9d4bd6676\", \"childbox\": \"c806187f-482e-4116-b1b0-6ee9421850ff\", \"subtext\": \"e4ea77d3-2fdc-4d98-bf4f-09a1f4876495\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 513, \"\"], [\"\", \"Unmapped\", \"text\", \"If such withdrawal occurs, or if the subject fails to return for visits, the investigator should determine the primary reason for a subject\\u2019s premature withdrawal from the study and record the reason in the respective subject\\u2019s study records.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"269b2b38-36d8-4a3d-ab0a-c1cb9324935d\", \"childbox\": \"7aba1bab-9672-44c2-8757-e6744955ab99\", \"subtext\": \"11862afd-54cb-441b-af71-3eee44d76a85\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 514, \"\"], [\"\", \"Unmapped\", \"text\", \"Premature withdrawal may occur for any of the following reasons:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6b570553-3819-4e21-86f5-2a9e5fc301df\", \"childbox\": \"bccc242e-d2d5-4d09-b35d-1bd0ef151501\", \"subtext\": \"bca82cb6-a396-47fd-9c80-39a80c360389\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 515, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Noncompliance with the protocol requirements\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ff1fd142-531d-4c10-847b-07257b41d879\", \"childbox\": \"ed44ef09-1899-4aac-b4f1-9816340ebb45\", \"subtext\": \"020bef90-2fda-45fc-aaa8-cca98df689aa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 516, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Pregnancy\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e23c3ab7-8d4d-4335-b57e-4c1d2d58db0d\", \"childbox\": \"ffafee0d-9190-4d4d-9325-d30e1edd1301\", \"subtext\": \"70218749-1f3d-4d6f-9a9f-4230ab2515e2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 517, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Death\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"67c467bd-2c93-4d36-8ddb-5fd825d006f2\", \"childbox\": \"a8ef6fb9-c2ca-4481-9003-fcc3bfad3584\", \"subtext\": \"ea6c22b5-251f-4e76-96da-f6f38b270456\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 518, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Adverse event (AE)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a11c1389-e9d9-4bbf-8a71-d9654cc9de8a\", \"childbox\": \"a6494ecc-93c7-4927-8110-550fe73f6a5c\", \"subtext\": \"8f3b8ee3-ce77-4e1a-b695-6427aec096a4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 519, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Lack of efficacy\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"05ee25fa-880e-4ba0-ae5a-4aa6f6498fb3\", \"childbox\": \"4992653a-f314-45b6-b043-2c21bf43f888\", \"subtext\": \"2e07d967-75d0-4f5f-81ac-d59d0f930bad\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 520, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Subject request\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8a0ed20f-6be0-41f4-a8b9-dab38bf062d5\", \"childbox\": \"d4e68e62-b053-4f83-9755-d248a99b7034\", \"subtext\": \"5f7331cc-ec63-48f3-9830-ec8b291da713\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 521, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Investigator request\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3bfc2c24-e60a-40b7-9d0d-608bf55af94a\", \"childbox\": \"0a712282-83d5-4b9b-a35b-7c13a7b85402\", \"subtext\": \"8796a30a-d826-458b-9b72-746638004732\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 522, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Sponsor request\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b4c9d357-9b7b-4823-8743-5b8be3594ffa\", \"childbox\": \"02506606-fb89-462c-99b5-31eb8e8a74ad\", \"subtext\": \"b32bff2d-f1a4-4277-bcfc-da299986dd75\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 523, \"\"], [\"\", \"Unmapped\", \"text\", \"All subjects who prematurely discontinue their assigned study drug treatment should have an EOT visit and return for all of the post-EOT follow-up visits, as described in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b95339c7-48ef-4ce4-95f0-c3e706014ff6\", \"childbox\": \"9b676463-c23d-4f27-b18d-e03a618fc2af\", \"subtext\": \"b125adb5-89f5-4565-bed0-7b39777da77a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 524, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who have received at least one dose of samatasvir or IDX21437 will then be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"b95339c7-48ef-4ce4-95f0-c3e706014ff6\", \"childbox\": \"72a2687b-d0d4-4c7a-b76a-82cf9e077010\", \"subtext\": \"0becb456-a0ea-4098-a411-d9571f5149eb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 525, \"\"], [\"\", \"Unmapped\", \"text\", \"Those subjects who fail investigational treatment and start another HCV treatment will not be followed in the extended observational follow-on phase of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b95339c7-48ef-4ce4-95f0-c3e706014ff6\", \"childbox\": \"5fbe3e47-c4a5-43a5-a32c-d2ee5557fa85\", \"subtext\": \"44f3192f-233e-4c93-8cbb-f3aa5fb51382\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 526, \"\"], [\"\", \"Unmapped\", \"text\", \"For subjects who are lost to follow-up (i.e., those subjects whose status is unclear because they fail to appear for study visits without stating an intention to withdraw), the investigator should show due diligence by documenting in the source documents all steps taken to contact the subject, e.g., dates of telephone calls, registered letters, etc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e95b60b2-c763-4d58-804d-ef51ede36419\", \"childbox\": \"0b3953aa-dad4-4116-a3bb-bd877d1f9409\", \"subtext\": \"bbfd9299-bbb7-40d5-9454-1153cae9aecb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 527, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who prematurely withdraw from the study for reasons other than safety or efficacy may be replaced by an equal number of newly enrolled subjects at the Sponsor\\u2019s discretion.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f1b15517-bc36-4224-89a3-82ed30d073f6\", \"childbox\": \"3e94b3d4-56f9-4a40-954d-a2c811333764\", \"subtext\": \"79b33d05-9fce-4e2d-8b07-e49907768819\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Premature subject withdrawal\", \"5.2\", \"2\", 528, \"\"], [\"\", \"Unmapped\", \"header\", \"6 Treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"6ad20987-ba0d-4f6d-8799-b52bf020c260\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment\", \"6\", \"1\", 529, \"\"], [\"\", \"Unmapped\", \"header\", \"6.1 Subject numbering\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"607b1cca-32c0-4ce3-b6aa-b370bba7b42a\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject numbering\", \"6.1\", \"2\", 530, \"\"], [\"\", \"Unmapped\", \"text\", \"At Screening, each subject will receive a unique subject number.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aad065a6-c153-4315-981c-2952c8c7d7bc\", \"childbox\": \"15f95f08-10ca-4597-8b27-2d27ecf847b6\", \"subtext\": \"059e1f29-a361-4c4a-bf28-9f7734078b33\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject numbering\", \"6.1\", \"2\", 531, \"\"], [\"\", \"Unmapped\", \"text\", \"If a subject fails to be randomized, the reason for not being randomized should be documented in the source documents.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aad065a6-c153-4315-981c-2952c8c7d7bc\", \"childbox\": \"506eb73f-8329-46b1-af02-d4dec0e6423a\", \"subtext\": \"059e1f29-a361-4c4a-bf28-9f7734078b33\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject numbering\", \"6.1\", \"2\", 532, \"\"], [\"\", \"Unmapped\", \"header\", \"6.2 Investigational and control drugs\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"c614e1af-6c9e-4b3c-a146-cdaecdfffaa6\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigational and control drugs\", \"6.2\", \"2\", 533, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 will be supplied as 150 mg tablets.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"4f98ed48-40d3-4240-8ddf-2ef9d6e77c4c\", \"childbox\": \"08e42caf-c733-4e15-bc41-4cdba2dab109\", \"subtext\": \"efd3bd73-a59b-4f85-9501-858a3fbaed55\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigational and control drugs\", \"6.2\", \"2\", 534, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 storage conditions will be included on the label.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"4f98ed48-40d3-4240-8ddf-2ef9d6e77c4c\", \"childbox\": \"4b4fe051-a4fe-4418-958f-d88b4c045004\", \"subtext\": \"efd3bd73-a59b-4f85-9501-858a3fbaed55\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigational and control drugs\", \"6.2\", \"2\", 535, \"\"], [\"\", \"Unmapped\", \"text\", \"Samatasvir will be supplied as 50 mg tablets.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"0f8dafb6-62c3-4b90-a723-36da2432a913\", \"childbox\": \"d32b82df-292c-4be9-9fb8-933311dc870d\", \"subtext\": \"7a5deeb0-db8b-4b47-87e5-0a9190079391\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigational and control drugs\", \"6.2\", \"2\", 536, \"\"], [\"\", \"Unmapped\", \"text\", \"Storage conditions of samatasvir will be included on the label.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 22, \"end_idx\": 31, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"0f8dafb6-62c3-4b90-a723-36da2432a913\", \"childbox\": \"768b9652-7bda-4a29-ada4-45f100720778\", \"subtext\": \"7a5deeb0-db8b-4b47-87e5-0a9190079391\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigational and control drugs\", \"6.2\", \"2\", 537, \"\"], [\"\", \"Unmapped\", \"text\", \"Ribavirin will be supplied as 200 mg tablets in its commercial packaging and should be stored according to the approved product label.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f933fa20-ae4c-48b0-b640-1248a380e610\", \"childbox\": \"7c072542-1fc1-4012-a516-8e8edb09cf8c\", \"subtext\": \"5c36109c-a811-405f-9508-30c46ccd9a3f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Investigational and control drugs\", \"6.2\", \"2\", 538, \"\"], [\"\", \"Unmapped\", \"header\", \"6.3 Treatment arms\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"711de632-5093-49d2-a70b-2c8880070018\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment arms\", \"6.3\", \"2\", 539, \"\"], [\"\", \"Unmapped\", \"text\", \"Eligible subjects will be assigned to treatment via a computer-generated randomization/enrollment list to one of the treatment groups specified in Table 4-1 and as described in Section 4, Study Design.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b93e620e-4f4e-495c-a136-0256e4e6128f\", \"childbox\": \"a6387ac0-3c7c-44b0-8188-ffd8d4d87e8d\", \"subtext\": \"606056e0-66af-4856-bc0b-6a28035462ed\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment arms\", \"6.3\", \"2\", 540, \"\"], [\"\", \"Unmapped\", \"header\", \"6.4 Treatment assignment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"5b1476b7-6c6c-4e04-b85e-fc1df98aef79\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment assignment\", \"6.4\", \"2\", 541, \"\"], [\"\", \"Unmapped\", \"text\", \"Randomization schedules will be prepared across all investigators by the Sponsor\\u2019s biostatistician (or designee).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f7242a2-d76d-4c1a-a8e1-5493fd2530a5\", \"childbox\": \"a05f3aab-90a4-4b00-be89-68c8fb174061\", \"subtext\": \"faeb971a-db0d-4024-a26c-099e922717e6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment assignment\", \"6.4\", \"2\", 542, \"\"], [\"\", \"Unmapped\", \"text\", \"Once screening eligibility data are available, including laboratory results, and it has been determined that the subject is eligible for randomization, the subject must be contacted by telephone to confirm that he/she is still willing to participate in the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f7242a2-d76d-4c1a-a8e1-5493fd2530a5\", \"childbox\": \"7e9fb383-20bc-4bb7-844a-2221a90affb9\", \"subtext\": \"faeb971a-db0d-4024-a26c-099e922717e6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment assignment\", \"6.4\", \"2\", 543, \"\"], [\"\", \"Unmapped\", \"text\", \"Through a centralized randomization process, the subject will then be randomized by the site personnel to a treatment assignment and a randomization number assigned.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f7242a2-d76d-4c1a-a8e1-5493fd2530a5\", \"childbox\": \"66aae405-0680-4745-832e-cd5fd411d4ab\", \"subtext\": \"5e521292-35f4-4e9a-8ca7-9dc1bc087fd0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment assignment\", \"6.4\", \"2\", 544, \"\"], [\"\", \"Unmapped\", \"text\", \"Randomization will occur prior to dosing and will define the subject\\u2019s entry into the study, which must be documented in the source documents and case report form (CRF).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f12aa73b-831e-47dc-b13f-fec39ede93b9\", \"childbox\": \"0da8ca20-80b6-448c-b5d3-4bcb94614e35\", \"subtext\": \"cd060ae5-88c8-4aff-b078-694b54687275\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment assignment\", \"6.4\", \"2\", 545, \"\"], [\"\", \"Unmapped\", \"text\", \"If a subject is randomized but does not receive study drug for any reason, the reason should be documented in the source documents and the Sponsor should be notified immediately.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f12aa73b-831e-47dc-b13f-fec39ede93b9\", \"childbox\": \"dd489ab7-22a1-4df3-b574-da8d6a0da62a\", \"subtext\": \"aa532df5-778a-4584-ad34-71375f975394\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment assignment\", \"6.4\", \"2\", 546, \"\"], [\"\", \"Unmapped\", \"header\", \"6.5 Treatment blinding\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"168e4e39-6d63-4332-a2e9-16ba87072e61\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment blinding\", \"6.5\", \"2\", 547, \"\"], [\"\", \"Unmapped\", \"text\", \"This study is not blinded to treatment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c9894ba-fbae-43a0-b7dd-3b01bc9a451e\", \"childbox\": \"b0a7abca-e6a3-4f29-bc87-51666481af4d\", \"subtext\": \"8173a951-f30b-4d61-9a2a-afa9201cce1f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treatment blinding\", \"6.5\", \"2\", 548, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6 Treating the subject\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"ba1fea63-3e2e-4aec-8401-bddf4f05e5e6\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Treating the subject\", \"6.6\", \"2\", 549, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.1 Dispensing the study drug\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"1b9e1caf-c185-4c0c-a585-a7eaaa2b35e4\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Dispensing the study drug\", \"6.6.1\", \"3\", 550, \"\"], [\"\", \"Unmapped\", \"text\", \"Study drugs will be dispensed to the subjects by the study center personnel, under the supervision of the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"00f45a8e-3679-4d2b-9b92-092d134bd728\", \"childbox\": \"7ae909ec-eda5-41b7-91f8-8c640bcc7f7e\", \"subtext\": \"8b51f04c-cee9-4fa0-8f54-6a5e070ef229\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Dispensing the study drug\", \"6.6.1\", \"3\", 551, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.2 Instructions for prescribing and taking the study drug\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"44cd58ed-08d5-4fc5-9402-09999f5b2992\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 552, \"\"], [\"\", \"Unmapped\", \"text\", \"For all study drugs, the investigator should communicate the importance of compliance and timing of dose to the subject.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6360494d-f2e5-4520-a18c-c91f7a885aac\", \"childbox\": \"2c9cc011-7387-42c8-8a92-0ea2b5ddb205\", \"subtext\": \"85c63554-c077-4a17-a11f-fc93b95b86cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 553, \"\"], [\"\", \"Unmapped\", \"text\", \"The subject should be instructed to take their study drugs at approximately the same time each day, and to contact the investigator if he/she is unable to take the study drug as prescribed.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6360494d-f2e5-4520-a18c-c91f7a885aac\", \"childbox\": \"f41c7a53-8825-4338-b39f-9892d47ab1d2\", \"subtext\": \"85c63554-c077-4a17-a11f-fc93b95b86cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 554, \"\"], [\"\", \"Unmapped\", \"text\", \"All dosages prescribed and dispensed to the subject during the study must be recorded in the source documents.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"972e4c99-9324-4f0a-aec2-21285d8017c3\", \"childbox\": \"84570bba-5f93-4b22-9107-d009ce2bb35d\", \"subtext\": \"86f66608-bbd5-408f-a2ba-00c7ceae603d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 555, \"\"], [\"\", \"Unmapped\", \"text\", \"Administration of the first dose of study drugs (Day 1)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c2ae0770-593e-41b7-8ddc-3b403c468155\", \"childbox\": \"4b5cc394-988c-4219-9115-cafc285927f8\", \"subtext\": \"9d41e621-5877-40ee-822c-d306123fca4a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 556, \"\"], [\"\", \"Unmapped\", \"text\", \"must occur in the clinic\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c2ae0770-593e-41b7-8ddc-3b403c468155\", \"childbox\": \"4b5cc394-988c-4219-9115-cafc285927f8\", \"subtext\": \"5a2d7112-829e-4b89-b787-598bd81288bf\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 557, \"\"], [\"\", \"Unmapped\", \"text\", \".\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c2ae0770-593e-41b7-8ddc-3b403c468155\", \"childbox\": \"4b5cc394-988c-4219-9115-cafc285927f8\", \"subtext\": \"76417c6e-353d-4d63-bb72-1f382ff4a688\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 558, \"\"], [\"\", \"Unmapped\", \"text\", \"Samatasvir, IDX21437 and the\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 12, \"end_idx\": 19, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"c2ae0770-593e-41b7-8ddc-3b403c468155\", \"childbox\": \"313df2c6-153d-407b-b9a3-f5c39db85332\", \"subtext\": \"76417c6e-353d-4d63-bb72-1f382ff4a688\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 559, \"\"], [\"\", \"Unmapped\", \"text\", \"morning\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c2ae0770-593e-41b7-8ddc-3b403c468155\", \"childbox\": \"313df2c6-153d-407b-b9a3-f5c39db85332\", \"subtext\": \"687886c7-2c95-4b9d-8ab3-309b10968a1c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 560, \"\"], [\"\", \"Unmapped\", \"text\", \"dose of RBV (if applicable) will be administered at the same time with a standard breakfast (approximately 400-500 calories: 20 g fat, 25 g protein, and 50 g carbohydrate).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c2ae0770-593e-41b7-8ddc-3b403c468155\", \"childbox\": \"313df2c6-153d-407b-b9a3-f5c39db85332\", \"subtext\": \"99af4c59-19aa-49a0-89c7-57064a7fe1e9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 561, \"\"], [\"\", \"Unmapped\", \"text\", \"For those subjects participating in the optional predose PK sampling on\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"b58f0811-6c3d-483a-b1fa-bc245c853783\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 562, \"\"], [\"\", \"Unmapped\", \"text\", \"Day 2\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"e077fb2e-8173-4eca-869f-6c7cf5d6e39b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 563, \"\"], [\"\", \"Unmapped\", \"text\", \"and/or the intensive PK sampling on\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"db4b080d-3906-4f45-be53-79edce7f4e9b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 564, \"\"], [\"\", \"Unmapped\", \"text\", \"Day 15\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"2d8d5d19-e98c-49c4-8f1f-f65af4d9bfa3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 565, \"\"], [\"\", \"Unmapped\", \"text\", \"the morning doses of study drug\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"c7042b83-1e63-42b9-97f7-fccb899c4d5f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 566, \"\"], [\"\", \"Unmapped\", \"text\", \"must also be taken while\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"5f8ac2c8-254e-45f6-933b-4f695906117c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 567, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"42bf4f25-d940-44cb-8441-9a0b9cd494ee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 568, \"\"], [\"\", \"Unmapped\", \"text\", \"in the clinic\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"1c117b6b-a50d-4c58-84c4-3afc75fbd637\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 569, \"\"], [\"\", \"Unmapped\", \"text\", \"with a standard breakfast.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"46a7a895-10c8-4181-a239-405ab4839ce2\", \"subtext\": \"832cbbf7-ca7a-4061-aed4-fbea4df45c48\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 570, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"27d18e0f-ddc1-4fe0-82a6-a8546b5d2aab\", \"subtext\": \"832cbbf7-ca7a-4061-aed4-fbea4df45c48\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 571, \"\"], [\"\", \"Unmapped\", \"text\", \"Note: The predose PK sample on Day 2 should occur no later than 28 h after the Day 1 dose.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"27d18e0f-ddc1-4fe0-82a6-a8546b5d2aab\", \"subtext\": \"a225ee3d-9c7c-4850-9fa3-43b3f6d188bf\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 572, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"415c0d5f-801a-4d31-a482-fb6015de9a7c\", \"childbox\": \"27d18e0f-ddc1-4fe0-82a6-a8546b5d2aab\", \"subtext\": \"47a7d73c-752b-4e4d-a525-5505ef77d929\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 573, \"\"], [\"\", \"Unmapped\", \"text\", \"On the morning of all other dosing days, samatasvir and IDX21437 may be administered with the\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 41, \"end_idx\": 50, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 41, \"end_idx\": 50, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 41, \"end_idx\": 50, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 56, \"end_idx\": 63, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 56, \"end_idx\": 63, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 56, \"end_idx\": 63, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"0010db7b-5c9b-4f5a-bef2-39bb9c0de3f3\", \"childbox\": \"68c18843-05f7-4d5f-8b2e-24ff8899fc4e\", \"subtext\": \"1af82ec2-73f5-4446-afa9-f8913bc8bcba\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 574, \"\"], [\"\", \"Unmapped\", \"text\", \"morning\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0010db7b-5c9b-4f5a-bef2-39bb9c0de3f3\", \"childbox\": \"68c18843-05f7-4d5f-8b2e-24ff8899fc4e\", \"subtext\": \"03722d80-4482-412b-a399-03aa85bedfa2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 575, \"\"], [\"\", \"Unmapped\", \"text\", \"dose of RBV (if applicable), which must be administered with food.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0010db7b-5c9b-4f5a-bef2-39bb9c0de3f3\", \"childbox\": \"68c18843-05f7-4d5f-8b2e-24ff8899fc4e\", \"subtext\": \"ffdb5039-a869-46e5-8e1c-fd83e45f78df\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 576, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"16974f12-8c76-46ea-ab68-862e8d76b78c\", \"childbox\": \"67c1d12c-8717-42a2-8109-8ebae7f03192\", \"subtext\": \"c0a1cc9d-7ebb-4317-a54d-34c834072590\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 577, \"\"], [\"\", \"Unmapped\", \"text\", \"IDX21437 300 mg QD will be administered once daily as 2 x 150 mg tablets.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 0, \"end_idx\": 7, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"1395fc09-9f2b-4f8b-bced-331b6cfc0086\", \"childbox\": \"eb28df90-a0b4-4eeb-adbd-35923e91c31b\", \"subtext\": \"b658ec86-a64e-443a-8de1-69eaf8dd509d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 578, \"\"], [\"\", \"Unmapped\", \"header\", \"Samatasvir\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"Samatasvir\"}], \"roi_id\": {\"para\": \"e243b8ce-e054-471b-956c-9aa91a25145f\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 579, \"\"], [\"\", \"Unmapped\", \"text\", \"Samatasvir 50 mg QD will be administered once daily as 1 x 50 mg tablet.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 87.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"Samatasvir\"}, {\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"Samatasvir\"}], \"roi_id\": {\"para\": \"012ced27-b3ab-4fe4-b2c4-cfd72537c1ad\", \"childbox\": \"5be83402-859b-4b2d-ae38-85beeb1d540b\", \"subtext\": \"d53ddc64-8a8a-4432-8743-9804b888491d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 580, \"\"], [\"\", \"Unmapped\", \"text\", \"Samatasvir 100 mg QD will be administered once daily as 2 x 50 mg tablets.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 9, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 87.0, \"text\": \"Samatasvir\"}], \"roi_id\": {\"para\": \"012ced27-b3ab-4fe4-b2c4-cfd72537c1ad\", \"childbox\": \"eb342b68-7513-4cbe-85e4-21f3a309e258\", \"subtext\": \"d53ddc64-8a8a-4432-8743-9804b888491d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 581, \"\"], [\"\", \"Unmapped\", \"text\", \"See Section 6.6.6 for special dosing instructions for subjects taking acid blockers or antacids.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"012ced27-b3ab-4fe4-b2c4-cfd72537c1ad\", \"childbox\": \"aa21bc4f-3161-474a-b637-50249034fd35\", \"subtext\": \"d53ddc64-8a8a-4432-8743-9804b888491d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 582, \"\"], [\"\", \"Unmapped\", \"header\", \"Ribavirin\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"bcb054af-d839-4bd7-8846-951d10162aa8\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 583, \"\"], [\"\", \"Unmapped\", \"text\", \"Starting on Day 1, for those subjects assigned to receive RBV, the bodyweight-dependent dose of RBV will be divided into a morning and evening dose for the duration of the study (Table 6-1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"906825a9-dd78-462e-ab29-ffb79f5ac8ef\", \"childbox\": \"d7a052ca-0f8b-4c8c-b6bf-641c887a67fe\", \"subtext\": \"2fbeef1a-137d-42d4-8606-fcf980e0ef78\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 584, \"\"], [\"\", \"Unmapped\", \"text\", \"The RBV doses should be taken with food, and at approximately the same times each day.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"906825a9-dd78-462e-ab29-ffb79f5ac8ef\", \"childbox\": \"bfa8578d-49af-4875-b64e-03bab60f30ce\", \"subtext\": \"2fbeef1a-137d-42d4-8606-fcf980e0ef78\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Instructions for prescribing and taking the study drug\", \"6.6.2\", \"3\", 585, \"\"], [\"\", \"Unmapped\", \"header\", \"Table 6-1 Ribavirin dosing schedule\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"Heading6\", \"entity\": [], \"roi_id\": {\"para\": \"805d703c-8422-4b11-b4bd-20bbfd6c28a2\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Ribavirin dosing schedule\", \"Table 6\", \"4\", 586, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Body weight</td>\\n      <td>Time of dose</td>\\n      <td>Ribavirin dose</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>< 75 kg</td>\\n      <td>AM</td>\\n      <td>2 x 200 mg tablets with food</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td></td>\\n      <td>PM</td>\\n      <td>3 x 200 mg tablets with food</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>\\u2265 75 kg</td>\\n      <td>AM</td>\\n      <td>3 x 200 mg tablets with food</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Body weight\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"07637b76-d6c4-43e1-b3e7-4bb1e56ed0a6\\\",\\\"column_roi_id\\\":\\\"3b9d8d08-bd56-4763-b55f-9aaf28add2ed\\\",\\\"datacell_roi_id\\\":\\\"881912b7-7630-4087-86b2-44c0e8318167\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Time of dose\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"07637b76-d6c4-43e1-b3e7-4bb1e56ed0a6\\\",\\\"column_roi_id\\\":\\\"8bd52dbb-5f46-4a7f-91c8-d57ac92190ff\\\",\\\"datacell_roi_id\\\":\\\"6327b592-1793-4995-a983-a05e26d66d68\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Ribavirin dose\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"07637b76-d6c4-43e1-b3e7-4bb1e56ed0a6\\\",\\\"column_roi_id\\\":\\\"3b571f9d-f5b9-4fe6-b548-432ab158cf63\\\",\\\"datacell_roi_id\\\":\\\"0a168bbe-4c7f-4629-90bb-eaf48381df06\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"< 75 kg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"2ca414c9-6fcf-400d-b8fb-71e2a23c8814\\\",\\\"column_roi_id\\\":\\\"665cfc74-afe6-4250-a8fe-7244752c4089\\\",\\\"datacell_roi_id\\\":\\\"74165040-fcaa-40bf-a572-12bff4b57e80\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"2ca414c9-6fcf-400d-b8fb-71e2a23c8814\\\",\\\"column_roi_id\\\":\\\"bcd1f573-af11-4a5f-ad1c-99c7e97b16be\\\",\\\"datacell_roi_id\\\":\\\"fc76158f-1340-4f78-9f3a-194f0d91e115\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"2 x 200 mg tablets with food\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"2ca414c9-6fcf-400d-b8fb-71e2a23c8814\\\",\\\"column_roi_id\\\":\\\"88cb2d59-a2d2-46d6-895c-13af4b3f1447\\\",\\\"datacell_roi_id\\\":\\\"7ec8478c-a5a7-42f4-99fb-e3ec7760db0a\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"PM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"13818973-9999-4af6-aa5d-eded52ba14fa\\\",\\\"column_roi_id\\\":\\\"68abf511-3a84-4f66-b3f5-e51d7b5379b1\\\",\\\"datacell_roi_id\\\":\\\"fd1a07c2-25b9-400e-b0ff-b653a481ac44\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3 x 200 mg tablets with food\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"13818973-9999-4af6-aa5d-eded52ba14fa\\\",\\\"column_roi_id\\\":\\\"503f70b1-5500-41f4-abb8-57eceb28c727\\\",\\\"datacell_roi_id\\\":\\\"e237777b-5e18-4cc8-ab5b-b9825aee83c0\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2265 75 kg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"432e7b9e-fe01-41ed-91f6-4ddd76afc89e\\\",\\\"column_roi_id\\\":\\\"34e88111-52ae-41d9-8370-232c7ccd9674\\\",\\\"datacell_roi_id\\\":\\\"7d235f9a-299d-4f7f-ba12-bff824fbfcf3\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"432e7b9e-fe01-41ed-91f6-4ddd76afc89e\\\",\\\"column_roi_id\\\":\\\"a6e1b131-b04f-4868-a8c0-208052dc0288\\\",\\\"datacell_roi_id\\\":\\\"62d513d4-3eb8-4be5-b966-9daafa321a1a\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3 x 200 mg tablets with food\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"432e7b9e-fe01-41ed-91f6-4ddd76afc89e\\\",\\\"column_roi_id\\\":\\\"ba169d3e-e03a-4f80-a7bc-06a87a1cc9f9\\\",\\\"datacell_roi_id\\\":\\\"7397f23d-eccf-4213-9403-71a50717d31b\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"26\", \"TableIndex\": \"11.0\", \"TableName\": \"Table 6-1 Ribavirin dosing schedule\", \"Header\": [0]}, {\"IsBold\": true, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"881912b7-7630-4087-86b2-44c0e8318167\", \"childbox\": \"53e8107b-7cda-46c2-942e-8d54e2237a80\", \"subtext\": \"9b81a537-c492-4895-9591-4dba4ac7b6ca\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Ribavirin dosing schedule\", \"Table 6\", \"4\", 587, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e529d65f-7141-4c03-a155-f9624e066cc2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Ribavirin dosing schedule\", \"Table 6\", \"4\", 588, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5bb10180-a686-4dd7-b3c9-9a2c93619d4b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Ribavirin dosing schedule\", \"Table 6\", \"4\", 589, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.3 Permitted study drug dose modifications or interruptions\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"b1ca891a-dd8c-4c7d-8948-2b61163671c9\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Permitted study drug dose modifications or interruptions\", \"6.6.3\", \"3\", 590, \"\"], [\"\", \"Unmapped\", \"text\", \"Study drug dose adjustments and interruptions are not permitted for IDX21437 or samatasvir without prior discussion with the Sponsor.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 68, \"end_idx\": 75, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 68, \"end_idx\": 75, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 68, \"end_idx\": 75, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 80, \"end_idx\": 89, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 80, \"end_idx\": 89, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 80, \"end_idx\": 89, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"d995c56c-59ed-4730-9c13-58e62433ae54\", \"childbox\": \"1ea9ec0f-bb10-4b75-86bb-99a1f55b316e\", \"subtext\": \"dc69dee8-5910-4090-b3d8-7426d4a04519\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Permitted study drug dose modifications or interruptions\", \"6.6.3\", \"3\", 591, \"\"], [\"\", \"Unmapped\", \"text\", \"Dose modifications for RBV, if applicable, are permitted per the approved product label.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d995c56c-59ed-4730-9c13-58e62433ae54\", \"childbox\": \"be4e60a3-0205-496d-b03d-0f03a97bdfcb\", \"subtext\": \"dc69dee8-5910-4090-b3d8-7426d4a04519\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Permitted study drug dose modifications or interruptions\", \"6.6.3\", \"3\", 592, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.4 Study drug discontinuation\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"4fbf5477-274f-4e05-8186-28decc4eaade\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study drug discontinuation\", \"6.6.4\", \"3\", 593, \"\"], [\"\", \"Unmapped\", \"text\", \"If any of the investigational DAA drugs (e.g., samatasvir or IDX21437) must be discontinued for any reason, all study drugs should be permanently discontinued at the same time and subjects asked to complete an EOT visit and return for all of the post-EOT follow-up visits, as described in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 47, \"end_idx\": 56, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 47, \"end_idx\": 56, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 47, \"end_idx\": 56, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 61, \"end_idx\": 68, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 61, \"end_idx\": 68, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 61, \"end_idx\": 68, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"615a557e-1761-41f5-8b7e-32b7e539f8c3\", \"childbox\": \"0a6650cc-9ebe-4c7f-9db5-a47bb6f91c8e\", \"subtext\": \"fa45b93e-6ae2-4c1a-a33c-cb949ae205e3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study drug discontinuation\", \"6.6.4\", \"3\", 594, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who have received at least one dose of samatasvir or IDX21437 in this protocol will then be followed in the observational follow-on phase (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"d2ec6bff-d245-4fa2-a6bd-59d4d91f86af\", \"childbox\": \"0e3083c2-8490-40db-8b50-d02004f3e583\", \"subtext\": \"6fcd8275-2262-4e65-b61d-931daa122a5f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study drug discontinuation\", \"6.6.4\", \"3\", 595, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d2ec6bff-d245-4fa2-a6bd-59d4d91f86af\", \"childbox\": \"44e964a0-07b7-45b5-a71d-19d5cd900655\", \"subtext\": \"61325f60-7bf2-475c-83b5-93e015f53e64\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Study drug discontinuation\", \"6.6.4\", \"3\", 596, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.5 Concomitant medications\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"bef8607d-83e2-46cf-b789-afd26528eca7\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Concomitant medications\", \"6.6.5\", \"3\", 597, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant medications should be administered only as medically necessary during the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42d391fd-b11e-4221-ad65-723d93dabcf7\", \"childbox\": \"b9e4b583-6b70-43fc-b2e6-59ee20d9b731\", \"subtext\": \"4409471d-298b-4cf9-9eb6-4cc5811d3ea4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Concomitant medications\", \"6.6.5\", \"3\", 598, \"\"], [\"\", \"Unmapped\", \"text\", \"Any concomitant medications should be initiated with caution, since they may increase the possibility of AEs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42d391fd-b11e-4221-ad65-723d93dabcf7\", \"childbox\": \"b553f31d-deb7-4c81-aa5b-280b844ad7b7\", \"subtext\": \"4409471d-298b-4cf9-9eb6-4cc5811d3ea4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Concomitant medications\", \"6.6.5\", \"3\", 599, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator should instruct the subject to notify the study site about any new medications he/she takes during the course of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42d391fd-b11e-4221-ad65-723d93dabcf7\", \"childbox\": \"4dde7db8-7c9b-4f68-b1a7-655c56476ccb\", \"subtext\": \"6e44fb07-1fd7-4dcc-a747-7622bac85139\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Concomitant medications\", \"6.6.5\", \"3\", 600, \"\"], [\"\", \"Unmapped\", \"text\", \"Relevant drug-drug interaction studies with samatasvir or IDX21437 have not been conducted to date; therefore, the potential for drug interactions is unpredictable at this stage of clinical development.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 44, \"end_idx\": 53, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 58, \"end_idx\": 65, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"42d391fd-b11e-4221-ad65-723d93dabcf7\", \"childbox\": \"78cca03c-ec4e-40a7-bebc-91ef7707f7e6\", \"subtext\": \"6e44fb07-1fd7-4dcc-a747-7622bac85139\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Concomitant medications\", \"6.6.5\", \"3\", 601, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant medications should be recorded in the site\\u2019s study records and entered into the appropriate CRF page, per the schedule of assessments in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42d391fd-b11e-4221-ad65-723d93dabcf7\", \"childbox\": \"c7efa074-02e0-493f-998f-d608e288c3c7\", \"subtext\": \"87694fa0-b2be-4cf1-a7cd-4e54d6b65565\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Concomitant medications\", \"6.6.5\", \"3\", 602, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.6 Prohibited medications\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"d3468b0e-cef6-4ebf-be2a-e6da8c8955ba\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 603, \"\"], [\"\", \"Unmapped\", \"text\", \"Use of the following medications is prohibited during the study:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"01d3fd4a-4ae4-472e-9123-3cd2ca661a10\", \"childbox\": \"0c08ab96-dbd8-476f-8454-b9de059d647d\", \"subtext\": \"5b542233-9fa9-4418-9491-14614837b2d7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 604, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 All investigational drugs other than samatasvir and IDX21437.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 39, \"end_idx\": 48, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 39, \"end_idx\": 48, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 39, \"end_idx\": 48, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 54, \"end_idx\": 61, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 54, \"end_idx\": 61, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 54, \"end_idx\": 61, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"b818571e-17e2-4571-89db-828a579b7a34\", \"childbox\": \"1672ce55-0f71-43d9-a0e3-60b94a017f8c\", \"subtext\": \"b8e04981-2725-46df-947f-aef6c82ab9f9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 605, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 All other treatments for HCV.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7c008c97-166d-4c54-9bda-8d873424b0e1\", \"childbox\": \"08c7ca22-c2f2-45e8-a5ac-b961f7cc438a\", \"subtext\": \"42aa05bd-1a0c-4d5d-b8c9-557ddd37d182\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 606, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Pharmaceutical agents associated with significant renal or hepatic toxicity.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"87358e9c-8dc0-4fa4-853d-641f3f799c31\", \"childbox\": \"330fe82c-1928-4a4c-a9ba-2dccb07a0f4f\", \"subtext\": \"15691be4-ea90-4e33-b43f-466ad23ce535\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 607, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Drugs which are major inhibitors, inducers or substrates of P-gp.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27bc19c4-e494-4695-bfc6-9cde4cf3340b\", \"childbox\": \"999bc615-acf3-44fc-953d-e706fd907891\", \"subtext\": \"faf683a5-4c2e-4edc-b847-8c3a034c8324\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 608, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Drugs which are major inducers or inhibitors of CYP3A.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e15ff6ae-ff3b-4b67-86a4-d4b686a59415\", \"childbox\": \"34d6591a-6efb-4ef8-9ac4-3d3193060b1b\", \"subtext\": \"183d1e44-6504-489b-ad18-0e37ffb3d8a2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 609, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"814a7f2e-d06b-4aea-9c64-9ffce353f3c6\", \"childbox\": \"ebaf02c9-f02c-4e3d-9844-050d53b28859\", \"subtext\": \"dabc1ae2-0598-4206-bde3-a994ae8c086c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 610, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"814a7f2e-d06b-4aea-9c64-9ffce353f3c6\", \"childbox\": \"ebaf02c9-f02c-4e3d-9844-050d53b28859\", \"subtext\": \"0c2a5293-28b4-41be-bc8a-ffaf9cf1e22c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 611, \"\"], [\"\", \"Unmapped\", \"text\", \"CYP3A4 inducers, such as:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"814a7f2e-d06b-4aea-9c64-9ffce353f3c6\", \"childbox\": \"ebaf02c9-f02c-4e3d-9844-050d53b28859\", \"subtext\": \"dcbba926-4f45-46d4-b379-735f12ad7d2b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 612, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"974a2b32-c604-4777-8cf5-4140085d0287\", \"childbox\": \"5bd63073-009e-4286-a6c9-08ccd5838e76\", \"subtext\": \"6ee2b9c7-cab4-4f3e-bc91-8572e51f5945\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 613, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"974a2b32-c604-4777-8cf5-4140085d0287\", \"childbox\": \"5bd63073-009e-4286-a6c9-08ccd5838e76\", \"subtext\": \"adb4bb82-2bc6-413f-8aea-2c935a49ad21\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 614, \"\"], [\"\", \"Unmapped\", \"text\", \"The anti-epileptics: carbamazepine, phenytoin and phenobarbital.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"974a2b32-c604-4777-8cf5-4140085d0287\", \"childbox\": \"5bd63073-009e-4286-a6c9-08ccd5838e76\", \"subtext\": \"e868d1a5-9ceb-435f-a20c-2caef9c2ceaa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 615, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7aa7aec2-608c-4059-bf16-94e61117fe8f\", \"childbox\": \"d03c0037-a01a-4f43-b017-e4185ee1f865\", \"subtext\": \"0b0e1f5c-03c5-4998-b6a3-1fc7f97660f7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 616, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7aa7aec2-608c-4059-bf16-94e61117fe8f\", \"childbox\": \"d03c0037-a01a-4f43-b017-e4185ee1f865\", \"subtext\": \"2a357c65-5a71-4891-9b1c-a6766ef0ba10\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 617, \"\"], [\"\", \"Unmapped\", \"text\", \"The anti-tuberculosis drugs: rifabutin, rifampin.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7aa7aec2-608c-4059-bf16-94e61117fe8f\", \"childbox\": \"d03c0037-a01a-4f43-b017-e4185ee1f865\", \"subtext\": \"a2cd034c-db1d-4f48-9595-9f1ec93302cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 618, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"504be726-77b5-4700-bb21-518becb72843\", \"childbox\": \"86a92fd8-05b2-4727-9c3f-4e4f797dbaad\", \"subtext\": \"8d80df0d-4e5b-4393-9eaf-add1d988a767\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 619, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"504be726-77b5-4700-bb21-518becb72843\", \"childbox\": \"86a92fd8-05b2-4727-9c3f-4e4f797dbaad\", \"subtext\": \"05285acc-d8e3-43ac-a550-eaa0b61891c2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 620, \"\"], [\"\", \"Unmapped\", \"text\", \"Systemic dexamethasone.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"504be726-77b5-4700-bb21-518becb72843\", \"childbox\": \"86a92fd8-05b2-4727-9c3f-4e4f797dbaad\", \"subtext\": \"10cfe34b-cf84-47fb-a228-ae3fbd20bd8e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 621, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7ec0592-30fd-4452-a146-29433e530803\", \"childbox\": \"7bd6f2fc-0b21-4489-8fcb-c97027e5813e\", \"subtext\": \"6bcaed7b-b344-413d-88de-2220181a7aff\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 622, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7ec0592-30fd-4452-a146-29433e530803\", \"childbox\": \"7bd6f2fc-0b21-4489-8fcb-c97027e5813e\", \"subtext\": \"1e2486d3-57ba-4980-b096-46aa651c2068\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 623, \"\"], [\"\", \"Unmapped\", \"text\", \"Miscellaneous: products containing Hypericum perforatum (e.g., St. John\\u2019s Wort).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7ec0592-30fd-4452-a146-29433e530803\", \"childbox\": \"7bd6f2fc-0b21-4489-8fcb-c97027e5813e\", \"subtext\": \"6d169128-5861-4c4a-aada-5674d9344a19\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 624, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7ec0592-30fd-4452-a146-29433e530803\", \"childbox\": \"a0ac2a89-eabf-497e-a048-c2987e4aa0bd\", \"subtext\": \"06cbf3ae-5b31-443d-b318-5db3b77ac7f2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 625, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7ec0592-30fd-4452-a146-29433e530803\", \"childbox\": \"a0ac2a89-eabf-497e-a048-c2987e4aa0bd\", \"subtext\": \"c6e7ede3-ffdd-44fa-b733-f3add9a5e96f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 626, \"\"], [\"\", \"Unmapped\", \"text\", \"CYP3A4 inhibitors, such as:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7ec0592-30fd-4452-a146-29433e530803\", \"childbox\": \"a0ac2a89-eabf-497e-a048-c2987e4aa0bd\", \"subtext\": \"44c10b2d-14b4-45e8-9b63-59270ad36dc1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 627, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a7330b80-045e-463a-9799-c9780fc6d8be\", \"childbox\": \"ecc30339-8264-4923-bcf6-2aec490c97d4\", \"subtext\": \"f367f82c-ce48-4734-8a73-1281b488d80f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 628, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a7330b80-045e-463a-9799-c9780fc6d8be\", \"childbox\": \"ecc30339-8264-4923-bcf6-2aec490c97d4\", \"subtext\": \"b50f8632-1564-4323-b17f-d1454cf22c59\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 629, \"\"], [\"\", \"Unmapped\", \"text\", \"The antifungals (systemic): ketoconazole, itraconazole, posaconazole, voriconazole.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a7330b80-045e-463a-9799-c9780fc6d8be\", \"childbox\": \"ecc30339-8264-4923-bcf6-2aec490c97d4\", \"subtext\": \"767c43f7-dcac-474d-8391-40cb59f47a69\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 630, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"79370f30-ee44-4a26-94d2-348514483a97\", \"childbox\": \"df0bf61e-7de5-4f34-b862-408c17541d01\", \"subtext\": \"912675f7-7ea7-4305-b9d0-b65d5148861d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 631, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"79370f30-ee44-4a26-94d2-348514483a97\", \"childbox\": \"df0bf61e-7de5-4f34-b862-408c17541d01\", \"subtext\": \"a95df44c-a9e5-46d7-833d-6920d0948dd4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 632, \"\"], [\"\", \"Unmapped\", \"text\", \"The macrolide antibiotics: clarithromycin, erythromycin, telithromycin (azithromycin is the preferred option).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"79370f30-ee44-4a26-94d2-348514483a97\", \"childbox\": \"df0bf61e-7de5-4f34-b862-408c17541d01\", \"subtext\": \"0469af87-5bb9-4bba-9b3f-c21fc7e0a498\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 633, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Concomitant use of acid blockers (proton pump inhibitors, e.g., omeprazole, or H2 blockers, e.g., cimetidine).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"28fa8245-7a64-47b8-92f3-35b108d84150\", \"childbox\": \"5e375b80-5929-4400-a32d-4a7dd920aa1d\", \"subtext\": \"9ca98b50-49fd-4865-8eda-26f3b33c0da0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 634, \"\"], [\"\", \"Unmapped\", \"text\", \"Antacids (stomach acid neutralizers such as calcium carbonate or aluminum hydroxide-based products) will be allowed during the study, except \\u00b1 4 h of dosing.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"28fa8245-7a64-47b8-92f3-35b108d84150\", \"childbox\": \"19a8aef6-3399-4abc-bf9e-916d51b81f4f\", \"subtext\": \"9ca98b50-49fd-4865-8eda-26f3b33c0da0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 635, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 All herbal medications (e.g., St. John\\u2019s Wort, echinacea, gingko, milk thistle or its derivatives, etc.) and dietary supplements.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d48424ca-b993-47b8-8fff-4b9e1e76bca4\", \"childbox\": \"45b25277-8b60-402b-86cd-280f93f2cdd0\", \"subtext\": \"717d36f6-0dba-4374-b8ef-130ae35f8cbd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 636, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Concomitant use of the following medications:  amlodipine, aripiprazole, atorvastatin, carvedilol, diazepam, diltiazem, fluoxetine, isradipine, perphenazine, procainamide, simvastatin, thioridazine or verapamil.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"74e6bc3c-e69e-472c-8de6-c627c5c61b33\", \"childbox\": \"44d96f6a-7201-4f51-a620-ed66973da328\", \"subtext\": \"65935a42-50b4-4618-b9c3-eadc2327269d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 637, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Concomitant use of opioid substitution drugs (e.g., buprenorphine and methadone).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ef1a1fc0-80e8-45e6-bc67-7ef7ccbe878b\", \"childbox\": \"6986e25a-e4f7-46b4-940d-825ea8e60d63\", \"subtext\": \"d4b93cc0-c935-4caa-a256-3bf6b4a55280\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 638, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Drugs that are contraindicated in the product label for RBV.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ded0923d-a26c-47af-8947-b4d4324422be\", \"childbox\": \"acdc74ca-33e2-4695-a4d2-902c2b7d9c1e\", \"subtext\": \"72ba57b8-db54-4719-ab49-c4449eb0b46e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 639, \"\"], [\"\", \"Unmapped\", \"text\", \"The list of disallowed concomitant medication is not exhaustive; any questions regarding the concomitant use of a medication should be directed to the Sponsor to determine whether the drug can be allowed.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"711527bc-c703-4cb1-8c30-d8cf280c39f3\", \"childbox\": \"2c11c36d-2b9d-42f7-962f-1bda7ee6e06c\", \"subtext\": \"069cf4c9-74f0-4611-a757-2de6d97ad17c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Prohibited medications\", \"6.6.6\", \"3\", 640, \"\"], [\"\", \"Unmapped\", \"header\", \"6.6.7 Emergency unblinding of treatment assignment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"f4a742ab-16cf-472d-a00b-57cfb3f28b20\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Emergency unblinding of treatment assignment\", \"6.6.7\", \"3\", 641, \"\"], [\"\", \"Unmapped\", \"text\", \"This study is not blinded to treatment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2c42afc6-da02-43a6-bc6b-166b1639c2ed\", \"childbox\": \"7bbf0fdf-f1f1-4027-b5de-a6b41ad9a20c\", \"subtext\": \"1daf1e4e-e704-4f0a-b45f-854c5278d9a6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Emergency unblinding of treatment assignment\", \"6.6.7\", \"3\", 642, \"\"], [\"\", \"Unmapped\", \"header\", \"7 Visit schedule and assessments\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"a38d9fc5-7463-42d9-9a5f-1bf5df001d39\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 643, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-1 lists the study assessments with an \\u201cX\\u201d indicating when the assessments are performed.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0232e4aa-62c7-4a23-b3df-8851172413d0\", \"childbox\": \"ba367cf9-6adf-43d0-a57b-dd2b131a17b5\", \"subtext\": \"3eb37db2-cc81-4da4-8e50-7d0adcc79ea4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 644, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-2 lists the study assessments for the extended observational follow-on phase to assess durability of SVR or monitoring of resistance.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0232e4aa-62c7-4a23-b3df-8851172413d0\", \"childbox\": \"81401780-ea1e-44c2-ae8d-7c7455543d1c\", \"subtext\": \"ded90ea7-1c29-46cf-91e8-0cfe4f30065b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 645, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-3 displays the schedule of PK assessments.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0232e4aa-62c7-4a23-b3df-8851172413d0\", \"childbox\": \"850994d1-2d63-40ce-b7c3-7b7087dde7e4\", \"subtext\": \"7232433b-d175-49f7-9075-df2737d303ba\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 646, \"\"], [\"\", \"Unmapped\", \"text\", \"All subjects who prematurely discontinue their assigned study drugs should have an EOT visit and return for all of the post-EOT follow-up visits, as described in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6a07b0d8-f354-4a1c-adcf-fcb9b4eab1e8\", \"childbox\": \"52cfce0d-bca2-4449-aa1c-1b9d91903dc7\", \"subtext\": \"5121768e-684d-4058-8e4e-7152933ff6b1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 647, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who have received at least one dose of samatasvir or IDX21437 will then be followed in the observational follow-on phase to evaluate the durability of SVR and the kinetics of antiviral resistant HCV (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 48, \"end_idx\": 57, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 62, \"end_idx\": 69, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"6a07b0d8-f354-4a1c-adcf-fcb9b4eab1e8\", \"childbox\": \"753cb68c-1d74-4ea5-a734-886b1150d442\", \"subtext\": \"34534efb-e45f-4e5f-9c1a-4c71d878bd49\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 648, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6a07b0d8-f354-4a1c-adcf-fcb9b4eab1e8\", \"childbox\": \"817314e3-3994-402e-ae49-de1dc8e252d3\", \"subtext\": \"403716cb-4e9e-4a56-8d39-6ac9791b237b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 649, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dfb34a54-6827-426f-9223-ee8217e3f61d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 650, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c87971c3-d9c5-459a-8dae-589b770a511d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 651, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"5439167c-0969-4991-8a1d-ec6f5c6387da\", \"childbox\": \"acb73b53-8965-4e24-8d39-bea44997cc02\", \"subtext\": \"6bd1d969-bada-4bf6-89e3-f3760ada31b8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 652, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5439167c-0969-4991-8a1d-ec6f5c6387da\", \"childbox\": \"7893bbd2-8a7b-4567-9b76-d5464419289d\", \"subtext\": \"c1fd9964-72e0-4f80-9447-51e77a19d379\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 653, \"\"], [\"\", \"Unmapped\", \"text\", \"Confidential\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5439167c-0969-4991-8a1d-ec6f5c6387da\", \"childbox\": \"ca5dabec-201c-468e-9e18-5a24153c2890\", \"subtext\": \"c1fd9964-72e0-4f80-9447-51e77a19d379\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 654, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5439167c-0969-4991-8a1d-ec6f5c6387da\", \"childbox\": \"ed3253e7-5011-4e6f-b7b1-3754fad0a183\", \"subtext\": \"af63c13d-ea36-483b-ab24-2c546bd75224\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 655, \"\"], [\"\", \"Unmapped\", \"text\", \"Page 30\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5439167c-0969-4991-8a1d-ec6f5c6387da\", \"childbox\": \"da3cf22d-8b9e-4c02-9219-92a32a65a941\", \"subtext\": \"af63c13d-ea36-483b-ab24-2c546bd75224\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 656, \"\"], [\"\", \"Unmapped\", \"text\", \"Clinical Study Protocol (Original) \\u2013 08-May-2014\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"650ff2a0-6114-4a0c-89f5-4d5f28c53f31\", \"childbox\": \"170605f2-9266-46dc-9b9c-e8a302b0efd6\", \"subtext\": \"2713c891-b0c4-4c87-9f7c-72f4ca89c124\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 657, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"650ff2a0-6114-4a0c-89f5-4d5f28c53f31\", \"childbox\": \"86e6082d-8358-4e95-8f61-352b94301c5b\", \"subtext\": \"757b6fd4-ad30-4432-aabf-61dba8a5ae99\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 658, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"650ff2a0-6114-4a0c-89f5-4d5f28c53f31\", \"childbox\": \"99c0a4bb-9cb7-4164-a1da-c8ebfbfe414c\", \"subtext\": \"4d26ad2f-1c58-4124-b7dc-32a28cecc750\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 659, \"\"], [\"\", \"Unmapped\", \"text\", \"Study No. IDX-04B-004\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"650ff2a0-6114-4a0c-89f5-4d5f28c53f31\", \"childbox\": \"6e21eff3-55a3-412e-a37d-8322ab4554d3\", \"subtext\": \"4d26ad2f-1c58-4124-b7dc-32a28cecc750\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"single\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 660, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ae85a00d-e3a8-4fb5-9eb3-a28bf12d48ec\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Visit schedule and assessments\", \"7\", \"1\", 661, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-1\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b823da6-0c2c-49a7-acf7-09b9d939e605\", \"childbox\": \"cea632b7-e44b-4dec-9637-9cbcf9776a3a\", \"subtext\": \"f6823f8b-0b0b-4100-927e-e2161f266492\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 662, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b823da6-0c2c-49a7-acf7-09b9d939e605\", \"childbox\": \"fa1c97bc-b04a-4c83-be5a-ceb7d45e0b84\", \"subtext\": \"429ede9f-fc04-47aa-9059-874c4da182eb\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 663, \"\"], [\"\", \"Unmapped\", \"text\", \"Schedule of assessments\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b823da6-0c2c-49a7-acf7-09b9d939e605\", \"childbox\": \"8502d567-36f5-4891-bb01-dce9096a3533\", \"subtext\": \"429ede9f-fc04-47aa-9059-874c4da182eb\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 664, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cfd977f3-83ff-4db6-8d7e-379da6ad2b41\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 665, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n      <th>7.0</th>\\n      <th>8.0</th>\\n      <th>9.0</th>\\n      <th>10.0</th>\\n      <th>11.0</th>\\n      <th>12.0</th>\\n      <th>13.0</th>\\n      <th>14.0</th>\\n      <th>15.0</th>\\n      <th>16.0</th>\\n      <th>17.0</th>\\n      <th>18.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td></td>\\n      <td>SCR</td>\\n      <td>Pre-TX</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Treatment Period</td>\\n      <td>Treatment Period</td>\\n      <td>Treatment Period</td>\\n      <td>Treatment Period</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Post EOT Follow-up</td>\\n      <td>Post EOT Follow-up</td>\\n      <td>Post EOT Follow-up</td>\\n      <td>Post EOT Follow-up</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>STUDY DAY \\u21d2  ASSESSMENT \\u21d3</td>\\n      <td>-75 to  -7</td>\\n      <td>-6 to -1</td>\\n      <td>1</td>\\n      <td>2 (opt)</td>\\n      <td>4\\u00b11</td>\\n      <td>8\\u00b11 W1</td>\\n      <td>11\\u00b11</td>\\n      <td>15\\u00b11 W2</td>\\n      <td>22\\u00b13 W3</td>\\n      <td>29\\u00b13 W4</td>\\n      <td>43\\u00b13 W6</td>\\n      <td>57\\u00b13 W8 (EOT) <sup>10</sup></td>\\n      <td>85\\u00b13 W12 (EOT) <sup>11</sup></td>\\n      <td>28\\u00b17 Days Post EOT (SVR 4 )</td>\\n      <td>56\\u00b17 Days Post EOT (SVR 8 )</td>\\n      <td>84\\u00b17 Days Post EOT (SVR 12 )</td>\\n      <td>168\\u00b17 Days Post EOT (SVR 24 )</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Informed Consent</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>IWR (drug assignment/shipment)</td>\\n      <td>X<sup> (Day -14 to Day -1)</sup></td>\\n      <td>X<sup> (Day -14 to Day -1)</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X<sup> 11 </sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>Inclusion/Exclusion Criteria & Medical History</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>Study Drug Dosing</td>\\n      <td></td>\\n      <td></td>\\n      <td>X <sup>7</sup></td>\\n      <td>X <sup>7</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>7</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X<sup> 11 </sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>HIV-1 and HIV-2 Ab, HBsAg, Hemoglobin A1c</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>FSH (females of nonchildbearing potential only)</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td>Height <sup>1</sup> & Weight & BMI <sup>1</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>Vital Signs (excluding temperature)</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>Complete Physical Exam</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X<sup> 10 </sup></td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td>Adverse Events <sup></sup> (with targeted physical exam) <sup>3</sup></td>\\n      <td>SAE only</td>\\n      <td>SAE only</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>SAE only</td>\\n      <td>SAE only</td>\\n      <td>SAE only</td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>Concomitant Medications</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>13</th>\\n      <td>Echocardiogram <sup>4</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>14</th>\\n      <td>12-Lead ECG <sup>5</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X<sup> 2</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X<sup> 10 </sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>15</th>\\n      <td>HCV RNA Quantitation</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X<sup> 2, 6 </sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>16</th>\\n      <td>HCV Genotyping</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>17</th>\\n      <td>Host IL28B</td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>18</th>\\n      <td>PK Sample Collection <sup>7</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>19</th>\\n      <td>Hematology, Clinical Chemistry, GFR, Coagulation <sup></sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>20</th>\\n      <td>FibroTest</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>21</th>\\n      <td>TSH</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>22</th>\\n      <td>Pregnancy Test <sup>8</sup></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X<sup> 10 </sup></td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>23</th>\\n      <td>Plasma and/or Serum Stored Samples <sup>9</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>24</th>\\n      <td>Urinalysis</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SCR\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"1e801b0d-fa39-47b4-ab9a-3a51f3595826\\\",\\\"datacell_roi_id\\\":\\\"57a33e73-fe9a-4b1b-9240-b925f797c1df\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pre-TX\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"cb658929-10aa-431a-96aa-69802f665825\\\",\\\"datacell_roi_id\\\":\\\"28ab479f-e686-475e-b291-72bd98287353\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"STUDY DAY \\\\u21d2  ASSESSMENT \\\\u21d3 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"a8b05188-082b-4bf5-a21e-4dd0025f9af5\\\",\\\"datacell_roi_id\\\":\\\"709bf40c-a1f3-4923-9104-cb6c017c9898\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"-75 to  -7\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"622a8976-e452-4509-8cf2-38afe57c81fd\\\",\\\"datacell_roi_id\\\":\\\"80520a67-ed6b-4335-a267-18c7877b12d3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"-6 to -1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"9f6139e3-0c99-44c4-9156-cf2a8282827f\\\",\\\"datacell_roi_id\\\":\\\"d77bed2e-157a-42eb-8f19-ecb40bf4c1cb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"08cef0fe-cb0f-41ec-b3e1-963e8c0f190c\\\",\\\"datacell_roi_id\\\":\\\"53b19dde-a894-47a3-937a-e616b9a37da8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"2 (opt)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"13bdb472-2510-4c6d-916c-3fd84f01b61b\\\",\\\"datacell_roi_id\\\":\\\"3cc464f7-e76c-4da5-a480-a65fd6ae79b3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"4\\\\u00b11\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"95177c6f-98fe-4c94-b11a-af4e8614bb58\\\",\\\"datacell_roi_id\\\":\\\"c4ccc303-910f-4ee6-b067-a683a603e3ce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"8\\\\u00b11 W1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"94cec2ac-8c78-4fdd-8f59-32b2e7ce9b94\\\",\\\"datacell_roi_id\\\":\\\"e993aff6-ed36-4a69-97bb-6ba09c075141\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"11\\\\u00b11\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"61d52611-9890-4586-bb31-a002a344ebed\\\",\\\"datacell_roi_id\\\":\\\"1de01484-f8ea-4f76-a696-73042cea8f05\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"15\\\\u00b11 W2\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"8986ce57-96c6-4fe3-894e-987fb9758089\\\",\\\"datacell_roi_id\\\":\\\"8fb75348-c88a-4db8-88fc-d7c2f93b7f28\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"22\\\\u00b13 W3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"e23798da-f733-4b14-95c5-ba843b14f219\\\",\\\"datacell_roi_id\\\":\\\"0c503bf5-c462-493d-a252-3b69f024cbde\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"29\\\\u00b13 W4\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"39187b1b-8679-4db5-8ad3-1269675c22f1\\\",\\\"datacell_roi_id\\\":\\\"59da473e-98c9-4621-bc1a-0bfdc2f63d23\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"43\\\\u00b13 W6\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"cf7c12ae-250c-4f15-97db-60d156072806\\\",\\\"datacell_roi_id\\\":\\\"69d51f69-3e66-4bfc-9b79-e94fba951187\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"57\\\\u00b13 W8 (EOT) <sup>10<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"1c56216a-dee8-439c-acdb-72cdd0addf90\\\",\\\"datacell_roi_id\\\":\\\"ed23015c-e954-41e6-ab7f-39d2f32c4d95\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"85\\\\u00b13 W12 (EOT) <sup>11<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"f9f3956b-c5c9-47e2-bdaa-945214fa93e7\\\",\\\"datacell_roi_id\\\":\\\"e215db2d-9afb-4768-ac6b-5edc22e35611\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"28\\\\u00b17 Days Post EOT (SVR 4 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"663aaef2-49e6-4d9b-b49f-9cfd99f964b1\\\",\\\"datacell_roi_id\\\":\\\"ba80e523-91ab-4630-ae6f-7f0f60149373\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"56\\\\u00b17 Days Post EOT (SVR 8 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"8c502957-88da-4881-a006-a7059e047fd1\\\",\\\"datacell_roi_id\\\":\\\"557ac7f3-d5e0-4813-9857-0c4d46ba8d29\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"84\\\\u00b17 Days Post EOT (SVR 12 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"4389a1e3-14a9-4a66-9726-be38fbcde56b\\\",\\\"datacell_roi_id\\\":\\\"de2ffbbe-94b9-46a2-a433-3c13df0ea8f3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"168\\\\u00b17 Days Post EOT (SVR 24 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"c8e5e335-2910-430a-b27d-ebc5335970e7\\\",\\\"datacell_roi_id\\\":\\\"de60f474-ed88-4a0c-9092-e90653a10610\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Informed Consent\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d6f69d91-e88c-448d-a994-173ab9899bb3\\\",\\\"column_roi_id\\\":\\\"839489fc-fe1e-41d8-8f29-ed26c7e40b1d\\\",\\\"datacell_roi_id\\\":\\\"26a672a6-bf1e-4972-8e6c-c601354c0c3b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d6f69d91-e88c-448d-a994-173ab9899bb3\\\",\\\"column_roi_id\\\":\\\"c9b27562-7b6e-45eb-add3-eb676fe39fe4\\\",\\\"datacell_roi_id\\\":\\\"aa853df9-d5c3-45fb-bd67-c6192b6c54f2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IWR (drug assignment\\\\/shipment)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"5ac44db9-97d6-45df-80e0-270ed1b1e56b\\\",\\\"datacell_roi_id\\\":\\\"44a1480c-e2b4-403e-b880-2817f90debbd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> (Day -14 to Day -1)<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"9b242ecd-7801-4a34-a6d5-4ca5921d6c9a\\\",\\\"datacell_roi_id\\\":\\\"89cd3bba-04d2-4b35-83f5-c408725f5ba5\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> (Day -14 to Day -1)<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"9b242ecd-7801-4a34-a6d5-4ca5921d6c9a\\\",\\\"datacell_roi_id\\\":\\\"89cd3bba-04d2-4b35-83f5-c408725f5ba5\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"565bb253-81b5-49f5-b274-e205ba2c8533\\\",\\\"datacell_roi_id\\\":\\\"e855d3fd-c4e4-4d6b-b517-2f5df1601333\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 11 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"17f967fd-9205-48f6-8d20-509a3c88a99a\\\",\\\"datacell_roi_id\\\":\\\"77ce8ef6-4a51-40cb-bf6a-500e9f6f1538\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Inclusion\\\\/Exclusion Criteria & Medical History\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d4f99144-a664-47aa-b6ac-7883783cb074\\\",\\\"column_roi_id\\\":\\\"ec3dafed-95d7-48f4-981b-6349073849c6\\\",\\\"datacell_roi_id\\\":\\\"25de6a36-e4d8-4e82-b106-515028cc378a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d4f99144-a664-47aa-b6ac-7883783cb074\\\",\\\"column_roi_id\\\":\\\"490bce2a-6da6-486b-8abb-6eb28392cbea\\\",\\\"datacell_roi_id\\\":\\\"3ed58d28-b150-472a-bde9-0d3f3590060e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d4f99144-a664-47aa-b6ac-7883783cb074\\\",\\\"column_roi_id\\\":\\\"490bce2a-6da6-486b-8abb-6eb28392cbea\\\",\\\"datacell_roi_id\\\":\\\"3ed58d28-b150-472a-bde9-0d3f3590060e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Study Drug Dosing\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"96d570db-bfe6-4225-a17d-9502ed0993d7\\\",\\\"datacell_roi_id\\\":\\\"4ffead3f-afb0-45b1-82db-c359016e4fa6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>7<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"c516ef85-1db0-43ad-b1b5-73053026c8c9\\\",\\\"datacell_roi_id\\\":\\\"ad893956-2bf3-4582-bdb3-ccbbaec8dc75\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>7<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"efdabde9-895d-4134-8785-a24fbd05d6dd\\\",\\\"datacell_roi_id\\\":\\\"ebbadcb2-6860-4b25-85df-d782280f9c8e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"860ae6f4-bd4b-42ef-94fc-f928401e8cb4\\\",\\\"datacell_roi_id\\\":\\\"2c540b41-ff3f-487e-a448-f93fa5049d10\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"4d392516-f9a4-43c4-b7d3-e6294b3795fd\\\",\\\"datacell_roi_id\\\":\\\"d04feb05-51bc-47ec-9062-0f4effc2ef97\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"d8238632-8444-4b12-9806-fca397f3ba63\\\",\\\"datacell_roi_id\\\":\\\"d6ca8e23-893a-4b02-b2a0-e74e5b904cc9\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>7<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"41f1536a-2359-410f-ae57-64973f321cc2\\\",\\\"datacell_roi_id\\\":\\\"f563b03f-f9a6-4c65-bcf8-129517f84ca6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"37edb22e-346d-4983-bd2f-da4bf73ea51a\\\",\\\"datacell_roi_id\\\":\\\"67c22046-044f-425d-9bfb-e2ae164b5fd3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"de98de69-7d09-4806-afc1-96c915a203eb\\\",\\\"datacell_roi_id\\\":\\\"5dfa0313-a30f-4b3c-9a14-01c00a8c9bfb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"7f4b5817-1044-4978-9eff-0f00397946f0\\\",\\\"datacell_roi_id\\\":\\\"1f5b72ad-e955-4241-a266-d0f38f90357d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 11 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"334adbf9-b0c0-4140-9831-3bf552836f73\\\",\\\"datacell_roi_id\\\":\\\"21d39d1f-2397-4e79-87aa-28e76d9117c9\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HIV-1 and HIV-2 Ab, HBsAg, Hemoglobin A1c\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"b2617bb6-5d94-4593-8a8b-5f988489d016\\\",\\\"column_roi_id\\\":\\\"adc4d96b-08e6-43df-b126-848b09d53b75\\\",\\\"datacell_roi_id\\\":\\\"1bf8634e-a022-4d02-b90c-26247357c888\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"b2617bb6-5d94-4593-8a8b-5f988489d016\\\",\\\"column_roi_id\\\":\\\"1ecfbaaf-cdaf-40df-8a32-81d472db66a8\\\",\\\"datacell_roi_id\\\":\\\"27884d52-22d8-47ae-9fc1-9c0694b0b067\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"FSH (females of nonchildbearing potential only)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"01ebbb90-3753-4bdd-bb20-da9427a90934\\\",\\\"column_roi_id\\\":\\\"885f1fed-36e0-4f22-8a9f-7f79a6f77928\\\",\\\"datacell_roi_id\\\":\\\"23fc22f6-8726-4162-960a-f2a08fbe6cfd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"01ebbb90-3753-4bdd-bb20-da9427a90934\\\",\\\"column_roi_id\\\":\\\"a1deb5d0-4081-448c-b6f1-1d6ea749834c\\\",\\\"datacell_roi_id\\\":\\\"e76e9b69-7426-44eb-bd3c-f18890111ed3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Height <sup>1<\\\\/sup> & Weight & BMI <sup>1<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"967b8522-0202-4590-8d9f-1c6d09d67348\\\",\\\"datacell_roi_id\\\":\\\"6c82b352-c3f3-4a76-ba7c-9e3c8a22eb6e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"cd4bb688-a835-4605-a80a-14fd5eb5a0d0\\\",\\\"datacell_roi_id\\\":\\\"3be78164-4e69-4d41-b86a-264ad1e05391\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"4e44c891-4310-4e69-81c0-eb61599e5c54\\\",\\\"datacell_roi_id\\\":\\\"d72ef135-30f2-455f-8aa6-57fe34fa905c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"83ccbe48-e5bf-4c6f-b9e6-20d5689c3209\\\",\\\"datacell_roi_id\\\":\\\"17261db7-505f-4395-a397-d93f7468a839\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"041eff1e-647b-4929-b21e-602423a6d579\\\",\\\"datacell_roi_id\\\":\\\"83a96b81-b544-4857-b5e4-cdb8ea0f21f4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"7e15d742-561c-4fb1-96c8-816abe7d8eef\\\",\\\"datacell_roi_id\\\":\\\"85723074-7022-4438-a070-8ab773ca13ae\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"a09352cf-2539-4781-8d0a-116975584149\\\",\\\"datacell_roi_id\\\":\\\"233d9e44-8544-4728-a5c1-1253e1889008\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"ffdb0c0f-85d0-4f2e-aff4-4fb84dafd844\\\",\\\"datacell_roi_id\\\":\\\"809d987c-f461-4405-b82e-6c9a284c92d2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"3d6d3338-cf34-482e-9011-c19340501d7c\\\",\\\"datacell_roi_id\\\":\\\"51a16c62-9236-431c-89ec-deeb35be0c94\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"45b0cb60-f74b-462b-9253-f7cbde367846\\\",\\\"datacell_roi_id\\\":\\\"6e059c89-1a52-44f6-b11f-d473405d4fd9\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"994ee668-b35b-4928-a89d-9dabce541494\\\",\\\"datacell_roi_id\\\":\\\"d978592b-d9c3-4ffa-b033-8ccc1ac909f4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"9d4c2724-77de-478d-9d77-4f7029b9e0e0\\\",\\\"datacell_roi_id\\\":\\\"d9c8a235-8e35-4447-beb4-2b254b34e76c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"06126bf5-8c92-4c5c-9628-f5e63d52ff28\\\",\\\"datacell_roi_id\\\":\\\"15f01212-5550-4ab6-80bb-230374a69841\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"9e39582a-c563-4f15-907a-f926af9c5a7e\\\",\\\"datacell_roi_id\\\":\\\"915ff12d-fa52-427e-b847-fa23455155a4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Vital Signs (excluding temperature)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"7fc7679e-40bd-43eb-8900-6bab02eff144\\\",\\\"datacell_roi_id\\\":\\\"8fe2eea8-4808-4019-a107-7e771a8a9b7c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"f6b45f5e-6a22-4b65-8169-8d205b6b4393\\\",\\\"datacell_roi_id\\\":\\\"214d9a94-f214-4d25-93b7-16043a8727ce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"4040c8aa-6bc6-40d3-ab50-1c9e07e85ecd\\\",\\\"datacell_roi_id\\\":\\\"0486e550-c9a2-48fe-884b-b5315db9f4b7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"1952a47b-2820-4948-b9c8-baa60f2a3147\\\",\\\"datacell_roi_id\\\":\\\"d3b5f316-d756-42b6-bff9-9fdc58bf8ea0\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"c5cac133-48f0-4c66-970d-712a9b205646\\\",\\\"datacell_roi_id\\\":\\\"6ec4c87f-2097-4fda-b932-23196823f590\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"191efb82-ccdd-4462-a019-42287ca6d3b8\\\",\\\"datacell_roi_id\\\":\\\"fb714441-c8b7-4cce-bcbd-3d89341c76fa\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"cfc47cb0-abdb-49db-82dc-37e2d5a5a796\\\",\\\"datacell_roi_id\\\":\\\"b691bf30-6b2e-4d3d-8add-f10c7c0b4c97\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"cdacade0-4caf-4672-88e1-deb5e38f6abe\\\",\\\"datacell_roi_id\\\":\\\"f81b6308-9775-4d81-b2ff-4d77191814f3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"e91a39c7-342f-42dd-b6be-5e8df4db5bb1\\\",\\\"datacell_roi_id\\\":\\\"d94cc14f-c727-4527-93ed-75ac99a850d8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"e600745d-9d06-4d56-aa51-10b1197b8aa1\\\",\\\"datacell_roi_id\\\":\\\"381fe25b-800d-4e5a-bb8c-89d4f2d13508\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"cf88dc6d-4513-4549-8f88-faa0f2b5fdfd\\\",\\\"datacell_roi_id\\\":\\\"035e2fb0-bb54-4345-b932-ac95a0f914c2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"542378a5-4bdf-4941-8871-2ba29b96529e\\\",\\\"datacell_roi_id\\\":\\\"cd8bdf9d-33ae-4d12-b2b3-d77a1ae0f374\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"a42004de-e674-4366-b056-3fd48c79ab68\\\",\\\"datacell_roi_id\\\":\\\"35e819d2-04c0-4231-ac5e-c13bc9ddbaed\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"d5149688-a3b9-4241-86ad-61eeb150e572\\\",\\\"datacell_roi_id\\\":\\\"ce6f9e22-8ad7-4150-942c-60ecf5cf389a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Complete Physical Exam\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"1c5b08b3-63c4-4941-9807-a1f1e6b7a80d\\\",\\\"datacell_roi_id\\\":\\\"ae40a7cc-555f-4db8-a64b-56cfbb651455\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"2cd99946-8100-4fd5-82ea-ac47811d6c30\\\",\\\"datacell_roi_id\\\":\\\"e50c584e-b566-47fd-85be-ae1cb54ef62d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"aabcaf28-79fd-4ab3-993c-c6c876717af6\\\",\\\"datacell_roi_id\\\":\\\"856ac7dc-c388-4338-a459-3144130fe8eb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 10 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"4415bb96-b7dc-4e59-a82c-78a180283058\\\",\\\"datacell_roi_id\\\":\\\"f09c0fbd-3a9b-49fa-b519-26471b44c7b3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"c5cd1bbc-5509-4f20-b913-005cdc9eab52\\\",\\\"datacell_roi_id\\\":\\\"055a866a-d22b-478b-a575-eefd59fbe4f4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Adverse Events <sup><\\\\/sup> (with targeted physical exam) <sup>3<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"09137094-939e-4e65-ac1c-f2316757bedc\\\",\\\"datacell_roi_id\\\":\\\"9f9f064f-05b8-4d23-88ed-5d84be560dd1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"9fb3fb12-5349-4fb2-becb-1fe25e3f2b4f\\\",\\\"datacell_roi_id\\\":\\\"8174d6aa-10ce-4373-919d-3f3602e4a562\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"feb26dcd-25ce-4cf0-99d9-ccdd84bc31bd\\\",\\\"datacell_roi_id\\\":\\\"aa94f67d-d28f-4015-86bc-c402973b483c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"933d7e4f-d192-4fff-acc8-a6d974e62c0b\\\",\\\"datacell_roi_id\\\":\\\"79f449cc-4fd1-4503-8e4a-703c51eaca53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"755410dc-5deb-4294-9f9b-9651659b780b\\\",\\\"datacell_roi_id\\\":\\\"bd0f8fc3-0e6a-447a-8e54-1dfcfb1d1f51\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"bb378650-ad85-4fb8-a912-c22540a016d4\\\",\\\"datacell_roi_id\\\":\\\"6b4d6fb9-1d68-490b-828a-fc34607c015d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"1e7e8859-7e06-4eab-8118-017f5abbed05\\\",\\\"datacell_roi_id\\\":\\\"45404fe8-f15a-4e92-89c7-41f47e57cc94\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"5d5ec45f-4e07-4964-9d6a-c9f10e7d8bc2\\\",\\\"datacell_roi_id\\\":\\\"43d67b43-9144-4350-9854-3eaaa9c8fd9e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"51d97d86-4f55-4ab5-b8bc-dcbbb4a12178\\\",\\\"datacell_roi_id\\\":\\\"1e99edc0-a878-4921-abe9-8ed92765a4ea\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"e1ab3c6c-f864-4522-aea3-eb1022a0d480\\\",\\\"datacell_roi_id\\\":\\\"2a764b02-ecd0-400f-a19f-97da93b86f0e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"3d8b6828-b8fa-441a-9f4f-ed3fb3443ad5\\\",\\\"datacell_roi_id\\\":\\\"e5a11ac1-ed22-4649-89db-e7edfeedbc93\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"2e3a6909-9db9-4c99-9f22-d1095c5d0d33\\\",\\\"datacell_roi_id\\\":\\\"5450d0e5-0895-4281-af2e-25817a7f8273\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"21bc5822-87b8-465d-9676-8c053dcc8366\\\",\\\"datacell_roi_id\\\":\\\"a030631f-a0a9-41ee-af60-8dacff26cf0a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"81eb10e3-5de7-4c53-9e6c-226e9c0574ab\\\",\\\"datacell_roi_id\\\":\\\"2561eb45-69ff-45b1-b1f8-58d34e808991\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"2444aa45-8487-4a81-bfd5-2ec7519a3d85\\\",\\\"datacell_roi_id\\\":\\\"2dee2057-8490-4945-9cc1-a8a6041f1175\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"d4ae35ad-3200-42cb-a292-b4d561c69382\\\",\\\"datacell_roi_id\\\":\\\"2aab8f87-fb19-4b99-8a1f-272a381f1ff6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"d4ae35ad-3200-42cb-a292-b4d561c69382\\\",\\\"datacell_roi_id\\\":\\\"2aab8f87-fb19-4b99-8a1f-272a381f1ff6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"d4ae35ad-3200-42cb-a292-b4d561c69382\\\",\\\"datacell_roi_id\\\":\\\"2aab8f87-fb19-4b99-8a1f-272a381f1ff6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Concomitant Medications\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"7a5df1c7-3a68-4c90-88e5-e3149b07c260\\\",\\\"datacell_roi_id\\\":\\\"431987f0-b3ac-4a52-8dbb-08cdfe5fc16c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"87987f29-63d8-4aec-b031-58323fe7063f\\\",\\\"datacell_roi_id\\\":\\\"88ff2d06-40a0-4530-ade8-a7f6ce269674\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"5c21d7db-7177-4d44-9de6-892b345640a1\\\",\\\"datacell_roi_id\\\":\\\"a4f74c9c-df1b-4b7f-b700-26582342759e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"477d0224-185c-4a4d-8392-9fed3c04cc06\\\",\\\"datacell_roi_id\\\":\\\"eab8f875-a814-4410-981b-6a6599fbf7e8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"009d3037-4644-4b3a-aba9-f7271db5e919\\\",\\\"datacell_roi_id\\\":\\\"70912f1b-6c69-412e-ae5b-94a4e6ffc13b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"75c7ca7b-66e0-420e-88e8-e6f75b8025c9\\\",\\\"datacell_roi_id\\\":\\\"3a5d1b72-b3da-4ca5-bd26-0c7f64447765\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"3f0caf85-9cd9-4e47-bfcf-c673d154bb11\\\",\\\"datacell_roi_id\\\":\\\"3ffedd45-8a67-4ca1-b394-ef35eeeb84dd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"0d27c99b-3bdf-4cf6-920e-51d06275d76c\\\",\\\"datacell_roi_id\\\":\\\"b94fd708-0393-4ec8-b46f-0d2b0f2f6697\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"e1ef8e98-df77-401d-a77e-11a5b68f09af\\\",\\\"datacell_roi_id\\\":\\\"8528fc77-736c-473a-9465-abb177e9e4b4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"f189fc18-6cd6-43c8-9358-2355f17489b7\\\",\\\"datacell_roi_id\\\":\\\"53aef581-df7f-4b04-a05e-1d7ab03be0c8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"2904cd17-0dab-4b12-9170-c5333c7f3a04\\\",\\\"datacell_roi_id\\\":\\\"38d615ff-4bfb-4eeb-b14f-b541b8232f47\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"7d40a692-6311-449a-b7bd-b9931970c9d7\\\",\\\"datacell_roi_id\\\":\\\"cf93eae2-97e0-4fa7-8da0-d38a80a1e318\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"a8a1c338-f933-49e3-bf77-cf9ce13b8c0c\\\",\\\"datacell_roi_id\\\":\\\"79026822-cf86-4d2c-9d0a-435388156d70\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"55a2e6a2-3718-454a-b25c-a5f006d0a5a7\\\",\\\"datacell_roi_id\\\":\\\"a9c4796c-c1d1-4a52-a988-7cb64f5d20f7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"8a99c40f-ecde-4084-87c8-12ea52a4286c\\\",\\\"datacell_roi_id\\\":\\\"28be0043-ec75-445b-b5f3-73a1065cf54b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"22bc1055-c05b-4e1c-a783-f801635666f9\\\",\\\"datacell_roi_id\\\":\\\"f06907ae-3784-4de6-b4e2-b3b6d7b0713f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"f43d98ef-5189-4696-a00f-a9c16314cc9a\\\",\\\"datacell_roi_id\\\":\\\"93296b5d-47af-485c-984b-5aa6643dc5d3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"5b55426b-9dfd-45bf-b494-86b46bed1ec1\\\",\\\"datacell_roi_id\\\":\\\"33419b6c-27a3-4c9f-ae59-b5565556fb3a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Echocardiogram <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4457acf-1deb-4695-b8c3-41e8143559a0\\\",\\\"column_roi_id\\\":\\\"188d99d0-4f68-4820-b5a4-6beaf92c4880\\\",\\\"datacell_roi_id\\\":\\\"61cc6976-c27c-4bb9-ac4b-9bb310ceadeb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4457acf-1deb-4695-b8c3-41e8143559a0\\\",\\\"column_roi_id\\\":\\\"a63f010b-3839-4f11-a6d7-a6f4db998d36\\\",\\\"datacell_roi_id\\\":\\\"96bdb292-ac52-4713-b03e-97eda75a9c51\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4457acf-1deb-4695-b8c3-41e8143559a0\\\",\\\"column_roi_id\\\":\\\"a63f010b-3839-4f11-a6d7-a6f4db998d36\\\",\\\"datacell_roi_id\\\":\\\"96bdb292-ac52-4713-b03e-97eda75a9c51\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12-Lead ECG <sup>5<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"9f0b8043-4a95-4415-9a5e-cc6b833c43a2\\\",\\\"datacell_roi_id\\\":\\\"3fda0317-1fb5-4c2c-9b53-c2eee3596540\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"4a0e8496-d289-4792-859c-7b9663869497\\\",\\\"datacell_roi_id\\\":\\\"4ece5a9a-26ad-4676-b4d9-75bad3178cfd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"e8193307-a187-43fb-86cc-fe11b0c86965\\\",\\\"datacell_roi_id\\\":\\\"653b33d6-1e21-4a7b-a50c-8ff915f1f247\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 2<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"67dc46d6-01a9-49f2-9bb5-31cc21a8522e\\\",\\\"datacell_roi_id\\\":\\\"0f07cb71-e276-46c3-a088-7d3529fa9bd6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"9fe69256-2e1e-406c-bdef-d85aa038ada4\\\",\\\"datacell_roi_id\\\":\\\"d67ecbd4-ec9a-484a-9544-008ae26505d1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 10 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"644bfd27-74c2-4ef7-9ffb-725b05a7b03c\\\",\\\"datacell_roi_id\\\":\\\"8343f791-0710-4dad-be26-8e7ed2d5beeb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"a1898b36-eb61-488c-82d1-1aed0c34f699\\\",\\\"datacell_roi_id\\\":\\\"3837237b-148b-4509-9be2-b42833a4fa10\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"cbf39403-a21a-4e71-83e9-5297c464d0a5\\\",\\\"datacell_roi_id\\\":\\\"523530a6-3782-4e25-a429-33454994c3dd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV RNA Quantitation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"c7c604d7-d8cf-4d52-8cb8-8cc5a87ea30b\\\",\\\"datacell_roi_id\\\":\\\"42b4786f-cede-4eae-84da-18e298162c9d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"4f2542d5-b188-41cd-a97f-e34ac33a5880\\\",\\\"datacell_roi_id\\\":\\\"53328735-c943-40b1-9dcb-3e308a5a0341\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"9fc9a061-02ad-4928-ad00-4b3e2da4de98\\\",\\\"datacell_roi_id\\\":\\\"0c5b7c9b-ebfe-4423-ae10-7e67844cf343\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 2, 6 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"ee7d5011-480a-4f50-bb57-4a7f4dd8a7f0\\\",\\\"datacell_roi_id\\\":\\\"4bb122d6-1602-4e37-b705-5661aadfa123\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"7c50fa85-5410-4eb0-8a9c-65fefb3b29d1\\\",\\\"datacell_roi_id\\\":\\\"021187be-c186-47da-8a46-ecb4b8f5c880\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"0706902d-71b2-4cc2-b0a9-6ae843c258a9\\\",\\\"datacell_roi_id\\\":\\\"4e85d3b7-9da5-4ee8-a8a8-ba168b5e0b95\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"cc50b624-8711-42f9-88eb-10465d9471e6\\\",\\\"datacell_roi_id\\\":\\\"ea1fc0d9-ee3d-449d-b891-fbf859e780ce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"2acf2f89-7d5a-4b2b-81b5-cc1ce70a0185\\\",\\\"datacell_roi_id\\\":\\\"b7397db4-8b11-42aa-b2cc-5b8d85c32bd3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"cb72c9eb-5a34-4958-bc27-0718c70d337b\\\",\\\"datacell_roi_id\\\":\\\"422cba2e-aa6d-4815-83ac-113f9b056d9c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"d6159f0e-2066-4efe-8c2b-28c51592b579\\\",\\\"datacell_roi_id\\\":\\\"29440c1c-8b7d-4439-9a17-2efed42b5486\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"410aab82-a00c-451f-a92f-b7a49314a983\\\",\\\"datacell_roi_id\\\":\\\"f1c42d24-f10a-4346-9cf3-5947709a6573\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"9f262621-e842-416b-ae41-c281ec96ff62\\\",\\\"datacell_roi_id\\\":\\\"fa1eec34-4e1d-4fd6-ac7c-fc56dfa8398c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"a26d05cc-5ca2-4e30-854b-44d599d86e11\\\",\\\"datacell_roi_id\\\":\\\"e8baa958-91ab-4c61-a567-62cd6293f4f6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"561f558c-c760-4c82-8967-475489ae4b24\\\",\\\"datacell_roi_id\\\":\\\"f04c332a-19dd-48aa-b865-799ba8fc3c74\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"f64ab053-211a-40ea-9030-872e39f2925d\\\",\\\"datacell_roi_id\\\":\\\"a7fc47b4-baea-428c-af8f-9e1c617fc58d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"a7f2debf-e933-4892-bf1c-dbabda97d706\\\",\\\"datacell_roi_id\\\":\\\"e0ba9365-3f79-4486-bea4-bb57020181ed\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"9638cdaf-7cb5-4e04-baef-684bf6f0a991\\\",\\\"datacell_roi_id\\\":\\\"71ad2f18-cafa-48d1-a1bc-4c95cdbbaa97\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"8a27efbb-58ce-4900-b809-974911977a2c\\\",\\\"datacell_roi_id\\\":\\\"32b84b1f-12c7-4d08-8ee0-bfb231286858\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV Genotyping\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"09815511-ed90-4423-850a-b460ec502a88\\\",\\\"column_roi_id\\\":\\\"b4e770fc-edb5-4eeb-89c9-5c3686a2557f\\\",\\\"datacell_roi_id\\\":\\\"a2242fa2-fbe2-49f5-a130-0911e2ebd2fc\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"09815511-ed90-4423-850a-b460ec502a88\\\",\\\"column_roi_id\\\":\\\"be420234-98df-4f08-84d1-d9e443592d6c\\\",\\\"datacell_roi_id\\\":\\\"8d4f15f6-58b1-435b-b5ca-663a64652713\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Host IL28B\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"748503eb-7339-40fc-b448-cceba395784e\\\",\\\"column_roi_id\\\":\\\"32a0b1c1-f699-4ea2-bb1e-802964638b7a\\\",\\\"datacell_roi_id\\\":\\\"061eafc5-e911-42d2-abe9-261bee9a57a8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"748503eb-7339-40fc-b448-cceba395784e\\\",\\\"column_roi_id\\\":\\\"bea236b8-51a1-4c09-9d44-8b30fa9e1be4\\\",\\\"datacell_roi_id\\\":\\\"432d0688-0dd4-4987-b78c-faa14a375450\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"PK Sample Collection <sup>7<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"b45411e7-2b01-44ae-8843-b289d6836f9a\\\",\\\"datacell_roi_id\\\":\\\"aba882c1-88ed-4b87-8932-2fa333f9374f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"565990ac-6527-455b-961e-7c3f8c9b5264\\\",\\\"datacell_roi_id\\\":\\\"0d20a939-878a-4b10-8225-ad7a915ce67a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"456d8467-00f2-47b9-9d9a-2cd2c5198606\\\",\\\"datacell_roi_id\\\":\\\"068803b0-6f96-4306-a4d9-e46ddc137ade\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"60e28192-0586-4fb2-8949-2cc4cf1cfdb2\\\",\\\"datacell_roi_id\\\":\\\"8dc3c161-1f97-454b-a3b6-798368eafed6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"30afcb60-9a60-4de0-83e7-3eb1ffc1a311\\\",\\\"datacell_roi_id\\\":\\\"fc6f2724-3ab0-404a-b819-b2bd999d953b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"9c2f3afc-eaef-4f04-a3ae-c2c92c970cd7\\\",\\\"datacell_roi_id\\\":\\\"c7419d36-b64a-4c60-b13d-972ce98285fa\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"1a8347b5-88ac-4d81-aa33-fcc1ea1fd6e6\\\",\\\"datacell_roi_id\\\":\\\"00e8fafa-aecb-4888-b55a-9897a4bac10f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"53559c71-7c12-472c-b6f3-2babbfbb5a2b\\\",\\\"datacell_roi_id\\\":\\\"f7068af1-d7ce-4251-9a1c-f7cea8b34db2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"91567dce-2b53-486e-90e6-290e5cd97a6a\\\",\\\"datacell_roi_id\\\":\\\"9df333fa-500d-4b33-9f9a-ebf23bc65e9f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"70609a68-cb7b-4adf-8cb6-4959d3628004\\\",\\\"datacell_roi_id\\\":\\\"5c6d9b00-6e8f-48a5-a29c-7d046946b46b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"955f0731-7811-44f1-bf6c-c165ef134561\\\",\\\"datacell_roi_id\\\":\\\"8781aeda-ec1f-425a-8a56-140407628166\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"036131a0-5f9c-45af-a701-395570aab775\\\",\\\"datacell_roi_id\\\":\\\"13bf3e4c-2458-4f48-9e72-de7e846fd408\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"f27bf6d1-cc49-4de7-87b4-adda93eab7f8\\\",\\\"datacell_roi_id\\\":\\\"54a2255b-1b8a-45d8-9386-ccb98830ad3d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hematology, Clinical Chemistry, GFR, Coagulation <sup><\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"6a899bf3-be86-4cd1-bc57-bcff845b0485\\\",\\\"datacell_roi_id\\\":\\\"c32d1644-1916-4834-88b2-f63882902ac2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"bb8e2979-1c25-469c-9d0a-a6958b83d7be\\\",\\\"datacell_roi_id\\\":\\\"56226d8e-39e4-4d90-940a-41648e2a5d39\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"2af0551a-5d16-460e-8888-99009f5f1ba1\\\",\\\"datacell_roi_id\\\":\\\"8e70bc46-37c5-459b-b7f9-b13f64ad9dfb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"77f4a5fb-d622-49ed-b1fb-2f54ba3d04ce\\\",\\\"datacell_roi_id\\\":\\\"9911805f-ee2a-4709-9779-36cdcddf0cea\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"e7cef2dc-36d4-48f4-a177-2ead1377207f\\\",\\\"datacell_roi_id\\\":\\\"747eb240-1646-4c18-a8c7-4528ec61bca7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"229079d3-ccfd-4a34-abf4-15f337b005ff\\\",\\\"datacell_roi_id\\\":\\\"93e06157-7473-4fc6-8836-d66011e8d7fa\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"0d6d2f5e-0956-423e-bff1-5270fabe61ab\\\",\\\"datacell_roi_id\\\":\\\"e0421169-7c2e-43fd-8009-e71b463a8732\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"e04d834a-a2c5-4a30-8af2-94c7a0fd0160\\\",\\\"datacell_roi_id\\\":\\\"3158cacf-a1ca-4069-a2cc-8fb4ea89fcb1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"348d293f-41d3-478e-ae39-63ee89240659\\\",\\\"datacell_roi_id\\\":\\\"85fffd5e-870d-4c7c-8e60-93527a70ca80\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"77a551c1-8756-472d-819f-a07cd140d1b3\\\",\\\"datacell_roi_id\\\":\\\"15fbb9ef-aaac-47e1-99c6-842f41d44dba\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"5e978d4f-4a45-4b21-874b-09a346c273de\\\",\\\"datacell_roi_id\\\":\\\"3c3de1c4-97e6-40f3-ab95-391161f44e8e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"025de810-6026-4105-929d-cd486feaeafb\\\",\\\"datacell_roi_id\\\":\\\"ba0e749a-b08e-4075-b75e-92cf7f187267\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"c19cff3f-2f61-402c-85a1-373185b28f64\\\",\\\"datacell_roi_id\\\":\\\"b59a0aa5-0144-43ed-bb7d-79e235326fce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"4d08c3e0-7224-4034-af2e-b96d67b743f4\\\",\\\"datacell_roi_id\\\":\\\"357e876f-8d2b-4ef8-b85d-6ca0c89245f7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"FibroTest\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"40808a4a-8cbd-48b7-82ea-5860c93bca1f\\\",\\\"column_roi_id\\\":\\\"60e08319-711a-4e1a-a288-91111c17104b\\\",\\\"datacell_roi_id\\\":\\\"32bc2ef8-d569-46e0-b6ab-d46011f7b9f6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"40808a4a-8cbd-48b7-82ea-5860c93bca1f\\\",\\\"column_roi_id\\\":\\\"5f146903-1ef3-499d-a5fe-4e94d86474e7\\\",\\\"datacell_roi_id\\\":\\\"5bc2ebe3-e446-4963-a6da-7b54d198c887\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"TSH\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"71fd8876-0c4a-43b1-a28f-b4302fe7ce4d\\\",\\\"column_roi_id\\\":\\\"270228a7-3ab9-49e7-8122-0801903c372d\\\",\\\"datacell_roi_id\\\":\\\"0df03380-91fb-4188-861b-ffb840175928\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"71fd8876-0c4a-43b1-a28f-b4302fe7ce4d\\\",\\\"column_roi_id\\\":\\\"c32b6046-7ac5-41e4-af55-246e3a0ec89d\\\",\\\"datacell_roi_id\\\":\\\"0655d982-f809-465b-9fcd-39f7f3321edd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pregnancy Test <sup>8<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"998936af-ba5e-4ec3-9374-eb03d078c225\\\",\\\"datacell_roi_id\\\":\\\"c4def994-9977-42df-9a8d-4b28ff40b095\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"e504dd8c-24d3-496b-9c28-f787353fcf65\\\",\\\"datacell_roi_id\\\":\\\"8b23cc83-b87d-4209-abb3-30c7b7e80923\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"681f14b5-9a24-4557-9374-389070cc8dac\\\",\\\"datacell_roi_id\\\":\\\"3d7f95f5-5bbf-4d51-a58b-9e2750f5b7ae\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"152509b8-af60-4686-a664-b53399e26a02\\\",\\\"datacell_roi_id\\\":\\\"84513341-f1d5-4dc0-b5b6-62d6a320504e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 10 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"a7a0c6ae-1c95-4535-83c3-a76701113176\\\",\\\"datacell_roi_id\\\":\\\"251b3a37-fdb6-47fe-8303-a6e824fe5f9f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"87026149-772e-4d36-998d-a5cd2a5e6a2d\\\",\\\"datacell_roi_id\\\":\\\"b3f2de37-2a1d-4d58-bacd-082ab617eb18\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"da926df7-f429-4b99-8cc2-59dfd7941408\\\",\\\"datacell_roi_id\\\":\\\"164b332c-b340-431c-bbf0-471cd11ce756\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Plasma and\\\\/or Serum Stored Samples <sup>9<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"4d9f09cf-6b45-4cda-9fda-27c907a1a1ad\\\",\\\"datacell_roi_id\\\":\\\"6a65e55e-4eb8-42de-8ae2-be6d3b77200c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"ab443f65-da12-493a-b6b5-3b671f329740\\\",\\\"datacell_roi_id\\\":\\\"64ae7744-fc88-4da3-be05-dc98bca3de18\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"7fbac492-bfee-48ee-b3ef-9f73a087e8fe\\\",\\\"datacell_roi_id\\\":\\\"1c5789d8-314b-41e9-9b33-0e4b7b05e449\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"d0243c16-4e5a-48b5-89a9-e63818561d3f\\\",\\\"datacell_roi_id\\\":\\\"a58dd5a6-1e68-4f45-9cf9-a3c2b3254362\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"0f99e3aa-e3bf-44c5-8264-9d56f90ee7f6\\\",\\\"datacell_roi_id\\\":\\\"b3af2591-5612-4e76-b3f7-49278b5ebbca\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"9a75dbb4-283b-4170-af5d-76fcd6bdc172\\\",\\\"datacell_roi_id\\\":\\\"6165d699-6a67-45d5-9747-c5d1d19869d8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"930f6d57-81de-4e37-8ac9-47767505b619\\\",\\\"datacell_roi_id\\\":\\\"aab60d1c-3021-4432-8ba0-82ea321d7835\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"9476702c-28e6-49c5-8e20-edb68fe7908e\\\",\\\"datacell_roi_id\\\":\\\"44476a3c-f689-4512-962b-9d0ca5201cdf\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"17f2b418-e49a-46c0-ba1d-5411c5152188\\\",\\\"datacell_roi_id\\\":\\\"cc2ef3de-decf-4c48-985a-adea0f33229a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"c10216b3-9333-4b15-8493-570bb314ab80\\\",\\\"datacell_roi_id\\\":\\\"d5bb82bf-fb1b-4302-acd5-7dde2f3d7a7f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"2d96bf81-55e9-4d32-9704-961dac033ab5\\\",\\\"datacell_roi_id\\\":\\\"4f746187-b5d3-4509-a2cd-9932de24117f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"1f5241c6-94f4-4d1a-bd7b-02ea9b253d99\\\",\\\"datacell_roi_id\\\":\\\"f2f8065f-6f21-4085-9d72-fec086f1de18\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"96e2348a-7322-4ead-beae-5058b76db2c5\\\",\\\"datacell_roi_id\\\":\\\"5e0af5b1-a981-4b01-ac40-940e5563ae60\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"ad1a1ab1-f0fb-4739-bcaf-1f5cb182ce01\\\",\\\"datacell_roi_id\\\":\\\"fbcc3eb4-bbf1-4dce-bddd-c8312a1350de\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"1c4c762e-f371-4240-b18f-2d53ca910de8\\\",\\\"datacell_roi_id\\\":\\\"989ead58-33f2-4154-9f9b-6f84f46efb61\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"8a1af937-4c35-4a3b-813c-87ed9d72622f\\\",\\\"datacell_roi_id\\\":\\\"ee7d527e-7d2d-476c-b33e-18f84a9f8f20\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"322b6196-5699-463c-a9f4-077339fc8a62\\\",\\\"datacell_roi_id\\\":\\\"9a088b2d-7f90-428c-b3fe-10e979c5cc6a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"e89ce0b6-e483-4a66-967f-5b17e446388c\\\",\\\"datacell_roi_id\\\":\\\"b00fef68-8364-45f8-a873-eabfc01e3ce6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Urinalysis\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"6aa1f0ad-181a-4d5b-8d5f-38528aca620e\\\",\\\"datacell_roi_id\\\":\\\"4d6a0f49-ab80-4aa2-bd09-e93403652e20\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"db086ca3-7eb6-435c-95ee-1bab502db907\\\",\\\"datacell_roi_id\\\":\\\"9811cbf1-753e-4c90-8cc6-7618c410cf17\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"162b0574-41a1-444c-8a6e-2ba03e305174\\\",\\\"datacell_roi_id\\\":\\\"288fa44a-0db5-486f-830b-1cc3955ebdd2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"f200fa10-5098-4ec3-923b-431146edc9c2\\\",\\\"datacell_roi_id\\\":\\\"b718311a-37e9-491a-91ad-f3a0fad34b46\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"8e53cd7e-8e60-4450-8ff7-781b005311e0\\\",\\\"datacell_roi_id\\\":\\\"e52ee90b-fcaf-42d1-9a53-7b21532ecd4b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"602c1818-a5df-44f7-8a95-17d4f8d265be\\\",\\\"datacell_roi_id\\\":\\\"e29c3de2-0a19-4875-b4f2-020c19055669\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"71270f93-030b-4d2c-ae1b-749fe9a9bcd1\\\",\\\"datacell_roi_id\\\":\\\"465f2ea8-26c9-4070-ad6c-ce06e4d58bd3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"7cd65510-deed-41c3-b75f-e862bfad15e5\\\",\\\"datacell_roi_id\\\":\\\"85fdd49b-581b-4495-a9e2-d691cfe116c3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"7ba7c8f4-d136-4338-908e-83d30889ad13\\\",\\\"datacell_roi_id\\\":\\\"aea9b038-6581-49af-93bd-9bb040566b32\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"9c990110-fcb6-4ce2-9246-8ee8c7dfca15\\\",\\\"datacell_roi_id\\\":\\\"72976f49-fb6d-43ba-903b-4ddf3b15da07\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"4207fb4c-dde1-47ad-9aa8-503f58eb84f1\\\",\\\"datacell_roi_id\\\":\\\"6d2faebc-6340-4eb9-bf6c-1bf874cbcfc1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"8ad4303c-7620-437e-83c0-523d3554d6a8\\\",\\\"datacell_roi_id\\\":\\\"2da6e3e8-3491-4165-9926-59789a070e4f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"6b34a902-a9e8-4b99-8da0-aa4d5b25ba18\\\",\\\"datacell_roi_id\\\":\\\"c451ad4a-543b-400f-9f20-ad1e43db0920\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"50d45da4-3888-4f4e-a78d-5977e5e9d843\\\",\\\"datacell_roi_id\\\":\\\"16065a7a-4970-485e-ab50-616b37bad6ff\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"}]\", \"SectionHeaderPrintPage\": \"29\", \"TableIndex\": \"12.0\", \"TableName\": \"Table 7-1 Schedule of assessments (Schedule of Assessment)\", \"AttachmentListProperties\": [{\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 0.0, \"AttachmentId\": \"af987d26-4070-11ec-8bde-005056ab6469\", \"Key\": \"1\", \"Text\": \"Table 7-1 Schedule of assessments SCR=Screening Period; Pre-TX=Pre-Treatment Period; W=Week; opt=optional; EOT=End of Treatment; SVR=Sustained Virologic Response; IWR=Interactive Web Response; FSH=Follicle Stimulating Hormone; BMI=Body Mass Index; IL28B=interleukin-28B; GFR= Glomerular Filtration Rate\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 1.0, \"AttachmentId\": \"afb1d4df-4070-11ec-aed1-005056ab6469\", \"Key\": \"1\", \"Text\": \"1. Height will be measured at Screening only. BMI will be calculated at Screening only.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 2.0, \"AttachmentId\": \"afb1d4eb-4070-11ec-be0d-005056ab6469\", \"Key\": \"3\", \"Text\": \"3. SAEs will be reported from time of informed consent through 168 days post EOT visit.  Nonserious AEs will be recorded from time of first dose of study drug through 28 days post EOT visit.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 3.0, \"AttachmentId\": \"afb1d4f1-4070-11ec-931c-005056ab6469\", \"Key\": \"4\", \"Text\": \"4. Echocardiogram to be scheduled during Screening period but not performed until subject qualifies for entry into the study.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 4.0, \"AttachmentId\": \"afb1f928-4070-11ec-a64c-005056ab6469\", \"Key\": \"5\", \"Text\": \"5. Three consecutive ECG determinations collected within 5 minutes apart from each other at each scheduled time point.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 5.0, \"AttachmentId\": \"afb1f92e-4070-11ec-9dd7-005056ab6469\", \"Key\": \"6\", \"Text\": \"6. If optional intensive PK assessments are performed on Day 1, HCV RNA determinations will be time-matched up to and including the 8 h PK timepoint.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 6.0, \"AttachmentId\": \"afb22038-4070-11ec-889a-005056ab6469\", \"Key\": \"7\", \"Text\": \"7. Refer to Table 7-3 for PK schedule. Study drugs must be taken while in the clinic on Day 1 for all subjects, and on Days 2 and 15 for those subjects who elect to participate in the optional PK sampling timepoints ( Table 7-3 ). \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 7.0, \"AttachmentId\": \"afb22053-4070-11ec-828e-005056ab6469\", \"Key\": \"8\", \"Text\": \"8. Pregnancy tests should be performed at the indicated visits; however, additional tests should be done if required by the local standard of care. A serum pregnancy test will be conducted during Screening, and a urine pregnancy test will be conducted on Day 1, prior to dosing. In addition, per the local standard of care, male subjects may be queried at each visit to ensure their female  partners have not become pregnant. \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 8.0, \"AttachmentId\": \"afb24760-4070-11ec-81c8-005056ab6469\", \"Key\": \"9\", \"Text\": \"9. Stored plasma samples will be dedicated for HCV antiviral resistance testing.  In addition, stored plasma or serum samples may be used for testing safety or PK parameters.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 9.0, \"AttachmentId\": \"afb24766-4070-11ec-bc94-005056ab6469\", \"Key\": \"10\", \"Text\": \"10. Applies to Groups A and C only.  Last dose of study drugs for Groups A and C is Day 56.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 8 visit.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 10.0, \"AttachmentId\": \"afb26e2f-4070-11ec-b571-005056ab6469\", \"Key\": \"11\", \"Text\": \"11. Applies to Groups B, D, E and F only. Last dose of study drugs for Groups B, D, E and F is Day 84.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 12 visit.\", \"qc_change_type\": \"\", \"entities\": []}], \"FootnoteText_0\": \"1 Table 7-1 Schedule of assessments SCR=Screening Period; Pre-TX=Pre-Treatment Period; W=Week; opt=optional; EOT=End of Treatment; SVR=Sustained Virologic Response; IWR=Interactive Web Response; FSH=Follicle Stimulating Hormone; BMI=Body Mass Index; IL28B=interleukin-28B; GFR= Glomerular Filtration Rate\", \"FootnoteText_1\": \"1 1. Height will be measured at Screening only. BMI will be calculated at Screening only.\", \"FootnoteText_2\": \"3 3. SAEs will be reported from time of informed consent through 168 days post EOT visit.  Nonserious AEs will be recorded from time of first dose of study drug through 28 days post EOT visit.\", \"FootnoteText_3\": \"4 4. Echocardiogram to be scheduled during Screening period but not performed until subject qualifies for entry into the study.\", \"FootnoteText_4\": \"5 5. Three consecutive ECG determinations collected within 5 minutes apart from each other at each scheduled time point.\", \"FootnoteText_5\": \"6 6. If optional intensive PK assessments are performed on Day 1, HCV RNA determinations will be time-matched up to and including the 8 h PK timepoint.\", \"FootnoteText_6\": \"7 7. Refer to Table 7-3 for PK schedule. Study drugs must be taken while in the clinic on Day 1 for all subjects, and on Days 2 and 15 for those subjects who elect to participate in the optional PK sampling timepoints ( Table 7-3 ). \", \"FootnoteText_7\": \"8 8. Pregnancy tests should be performed at the indicated visits; however, additional tests should be done if required by the local standard of care. A serum pregnancy test will be conducted during Screening, and a urine pregnancy test will be conducted on Day 1, prior to dosing. In addition, per the local standard of care, male subjects may be queried at each visit to ensure their female  partners have not become pregnant. \", \"FootnoteText_8\": \"9 9. Stored plasma samples will be dedicated for HCV antiviral resistance testing.  In addition, stored plasma or serum samples may be used for testing safety or PK parameters.\", \"FootnoteText_9\": \"10 10. Applies to Groups A and C only.  Last dose of study drugs for Groups A and C is Day 56.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 8 visit.\", \"FootnoteText_10\": \"11 11. Applies to Groups B, D, E and F only. Last dose of study drugs for Groups B, D, E and F is Day 84.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 12 visit.\", \"Header\": [0, 1]}, {\"IsBold\": true, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"57a33e73-fe9a-4b1b-9240-b925f797c1df\", \"childbox\": \"3fd213c1-c7c1-4fe0-ab50-869d853f6529\", \"subtext\": \"05894802-e5f5-4231-8673-c128f1325969\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 666, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b0fa1e3a-651f-4eec-a962-d37715b571e2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 667, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cfee0464-829c-469a-aa9e-c5b7583552f5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 668, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2490d3e9-1589-4203-aca0-320bbb9c7235\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 669, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"887ec227-1388-494d-bc5b-6b33c68de24b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 670, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4d73cb49-5f21-4016-8902-de4567f020a6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 671, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"62b7850c-ed25-4fe2-a979-0c350e408808\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 672, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d62bc0ad-6e68-41f2-9c60-b13b000c3c03\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 673, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"97293e1b-6f8b-48f7-a50a-e081ab94e854\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 674, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c9f9d4f6-0dd8-4bba-af9b-f0c9a2ce8753\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 675, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"63fedac2-e8c0-4392-89e5-6fb4a8edc040\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 676, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a2002fc2-35cc-4fa7-b1b4-60d9889c097b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 677, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"395981da-4d09-4446-a442-89b871215442\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 678, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d9e76d8f-d873-4842-a41f-ade5e518f3ce\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 679, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"45c580ca-0491-4218-8393-20e186211e7a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 680, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"564b5851-7d68-4c2c-84a5-7821bf42d855\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 681, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a4351503-6d3f-4b32-83e5-f5a146b4a90a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 682, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8cf24477-065b-468c-9dc2-93bb1fb15609\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 683, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c82aa4d-8c5e-40f4-bf21-fbe4ab4a717a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 684, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8d9faeeb-9ab3-4688-8ff9-427be78f7a36\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 685, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"30f63e15-cf19-44a4-81bb-e524f6c51e00\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 686, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d314e57d-205a-40cb-9e44-d784bd586c87\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 687, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"55ed7d68-d90e-4ea4-b242-c6c7337a6a72\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 688, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9140cbd5-03e0-458e-876d-cfe6e2f00656\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 689, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a1ddf584-92fa-40fc-95da-37a95cb51872\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 690, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3e802134-5c9f-4443-aaaa-06119679759c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 691, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dbf87529-17de-4b9e-ae43-d367a27fffdc\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 692, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7b7ff741-25dc-4dc5-9b97-8a9b3d96db0e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 693, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"72409113-9ff9-41c1-828b-396ffd553e19\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 694, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"296edfe4-c452-421c-a601-14af1e6ba35c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 695, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7d7fceea-54e9-4e64-9b05-df787d325bb4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 696, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9f5bfad7-6284-4394-8ff2-08ac599c2e30\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 697, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0b615781-c7a6-412a-ac2d-980800cd0b0e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 698, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c614b2c4-a0a4-4167-b0e8-af90e622d0d3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 699, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dfcefe63-fada-42a9-ab0a-c0b42681cdad\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 700, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"681c7809-bd5e-41fa-ab09-020175025feb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 701, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9f803017-2840-4c4c-b855-5b82466807f7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 702, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"24c18763-733f-4223-8c2c-597fed11029c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 703, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6daf021c-48b4-4aa3-8f36-a71dd9b78d86\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 704, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"26ac54e1-1dec-42de-a08a-c30630b10b62\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 705, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b89d3965-6fba-423d-9bb8-91b7877a99b0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 706, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"83d4ad6c-7b8d-41b2-b529-60510b6950f1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 707, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ccb0bcf5-70bd-4ccf-8637-b673c60e15df\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 708, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"68323e17-5fc6-4cb6-94f7-9130f69e8a1b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 709, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc6e5460-a13b-454a-b6e8-598f41fa09e2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 710, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"240e1388-5ec3-4b34-9f72-936709236715\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 711, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"708f3113-880e-4c50-8f5c-c521886e4349\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 712, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7bdc2240-6001-4674-8267-8f9059531a1c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 713, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db45ca7f-8ae1-45f3-ace9-d84fd0aacb3e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 714, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e77a67ed-236c-42e2-8ade-1d2278b5d526\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 715, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1efec5d0-ad23-49dc-a755-324515fb565d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 716, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"14d000a6-a56d-4f6f-95b3-b008f0b0f695\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 717, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8dfc327e-7d2e-41c2-b2bb-a3e085d6ba9a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 718, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"94354366-1ae7-4a7f-9c98-e59bbb1bcc39\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 719, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0a7ce1c9-d44c-49c8-a8a3-907b4f60772b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 720, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"025afc76-e49f-47cd-a3ad-93ab086a0b68\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 721, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a8ef9924-9ad7-4e7f-bc61-e2034da7605b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 722, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"59cd5af1-8841-428c-a423-ebfef255ec63\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 723, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"73055cd3-8645-4f29-af2a-58a6f13858c7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 724, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8ceb48d-7576-4dd7-973d-e12b5f74e6fa\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 725, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a1f3bb4b-bb6a-4e4b-af18-0cd197940225\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 726, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cc76ce32-e366-43f9-bca8-44f3c7454c0b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 727, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"561c8f60-c1df-476b-b6dc-538151a87018\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 728, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f68a6845-b502-47a2-ac76-a8d468f06dc6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 729, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3cd6ec62-7378-450c-8415-f962094e1fd3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 730, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9e007abb-168f-4ca0-87ee-655553fc65b9\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 731, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"37957ebd-4d1d-4b99-9591-3c96a6f616e2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 732, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a27f5814-4156-4830-90a9-27456eeadd60\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 733, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"659007f9-80fc-4901-bc22-714832a4d51c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 734, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cbd444b8-0914-4af6-8aad-1b27bfeced3b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 735, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6e28d652-3dfc-4dc5-8aa0-86a6822f4185\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 736, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e5b81c13-d8b9-472f-9c05-c03feaae3bb2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 737, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ab3439f9-9ba8-452b-8b54-aacd09c6a560\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 738, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"97ea9349-a85c-4c87-a63b-03aa0a902eeb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 739, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7c3c9d21-5907-4d71-92b6-556611ebf376\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 740, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f5883f98-2c00-44a8-b26d-f04d4fb321d3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 741, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc65eea0-ee3b-42e3-a349-f4da57a621aa\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 742, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0057cd65-c009-403d-b4dd-e834d4ac6c30\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 743, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c1eded8d-3f44-4c24-8a84-fdeda4d2dac0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 744, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9e0207d5-e485-476b-82e5-f88a1b476e27\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 745, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"414aebfd-a025-4e86-a4b0-b9117afd9d3b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 746, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5f91a6b7-b5a6-4abf-a28a-c446d78f49bb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 747, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"04c50893-6917-450e-89ef-f2fecc066dc6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 748, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"89a517af-b6c7-44a8-92da-6c1ad2d72c6f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 749, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"356e3816-642a-4955-aa4c-ad81a89cce06\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 750, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"39449a9f-cc24-4bbf-a6f3-eb1cc70b383e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 751, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe8214ba-3695-4459-9393-c362d5127d2c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 752, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0ca3781b-eb93-4eaa-bf94-edeb01092214\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 753, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b05e4a02-3686-4ac2-9254-8528fccb4052\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 754, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cda52155-bcc3-4c26-b796-de45273a45b1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 755, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"31221c23-0db7-4f8f-8051-4351a0380335\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 756, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"14865343-548e-43bf-b069-695e72f9308d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 757, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"87e997cf-e69a-48b5-a549-877f4dc2ad5a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 758, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b9b46b82-1842-47f5-977d-919440390b79\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 759, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0e4c7980-9c5b-41e5-94e9-102d59293d2c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 760, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"21b09b23-5b0d-4ac4-b10c-5dc0fd087734\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 761, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"500afdb8-a455-462c-99ee-d506941a3d41\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 762, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3aff9909-54be-4d63-979b-476cda69965e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 763, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3b13a5fa-b4f4-4348-a8b7-6fcabc932eec\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 764, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"eb441485-9616-498d-8698-6e5f06625160\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 765, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a4b237b0-629d-4f66-a10b-2405a27a3aba\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 766, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42c946f1-9e9f-4666-a6c8-16c0a5c607ef\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 767, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cb591204-fb45-4a5d-a44d-88668e0c5283\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 768, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8fe7ac0d-318d-4bea-a2a4-1bfb388a05fe\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 769, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c33ff632-df4d-4dec-a310-5f60f28d4be8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 770, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"262867b1-ebdc-4074-bccd-a4e82887bc94\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 771, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8923fdcb-b161-468e-9a6c-0458dff78809\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 772, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d9f62c14-3d9a-49fd-884f-3e1740abcec6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 773, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"347aec69-241d-4901-afb2-82d6a01f0a79\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 774, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9eb28064-6c86-4ca6-99cf-08d3ab4c9c5f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 775, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d5f2adbc-9874-4167-b073-c33b6c0fc543\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 776, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3fb5305f-942b-47e9-a0dd-5321aa64b7f3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 777, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7d6537a7-547a-4104-98cf-dd4a0b8c55f3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 778, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0c67a55f-31fa-48c8-a83d-526e1d825c15\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 779, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5fe31c19-8ff8-4d56-b2f9-968b3a700b30\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 780, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fd4e8fc8-039b-4fb6-ba91-6d0333bdb302\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 781, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9fe99004-2393-48fd-aeaf-ffe088e69dbc\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 782, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c7ad3949-e566-460c-859a-28a7b0ed07a8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 783, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8f7591b-7283-4f0d-be06-3b38f3dd4d52\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 784, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20992c8c-2b5d-4046-85ed-0bc72655c50b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 785, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8df4bc08-67e8-42d8-af3b-76ddd0f38216\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 786, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bbd36421-7261-4b68-9ba6-64717bc08b3a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 787, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1cb463ec-3c75-44a4-a632-900d05fb183f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 788, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9f50b52c-fe67-4f62-9464-173600c0ccd6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 789, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"73290130-f7f1-400d-a0cc-efd56bbb6ef7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 790, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"95e228c5-0c03-44d1-8585-82d438692723\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 791, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"af98ae4c-f8c3-425d-8827-6c5c1979b304\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 792, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"770767fe-2cb1-483d-a481-9fd79b7b796b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 793, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b1e71207-11a8-44b6-ac3b-b7826647d387\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 794, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"99422d77-c049-4836-9f9e-cbf3e7a1aeca\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 795, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d3c66495-66ab-405c-9190-702fa774f9a6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 796, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"38faa3d4-b47f-4461-87fd-89a3556e586d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 797, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"746f03f7-c713-413f-bd59-ad499fa2d030\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 798, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0978f3bf-94b7-41ff-b5c9-0713f3c2031e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 799, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ab93042c-7b79-4285-883b-4a36b4ab7c7e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 800, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fea0963e-e2de-458e-9fae-4c5f853622c7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 801, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9e7d332f-84cf-43e0-9227-6e00ff549f00\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 802, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"10e81d4c-862b-4bf4-a8d0-972431fbdb60\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 803, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"83caffb1-0688-4457-8e0a-9b27cb16be5b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 804, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ae8cd070-6ea5-4313-8475-8b4f3b5ebc5f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 805, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"beeb90d2-135e-4687-8233-88b028b741ce\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 806, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8cbc3e83-689f-44d0-a8e5-b4c1e49acd0d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 807, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ff14617f-2365-45e9-8800-55641e03e39b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 808, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fbd12700-18b7-45b7-b0c3-6beaac0641ec\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 809, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7c9a0f93-77de-4a85-bb9b-c49f6c19c5e3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 810, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3baf6b98-1920-41a6-a16d-97f703eda6c2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 811, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0d046678-9766-4a48-a1ba-9fd0631429bf\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 812, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f8ab60a9-112b-4e95-8839-9c9f8dd1e1b4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 813, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"23b85c94-921c-48bf-957a-1a0d26aee2b7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 814, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4e74df6c-a586-43d0-b136-86fa21e7e335\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 815, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9f3fac91-19e0-457c-8253-0a3851dd6d07\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 816, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27f93765-723d-4c49-a2c6-67052dbc5793\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 817, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9b2c3a90-0f9d-4d06-948e-e98b9ef6435d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 818, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fddcf707-a999-4966-ab6e-5baa125e8b11\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 819, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"468ffee7-f035-4dfb-8f84-40a6569542d2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 820, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a1cb0865-0753-44aa-8736-ad02bf1c0109\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 821, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"be1988d0-6bee-4925-bd30-ff761de4fa68\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 822, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"522280ec-bbcc-43c4-8e0a-199e111f6f2e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 823, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1ec8b1a3-4995-4d2a-a468-cc95995f5462\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 824, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0137d7c2-2ed3-420c-b369-26285ea3b225\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 825, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6837f04c-36a5-4e4f-9b68-3e89397c6cb2\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 826, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f105427-4ea8-4c42-9deb-708e9f39d9b4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 827, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5e625451-c9b5-4692-acf7-c40bb74ca37d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 828, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dd8df16e-d9e8-4bc4-ae59-22c2a9bd988d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 829, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"33e6dcf9-b6f7-4540-bb32-6da1fa669d04\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 830, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0126e309-01fa-487a-9bc9-253d542db507\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 831, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bd5644c3-5d2d-4a61-b93e-f5e40fa488fc\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 832, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4c0c2749-ef6d-4e47-8171-054116693075\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 833, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"822c36e4-3098-4b57-825c-ba093be1a9c4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 834, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9a265be8-56ac-4357-8db4-2772f98ee87d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 835, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98094386-5e03-4ba5-9468-4f50d8d02cbe\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 836, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d44f2739-8867-422d-a9ea-3811e54690c5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 837, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9e2ae4bd-e12a-4cad-aa17-0a915fb0cb40\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 838, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"95c51649-558e-4a45-8f5c-5c193e684ec1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 839, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f396ac39-d626-4b84-bef7-38f1c5d359dd\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 840, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d0e2ed31-fe45-426a-9881-35644a0d2bba\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 841, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"59e4404c-4826-4888-b640-d61c4c5046c6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 842, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"115c9f83-eae1-46a9-9970-a75c7d6bd53a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 843, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4c45f6f9-76e4-401e-bb92-370642f0b66b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 844, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90cc1da3-e2cb-4220-b8ba-ee76a7308bb9\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 845, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c6508c1b-c7ef-4af5-8bcb-2b937eb6a704\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 846, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90461e11-3fb7-4083-bd73-8aaaccf364b1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 847, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"185895b5-d529-48f0-bdc0-9cadbcd5bcb0\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 848, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8a110e4a-1310-42c5-a9a3-a4e69706bca8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 849, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e0c07a1c-5562-47c4-9add-9618a3885895\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 850, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e1b39e9f-3ee1-472d-ba2a-22909efc5e9f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 851, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"77abb462-0219-48d8-81bf-f0b93f895bdf\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 852, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5e843f14-4e23-4d6b-8722-5fb324d819ec\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 853, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"be07a688-5579-4e5c-bcdf-dad7e0ffac54\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 854, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bb0c0393-1acd-4726-b2e9-f9801c1cb26d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 855, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2bb5bffc-4545-494f-9a88-e5c1ab918481\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 856, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f35e8cbe-7cfb-41bc-b96a-32d49b7012b3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 857, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"358d666d-235f-4bc0-9714-d9f1f642dae5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 858, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"67d495b5-7c61-4504-bab7-e9ceb88f6836\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 859, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0a169a38-21ff-4af7-97f3-fd683eace884\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 860, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"44067a9b-65df-483e-8414-0ae770ccf133\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 861, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d1510efe-c60a-4840-b2b5-5ebdeb91f5b1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 862, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"133ec473-9891-4e07-837b-4b3b6a73df45\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 863, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"94eda184-e629-4cea-a726-c8ba2828671f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 864, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2cc6ee9f-faa6-4930-909a-17d8ff219ebb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 865, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b767b69-b9dc-4875-a135-70b15e33cb41\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 866, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"34b6323a-6785-4ede-adbf-5b3d471a58d7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 867, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"03da18c5-0ff7-4139-88de-45b68eb6f640\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 868, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"34e30a02-eca4-4926-8782-56223d264667\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 869, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"835617a1-5911-4f6d-885b-acc6c95c2d78\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 870, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"43cc0001-4deb-4f87-8a8d-f5344638dfec\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 871, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ddb0aed7-8460-416c-83c6-7f028b3ca10f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 872, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bdec7f70-b353-4c7a-8e08-60712f1ee122\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 873, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a9a8b54f-18a0-41f2-b6a3-3211de18c5e7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 874, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"51a33e56-6a40-46a7-b44b-95baaed87c61\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 875, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d0ca400e-6ca4-4ffd-a605-01e4c1d0ed3d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 876, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6adb1fc1-6d61-4f6c-bae8-cf1bfe80d8ad\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 877, \"\"], [\"\", \"Unmapped\", \"table\", \"\", {\"IsBold\": true, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d0e47f5-dac5-4f0b-a843-db9829f1fe97\", \"childbox\": \"2c5ea113-b4bc-4603-a168-93b594fb5741\", \"subtext\": \"6d082f04-3024-4348-b1b5-ec55a56d3cc5\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 878, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0fad318e-bb53-4d8d-b378-40df749e1cb4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 879, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"542f3060-3dcc-4a89-9526-da49d3182323\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 880, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d533345f-fe74-4ded-896f-5cee861c0857\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 881, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"107596f0-e0da-44f5-a1cc-e4f90c79bf89\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 882, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ce3543de-bba7-4d0b-815c-116e9452bc8e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 883, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0f1e9d06-9042-482d-b867-86adb3017ce3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 884, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b75f4eb7-e6d4-4ad7-9d0a-f7966c183bc3\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 885, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db59b4a1-6ccd-4ab3-b875-9a26b73c68e4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 886, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"71d57591-f7a7-41b1-8acb-c8f99cadbe10\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 887, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3e246366-1cf7-4878-9944-798d815065ed\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 888, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"37318887-092a-4bc6-972c-694513cfc28b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 889, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2509675b-174b-4356-9f78-05e8ff8d290b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 890, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"91cf2cc3-6a7b-42bd-805a-608e2335d2ef\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 891, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"34817780-a093-4451-bbc2-246e7383e575\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 892, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ce74142e-fd3d-461b-9c12-fb93396cd77c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 893, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"38a21e69-9a6b-4438-9dd1-3c44abee9ace\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 894, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"580deb13-4a07-4074-9d5f-37f6a5f10502\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 895, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4cc7ebce-01c4-437f-98e7-4caf9e125ddc\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 896, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4ddd867a-7fa3-4603-910a-56f7e02db84d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 897, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b0aee3ec-f517-40f8-b3f1-5d31bbdac0de\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 898, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d006d323-37ae-4d7f-892e-580a5653e853\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 899, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"935a86eb-6606-44dc-bea6-09547ffa47cb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-1  Schedule of assessments\", \"Table 7\", \"2\", 900, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f1ae140-b795-4590-9a90-f53160b76285\", \"childbox\": \"ddff554a-9966-443a-acc5-fff6e3e23c4c\", \"subtext\": \"397c166f-7ccf-409d-bd3d-3483c757434e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-2  Schedule of assessments \\u2013 Extended observational follow-on phase\", \"Table 7\", \"2\", 901, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-2\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f1ae140-b795-4590-9a90-f53160b76285\", \"childbox\": \"f4203f26-4b05-44ba-80a1-a2517df53664\", \"subtext\": \"a1583ab2-67ca-4bc1-b314-4a093498338a\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-2  Schedule of assessments \\u2013 Extended observational follow-on phase\", \"Table 7\", \"2\", 902, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f1ae140-b795-4590-9a90-f53160b76285\", \"childbox\": \"ee84aaa0-b99c-41d4-a411-9011a4925d67\", \"subtext\": \"a31d73eb-3bfe-424a-b7d5-1f0fc9de7f68\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-2  Schedule of assessments \\u2013 Extended observational follow-on phase\", \"Table 7\", \"2\", 903, \"\"], [\"\", \"Unmapped\", \"text\", \"Schedule of assessments \\u2013 Extended observational follow-on phase\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f1ae140-b795-4590-9a90-f53160b76285\", \"childbox\": \"9a926098-30b2-4d31-acba-1adbcada71ab\", \"subtext\": \"a31d73eb-3bfe-424a-b7d5-1f0fc9de7f68\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-2  Schedule of assessments \\u2013 Extended observational follow-on phase\", \"Table 7\", \"2\", 904, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n      <th>7.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>STUDY DAY \\u21d2  ASSESSMENT \\u21d3</td>\\n      <td>252\\u00b114 Days Post EOT</td>\\n      <td>336\\u00b114 Days Post EOT (48 Weeks Post EOT)</td>\\n      <td>420\\u00b114 Days Post EOT</td>\\n      <td>504\\u00b114 Days Post EOT (72 Weeks Post EOT)</td>\\n      <td>588\\u00b114 Days Post EOT</td>\\n      <td>672\\u00b114 Days Post EOT (96 Weeks Post EOT)</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>HCV RNA Quantitation</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Stored Plasma Samples</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"STUDY DAY \\\\u21d2  ASSESSMENT \\\\u21d3 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"00c71948-657b-40ff-8309-ab8ec3eb0424\\\",\\\"datacell_roi_id\\\":\\\"b648faf6-5cdf-45b1-ad5d-09ef61f6ddab\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"252\\\\u00b114 Days Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"a6f2a5de-99c1-4e8e-bb81-95f5efc18017\\\",\\\"datacell_roi_id\\\":\\\"97197e8f-62c4-4076-aef6-e4785e9f9c81\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"336\\\\u00b114 Days Post EOT (48 Weeks Post EOT)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"a2bbb68d-35e5-450a-800a-31fbcba6ee1b\\\",\\\"datacell_roi_id\\\":\\\"d78db493-4cc1-4f4f-9af1-66ab03e20916\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"420\\\\u00b114 Days Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"b2b2559f-700d-4b45-956c-b7255be9b7af\\\",\\\"datacell_roi_id\\\":\\\"21292269-2e32-4969-adcb-85d9eb6ca06d\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"504\\\\u00b114 Days Post EOT (72 Weeks Post EOT)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"822f3acd-60c0-47dd-b6f3-064db0171f9b\\\",\\\"datacell_roi_id\\\":\\\"ec99ba7a-477e-43ba-b6ad-48e452e9181c\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"588\\\\u00b114 Days Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"f40602c6-5b5e-45fe-862c-fe9760a5427c\\\",\\\"datacell_roi_id\\\":\\\"9eaf9446-7105-4d7a-9de8-33878f73dbab\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"672\\\\u00b114 Days Post EOT (96 Weeks Post EOT)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"79731687-bef6-49b8-b039-43d682a26a56\\\",\\\"datacell_roi_id\\\":\\\"9a7c205d-c756-463b-bf27-f7158228c219\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV RNA Quantitation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"a525394b-b8a9-47de-a6f8-7ca995f5de99\\\",\\\"datacell_roi_id\\\":\\\"ae5a4895-dbae-4e43-a042-16a34839fb51\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"e300fef5-ab22-414a-b379-07d37be1954a\\\",\\\"datacell_roi_id\\\":\\\"37c99e4b-4974-429d-a037-988f1d86d04c\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"c88155b1-eec1-4cfe-b331-68f3333c08be\\\",\\\"datacell_roi_id\\\":\\\"b4398b34-66ef-475e-803d-85b61b5cb278\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"2122521c-98bf-4d50-95c0-ae06cdd59f0e\\\",\\\"datacell_roi_id\\\":\\\"cb30198b-9b44-43ae-8c7d-96dc100814fa\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"bf263fd3-6bbd-4275-ac2a-9bdb04004d9f\\\",\\\"datacell_roi_id\\\":\\\"8e639674-df7b-45b3-91c0-9d385719f932\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"0767f6fa-0be5-4cab-bf28-e7449436c57a\\\",\\\"datacell_roi_id\\\":\\\"8a2232c0-a0ad-4cb2-88c0-5feba163a567\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"95743e12-fdd3-4d1f-b28f-ca11654414c3\\\",\\\"datacell_roi_id\\\":\\\"60bfc0b7-743c-4b83-90ab-c10dbc11c274\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Stored Plasma Samples\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"2617a6c3-53ef-4e4f-8a64-5ee61ee2fd6c\\\",\\\"datacell_roi_id\\\":\\\"01764d2f-72d9-45d9-8a8b-961dc1e8d09e\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"9b848208-538a-413f-9c00-1ed55ad32c48\\\",\\\"datacell_roi_id\\\":\\\"ef7ce881-9b87-4ea5-b0ed-9f7fd11a341d\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"86421f6d-7ab7-4747-8c48-fcb93161c8d3\\\",\\\"datacell_roi_id\\\":\\\"3fe69cbe-44d2-449e-bac9-2fc29286e69d\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"25e6ce87-3ebe-491e-aa08-edaf1e57bc76\\\",\\\"datacell_roi_id\\\":\\\"a83c570b-9004-432e-8dc8-61e454349148\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"57bf2c9a-c4f0-446c-99d4-9700ecf29632\\\",\\\"datacell_roi_id\\\":\\\"01a4613b-eef8-44a4-9dc1-c997fcdc2d81\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"ff3a25e8-3b2f-48af-8a78-c5034dc80650\\\",\\\"datacell_roi_id\\\":\\\"09896c1b-9373-4ede-a87a-47132445ebe9\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"3262718b-182a-4366-9977-17c8543fa7e5\\\",\\\"datacell_roi_id\\\":\\\"31a4406c-c623-43b3-ade1-41bca442017f\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"30\", \"TableIndex\": \"14.0\", \"TableName\": \"Table 7-2 Schedule of assessments \\u2013 Extended observational follow-on phase(Schedule of Assessment)\", \"AttachmentListProperties\": [{\"TableId\": \"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\", \"AttachmentIndex\": 0.0, \"AttachmentId\": \"afb26e38-4070-11ec-a945-005056ab6469\", \"Key\": \"\", \"Text\": \"Table 7-2 Schedule of assessments  Extended observational follow-on phase\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\", \"AttachmentIndex\": 1.0, \"AttachmentId\": \"afb358b0-4070-11ec-967e-005056ab6469\", \"Key\": \"\", \"Text\": \"Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\", \"qc_change_type\": \"\", \"entities\": []}], \"FootnoteText_0\": \" Table 7-2 Schedule of assessments  Extended observational follow-on phase\", \"FootnoteText_1\": \" Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\", \"Header\": [0]}, {\"IsBold\": true, \"font_size\": 16, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98824566-407e-47a3-9322-3fc751485c09\", \"childbox\": \"69723d6c-7268-4a9a-bece-68017c3778d4\", \"subtext\": \"c78f3e78-97ec-4477-aa88-19afc92f6f47\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 16, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-2  Schedule of assessments \\u2013 Extended observational follow-on phase\", \"Table 7\", \"2\", 905, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b26ae769-90c2-4458-97f2-c17654656d97\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-2  Schedule of assessments \\u2013 Extended observational follow-on phase\", \"Table 7\", \"2\", 906, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 7-3\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b711ec26-15bd-4397-9318-fd826b6bf319\", \"childbox\": \"d61091aa-6600-4b86-8821-55c18dd33b2c\", \"subtext\": \"d7d25da2-c348-4256-b45c-a559229482df\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 907, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b711ec26-15bd-4397-9318-fd826b6bf319\", \"childbox\": \"7054e948-0857-4e05-80a3-0c0c2c0938b2\", \"subtext\": \"87cb6f50-aae2-4381-ad97-881d3a80af42\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 908, \"\"], [\"\", \"Unmapped\", \"text\", \"Schedule of PK assessments\", {\"IsBold\": true, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b711ec26-15bd-4397-9318-fd826b6bf319\", \"childbox\": \"49180dc7-2b8f-4424-a952-b91172ec2909\", \"subtext\": \"87cb6f50-aae2-4381-ad97-881d3a80af42\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 909, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Visit</td>\\n      <td>Mandatory PK schedule <sup>1</sup></td>\\n      <td>Optional PK schedule <sup>1, 2</sup></td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Day 1</td>\\n      <td>Predose (0 h) and at least 1 h post dose prior to leaving clinic</td>\\n      <td>Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h <sup></sup>  (HCV RNA timepoints to be timematched to PK timepoints) <sup>3</sup></td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Day 2</td>\\n      <td></td>\\n      <td>Predose (0 h) to be obtained no later than 28 h after the Day 1 dose</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Day 4</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>Day 8 (Week 1)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>Day 11</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>Day 15 (Week 2)</td>\\n      <td>Any time during visit <sup>4, 5</sup></td>\\n      <td>Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h</td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>Day 22 (Week 3)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td>Day 29 (Week 4)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>Day 43 (Week 6)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>Day 57 (Week 8)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td>Day 85 (Week 12)</td>\\n      <td>Any time during visit <sup>4, 6</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>28-Day Post EOT</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Visit\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"d100c104-d49c-4f3e-907d-32787476ad2a\\\",\\\"column_roi_id\\\":\\\"b2743ee7-c248-45b9-a809-035ba90eab06\\\",\\\"datacell_roi_id\\\":\\\"1851c8c1-0dc7-413d-a26a-3b5eb60b467c\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Mandatory PK schedule <sup>1<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"d100c104-d49c-4f3e-907d-32787476ad2a\\\",\\\"column_roi_id\\\":\\\"bc8f0fb4-ae7d-4b65-9c46-63b61d49b88f\\\",\\\"datacell_roi_id\\\":\\\"223ad18d-b4d6-4218-a89c-eeccd5cb6f07\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Optional PK schedule <sup>1, 2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"d100c104-d49c-4f3e-907d-32787476ad2a\\\",\\\"column_roi_id\\\":\\\"c66e47d4-af0b-495c-9401-134f9e60160a\\\",\\\"datacell_roi_id\\\":\\\"03a19be0-3ed4-4b9e-9ca5-3b5b37d7406e\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"dc2af793-d158-42ea-b0b6-aaffc662b257\\\",\\\"column_roi_id\\\":\\\"f1d40d52-6732-4dba-b28a-3208d2af3064\\\",\\\"datacell_roi_id\\\":\\\"7582a036-4ade-4f7d-a1bf-a25fa0ff39b4\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Predose (0 h) and at least 1 h post dose prior to leaving clinic\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"dc2af793-d158-42ea-b0b6-aaffc662b257\\\",\\\"column_roi_id\\\":\\\"bcfd39d5-ff90-425a-8e42-2961f3f41294\\\",\\\"datacell_roi_id\\\":\\\"7d2dbb2e-9aee-45ca-ad2e-a2aa28864549\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h <sup><\\\\/sup>  (HCV RNA timepoints to be timematched to PK timepoints) <sup>3<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"dc2af793-d158-42ea-b0b6-aaffc662b257\\\",\\\"column_roi_id\\\":\\\"82f2fbbd-8158-4246-8b62-6221cb84aef6\\\",\\\"datacell_roi_id\\\":\\\"50874e33-9241-4190-9ac8-2de050a777b9\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 2\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"087069bf-3dee-4ea6-95bc-5db45a8a208f\\\",\\\"column_roi_id\\\":\\\"6418e92b-2889-4c29-ad8e-230b31a8ea5a\\\",\\\"datacell_roi_id\\\":\\\"fc2704f7-afcd-4e4c-a3cd-8864b13f938b\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Predose (0 h) to be obtained no later than 28 h after the Day 1 dose\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"087069bf-3dee-4ea6-95bc-5db45a8a208f\\\",\\\"column_roi_id\\\":\\\"8f5f5a3e-c10c-4609-be8d-7527be3ed228\\\",\\\"datacell_roi_id\\\":\\\"bec5b120-8e0f-4567-b5aa-0a21682451f9\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 4\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"feb70bd4-bfe5-4171-995d-b32125112175\\\",\\\"column_roi_id\\\":\\\"629b19ac-bcc1-4fee-9e9b-04d08c981e5c\\\",\\\"datacell_roi_id\\\":\\\"e8ae00df-5546-4091-ae2e-33c2930938e3\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"feb70bd4-bfe5-4171-995d-b32125112175\\\",\\\"column_roi_id\\\":\\\"2d15d4ef-16aa-4970-bb8c-b3356a3b8370\\\",\\\"datacell_roi_id\\\":\\\"16f83176-2593-4434-a0a2-b5291b2c642d\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 8 (Week 1)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1cd3358c-aac0-4158-901b-34fd957b2f43\\\",\\\"column_roi_id\\\":\\\"a2b49ae5-3652-473b-a72d-f39337d8e590\\\",\\\"datacell_roi_id\\\":\\\"4310450f-3617-4803-b190-7bc3074e9275\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1cd3358c-aac0-4158-901b-34fd957b2f43\\\",\\\"column_roi_id\\\":\\\"e7a994be-abca-446d-b302-71f49d2b0af4\\\",\\\"datacell_roi_id\\\":\\\"c622dd2c-3141-4c61-bffe-638a63ff4433\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 11\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"ca4d5259-d758-439f-8102-068ba0786aee\\\",\\\"column_roi_id\\\":\\\"14cbb8fb-7f95-47b8-bbf3-afb7b9ca4a62\\\",\\\"datacell_roi_id\\\":\\\"4d3a937b-64df-4373-b057-752df344c706\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"ca4d5259-d758-439f-8102-068ba0786aee\\\",\\\"column_roi_id\\\":\\\"ec04a55a-7783-4814-9aa1-3159c774e579\\\",\\\"datacell_roi_id\\\":\\\"b42d6c41-1dfc-4a7d-ba79-eceb1ff4aa4a\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 15 (Week 2)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"2aa5ff57-f31e-424f-a927-264dbab9ccf7\\\",\\\"column_roi_id\\\":\\\"98bd1692-6457-4cfb-9cf5-2072044210a1\\\",\\\"datacell_roi_id\\\":\\\"9eae9152-f83f-46fa-ae30-ee6435228835\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4, 5<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"2aa5ff57-f31e-424f-a927-264dbab9ccf7\\\",\\\"column_roi_id\\\":\\\"e1e7b8c6-7539-4e19-94b9-f064cdbf7382\\\",\\\"datacell_roi_id\\\":\\\"40e37822-e3f4-4811-a650-84535da49b91\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"2aa5ff57-f31e-424f-a927-264dbab9ccf7\\\",\\\"column_roi_id\\\":\\\"cbe20238-be7c-4790-aa9e-a8f277981980\\\",\\\"datacell_roi_id\\\":\\\"2dcee231-d9b9-486c-be8a-4301a4015932\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 22 (Week 3)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"cba23932-5e14-4c78-ae38-e194b669204c\\\",\\\"column_roi_id\\\":\\\"1012dc08-6fb6-46d2-829c-c6ca0218b89c\\\",\\\"datacell_roi_id\\\":\\\"d21aeb9d-f069-458e-ad94-16c90fdb2a09\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"cba23932-5e14-4c78-ae38-e194b669204c\\\",\\\"column_roi_id\\\":\\\"9cbbfdb4-1327-4041-80e3-22c898688a51\\\",\\\"datacell_roi_id\\\":\\\"8790b856-63a9-4962-b829-7dd9f8c6746f\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 29 (Week 4)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1b5ff819-9302-46a7-a876-0c1ed611da33\\\",\\\"column_roi_id\\\":\\\"77c14c8e-4cb4-45af-9d76-d6c1f7b30225\\\",\\\"datacell_roi_id\\\":\\\"41d1cb53-4bb8-4ec8-9937-34e45622245f\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1b5ff819-9302-46a7-a876-0c1ed611da33\\\",\\\"column_roi_id\\\":\\\"5ed4300a-5509-479e-82f4-616639b8cfd5\\\",\\\"datacell_roi_id\\\":\\\"99c45fd6-5dce-461f-a369-1e56b4ac52f9\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 43 (Week 6)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"3c38e9fc-a15a-4db0-81a0-aa3dc3d5ba4e\\\",\\\"column_roi_id\\\":\\\"0f64ef3b-772f-44f5-9251-3cefa880640c\\\",\\\"datacell_roi_id\\\":\\\"522190b3-7a6f-4e35-9b64-fd2b7cbf54cf\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"3c38e9fc-a15a-4db0-81a0-aa3dc3d5ba4e\\\",\\\"column_roi_id\\\":\\\"97c1afee-a967-4e9a-b952-189392c751f0\\\",\\\"datacell_roi_id\\\":\\\"4c8aadbd-f49e-4c2a-a949-0eb4f638c756\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 57 (Week 8)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"9d4bc3eb-2896-457e-a98f-49a521e809bd\\\",\\\"column_roi_id\\\":\\\"59f77455-6245-4043-894b-e643528e1d87\\\",\\\"datacell_roi_id\\\":\\\"cffa73cc-8e9a-484c-83cb-06d1e499a807\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"9d4bc3eb-2896-457e-a98f-49a521e809bd\\\",\\\"column_roi_id\\\":\\\"46e78e3c-d98c-46e5-8a1b-472c5811f36d\\\",\\\"datacell_roi_id\\\":\\\"849c212a-733d-4f32-bd56-8961a78557f1\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 85 (Week 12)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"a9396f88-ca93-4862-b64f-00aef52b4977\\\",\\\"column_roi_id\\\":\\\"b60de049-d2c5-47cc-a467-792f6b5ef348\\\",\\\"datacell_roi_id\\\":\\\"cf15f723-7abe-40de-b45f-bf43d73b94cc\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4, 6<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"a9396f88-ca93-4862-b64f-00aef52b4977\\\",\\\"column_roi_id\\\":\\\"f237b9dc-0ae0-48c5-80a1-e5f3139aa14b\\\",\\\"datacell_roi_id\\\":\\\"b99690e5-3853-4f3f-98f6-b7e73d5c175b\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"28-Day Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"c4778e57-05a4-4619-bd05-1ca8a0b8fd7c\\\",\\\"column_roi_id\\\":\\\"262e246d-b4a2-4f70-a053-0f8ac2bae68f\\\",\\\"datacell_roi_id\\\":\\\"961ae110-8cdb-4df5-99d7-04f7ed52873c\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"c4778e57-05a4-4619-bd05-1ca8a0b8fd7c\\\",\\\"column_roi_id\\\":\\\"817c7a2b-195d-4338-a7a1-6b935031cc6a\\\",\\\"datacell_roi_id\\\":\\\"a1582fb4-f2e5-4b0a-a850-77ee4f127609\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"}]\", \"SectionHeaderPrintPage\": \"31\", \"TableIndex\": \"15.0\", \"TableName\": \"Table 7-3 Schedule of PK assessments\", \"AttachmentListProperties\": [{\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 0.0, \"AttachmentId\": \"afb3cdf5-4070-11ec-8d47-005056ab6469\", \"Key\": \"1\", \"Text\": \"Table 7-3 Schedule of PK assessments\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 1.0, \"AttachmentId\": \"afb57bf4-4070-11ec-b61f-005056ab6469\", \"Key\": \"1\", \"Text\": \"1 Timepoints are relative to the last study drug dosing.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 2.0, \"AttachmentId\": \"afb57bfa-4070-11ec-8c82-005056ab6469\", \"Key\": \"2\", \"Text\": \"2 Optional schedule, open to all subjects, will assess one or all of the following: predose (trough) on Day 2, and/or intensive PK on Days 1 and/or 15. \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 3.0, \"AttachmentId\": \"afb57c09-4070-11ec-8f10-005056ab6469\", \"Key\": \"3\", \"Text\": \"3 HCV RNA samples should be obtained within 10 min following the PK sample.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 4.0, \"AttachmentId\": \"afb57c0f-4070-11ec-9df7-005056ab6469\", \"Key\": \"4\", \"Text\": \"4 Time of PK sampling, time of last dose, and time of last meal will be recorded.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 5.0, \"AttachmentId\": \"afb5a29e-4070-11ec-adf3-005056ab6469\", \"Key\": \"5\", \"Text\": \"5 A single sample at any time during the Day 15 visit will be obtained from subjects not participating in the intensive PK sampling. \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 6.0, \"AttachmentId\": \"afb5a2ad-4070-11ec-ad48-005056ab6469\", \"Key\": \"6\", \"Text\": \"6 Day 85 (Week 12) visit applies only to Groups B, D, E and F. For plasma PK samples, all predose timepoints must be drawn within 30 minutes prior to dosing. For intensive PK sampling, blood samples will be collected within a 5 min window for timepoints 4 h and a window of 10 min for time points > 4h.\", \"qc_change_type\": \"\", \"entities\": []}], \"FootnoteText_0\": \"1 Table 7-3 Schedule of PK assessments\", \"FootnoteText_1\": \"1 1 Timepoints are relative to the last study drug dosing.\", \"FootnoteText_2\": \"2 2 Optional schedule, open to all subjects, will assess one or all of the following: predose (trough) on Day 2, and/or intensive PK on Days 1 and/or 15. \", \"FootnoteText_3\": \"3 3 HCV RNA samples should be obtained within 10 min following the PK sample.\", \"FootnoteText_4\": \"4 4 Time of PK sampling, time of last dose, and time of last meal will be recorded.\", \"FootnoteText_5\": \"5 5 A single sample at any time during the Day 15 visit will be obtained from subjects not participating in the intensive PK sampling. \", \"FootnoteText_6\": \"6 6 Day 85 (Week 12) visit applies only to Groups B, D, E and F. For plasma PK samples, all predose timepoints must be drawn within 30 minutes prior to dosing. For intensive PK sampling, blood samples will be collected within a 5 min window for timepoints 4 h and a window of 10 min for time points > 4h.\", \"Header\": [0, 1]}, {\"IsBold\": true, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1851c8c1-0dc7-413d-a26a-3b5eb60b467c\", \"childbox\": \"4c514aca-ce62-41a4-bd5e-7f4ac29602c5\", \"subtext\": \"d037f300-cc0d-44c8-a684-c52397223eb3\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 910, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7d349f0d-821b-4762-8662-241b88ba414b\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 911, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8a7b28b9-07e8-44de-b402-08b2bc073b4d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 912, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3aa28b31-d493-4ec7-9c44-9b52dfb0ec10\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 913, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1790fcad-a598-4d76-b92e-a80f410e7122\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 914, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5e358f7d-5484-4bd6-8a2e-66ee86b3e219\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 915, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"534a0783-093a-47e6-8de6-5cf26f6f78d6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 916, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"23475dee-8d0f-4b76-ab4d-dcd3f4d9b33a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 917, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1eecb8d0-8675-42ec-afda-6a296dac5bdd\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 918, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6a2f26bd-5fd3-47d3-8ba8-b638e39e7543\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 919, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bcb513d6-4e73-4811-bdea-9cc596d0e7f8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"-3  Schedule of PK assessments\", \"Table 7\", \"2\", 920, \"\"], [\"\", \"Unmapped\", \"header\", \"7.2 Subject demographics/other baseline characteristics\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"e5f269b1-7a6c-4b31-b82b-6633fd924e4b\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 921, \"\"], [\"\", \"Unmapped\", \"text\", \"The following demographic and baseline characteristics will be collected during Screening:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5317807e-822f-4e6a-8ff5-311c2a3bcc08\", \"childbox\": \"d046b677-8ccf-46c2-b39f-4ac9ed4ffba0\", \"subtext\": \"2436d714-ba2a-41b0-a8f1-80c6c5001cd8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 922, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 subject initials\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"490f45be-e41e-490c-b33f-d0b9302d8094\", \"childbox\": \"9ef6a9a6-7868-4059-add9-fe2fc9fd2503\", \"subtext\": \"f44ff2c6-6fc7-4ef2-acb4-1a1f2905a084\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 923, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 age\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0d5466e4-168a-446c-bc3f-1d74700af1cf\", \"childbox\": \"be3f67fb-23b6-4d06-9de7-ef2b310a3ed4\", \"subtext\": \"a541e6b6-f1b4-41df-887d-419b239df7f4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 924, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 gender\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b4bfc39e-5867-4982-8480-3d834959f203\", \"childbox\": \"6adcbbf5-ec77-49f3-8846-8f134e51bbe3\", \"subtext\": \"143c27ba-86ea-428a-aeb4-0b0fee232b88\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 925, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 race/ethnicity\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e919184e-9bec-4a5c-8ef6-f361373b2fa4\", \"childbox\": \"c0ba1113-1be6-478b-8239-b88280300306\", \"subtext\": \"98a4a5cb-0848-42e4-9774-dc84cef0e3ea\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 926, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 height\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7044a233-ae0e-42d7-976b-7d23bc6605fe\", \"childbox\": \"014d64eb-d97c-476d-acfe-41f4e2e395d6\", \"subtext\": \"ee4a566f-f81e-4121-a1e3-aa9887e55d2d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 927, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 weight\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e7ac76a-4e07-4b26-90e1-ffb707229b99\", \"childbox\": \"b31c587d-3909-4045-9851-cf274866138e\", \"subtext\": \"868c2c00-10f2-4e3f-9427-ce73f1c34cee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 928, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 BMI\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"41a634a1-5b0f-46e9-8a3e-f67c90333fd2\", \"childbox\": \"c37858e7-234c-43bc-9aa8-dde6ddd39bfa\", \"subtext\": \"cab7ce77-f9a0-4f1a-b587-3eef4075954f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 929, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 current medications\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e8bf4e3d-caa0-4c7a-a893-020256de89f1\", \"childbox\": \"77ce92af-9aec-447a-8ed4-83f4bea396a9\", \"subtext\": \"ff5907f5-22a7-4636-8cae-b42aed110a30\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 930, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 medical/surgical history\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1c0315cc-6f26-4189-bb07-27cb5cd372ec\", \"childbox\": \"02559e24-2fcf-46ce-88d2-3c6ad627dc1f\", \"subtext\": \"cd387665-290b-4027-89de-71278bdbaced\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 931, \"\"], [\"\", \"Unmapped\", \"header\", \"7.3 Treatment exposure and compliance\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"3b9dd686-c30e-49f7-b10d-2067847c794a\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 932, \"\"], [\"\", \"Unmapped\", \"text\", \"Study drug dosing will occur as described in Section 6.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f47d8551-e1f3-4fed-9f0d-f90782ed2ebf\", \"childbox\": \"67bf9c33-864e-497d-9959-343900ba40ef\", \"subtext\": \"74e256f9-4f13-4e0d-95fb-ad80de8443f3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 933, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects should bring used or partially used IDX21437 and samatasvir study drug kits and RBV bottle with them to each study visit, in order for study personnel at study sites to assess subject compliance.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 45, \"end_idx\": 52, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 58, \"end_idx\": 67, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"samatasvir\"}], \"roi_id\": {\"para\": \"f47d8551-e1f3-4fed-9f0d-f90782ed2ebf\", \"childbox\": \"e22ea3bf-975a-4417-902c-2e8d03afa539\", \"subtext\": \"051a301c-6a97-4363-b71d-685cf0ba58ee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 934, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects will be asked to return all unused study drugs at the end of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f47d8551-e1f3-4fed-9f0d-f90782ed2ebf\", \"childbox\": \"4231e9b0-89eb-4707-b1b5-5f659bc2dd8d\", \"subtext\": \"051a301c-6a97-4363-b71d-685cf0ba58ee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 935, \"\"], [\"\", \"Unmapped\", \"text\", \"Complete and accurate records of receipt and disposition of all study drugs must be kept.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f47d8551-e1f3-4fed-9f0d-f90782ed2ebf\", \"childbox\": \"e077f591-d947-4c36-b740-f69c9370f36c\", \"subtext\": \"b77e0196-858f-43e5-9526-05fc79086efb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 936, \"\"], [\"\", \"Unmapped\", \"text\", \"Drug accountability will be noted by the study monitor during site visits and at the completion of the trial.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f47d8551-e1f3-4fed-9f0d-f90782ed2ebf\", \"childbox\": \"debeb8e4-fc3a-4d42-8a3d-4cc8e8f3ea85\", \"subtext\": \"b77e0196-858f-43e5-9526-05fc79086efb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Subject demographics/other baseline characteristics\", \"7.2\", \"2\", 937, \"\"], [\"\", \"Unmapped\", \"header\", \"The key a 7.4 Antiviral activity\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"d40633eb-ae11-45c9-bfe6-d90c6dec69d7\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 938, \"\"], [\"\", \"Unmapped\", \"text\", \"The key antiviral activity endpoints are:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c002e3a-05bf-41fc-a835-cfb413e79a5e\", \"childbox\": \"27d69aa8-8c8e-4c14-bb4e-1346c641c1cb\", \"subtext\": \"d39bce75-3745-4192-a064-38ba3c821217\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 939, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Proportion of subjects with plasma HCV RNA <LLOQ\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db6345ca-e680-444c-87f9-f6d91b504884\", \"childbox\": \"14270646-82f6-4ac5-ab15-791fe5bb6ac3\", \"subtext\": \"2730d689-c481-4a6f-954d-47432106779e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 940, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db6345ca-e680-444c-87f9-f6d91b504884\", \"childbox\": \"14270646-82f6-4ac5-ab15-791fe5bb6ac3\", \"subtext\": \"ccc0fa24-c200-4a13-b9b7-3b8dc60ebfcb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 941, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db6345ca-e680-444c-87f9-f6d91b504884\", \"childbox\": \"14270646-82f6-4ac5-ab15-791fe5bb6ac3\", \"subtext\": \"fe745019-aba5-490c-92d5-b6cb17698f6f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 942, \"\"], [\"\", \"Unmapped\", \"text\", \"Primary:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"db6345ca-e680-444c-87f9-f6d91b504884\", \"childbox\": \"14270646-82f6-4ac5-ab15-791fe5bb6ac3\", \"subtext\": \"ee318869-a130-4952-8fc5-17a9e408ae0d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 943, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"d0303797-61a9-4369-b9a5-cc544a7c7dab\", \"subtext\": \"ee1524ee-a1f5-494f-a979-0efaebb887ce\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 944, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"d0303797-61a9-4369-b9a5-cc544a7c7dab\", \"subtext\": \"5ffbe2d8-7580-4c93-812c-2b752075bbcc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 945, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"d0303797-61a9-4369-b9a5-cc544a7c7dab\", \"subtext\": \"daa30af3-8aba-41c2-bc22-d588090bd88c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 946, \"\"], [\"\", \"Unmapped\", \"text\", \"12\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"d0303797-61a9-4369-b9a5-cc544a7c7dab\", \"subtext\": \"b18165f4-a5d6-46d2-8c87-67511a194aee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 947, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"d0303797-61a9-4369-b9a5-cc544a7c7dab\", \"subtext\": \"3dfbbc21-0fe4-4ebd-8bcc-3329208974f2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 948, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"1814eb39-ee84-4986-a8d1-87b3a5764df1\", \"subtext\": \"e82c6d68-1594-48eb-8143-61c8560cc6d7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 949, \"\"], [\"\", \"Unmapped\", \"text\", \"12 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"ef902c5c-dac9-4348-8214-2ce452b0e57d\", \"subtext\": \"e82c6d68-1594-48eb-8143-61c8560cc6d7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 950, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"ef902c5c-dac9-4348-8214-2ce452b0e57d\", \"subtext\": \"5f92f469-8915-4411-85c4-77ab36c48f01\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 951, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"ef902c5c-dac9-4348-8214-2ce452b0e57d\", \"subtext\": \"897c03fc-e37c-4978-a7fe-010662183bfe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 952, \"\"], [\"\", \"Unmapped\", \"text\", \"Secondary\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90613201-827b-462e-9c81-babd4f911c89\", \"childbox\": \"ef902c5c-dac9-4348-8214-2ce452b0e57d\", \"subtext\": \"0758654c-ce31-46fe-a120-a7fe16d533db\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 953, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"53294fd4-eddf-4d73-a520-80e818d9a302\", \"childbox\": \"0f00610b-767f-41fe-b825-4ad4050c01db\", \"subtext\": \"ce29aa7a-7061-43b7-bc28-4fd5f54f68ee\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 954, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"53294fd4-eddf-4d73-a520-80e818d9a302\", \"childbox\": \"0f00610b-767f-41fe-b825-4ad4050c01db\", \"subtext\": \"ec6a0895-f601-4a79-87aa-3180f55407af\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 955, \"\"], [\"\", \"Unmapped\", \"text\", \"Week 4 during treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"53294fd4-eddf-4d73-a520-80e818d9a302\", \"childbox\": \"0f00610b-767f-41fe-b825-4ad4050c01db\", \"subtext\": \"10373aab-8b9b-4cc6-9dbc-480951d88427\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 956, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e7c891b3-0dd9-473c-a570-1946d5a9a829\", \"childbox\": \"52546938-1485-450c-9da6-81b21cb8cccd\", \"subtext\": \"821840bd-bc4b-4bf5-970c-0940b2a0bf16\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 957, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e7c891b3-0dd9-473c-a570-1946d5a9a829\", \"childbox\": \"52546938-1485-450c-9da6-81b21cb8cccd\", \"subtext\": \"578618b2-8d1b-4b47-8d94-d5baea0b1e34\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 958, \"\"], [\"\", \"Unmapped\", \"text\", \"End of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e7c891b3-0dd9-473c-a570-1946d5a9a829\", \"childbox\": \"52546938-1485-450c-9da6-81b21cb8cccd\", \"subtext\": \"d41aabec-cfb5-47c9-8659-294738a5fd68\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 959, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"dc3bd84b-fcc7-4251-91b3-380f2be60f09\", \"subtext\": \"032a5ef6-26d2-465a-96b6-070abead92e2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 960, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"c5440094-4ad9-43f2-a83e-ab22af7fbd7f\", \"subtext\": \"b9cebdc4-f94b-48a3-ac7c-5e42f04d7bb2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 961, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"c5440094-4ad9-43f2-a83e-ab22af7fbd7f\", \"subtext\": \"28bf2f68-c3f6-40db-b769-1a8d394df69f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 962, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"c5440094-4ad9-43f2-a83e-ab22af7fbd7f\", \"subtext\": \"24af1ddc-65b8-47aa-bf0d-0173e1664e20\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 963, \"\"], [\"\", \"Unmapped\", \"text\", \"4\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"c5440094-4ad9-43f2-a83e-ab22af7fbd7f\", \"subtext\": \"183edb02-d04c-4a10-b18b-e06b4f49ab0d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 964, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"c5440094-4ad9-43f2-a83e-ab22af7fbd7f\", \"subtext\": \"0bf5cda5-74c2-403e-b141-7225cbcefb60\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 965, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"bb1fbb0a-dc78-46f0-b004-7240cce8addb\", \"subtext\": \"90d281fd-ac35-4e02-b400-60fe2d7157c7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 966, \"\"], [\"\", \"Unmapped\", \"text\", \"4 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f3e1111-2512-4938-a209-ecb982f0ee25\", \"childbox\": \"4586eee4-ef52-47a4-b16a-4d1a57bba797\", \"subtext\": \"90d281fd-ac35-4e02-b400-60fe2d7157c7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 967, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"c27f4684-0e66-4087-a416-14cc2a940682\", \"subtext\": \"4e2ecc7b-33fa-4dcc-8bb7-c5bb1f36c1c2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 968, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"e8bbad8c-71d5-490a-95f2-56493ecd2b46\", \"subtext\": \"6262ec4b-5901-4485-afd3-6faa99de9a82\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 969, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"e8bbad8c-71d5-490a-95f2-56493ecd2b46\", \"subtext\": \"d81399e8-ee47-4f7f-9390-16bfed490357\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 970, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"e8bbad8c-71d5-490a-95f2-56493ecd2b46\", \"subtext\": \"744db497-3b4f-4582-bdfb-02af3b84eb5f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 971, \"\"], [\"\", \"Unmapped\", \"text\", \"8\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"e8bbad8c-71d5-490a-95f2-56493ecd2b46\", \"subtext\": \"64f3a0fa-db5f-48b7-ab36-f523b1e10958\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 972, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"e8bbad8c-71d5-490a-95f2-56493ecd2b46\", \"subtext\": \"541fd040-5529-4744-aec9-242249302ab9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 973, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"3c24f47e-b4e4-45b7-a22b-67e75a4477fb\", \"subtext\": \"3fc28b62-a263-467f-9d85-dd280e486cca\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 974, \"\"], [\"\", \"Unmapped\", \"text\", \"8 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a79ab51-8da3-4ce1-b439-d94017a5eb67\", \"childbox\": \"1bb1eb82-8024-4413-864b-15ebea05cdf4\", \"subtext\": \"3fc28b62-a263-467f-9d85-dd280e486cca\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 975, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"4c3a13b7-7fd8-4fe2-b38f-758cec5d99e2\", \"subtext\": \"79f6af60-faeb-450f-a781-3d55f17fc3ec\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 976, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"7b81dc7c-4439-45a3-b82f-0d9b87e4f3de\", \"subtext\": \"2f6242c1-72e7-4db7-a1be-06e68da4a949\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 977, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"7b81dc7c-4439-45a3-b82f-0d9b87e4f3de\", \"subtext\": \"8124dfb9-4f6c-4b85-9fce-86932cb94ce9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 978, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"7b81dc7c-4439-45a3-b82f-0d9b87e4f3de\", \"subtext\": \"1211a9df-002e-4e94-b33f-41ac0349d686\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 979, \"\"], [\"\", \"Unmapped\", \"text\", \"24\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"7b81dc7c-4439-45a3-b82f-0d9b87e4f3de\", \"subtext\": \"4ced9096-db74-4897-a872-e6f20552e51e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 980, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"7b81dc7c-4439-45a3-b82f-0d9b87e4f3de\", \"subtext\": \"8a6b5568-5be5-45d3-a1f4-37fdc214443a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 981, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"5dc38f95-13d3-40ab-8d3d-6f469a45b604\", \"subtext\": \"ffb9e2f9-170f-4f66-ac14-f9360201ae1a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 982, \"\"], [\"\", \"Unmapped\", \"text\", \"24 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8c0f3f7a-ae3b-40d5-9b49-9f1c5c4a2ad5\", \"childbox\": \"5548bdb3-c76e-468f-a0e4-8e68877344a3\", \"subtext\": \"ffb9e2f9-170f-4f66-ac14-f9360201ae1a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 983, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Emergence of resistance mutations\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"066e373d-b3dc-4cb3-8d65-ef29bf00bf84\", \"childbox\": \"d2e56f8e-815f-46ac-a0c6-d99279f5275a\", \"subtext\": \"61f3aaeb-7608-408b-a4ec-0931427be020\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 984, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Durability of SVR and the kinetics of antiviral resistant HCV\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e4c0e056-97a4-4a8b-aed5-aac46e0d9d49\", \"childbox\": \"74568808-f593-411c-a8ce-602e52e8240a\", \"subtext\": \"b7684cad-4dcc-47c5-8227-0ded3b7ac3bb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 985, \"\"], [\"\", \"Unmapped\", \"text\", \"Plasma HCV RNA determinations will be performed at a central laboratory through use of a validated commercial assay.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e8f3f802-7c4d-4557-bd5a-80a2d78caeb0\", \"childbox\": \"8189c68f-2cf2-4296-a937-de1e4a1bce14\", \"subtext\": \"18e1544a-61da-4a87-acd4-6b2461339242\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 986, \"\"], [\"\", \"Unmapped\", \"text\", \"HCV resistance testing will be performed to monitor HCV variants present at the timepoints indicated in the Schedule of Assessments.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e8f3f802-7c4d-4557-bd5a-80a2d78caeb0\", \"childbox\": \"55e5d7d7-3c5c-41f9-b366-c8a9316d9e8f\", \"subtext\": \"4ceeeca2-2238-4dfe-9a17-4e22fcb6fff6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 987, \"\"], [\"\", \"Unmapped\", \"text\", \"Plasma samples for viral sequencing and the determination of HCV RNA will be collected at visits specified in Table 7-1 and Table 7-2.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e8f3f802-7c4d-4557-bd5a-80a2d78caeb0\", \"childbox\": \"a72ce504-4bd4-4814-87da-abbb27b701a3\", \"subtext\": \"4ceeeca2-2238-4dfe-9a17-4e22fcb6fff6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Antiviral activity\", \"7.4\", \"3\", 988, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5 Safety\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"d2e8bc9c-d9eb-4db1-9361-0e3be5dfd042\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 989, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.1 Adverse events\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"7aa9f57a-ccc2-4665-bb03-c0b0d5ba965f\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 990, \"\"], [\"\", \"Unmapped\", \"text\", \"Adverse event:\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a81783e0-ff48-48e3-a649-dfabd30ff6f4\", \"childbox\": \"5e85aad6-0bba-4511-ac02-3522a7611f72\", \"subtext\": \"2021fea8-3345-4a5c-90b3-6c144cf407ab\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 991, \"\"], [\"\", \"Unmapped\", \"text\", \"An AE is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and that does not necessarily have a causal relationship with the study drug(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a81783e0-ff48-48e3-a649-dfabd30ff6f4\", \"childbox\": \"5e85aad6-0bba-4511-ac02-3522a7611f72\", \"subtext\": \"1743726a-0299-42af-94a0-7be962265082\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 992, \"\"], [\"\", \"Unmapped\", \"text\", \"An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drug(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a81783e0-ff48-48e3-a649-dfabd30ff6f4\", \"childbox\": \"46622730-0d14-49df-9f05-daad5576707e\", \"subtext\": \"237e982e-48ce-42fb-8f5f-e35907144505\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 993, \"\"], [\"\", \"Unmapped\", \"text\", \"All serious adverse events (SAEs) will be recorded from the time the subject signs the informed consent form (ICF) until completion of the post-EOT follow-up phase of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ded3677d-35f7-4c20-bb64-1381b428ddb4\", \"childbox\": \"37c14527-abd4-4536-bcaf-50cc2559862c\", \"subtext\": \"5ff45114-c80a-4266-b425-9eb3b414fe5b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 994, \"\"], [\"\", \"Unmapped\", \"text\", \"All nonserious AEs will be recorded from first dose of study drug until the 28-day post-EOT visits (Table 7-1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ded3677d-35f7-4c20-bb64-1381b428ddb4\", \"childbox\": \"a9d811cb-e3d8-4d52-91ae-4552fc2b833e\", \"subtext\": \"5ff45114-c80a-4266-b425-9eb3b414fe5b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 995, \"\"], [\"\", \"Unmapped\", \"text\", \"The occurrence of AEs should be sought by nondirective questioning of the subject at each visit during the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ded3677d-35f7-4c20-bb64-1381b428ddb4\", \"childbox\": \"a67b3831-136c-4988-bbc2-118c823b2ac4\", \"subtext\": \"3af8b014-b7ad-4352-a1bb-ba916548df39\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 996, \"\"], [\"\", \"Unmapped\", \"text\", \"Adverse events also may be detected when they are volunteered by the subject during or between visits or through physical examination, laboratory test, or other assessments.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ded3677d-35f7-4c20-bb64-1381b428ddb4\", \"childbox\": \"83ce7bcc-bf62-4b5b-b90f-920ca7927e61\", \"subtext\": \"3af8b014-b7ad-4352-a1bb-ba916548df39\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 997, \"\"], [\"\", \"Unmapped\", \"text\", \"All AEs must be recorded in the site\\u2019s study records and transcribed onto the Adverse Event CRF with the following information:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ded3677d-35f7-4c20-bb64-1381b428ddb4\", \"childbox\": \"e46d8eac-887e-4feb-8f25-abff8d06ae7a\", \"subtext\": \"5f02e4b9-2cec-4fc3-94e8-789c39ab9dad\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 998, \"\"], [\"\", \"Unmapped\", \"text\", \"Intensity grade: Grade 1, Grade 2, Grade 3, Grade 4, Grade 5\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bd63e0f9-b6ce-4834-8bd5-5785c729ecca\", \"childbox\": \"74aa2d20-5792-4fc0-81d6-d4e4a5d86c8b\", \"subtext\": \"833ec2e3-40f3-44c3-9b8f-9dda11da28ad\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 999, \"\"], [\"\", \"Unmapped\", \"text\", \"Note\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85a33591-ec7b-4b3e-ae86-09a2cf63af2f\", \"childbox\": \"12832b4e-bdc1-4143-84a1-da60546816cc\", \"subtext\": \"c184b038-8e9b-458a-a218-87714fb02753\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1000, \"\"], [\"\", \"Unmapped\", \"text\", \":  The intensity of each AE is to be assessed by the investigator according to the criteria in Appendix 2.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85a33591-ec7b-4b3e-ae86-09a2cf63af2f\", \"childbox\": \"12832b4e-bdc1-4143-84a1-da60546816cc\", \"subtext\": \"a2ff7095-ea3f-422c-a6e7-24f7148d2979\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1001, \"\"], [\"\", \"Unmapped\", \"text\", \"The terms above are used to describe the intensity of an AE and should not be confused with whether an AE should be considered serious.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85a33591-ec7b-4b3e-ae86-09a2cf63af2f\", \"childbox\": \"1aba4f01-7c85-4965-876e-d571a41a618d\", \"subtext\": \"4a575f6b-01f4-4d79-8675-6e1da08ee0dd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1002, \"\"], [\"\", \"Unmapped\", \"text\", \"Seriousness (not intensity) serves as a guide for defining regulatory obligations and the definition of SAEs is provided below.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85a33591-ec7b-4b3e-ae86-09a2cf63af2f\", \"childbox\": \"89f605cc-fc54-40e7-83cd-ebf2511faf0e\", \"subtext\": \"4a575f6b-01f4-4d79-8675-6e1da08ee0dd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1003, \"\"], [\"\", \"Unmapped\", \"text\", \"For example, a severe (grade 3) headache is not necessarily serious, unless it meets the definition of an SAE (described below).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"85a33591-ec7b-4b3e-ae86-09a2cf63af2f\", \"childbox\": \"2fdf3fcb-f720-4ecd-b975-5995606384c7\", \"subtext\": \"e48936a9-1cfe-46fd-ae46-8c76e5758acb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1004, \"\"], [\"\", \"Unmapped\", \"text\", \"Relationship to the study drug:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"acae21eb-c694-40e4-86dd-6b9cbec5e564\", \"childbox\": \"f45d5286-454a-471b-8b16-28fb6a8b5dd9\", \"subtext\": \"c7d51593-23fa-4219-bd12-8f513a979521\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1005, \"\"], [\"\", \"Unmapped\", \"text\", \"Reasonably or possibly related\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d2112004-a374-4986-94c0-3c15b55b32d6\", \"childbox\": \"6b302dc5-e168-4c6e-8f01-aa264d7b1b64\", \"subtext\": \"d98d022a-c075-419d-936f-df07581e226d\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1006, \"\"], [\"\", \"Unmapped\", \"text\", \"applies to those AEs that, after careful medical consideration at the time they are evaluated, are considered by the investigator (or other qualified designee) to have at least a possible relationship to study drug.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d2112004-a374-4986-94c0-3c15b55b32d6\", \"childbox\": \"6b302dc5-e168-4c6e-8f01-aa264d7b1b64\", \"subtext\": \"eb1cf1d2-2f7d-4962-8778-991927d5f7aa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1007, \"\"], [\"\", \"Unmapped\", \"text\", \"Not reasonably or not possibly related\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f4245cd8-a520-4bf9-907b-3f92645cd4a1\", \"childbox\": \"4b40c364-9f9f-4af3-a20c-cfaea14d2161\", \"subtext\": \"408de9ab-c0dd-4457-9956-bb8a89440fc5\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1008, \"\"], [\"\", \"Unmapped\", \"text\", \"applies to those AEs that, after careful medical consideration at the time they are evaluated, are considered by the investigator (or other qualified designee) to have no relationship, or no reasonable possibility of a relationship, to study drug.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f4245cd8-a520-4bf9-907b-3f92645cd4a1\", \"childbox\": \"4b40c364-9f9f-4af3-a20c-cfaea14d2161\", \"subtext\": \"292982ba-26f9-463c-94be-3ad4e7608dd8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1009, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f4245cd8-a520-4bf9-907b-3f92645cd4a1\", \"childbox\": \"4b40c364-9f9f-4af3-a20c-cfaea14d2161\", \"subtext\": \"00619c95-097f-4fb8-b1e0-c75cf28c7430\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1010, \"\"], [\"\", \"Unmapped\", \"text\", \"Duration: start and end dates or if continuing\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ba369000-3d95-4ebb-b3d2-be9fd2489431\", \"childbox\": \"8999edc5-e71a-4c69-90d1-0f63217ef30d\", \"subtext\": \"7ac704ed-25b1-4e57-9aeb-79e479f80243\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1011, \"\"], [\"\", \"Unmapped\", \"text\", \"Treatment required\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"83816bfc-6464-4d47-bf31-a0e4edccb703\", \"childbox\": \"df0a25b5-7dfe-4e6d-b68c-8c54f769bce9\", \"subtext\": \"ee10f448-9ea2-48a1-80e7-01824a65e354\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1012, \"\"], [\"\", \"Unmapped\", \"text\", \"Whether it constitutes a SAE, per definition below\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90765c14-0e6b-4243-b62d-bad6ef4fa132\", \"childbox\": \"3461f386-9e38-491f-b0ff-add218883fe0\", \"subtext\": \"651bb540-1508-44b3-87be-e360f3d27bd3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1013, \"\"], [\"\", \"Unmapped\", \"text\", \"Outcome: recovered/resolved, recovering/resolving, recovered/resolved with sequelae, not recovered/not resolved, fatal, or unknown (only for cases in which subjects are lost to follow-up)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"24f02ffb-7f9b-4c3c-80db-f7dc2deaff41\", \"childbox\": \"3f3dde9e-d48b-4574-ac09-5c76ef429856\", \"subtext\": \"233b81b8-b016-40bc-89be-13ff8b8d2f4e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1014, \"\"], [\"\", \"Unmapped\", \"text\", \"Note\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3ae44498-381d-4b26-ba0e-9d59ac05f6b5\", \"childbox\": \"84d52c26-f127-4706-84a0-d6a76d9ae859\", \"subtext\": \"34ea32af-3902-41ff-84fc-c4b47bf0759a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1015, \"\"], [\"\", \"Unmapped\", \"text\", \":  The recovered/resolved with sequelae option should only be used in cases where an event may be considered resolved by clinical standards, however, the subject continues to have residual effects or sequelae which may be considered chronic and stable by the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3ae44498-381d-4b26-ba0e-9d59ac05f6b5\", \"childbox\": \"84d52c26-f127-4706-84a0-d6a76d9ae859\", \"subtext\": \"d3f62449-e2d1-47ed-8cdb-e9e9c0f37742\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1016, \"\"], [\"\", \"Unmapped\", \"text\", \"For example, \\u201crecovered/ resolved with sequelae\\u201d may be checked for a subject who has experienced a cardiovascular accident\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3ae44498-381d-4b26-ba0e-9d59ac05f6b5\", \"childbox\": \"ed18a527-bbb5-4c44-835e-da60542632a7\", \"subtext\": \"2ec5fb87-666c-4694-ac9f-4c28f9f985ac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1017, \"\"], [\"\", \"Unmapped\", \"text\", \"(resolved), but may have partial paralysis in the limbs or speech impairment (sequelae).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cd432c7d-8457-4f4f-8839-f166e12a7f23\", \"childbox\": \"82df465b-1e8c-4a93-b01c-371b9a1b6a5d\", \"subtext\": \"bf285392-e26e-40de-9645-46c109d5121f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1018, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator should attempt to establish a diagnosis of the AE based on signs, symptoms, and/or other clinical information.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7fe170aa-583a-4df0-ba82-e26931b96f43\", \"childbox\": \"065d6630-9c64-4cd8-b7e7-5b77471fa4b3\", \"subtext\": \"a865c513-8be5-40fe-9b14-bc5c386c0c6a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1019, \"\"], [\"\", \"Unmapped\", \"text\", \"In such cases, the diagnosis, and not the individual signs/symptoms or laboratory abnormalities, should be documented in the subject\\u2019s source documentation and CRF, unless the etiology of the event is unknown.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7fe170aa-583a-4df0-ba82-e26931b96f43\", \"childbox\": \"38d3cfc9-210d-4d42-b33c-029db35c3d2e\", \"subtext\": \"a865c513-8be5-40fe-9b14-bc5c386c0c6a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1020, \"\"], [\"\", \"Unmapped\", \"text\", \"Serious adverse event:\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"55b13899-1496-4f9a-ad37-f41d2f6c3898\", \"childbox\": \"d0dfdbcd-0f7f-4cb5-ac16-21c41254d6ca\", \"subtext\": \"841dfe3b-aa1d-4a04-bd6d-eb789953931a\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1021, \"\"], [\"\", \"Unmapped\", \"text\", \"Any untoward medical occurrence that at any dose:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"55b13899-1496-4f9a-ad37-f41d2f6c3898\", \"childbox\": \"d0dfdbcd-0f7f-4cb5-ac16-21c41254d6ca\", \"subtext\": \"58245148-9009-4018-ae30-0f4ff164f0fe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1022, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Results in death:  This includes deaths that appear to be completely unrelated to study drug (e.g., car accident).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1a6da8fc-cf9b-4b0b-9b8e-388bc22ec1f7\", \"childbox\": \"1074986f-6451-42cc-a810-bce81d123414\", \"subtext\": \"df68af66-d107-4577-bbc5-5d724d6fec44\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1023, \"\"], [\"\", \"Unmapped\", \"text\", \"If a subject dies during the study and an autopsy is performed, autopsy results will become part of the subject\\u2019s record/chart.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1a6da8fc-cf9b-4b0b-9b8e-388bc22ec1f7\", \"childbox\": \"f2238ed6-0c6f-430d-9df2-a2d2f065ffe5\", \"subtext\": \"df68af66-d107-4577-bbc5-5d724d6fec44\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1024, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Is life-threatening:  A life-threatening adverse event is any AE that places the subject, in the view of the investigator, of immediate risk of death from the reaction as it occurred.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b2204026-ad4c-405a-a2d1-a903377e7136\", \"childbox\": \"f28b24e7-523a-4d7f-b200-c9d6baf16c9e\", \"subtext\": \"0c9cbfc7-24fb-481e-b988-f097fc9fc6ec\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1025, \"\"], [\"\", \"Unmapped\", \"text\", \"It does not include a reaction that, had it occurred in a more severe form, might have caused death.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b2204026-ad4c-405a-a2d1-a903377e7136\", \"childbox\": \"ca9c7502-f9ac-44e8-9801-078dfd60df57\", \"subtext\": \"cb7ddcec-3ca5-4f45-abb0-75600fc1acc3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1026, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Requires inpatient hospitalization or prolongation of existing hospitalization:  Exceptions would be hospitalizations for a) elective or preplanned treatment for a pre-existing condition that is unrelated to the indication under study and has not worsened since the start of study drug or b) treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE and not resulting in hospital admission.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a4432a25-e598-4919-979c-087133d55645\", \"childbox\": \"f6b0d5f1-4825-4383-88db-14fb52b0e1d9\", \"subtext\": \"be6f2b1f-b66e-42a5-b2d2-fbdb14659a4f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1027, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Results in persistent or significant disability/incapacity:  A persistent or significantly disabling AE is any AE that results in a substantial disruption of a person\\u2019s ability to conduct normal life functions.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9c3faf17-86f1-4ef6-ae83-629e9333d5e2\", \"childbox\": \"e92dee87-ebad-4ba4-89ab-c3987f79ef66\", \"subtext\": \"2779ef29-b682-488f-ac4b-e0706b2d8c41\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1028, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Is a congenital anomaly/birth defect.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"84db3fe2-de65-4cca-aa26-eb2ef413ec4f\", \"childbox\": \"03542d37-3fea-4f9c-97f6-470a429cc488\", \"subtext\": \"3e5cb259-ed6a-4b91-95df-98ab7481e5db\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1029, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Is an important medical event:  An event that may not result in death, be life-threatening, or require hospitalization may be considered a SAE when, based upon appropriate medical judgment, it may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"66a1058d-3f71-4051-aed7-9b447ce5ac7f\", \"childbox\": \"44120685-a7d8-43af-8f4c-850f3bfdcdf3\", \"subtext\": \"445c4caa-b674-465d-9baf-e8551e966f67\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1030, \"\"], [\"\", \"Unmapped\", \"text\", \"Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependence or drug abuse.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"66a1058d-3f71-4051-aed7-9b447ce5ac7f\", \"childbox\": \"3c107b5c-f583-4d40-85f3-df6556f0cce5\", \"subtext\": \"afe2cb48-adec-487a-a910-9021e9d519b4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1031, \"\"], [\"\", \"Unmapped\", \"text\", \"Unlike routine safety assessments, SAEs are monitored continuously and have special reporting requirements; see Section 8.1.\", {\"IsBold\": true, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3f91e995-a96a-44e0-b304-940af8cd72c0\", \"childbox\": \"a0c24dfa-791b-4527-a8c5-f3a53af6484c\", \"subtext\": \"654d3653-bfc8-449d-83be-9ea4a3688857\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1032, \"\"], [\"\", \"Unmapped\", \"text\", \"All AEs should be treated appropriately.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ab741d26-802a-457e-a3b4-3359b08f0f64\", \"childbox\": \"16c46d3e-339f-4797-b1a0-d59e3d37e521\", \"subtext\": \"89429ae8-988e-4819-8087-3bba9917cd3d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1033, \"\"], [\"\", \"Unmapped\", \"text\", \"Treatment may include one or more of the following: no action taken (i.e., further observation only); concomitant medication given or other nondrug therapy given.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ab741d26-802a-457e-a3b4-3359b08f0f64\", \"childbox\": \"55fbd6f9-8af1-4f69-80da-c73a44395e56\", \"subtext\": \"89429ae8-988e-4819-8087-3bba9917cd3d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1034, \"\"], [\"\", \"Unmapped\", \"text\", \"The action taken with study drug, if any, should be recorded on the AE CRF and could include one of the following: no action taken or study drug withdrawn.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ab741d26-802a-457e-a3b4-3359b08f0f64\", \"childbox\": \"85795603-b8c0-42bb-acee-357b2e344913\", \"subtext\": \"3cce5763-ade1-4a09-80ae-2656dac04792\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1035, \"\"], [\"\", \"Unmapped\", \"text\", \"An assessment should be made at each visit (or more frequently, if necessary) of any changes in intensity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"23724a56-ac49-458d-b29c-31cf64597a96\", \"childbox\": \"47ecac3c-c797-4c1c-b30d-78b586f5022f\", \"subtext\": \"94cd6175-3936-41b5-ab56-395994d87105\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1036, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.2 Management of anemia\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"f6851792-e544-4b0f-b81f-9f0436128ed6\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1037, \"\"], [\"\", \"Unmapped\", \"text\", \"Anemia is a common side effect of RBV.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c4d5063e-2f69-4a08-b912-63ef295b53dd\", \"childbox\": \"4a29a402-8a7f-425e-85db-9a3b4fe22f0b\", \"subtext\": \"a4a4cd33-d459-42db-b351-8925781c0583\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1038, \"\"], [\"\", \"Unmapped\", \"text\", \"Management of anemia should be consistent with guidelines in the prescribing information of RBV.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c4d5063e-2f69-4a08-b912-63ef295b53dd\", \"childbox\": \"fd54b048-5db7-4d70-abda-abe87390d487\", \"subtext\": \"7c42f8a6-dba3-41a4-89cb-27d0df7e6452\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1039, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.3 Physical examination\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"c661b4e5-2d3b-48b3-81df-a2e8bf861629\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1040, \"\"], [\"\", \"Unmapped\", \"text\", \"Complete physical examinations will be performed by a medically qualified and licensed individual as scheduled in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"205e3793-292a-441c-90a1-ea3024d41271\", \"childbox\": \"e76c0871-b10f-44f5-8070-80cf8cf09f05\", \"subtext\": \"80aac978-2536-447d-ad85-c9272b4a5c5c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1041, \"\"], [\"\", \"Unmapped\", \"text\", \"On study days not requiring a complete physical examination, a symptom-targeted physical exam should be done, if medically indicated.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"205e3793-292a-441c-90a1-ea3024d41271\", \"childbox\": \"6dfe9638-6bd5-48e1-8f81-364421db11d3\", \"subtext\": \"aa78b6c6-6ccf-4f59-ac51-1ce8816bb432\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1042, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.4 Vital signs\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"c3beab70-b579-4e2b-bf3d-2f9eed0a8730\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1043, \"\"], [\"\", \"Unmapped\", \"text\", \"Routine vital sign measurements will include pulse and sitting blood pressure (after 3 minutes of rest), as specified in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"feaf7fab-c4a7-4045-a6b3-681220254bf7\", \"childbox\": \"c9ec9028-d4c9-4139-85f8-c37a44b07e8d\", \"subtext\": \"dcff5ea2-c3cb-4c2d-b3e6-ff34cc6933dd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1044, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.5 Laboratory evaluations\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"413f82e4-5b99-4ba8-8a09-1832022562ca\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1045, \"\"], [\"\", \"Unmapped\", \"text\", \"Laboratory evaluations to be performed according to Table 7-1 are as follows:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b7cc1721-bc2d-4f0a-b4c7-1dd16c5f01c3\", \"childbox\": \"0e339d25-7d87-4c77-87a7-f7f083365dbc\", \"subtext\": \"12ea06d7-63b4-4dc7-9c95-77eb03ea8ef7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1046, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Hematology:  hematocrit, Hgb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), platelet count, red cell count, white blood cell (WBC) count and differential.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ed891829-4c3a-4eec-a0d6-6fc610a6b42c\", \"childbox\": \"cc0b47f7-1def-413c-8018-fe0822eac8c1\", \"subtext\": \"cf076fce-735b-4a0a-adad-25c69e2ffbc4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1047, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Hemoglobin A\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e39692d-57ed-4520-aa50-a66a421e28a4\", \"childbox\": \"d16eced9-dd5f-4ea6-9997-fad5b73e0499\", \"subtext\": \"257ddf52-e5f1-4eb7-98ea-fa3c851aa14a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1048, \"\"], [\"\", \"Unmapped\", \"text\", \"1c\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e39692d-57ed-4520-aa50-a66a421e28a4\", \"childbox\": \"d16eced9-dd5f-4ea6-9997-fad5b73e0499\", \"subtext\": \"3e8c54c4-95eb-4a49-b21e-0acd86376085\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1049, \"\"], [\"\", \"Unmapped\", \"text\", \"(Screening only).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e39692d-57ed-4520-aa50-a66a421e28a4\", \"childbox\": \"d16eced9-dd5f-4ea6-9997-fad5b73e0499\", \"subtext\": \"f1cd29ee-64d7-4ef4-82d0-d43d1713f267\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1050, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Clinical chemistry:  calcium, sodium, potassium, chloride, magnesium, bicarbonate, phosphate, albumin, total bilirubin, direct bilirubin, indirect bilirubin, ALT, AST, triglycerides, cholesterol, blood glucose, blood urea nitrogen (BUN), alkaline phosphatase, serum creatinine, creatine kinase (CK) and serum amylase.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4dbb8992-cbcb-4823-a641-2d9062e68788\", \"childbox\": \"ca0b4731-036e-4456-9525-7e2c29a13d57\", \"subtext\": \"875b76b8-084b-4cf6-ab8a-1bca1f948f8a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1051, \"\"], [\"\", \"Unmapped\", \"text\", \"o Elevations in serum amylase will trigger analysis of pancreatic amylase.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3176821-3ca2-4007-8afa-14d55dc430a1\", \"childbox\": \"3e3e7d0c-5dd5-42b9-af17-10cefed4ca2c\", \"subtext\": \"2a236cae-1a1d-43ef-9a1f-47d9f576c60c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1052, \"\"], [\"\", \"Unmapped\", \"text\", \"Elevations in CK will trigger analysis of CK isoenzymes (CK-MM, CK-MB, CK-BB).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3176821-3ca2-4007-8afa-14d55dc430a1\", \"childbox\": \"fe0ccfd2-30af-4768-ba07-19db4498bdb6\", \"subtext\": \"2a236cae-1a1d-43ef-9a1f-47d9f576c60c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1053, \"\"], [\"\", \"Unmapped\", \"text\", \"o The anion gap will be calculated and reported.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"36efa38e-4e9d-42ba-b344-49e1562ba802\", \"childbox\": \"ece48129-0a5e-49ef-941a-70da10343432\", \"subtext\": \"42dcc9f8-fe11-4a05-8b5a-7316828e7ddd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1054, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Thyroid stimulating hormone (TSH) (Screening only).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"95991570-f8f4-448c-b277-fc4e8ed8d587\", \"childbox\": \"e02cfbc6-57bd-466e-92b0-a59a77f05200\", \"subtext\": \"0782ed4e-f5a9-4646-b290-ff47a6b9d250\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1055, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Coagulation:  prothrombin time (PT) and International Normalized Ratio (INR).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"54ba49bd-513e-4663-94a7-22e4b35990e0\", \"childbox\": \"3e488e68-4bdc-4480-8afa-7cc1a344edf6\", \"subtext\": \"5141d9c0-b192-411f-bc2d-d02af28060c1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1056, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 FSH (females of non-childbearing potential at Screening only).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d1a064bb-0bee-478e-9e90-380cdd570d31\", \"childbox\": \"102dcf32-8bc4-4579-bb03-af940935e0d7\", \"subtext\": \"c228e38f-b78e-4541-ba80-e06bc62ec8eb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1057, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Urinalysis:  specific gravity, pH, protein, glucose, ketones, occult blood, bilirubin, urobilinogen, leukocyte esterase, and nitrite.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d9562cb6-b85d-49bb-88f6-adb8d23c6439\", \"childbox\": \"ef6fde56-acad-455e-89fa-838ac6073721\", \"subtext\": \"cc2e241f-1109-46b1-898d-ec7338b5e1c8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1058, \"\"], [\"\", \"Unmapped\", \"text\", \"Microscopy (identification of cells, casts and crystals) will be done if the urinalysis is abnormal.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d9562cb6-b85d-49bb-88f6-adb8d23c6439\", \"childbox\": \"346e81ab-6494-4658-b183-2576a34d30a9\", \"subtext\": \"cc2e241f-1109-46b1-898d-ec7338b5e1c8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1059, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 HIV antibody screen:  HIV-1 and HIV-2.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a64c5a67-d56d-4c37-9cae-9791890f5204\", \"childbox\": \"500b1345-2e2c-426c-ac50-4dd1736e0c4e\", \"subtext\": \"7e849118-cad1-46fc-9ea4-78b632143584\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1060, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Hepatitis B surface antigen screen.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"484f61a4-3685-416b-8768-4bab0789b168\", \"childbox\": \"931724b0-5aee-4c60-920a-6f6dbaf1bad5\", \"subtext\": \"64908a9b-e782-4f26-9ea0-563716d1eb9d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1061, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 HCV RNA genotype (Screening only).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"94011ead-a1b4-4b47-b22e-6eabac58a49e\", \"childbox\": \"b51c0f81-d371-43c5-b9e2-7d218bb8a6f5\", \"subtext\": \"bed3f741-54e9-49c9-bbd3-56e7e50e280b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1062, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 FibroTest (Screening only):  FibroTest results, as well as each of the additional individual serum markers (alpha 2-macroglobulin, haptoglobin, apolipoprotein A1 and gammaglutamyl transpeptidase (GGT)) which contribute to the FibroTest score, will be reported.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2be340a4-d971-4d4e-a7de-df0560f9ae56\", \"childbox\": \"ed198971-d642-482b-9016-70153ce944ae\", \"subtext\": \"ae7776b4-7547-4d71-aa65-d36bf973286e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1063, \"\"], [\"\", \"Unmapped\", \"text\", \"At each visit, a plasma and/or a serum sample will be collected and stored for testing of laboratory or PK parameters (if needed), with one sample dedicated for possible resistance analysis to determine potential mutations in the HCV genome.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aabc542c-f192-4911-b063-d21470f3fc3b\", \"childbox\": \"2c2b1189-f86d-4e1a-843a-efb9fdd00302\", \"subtext\": \"3ab67f19-39cf-486f-a2cf-202051361f4a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1064, \"\"], [\"\", \"Unmapped\", \"text\", \"A buccal or blood sample (or other, depending on laboratory process) will also be collected at Baseline (predose on Day 1) for interleukin-28B (IL28B) polymorphism determination.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98ddac13-9987-4568-9fb6-558d9085ebc8\", \"childbox\": \"c6c78479-50c6-4905-a88c-fd380bd424bf\", \"subtext\": \"17573d06-bdf6-4140-a507-7c10c0f3266e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety\", \"7.5\", \"2\", 1065, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.5.1 Pregnancy tests\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading6\", \"entity\": [], \"roi_id\": {\"para\": \"8621e6dd-90eb-4382-8fd9-fa8c18a4a4e2\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pregnancy tests\", \"7.5.5.1\", \"4\", 1066, \"\"], [\"\", \"Unmapped\", \"text\", \"Serum and urine \\u03b2-HCG pregnancy tests will be performed as specified in Table 7-1; however, additional tests should be done if required by the local standard of care.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"32fdcd06-e4c4-41f2-8cbe-a49d2057cddf\", \"childbox\": \"7f4234f8-3d65-4641-b25e-5672c4bbdf79\", \"subtext\": \"68f32b6a-0dc4-4c61-bc65-9bdad65e23cd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pregnancy tests\", \"7.5.5.1\", \"4\", 1067, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.5.2 Renal function\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading6\", \"entity\": [], \"roi_id\": {\"para\": \"eb2e7f45-53fd-46f6-8a6a-8ab8601d8029\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1068, \"\"], [\"\", \"Unmapped\", \"text\", \"Renal function will be assessed as specified in Table 7-1 using the abbreviated Modification of Diet in Renal Disease (MDRD) study equation to estimate GFR.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8dbe3ee4-5548-4c0a-850f-482aea76e15e\", \"childbox\": \"3afae64e-89a8-4ac8-83ab-c80b03a6ec5b\", \"subtext\": \"d854a600-a0ff-40f8-bc22-e25baa18b065\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1069, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.6 12-lead electrocardiogram (ECG)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"03f49052-08b2-412f-983b-6f24263c80b2\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1070, \"\"], [\"\", \"Unmapped\", \"text\", \"Twelve-lead ECGs will be performed as specified in Table 7-1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7ada7640-2281-45e6-aca4-1290b687ae9d\", \"childbox\": \"929472e4-880b-46b7-8347-653299a37dea\", \"subtext\": \"0ce99304-40b8-4bac-b9c4-86621df2f01d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1071, \"\"], [\"\", \"Unmapped\", \"text\", \"ECGs will be collected after subjects are supine for 5 minutes.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1b6c5833-7435-4497-a614-fd399231875c\", \"childbox\": \"3bbcdcff-1d08-4c7c-bc01-a1322d72ec12\", \"subtext\": \"e3253da2-6741-4544-bc02-eb10e0d1fdd7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1072, \"\"], [\"\", \"Unmapped\", \"text\", \"Three consecutive determinations, collected no more than 5 minutes apart from each other, will be performed at each scheduled time point.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1b6c5833-7435-4497-a614-fd399231875c\", \"childbox\": \"fb3c001d-d63f-4cca-b7b8-5b1f55ae4606\", \"subtext\": \"b30fc224-7b92-4a69-961d-c5cc7af34de1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1073, \"\"], [\"\", \"Unmapped\", \"text\", \"The individual details of each tracing, as well as their average, will be reported.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1b6c5833-7435-4497-a614-fd399231875c\", \"childbox\": \"930d878a-39af-41f3-bfcc-90d138f10472\", \"subtext\": \"b30fc224-7b92-4a69-961d-c5cc7af34de1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1074, \"\"], [\"\", \"Unmapped\", \"text\", \"The average QTcF value from the three determinations will be used to include subjects (inclusion criterion #6).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1b6c5833-7435-4497-a614-fd399231875c\", \"childbox\": \"148ce535-cf44-40f6-9c56-e8991df8064d\", \"subtext\": \"b30fc224-7b92-4a69-961d-c5cc7af34de1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Renal function\", \"7.5.5.2\", \"4\", 1075, \"\"], [\"\", \"Unmapped\", \"header\", \"7.5.7 Echocardiogram\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"ff204b1b-1019-40fc-a12b-e2da436c02c9\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1076, \"\"], [\"\", \"Unmapped\", \"text\", \"A baseline echocardiogram will be performed during the Screening period on all subjects who qualify for entry into the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"52b1684d-a9ae-4d71-9cbd-4b5b2237b37e\", \"childbox\": \"91d3f4cd-5050-4f41-ab83-dd3552d10f78\", \"subtext\": \"84440dae-2e24-47e6-b104-d9fa0f51ee27\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1077, \"\"], [\"\", \"Unmapped\", \"header\", \"7.6 Pharmacokinetics\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"b1044bb1-bf24-4a5c-a7c3-fb4866d6ed38\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1078, \"\"], [\"\", \"Unmapped\", \"text\", \"Blood samples will be collected at the time points specified in Table 7-3.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ba9a38af-a8e8-462b-a941-68f0a5d1f3d8\", \"childbox\": \"06204572-fc9d-4ebe-b160-3ad36e31e411\", \"subtext\": \"f4a09e28-2a33-4423-86ec-32ec4e9faa5e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1079, \"\"], [\"\", \"Unmapped\", \"text\", \"Time of PK sample, time of last dose prior to each sample, and time of last meal prior to PK sample will be recorded only on study visit days.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ba9a38af-a8e8-462b-a941-68f0a5d1f3d8\", \"childbox\": \"e3798ee3-608f-44e8-9a0e-5b3352df6099\", \"subtext\": \"014467b5-0ec9-45f2-a59a-e522e2d6b1e2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1080, \"\"], [\"\", \"Unmapped\", \"text\", \"On days of intensive PK assessments, PK sampling shall always take precedence over other concurrent assessments (such as ECG and vital sign measurements) unless otherwise instructed by the Principal Investigator or his or her designee.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7df29d6d-9bd8-4d07-aced-67875a69eba4\", \"childbox\": \"6c31f84c-f1d2-4231-82eb-8ddffad99b83\", \"subtext\": \"88e7fd21-5c09-46f1-b42a-10b1c524981a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1081, \"\"], [\"\", \"Unmapped\", \"text\", \"HCV RNA timepoints will be time-matched to the PK timepoints for subjects participating in the optional Day 1 intensive PK sampling.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7df29d6d-9bd8-4d07-aced-67875a69eba4\", \"childbox\": \"2ba8b92e-3ac6-404b-b923-ae91a408e02e\", \"subtext\": \"bfdce072-fbbf-4320-8bbe-f18a1df8078c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1082, \"\"], [\"\", \"Unmapped\", \"text\", \"HCV RNA samples should be obtained within 10 min following the PK sample.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7df29d6d-9bd8-4d07-aced-67875a69eba4\", \"childbox\": \"749f0132-910d-4453-b774-414de1cb473d\", \"subtext\": \"36bcf3e4-e313-428b-abdf-98dd13712a81\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1083, \"\"], [\"\", \"Unmapped\", \"text\", \"The following plasma PK parameters will be obtained using noncompartmental analysis:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e0c4f308-bd0b-46ad-b32f-70950e868dc9\", \"childbox\": \"507be845-f2e5-4b3e-8ea8-6e4a73d66212\", \"subtext\": \"c016ee46-de6c-4ef3-8ecc-238d1403d999\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1084, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 C\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"974a9d23-43ee-459c-8717-a166eed2db79\", \"childbox\": \"87171c63-9d0e-4711-87c3-2a1c0364cc92\", \"subtext\": \"08de8f62-bd07-45ac-ac9f-96e5f54331b6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1085, \"\"], [\"\", \"Unmapped\", \"text\", \"max\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"974a9d23-43ee-459c-8717-a166eed2db79\", \"childbox\": \"87171c63-9d0e-4711-87c3-2a1c0364cc92\", \"subtext\": \"069ccb6d-81d1-4196-94d4-287edbf927a5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1086, \"\"], [\"\", \"Unmapped\", \"text\", \":  Observed maximum plasma drug concentration.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"974a9d23-43ee-459c-8717-a166eed2db79\", \"childbox\": \"87171c63-9d0e-4711-87c3-2a1c0364cc92\", \"subtext\": \"f89a9b0d-77c7-4b29-89ea-ce905300448b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1087, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 T\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2cf7336f-2c27-4b4c-9003-674a6365c874\", \"childbox\": \"6dde6dc4-b163-42bc-8bbb-35744f61dc0b\", \"subtext\": \"390f8223-9bdc-485d-9331-e088a304c047\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1088, \"\"], [\"\", \"Unmapped\", \"text\", \"max\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2cf7336f-2c27-4b4c-9003-674a6365c874\", \"childbox\": \"6dde6dc4-b163-42bc-8bbb-35744f61dc0b\", \"subtext\": \"a77e3a8a-a7d2-49be-94b2-25240f195938\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1089, \"\"], [\"\", \"Unmapped\", \"text\", \":  Time to maximum concentration.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2cf7336f-2c27-4b4c-9003-674a6365c874\", \"childbox\": \"6dde6dc4-b163-42bc-8bbb-35744f61dc0b\", \"subtext\": \"2ea6d114-eef3-4388-8f83-4e0857ebcda0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1090, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 AUC\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"df207220-b90c-40d2-80c8-647593b82cfc\", \"childbox\": \"ebd41f84-d757-4e1b-8628-b185d76c2054\", \"subtext\": \"45ea4df8-a96b-4f68-92e7-eb8416989a97\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1091, \"\"], [\"\", \"Unmapped\", \"text\", \"0-t\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"df207220-b90c-40d2-80c8-647593b82cfc\", \"childbox\": \"ebd41f84-d757-4e1b-8628-b185d76c2054\", \"subtext\": \"afef7613-c81a-40b3-8244-207d57058294\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1092, \"\"], [\"\", \"Unmapped\", \"text\", \":  Area under the drug concentration-time curve calculated using trapezoidal summation from time zero to last measurable concentration.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"df207220-b90c-40d2-80c8-647593b82cfc\", \"childbox\": \"ebd41f84-d757-4e1b-8628-b185d76c2054\", \"subtext\": \"acd56a94-2a4d-4b37-85b2-8639a7f9b661\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1093, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 C\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93330187-0d2b-472d-976c-57c546317adf\", \"childbox\": \"f34c4655-a763-42f6-9a3a-9cd8b2021111\", \"subtext\": \"c0043819-9c20-4641-8ed1-fa4357ece27d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1094, \"\"], [\"\", \"Unmapped\", \"text\", \"24h\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93330187-0d2b-472d-976c-57c546317adf\", \"childbox\": \"f34c4655-a763-42f6-9a3a-9cd8b2021111\", \"subtext\": \"3c421a53-4a3b-4e05-ac01-705f1898ed44\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1095, \"\"], [\"\", \"Unmapped\", \"text\", \"or C\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93330187-0d2b-472d-976c-57c546317adf\", \"childbox\": \"f34c4655-a763-42f6-9a3a-9cd8b2021111\", \"subtext\": \"2dc76cdb-265d-463e-b998-9bf45058b45a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1096, \"\"], [\"\", \"Unmapped\", \"text\", \"trough\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93330187-0d2b-472d-976c-57c546317adf\", \"childbox\": \"f34c4655-a763-42f6-9a3a-9cd8b2021111\", \"subtext\": \"6f49dc36-5b67-4f00-b96b-e0c96812e91c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1097, \"\"], [\"\", \"Unmapped\", \"text\", \":  Plasma concentration 24 h after dosing or the predose trough plasma concentration following multiple dosing.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93330187-0d2b-472d-976c-57c546317adf\", \"childbox\": \"f34c4655-a763-42f6-9a3a-9cd8b2021111\", \"subtext\": \"698ee146-c4a9-44e2-8a23-0d40d8bc36f6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1098, \"\"], [\"\", \"Unmapped\", \"text\", \"Concentration data from intensive and sparse sampling will also be analyzed using appropriate modeling techniques.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7bd03e2d-0349-4768-91ac-807028699249\", \"childbox\": \"1ec4d459-d239-4ec5-b10e-d89a6e2edf22\", \"subtext\": \"53a1876e-00b6-4154-bdbc-944d7da525cd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1099, \"\"], [\"\", \"Unmapped\", \"text\", \"Plasma concentrations of samatasvir, IDX21437 and/or their metabolites, as appropriate, will be quantitated using validated liquid chromatographic methods with mass-spectrometric detection (LC/MS/MS).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 25, \"end_idx\": 34, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 25, \"end_idx\": 34, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 25, \"end_idx\": 34, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 37, \"end_idx\": 44, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 37, \"end_idx\": 44, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 37, \"end_idx\": 44, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"9dfcc5a0-e0a5-4899-af1d-97f9b24f1c0f\", \"childbox\": \"0a5c593f-3849-42d6-9fb0-e6580abd0c40\", \"subtext\": \"b9dcd27c-3f80-4182-9b94-db6f4030e11e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1100, \"\"], [\"\", \"Unmapped\", \"header\", \"7.6.1 Pharmacokinetic blood sampling and processing\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"fe088ac8-c9c3-4a61-8c2c-2e5eae0ea2fc\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1101, \"\"], [\"\", \"Unmapped\", \"text\", \"Blood samples will be collected at the timepoints specified in Table 7-3.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"44957dde-90bf-4f43-bc8d-1c5ccbc9afec\", \"childbox\": \"a06f5249-b0f8-4219-9090-648981a0e47c\", \"subtext\": \"08865511-ea97-496e-89fd-0f02695ea78d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1102, \"\"], [\"\", \"Unmapped\", \"text\", \"The processing of blood samples for PK analysis will be provided in a separate instruction to the investigational site.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"44957dde-90bf-4f43-bc8d-1c5ccbc9afec\", \"childbox\": \"866e3456-ba1b-45f5-ba1d-e0e56c9e83e4\", \"subtext\": \"faa02eb3-81ff-4fa3-ac33-e01b90fb7740\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1103, \"\"], [\"\", \"Unmapped\", \"header\", \"7.7 Pharmacodynamics\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"d510e177-d316-4911-88e1-77fcdde81423\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1104, \"\"], [\"\", \"Unmapped\", \"text\", \"Exploratory pharmacodynamic analyses may include, but are not limited to, evaluating the relationships between plasma concentrations of samatasvir, IDX21437 and/or their metabolites and HCV RNA viral load.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 136, \"end_idx\": 145, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 100.0, \"text\": \"samatasvir\"}, {\"start_idx\": 136, \"end_idx\": 145, \"standard_entity_name\": \"SAMATASVIR\", \"subcategory\": \"SAMATASVIR\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 136, \"end_idx\": 145, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 75.0, \"text\": \"samatasvir\"}, {\"start_idx\": 148, \"end_idx\": 155, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 148, \"end_idx\": 155, \"standard_entity_name\": \"IDX21437\", \"subcategory\": \"IDX21437\", \"confidence\": 100.0, \"text\": \"IDX21437\"}, {\"start_idx\": 148, \"end_idx\": 155, \"standard_entity_name\": \"Molecule\", \"subcategory\": \"Molecule\", \"confidence\": 100.0, \"text\": \"IDX21437\"}], \"roi_id\": {\"para\": \"619c6cb7-4c04-4f5e-a980-2ea4376d55e5\", \"childbox\": \"cddf58db-ab8b-4303-b8f3-59bf8b83ee9a\", \"subtext\": \"98ac99eb-2c2e-4bea-bd44-785f9852332b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1105, \"\"], [\"\", \"Unmapped\", \"header\", \"8 Safety monitoring\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"67b6ff2d-7fc8-4795-b58b-a823f14cac0b\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1106, \"\"], [\"\", \"Unmapped\", \"header\", \"8.1 Serious adverse event (SAE) reporting\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"9dc5fcff-670a-4742-83d0-da48a4666564\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1107, \"\"], [\"\", \"Unmapped\", \"text\", \"To ensure subject safety, every SAE, regardless of suspected causality, occurring after the subject has provided informed consent and through the end of the study must be reported to Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 183, \"end_idx\": 210, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 183, \"end_idx\": 210, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"b5c576eb-90d5-4039-a2e2-23a24a50aa22\", \"childbox\": \"902aaa08-caee-422d-bb9a-879008ae4899\", \"subtext\": \"1c734f17-556e-4e90-b2f7-51bb5e0bb605\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1108, \"\"], [\"\", \"Unmapped\", \"text\", \"or their designee by phone and fax (or email) within 24 hours of learning of its occurrence.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b5c576eb-90d5-4039-a2e2-23a24a50aa22\", \"childbox\": \"00e48025-fdd4-4e31-b852-fca34ba68de0\", \"subtext\": \"1c734f17-556e-4e90-b2f7-51bb5e0bb605\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1109, \"\"], [\"\", \"Unmapped\", \"text\", \"At a minimum, a description of the event and the investigator\\u2019s judgment of causality must be provided at the time of the initial report.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b5c576eb-90d5-4039-a2e2-23a24a50aa22\", \"childbox\": \"eb73d0ce-1111-4f31-beda-bc53c2505920\", \"subtext\": \"fc4e2a79-b11f-4cef-8ef2-bf6da4d57ff0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1110, \"\"], [\"\", \"Unmapped\", \"text\", \"These preliminary reports will be followed by detailed descriptions that will include copies of hospital case reports, autopsy reports, and other documents when requested and applicable.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b5c576eb-90d5-4039-a2e2-23a24a50aa22\", \"childbox\": \"fda32031-3c81-4f5c-8147-62afd189215b\", \"subtext\": \"fc4e2a79-b11f-4cef-8ef2-bf6da4d57ff0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1111, \"\"], [\"\", \"Unmapped\", \"text\", \"Complications or progression of an initial SAE must be reported as a follow-up SAE Report to the original SAE, regardless of when the follow-up information is received by the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e2a3f640-9728-43df-9031-4ebf0f842973\", \"childbox\": \"e01cbba7-ef39-4d53-9d70-5d5f8940c8c2\", \"subtext\": \"7865a346-5304-432e-b904-da1d1d133385\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1112, \"\"], [\"\", \"Unmapped\", \"text\", \"A follow-up SAE Report must be submitted within 24 hours of the investigator receiving the follow-up information.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e2a3f640-9728-43df-9031-4ebf0f842973\", \"childbox\": \"8e2fdad5-4c1a-4ed6-a371-042e1aeb8c53\", \"subtext\": \"66cfc10f-dcb4-4845-a748-0d28212f16da\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1113, \"\"], [\"\", \"Unmapped\", \"text\", \"A SAE that is considered completely unrelated to a previously reported one should be reported separately as a new SAE.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e2a3f640-9728-43df-9031-4ebf0f842973\", \"childbox\": \"f49e6809-8ac2-4926-8d40-9022bf28b53b\", \"subtext\": \"66cfc10f-dcb4-4845-a748-0d28212f16da\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1114, \"\"], [\"\", \"Unmapped\", \"text\", \"The procedures for reporting SAEs are as follows:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4279d28b-036f-4ee9-a395-11d54341f0e7\", \"childbox\": \"b1552667-dc00-4962-80af-cdbb466e3692\", \"subtext\": \"587c67e4-bc3d-4002-abe0-41d4dfec4598\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1115, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Complete the \\u201cSerious Adverse Event Report Form\\u201d in English.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b6d2c3da-7b57-4992-9b0f-2f9f57074a66\", \"childbox\": \"8a033696-d5d0-4d0d-92b8-eeffeb843b47\", \"subtext\": \"1e82a702-a497-48bd-bb5c-36f738c3741f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1116, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Fax or email the Serious Adverse Event Report Form to the attention of the Idenix Medical Monitor (below) within 24 hours of the investigator\\u2019s knowledge of the event.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 77, \"end_idx\": 82, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}], \"roi_id\": {\"para\": \"91051b4e-7594-4e94-a1f0-54e151f7eb70\", \"childbox\": \"1dbc7c1e-b102-4677-a561-c27d1480e341\", \"subtext\": \"813e7014-c27a-4698-a142-fb69105141cd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1117, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Confirm the occurrence of the SAE by phone by contacting the Idenix Medical Monitor (contact information listed below).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 63, \"end_idx\": 68, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}], \"roi_id\": {\"para\": \"634ac0ef-c43c-4c82-89c2-0e8cf6acadfd\", \"childbox\": \"5a0ed389-c306-4f99-8784-5d4ff53e71d5\", \"subtext\": \"2eb50286-d811-46ae-bef7-e0b40ea4e70b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1118, \"\"], [\"\", \"Unmapped\", \"text\", \"Contact information for SAE Reporting is as follows:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8687d30-f661-4478-acbc-640f2433cd32\", \"childbox\": \"89b43193-5b84-4c15-a2ba-09b0ae87f6c0\", \"subtext\": \"1e399093-5bd1-42e1-a04c-82d65b1123cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1119, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3b71e2d3-5a26-4d58-bb64-bede01202852\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1120, \"\"], [\"\", \"Unmapped\", \"text\", \"John Z. Sullivan-B\\u00f3lyai, MD, MPH (Idenix Medical Monitor) Vice President, Clinical Research Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 34, \"end_idx\": 39, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}, {\"start_idx\": 92, \"end_idx\": 97, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}, {\"start_idx\": 74, \"end_idx\": 119, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Clinical Research Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 22, \"standard_entity_name\": \"OTHER: Person Name\", \"subcategory\": \"OTHER: Person Name\", \"confidence\": 100.0, \"text\": \"John Z. Sullivan-B\\u00f3lyai\"}, {\"start_idx\": 23, \"end_idx\": 26, \"standard_entity_name\": \"OTHER: Person Title\", \"subcategory\": \"OTHER: Person Title\", \"confidence\": 100.0, \"text\": \", MD\"}, {\"start_idx\": 27, \"end_idx\": 31, \"standard_entity_name\": \"OTHER: Person Title\", \"subcategory\": \"OTHER: Person Title\", \"confidence\": 100.0, \"text\": \", MPH\"}, {\"start_idx\": 23, \"end_idx\": 31, \"standard_entity_name\": \"OTHER: Person Title\", \"subcategory\": \"OTHER: Person Title\", \"confidence\": 100.0, \"text\": \", MD, MPH\"}, {\"start_idx\": 34, \"end_idx\": 55, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Medical Monitor\"}], \"roi_id\": {\"para\": \"67540b00-e23b-49b3-b1ab-c2d414680433\", \"childbox\": \"c1828be1-5ff0-4e7c-8ffb-083a6f643360\", \"subtext\": \"19dfc04d-9364-405d-a25b-618a66974f0c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1121, \"\"], [\"\", \"Unmapped\", \"text\", \"320 Bent Street\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 14, \"standard_entity_name\": \"ANY: Address\", \"subcategory\": \"ANY: Address\", \"confidence\": 100.0, \"text\": \"320 Bent Street\"}], \"roi_id\": {\"para\": \"2bfc11bd-f4d9-42d9-bd5f-e8a9595768fd\", \"childbox\": \"17086c7c-116e-4380-a9b3-c7657b328d8b\", \"subtext\": \"fc4f57e5-67f3-42e0-9f61-4641b3181eb7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1122, \"\"], [\"\", \"Unmapped\", \"text\", \"Cambridge, MA 02141, USA\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 23, \"standard_entity_name\": \"ANY: Address\", \"subcategory\": \"ANY: Address\", \"confidence\": 100.0, \"text\": \"Cambridge, MA 02141, USA\"}], \"roi_id\": {\"para\": \"be3fc69b-4886-4330-8d6d-569c5eeaefc6\", \"childbox\": \"e7706d60-fe79-474f-b166-222077584c4f\", \"subtext\": \"4c346689-a81b-4858-87ae-17d401d055b7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1123, \"\"], [\"\", \"Unmapped\", \"text\", \"Telephone:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"831b56d0-b09e-4a5d-b154-a9ab5d3a0b8d\", \"childbox\": \"c39c8a7c-f239-4756-91f2-756b5f44ebfd\", \"subtext\": \"d4e147c2-a960-428f-a620-9beba98f1a80\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1124, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"831b56d0-b09e-4a5d-b154-a9ab5d3a0b8d\", \"childbox\": \"53b31eb4-45bd-4c46-b9d0-f5b4b5005d79\", \"subtext\": \"c296a93e-e022-4f7a-9a4f-8836c56027ff\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1125, \"\"], [\"\", \"Unmapped\", \"text\", \"+1 (617) 224-4473  Mobile:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"831b56d0-b09e-4a5d-b154-a9ab5d3a0b8d\", \"childbox\": \"b8c15970-a7f2-44a4-9aa2-02fbf1dfa261\", \"subtext\": \"c296a93e-e022-4f7a-9a4f-8836c56027ff\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1126, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"831b56d0-b09e-4a5d-b154-a9ab5d3a0b8d\", \"childbox\": \"a70607a7-3c2f-4b87-81f7-ef4ef3067fea\", \"subtext\": \"eb9e5135-d0e2-499a-87ee-9acec01552ed\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1127, \"\"], [\"\", \"Unmapped\", \"text\", \"+1 (617) 584-8011\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"831b56d0-b09e-4a5d-b154-a9ab5d3a0b8d\", \"childbox\": \"6896888e-4210-4b00-8331-4756217baa9e\", \"subtext\": \"eb9e5135-d0e2-499a-87ee-9acec01552ed\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1128, \"\"], [\"\", \"Unmapped\", \"text\", \"Fax:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe8b0c0e-343f-479d-b631-1efdb62b1c1e\", \"childbox\": \"91633ad9-85cf-4af9-ad64-2c0892fc7a5e\", \"subtext\": \"4ba0518e-29ec-4b40-9aa0-cffdfa196460\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1129, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe8b0c0e-343f-479d-b631-1efdb62b1c1e\", \"childbox\": \"b0b2e62c-75a4-437a-8ad9-1d8137e5338b\", \"subtext\": \"08bccfb9-bd05-4f71-ae90-070047269d79\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1130, \"\"], [\"\", \"Unmapped\", \"text\", \"+1 (617) 995-9940\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe8b0c0e-343f-479d-b631-1efdb62b1c1e\", \"childbox\": \"d79129a7-11c5-4051-8eb3-6f351359eae8\", \"subtext\": \"08bccfb9-bd05-4f71-ae90-070047269d79\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1131, \"\"], [\"\", \"Unmapped\", \"text\", \"E-mail:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4ac52ef6-f511-4f45-8b76-c56797a55ce6\", \"childbox\": \"95beb2bb-cc06-4c91-a9e2-9d8ef609289a\", \"subtext\": \"b283b131-290a-49c3-8ad4-7ed8a4828f2f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1132, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4ac52ef6-f511-4f45-8b76-c56797a55ce6\", \"childbox\": \"2eb89bdd-1e38-4239-bee3-2a655c2b3531\", \"subtext\": \"feb1e37a-cd49-4a25-b822-e2c8140c2374\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1133, \"\"], [\"\", \"Unmapped\", \"text\", \"sae@idenix.com\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 13, \"standard_entity_name\": \"ANY: Email\", \"subcategory\": \"ANY: Email\", \"confidence\": 100.0, \"text\": \"sae@idenix.com\"}, {\"start_idx\": 0, \"end_idx\": 13, \"standard_entity_name\": \"ANY: Email\", \"subcategory\": \"ANY: Email\", \"confidence\": 87.0, \"text\": \"sae@idenix.com\"}], \"roi_id\": {\"para\": \"4ac52ef6-f511-4f45-8b76-c56797a55ce6\", \"childbox\": \"dcdf5281-2894-478f-be6d-bfac6d9652ba\", \"subtext\": \"feb1e37a-cd49-4a25-b822-e2c8140c2374\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1134, \"\"], [\"\", \"Unmapped\", \"text\", \"The original copy of the SAE Report Form and the fax confirmation sheet must be kept with the source documentation at the study site.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"eb15c937-7b65-4828-8d67-52f02eb279a3\", \"childbox\": \"c4aa2104-0b8c-4edd-a224-543332a7e3a9\", \"subtext\": \"9a29bf21-11ea-4390-aa8c-b154f5b0a11b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1135, \"\"], [\"\", \"Unmapped\", \"text\", \"Follow-up information should be communicated the same way, using a new SAE Report Form stating that it is a follow-up to the previously reported SAE and giving the date of the original report.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"824d5855-9f13-4cfb-a4f3-3c34ec997afd\", \"childbox\": \"39f27eac-9df9-4b73-b207-1b81390dc7ea\", \"subtext\": \"3c05d44d-3d61-4276-a403-695e4cfbc289\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1136, \"\"], [\"\", \"Unmapped\", \"text\", \"The follow-up information should describe whether the event has resolved or continues, if and how it was treated, and whether the subject continued or withdrew from study participation.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"824d5855-9f13-4cfb-a4f3-3c34ec997afd\", \"childbox\": \"4ae0ff51-c1fd-41d2-b43c-d048e35b57b1\", \"subtext\": \"9c6148f2-6470-408b-a2bb-e3a2f52342c4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1137, \"\"], [\"\", \"Unmapped\", \"text\", \"If the SAE was not previously documented in the Investigator\\u2019s Brochure and is thought to be related to study drug(s), Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 119, \"end_idx\": 146, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 119, \"end_idx\": 146, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"2ed2162a-0aeb-4751-843e-c8086c2804ba\", \"childbox\": \"a2b1c5e2-b7f8-4cc4-86b1-9bab8f01475b\", \"subtext\": \"56b0bb4c-512d-4864-8fb5-789fcab6d9e0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1138, \"\"], [\"\", \"Unmapped\", \"text\", \"or their designee may urgently require further information from the investigator for regulatory authority reporting.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2ed2162a-0aeb-4751-843e-c8086c2804ba\", \"childbox\": \"8cf724f5-253b-45a8-95d3-76005800c589\", \"subtext\": \"56b0bb4c-512d-4864-8fb5-789fcab6d9e0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1139, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix may need to issue an Investigator Notification Letter to inform all investigators involved in any study with the same drug(s) that this SAE has been reported.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 5, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}, {\"start_idx\": 0, \"end_idx\": 5, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix\"}], \"roi_id\": {\"para\": \"2ed2162a-0aeb-4751-843e-c8086c2804ba\", \"childbox\": \"f37b7b11-7d71-450d-90eb-35a6e7f01f43\", \"subtext\": \"5e432ddf-6eed-4efd-b7e4-846792bba8f1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1140, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator and study personnel should institute any supplemental investigations of SAEs based on their clinical judgment of likely causative factors.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d76b8948-d474-43d1-afc3-e9f620b4d834\", \"childbox\": \"6195dcfc-2b6b-4c0e-9f78-d11425fc707e\", \"subtext\": \"7ec2cc09-b731-4c01-b434-7a36f1f4283e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1141, \"\"], [\"\", \"Unmapped\", \"text\", \"This may include clinical laboratory tests not specified in the protocol, histopathologic examinations, or consultations with specialists.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d76b8948-d474-43d1-afc3-e9f620b4d834\", \"childbox\": \"544d549a-b566-4db5-af47-dd260fcf5129\", \"subtext\": \"7afe70ed-9c95-4625-adbc-ebf17a75f8d2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1142, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"d76b8948-d474-43d1-afc3-e9f620b4d834\", \"childbox\": \"4e7f7e88-c1e3-4f17-9126-d25d5c559d49\", \"subtext\": \"7afe70ed-9c95-4625-adbc-ebf17a75f8d2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1143, \"\"], [\"\", \"Unmapped\", \"text\", \"or their designee may also request the investigator to conduct supplemental assessments.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d76b8948-d474-43d1-afc3-e9f620b4d834\", \"childbox\": \"1d99b38b-2b48-43f5-9e1a-c8c4b501ea7e\", \"subtext\": \"7afe70ed-9c95-4625-adbc-ebf17a75f8d2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1144, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator should notify the Idenix Medical Monitor of any death or SAE occurring after a subject has withdrawn from the study when such a death or SAE may reasonably be related to the study medication(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 35, \"end_idx\": 40, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}], \"roi_id\": {\"para\": \"75c329fc-1090-4fb3-ab90-5e7a1cb2ae37\", \"childbox\": \"a9fbbe49-3296-4577-84d5-9625a4d5bb5b\", \"subtext\": \"29d8b173-56a0-4a8c-8215-8e828f22baa7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1145, \"\"], [\"\", \"Unmapped\", \"text\", \"However, the investigator is not obligated to actively seek AEs in former study participants.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"75c329fc-1090-4fb3-ab90-5e7a1cb2ae37\", \"childbox\": \"ac327013-9381-4b07-b0eb-b9735ad1064b\", \"subtext\": \"62a51217-a100-4666-a8c1-91a7232b26d9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Echocardiogram\", \"7.5.7\", \"3\", 1146, \"\"], [\"\", \"Unmapped\", \"header\", \"8.2 Follow-up of adverse events\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"dd6c8937-23a0-4221-aef1-42472e380716\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1147, \"\"], [\"\", \"Unmapped\", \"text\", \"All SAEs will be recorded from the time the subject signs the ICF until completion of the post-EOT follow-up phase of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c30599ec-1426-49d5-be9d-318fb492f601\", \"childbox\": \"0fdf7b10-a088-4d57-9595-45773a902ca7\", \"subtext\": \"a323aab2-8beb-4af5-9eaa-a6b2e7e762e2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1148, \"\"], [\"\", \"Unmapped\", \"text\", \"All nonserious AEs will be recorded from first dose of study drug until the 28-day post-EOT visit (Table 7-1).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c30599ec-1426-49d5-be9d-318fb492f601\", \"childbox\": \"db86217a-e42b-4ebe-8f05-2e7c2a15eab5\", \"subtext\": \"dec8c99a-bca5-4167-b6cd-a7689a2be257\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1149, \"\"], [\"\", \"Unmapped\", \"text\", \"All SAEs, Grade 3/4 clinical AEs, Grade 3/4 laboratory abnormalities (other than asymptomatic triglyceride or cholesterol) or any other AEs/laboratory abnormalities resulting in premature discontinuation will be followed until they have resolved, returned to baseline, or are determined to be chronic or stable by the investigator.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0a01184f-0969-4648-887b-5125071432b7\", \"childbox\": \"f1e89de1-8925-4913-9c64-3a347c507353\", \"subtext\": \"36c61306-b6cc-4987-8863-2ff9b4b721de\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1150, \"\"], [\"\", \"Unmapped\", \"header\", \"8.3 Reporting safety information to the IRB/EC\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"76a5cf4b-97f5-4203-b069-edbbafe29bfb\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1151, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator is responsible for following all local regulations for the reporting of safety information, including the reporting of SAEs to the Institutional Review Board (IRB)/Ethics Committee (EC).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c203d08a-d36f-4c1b-bd68-425a1b5cda30\", \"childbox\": \"467e57d5-02b7-4a6d-a42d-d7120d5b079e\", \"subtext\": \"87cd0046-66e4-41ee-8ff2-ab874f244c13\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1152, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator must promptly report to his or her IRB/EC all unanticipated problems involving risks to subjects.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b58514ca-d23d-404f-9ed0-0455620400d5\", \"childbox\": \"0b50bca8-d255-40f8-89fd-fbd9439ac202\", \"subtext\": \"c2c695f9-c5aa-4f92-ab2d-a8f3a027a6ff\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1153, \"\"], [\"\", \"Unmapped\", \"text\", \"This includes death from any cause and all SAEs reasonably or possibly associated with the use of study drug(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b58514ca-d23d-404f-9ed0-0455620400d5\", \"childbox\": \"8eeed517-dad9-4bdc-9824-cf91733e9ce3\", \"subtext\": \"e35ef3f2-6154-4c96-94ba-ef7ba4dfbd32\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1154, \"\"], [\"\", \"Unmapped\", \"text\", \"It is recommended that all SAEs occurring at a site, regardless of causality, be reported to the site\\u2019s IRB/EC in accordance with the IRB/EC\\u2019s requirements.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b58514ca-d23d-404f-9ed0-0455620400d5\", \"childbox\": \"d05505da-4b3d-4503-abaa-b8a1ef794c98\", \"subtext\": \"e35ef3f2-6154-4c96-94ba-ef7ba4dfbd32\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1155, \"\"], [\"\", \"Unmapped\", \"text\", \"A SAE may require safety reports to be filed to regulatory agencies if the SAE is attributable to the study drug(s) and is unexpected based upon the current Investigator\\u2019s Brochure(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7a73759-3ecf-4f24-b6c2-fc676c9c786b\", \"childbox\": \"63fcaba3-e752-45fb-ac60-2fb33981bcd0\", \"subtext\": \"252847f7-5007-488f-9efe-86b0bc0412f7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1156, \"\"], [\"\", \"Unmapped\", \"text\", \"In this case, the investigator will receive a copy of the safety report as submitted to the regulatory agencies.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7a73759-3ecf-4f24-b6c2-fc676c9c786b\", \"childbox\": \"589edc34-38f7-446a-bf03-2049e70d6fca\", \"subtext\": \"f1b1593e-c393-42cb-b088-b80fa35f80cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1157, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator is responsible for submitting the safety report (initial and follow-up) or other safety information (e.g., revised Investigator\\u2019s Brochure(s)) to the IRB/EC in accordance with the IRB/EC\\u2019s requirements and keep a copy in the study files.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d7a73759-3ecf-4f24-b6c2-fc676c9c786b\", \"childbox\": \"29adea2f-784c-4f8c-96bb-eaf3a3a047a1\", \"subtext\": \"f1b1593e-c393-42cb-b088-b80fa35f80cb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1158, \"\"], [\"\", \"Unmapped\", \"header\", \"8.4 Pregnancies\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"6b0ca3a8-0107-41a6-9df9-404b866f3bfe\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1159, \"\"], [\"\", \"Unmapped\", \"text\", \"To ensure subject safety, any pregnancy in a subject must be reported to the medical monitor within 24 hours of learning of its occurrence.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42a14aa2-7089-49a6-b16b-d70037bfe217\", \"childbox\": \"58320130-2406-4fa3-9bdc-8adcc71f2367\", \"subtext\": \"0eaea964-590e-429c-ab35-89b7f349034d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1160, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects who become pregnant will be withdrawn from study drug(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42a14aa2-7089-49a6-b16b-d70037bfe217\", \"childbox\": \"611af2bc-af97-4a52-b17e-4e51c82fc61b\", \"subtext\": \"0c5c84a8-755a-42cf-972a-4d455d50de15\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1161, \"\"], [\"\", \"Unmapped\", \"text\", \"The pregnancy should be followed to determine outcome, including spontaneous or voluntary termination, details of the birth including the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"42a14aa2-7089-49a6-b16b-d70037bfe217\", \"childbox\": \"43ae6992-826d-43e7-843e-2a56874aeb79\", \"subtext\": \"0c5c84a8-755a-42cf-972a-4d455d50de15\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1162, \"\"], [\"\", \"Unmapped\", \"text\", \"Pregnancy should be recorded on a subject\\u2019s source documents and a Pregnancy Notification and Outcome Form and reported by the investigator to Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 143, \"end_idx\": 170, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 143, \"end_idx\": 170, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"967331a0-f5e5-45eb-8d95-335e6353312b\", \"childbox\": \"6ee4976b-586e-47fe-8c90-fc82f1a2fd6a\", \"subtext\": \"05795a52-2135-4b28-b263-8d1223f504eb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1163, \"\"], [\"\", \"Unmapped\", \"text\", \"(or designee) using the same procedure for reporting SAEs in Section 8.1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"967331a0-f5e5-45eb-8d95-335e6353312b\", \"childbox\": \"f9ee7016-4586-4da4-95c3-19054d073664\", \"subtext\": \"208a8517-7a57-41ff-bd4b-0155437baf5f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1164, \"\"], [\"\", \"Unmapped\", \"text\", \"Pregnancy follow-up should also be recorded and should include an assessment of the possible relationship to the study drug(s) of any pregnancy outcome.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"967331a0-f5e5-45eb-8d95-335e6353312b\", \"childbox\": \"e967c712-7a4d-4b4e-8787-1ebd8ccad0f8\", \"subtext\": \"4d174fcd-db9f-464b-b9f5-696187f6bc00\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1165, \"\"], [\"\", \"Unmapped\", \"text\", \"Any pregnancy-related SAE (e.g., spontaneous abortion) or any other SAE experienced during pregnancy must be recorded on a separate SAE Report Form and reported to the Sponsor per SAE reporting procedures in Section 8.1.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"967331a0-f5e5-45eb-8d95-335e6353312b\", \"childbox\": \"ffb030fd-06ff-450e-94cb-47b94071eb04\", \"subtext\": \"d1e76d7f-1125-4488-bdce-778f5b1746d6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1166, \"\"], [\"\", \"Unmapped\", \"text\", \"Pregnancy outcomes must be collected for the female partners of any males who took study drug(s) in this study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27c7749e-70fe-4e68-9288-7d654d5ce9bc\", \"childbox\": \"46592197-17c7-4684-a85b-23e24ebec0d1\", \"subtext\": \"423133d1-a90b-4694-b4bd-71fff44ee325\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1167, \"\"], [\"\", \"Unmapped\", \"text\", \"Consent to report information regarding these pregnancy outcomes should be obtained from the mother.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27c7749e-70fe-4e68-9288-7d654d5ce9bc\", \"childbox\": \"7685112a-d076-43e9-84ab-7889a144c050\", \"subtext\": \"423133d1-a90b-4694-b4bd-71fff44ee325\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1168, \"\"], [\"\", \"Unmapped\", \"header\", \"Ribavirin Pregnancy Registry\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"64c25ea6-f530-4a24-87a7-9f46c87409aa\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1169, \"\"], [\"\", \"Unmapped\", \"text\", \"As described in the product label, a Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies of female patients and female partners of male patients exposed to ribavirin during treatment and for 7 months following cessation of treatment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e0563ef8-ede5-4a2d-93fb-11003cfe6efc\", \"childbox\": \"eb973198-c5d8-407e-be36-8cb95c40edbb\", \"subtext\": \"2f47ab92-903c-41b9-a597-60b322fbbe3c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1170, \"\"], [\"\", \"Unmapped\", \"text\", \"Healthcare providers and patients are encouraged to report such cases.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e0563ef8-ede5-4a2d-93fb-11003cfe6efc\", \"childbox\": \"8743bc9a-3d18-4710-88fe-5b79b66b3d89\", \"subtext\": \"5a306a26-03bd-4dfe-9df9-b049b48af403\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1171, \"\"], [\"\", \"Unmapped\", \"text\", \"Contact information is provided in the product label.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e0563ef8-ede5-4a2d-93fb-11003cfe6efc\", \"childbox\": \"c5344823-a5db-41c5-b00b-d2d4d16b023b\", \"subtext\": \"5a306a26-03bd-4dfe-9df9-b049b48af403\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1172, \"\"], [\"\", \"Unmapped\", \"header\", \"9 Data review and database management\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"70d1c539-5e0b-4921-a74a-0de9b9612587\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1173, \"\"], [\"\", \"Unmapped\", \"header\", \"9.1 Site monitoring\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"76d13535-2252-42cb-95b9-ecb227bfd395\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1174, \"\"], [\"\", \"Unmapped\", \"text\", \"Before study initiation, at a site initiation visit or teleconference, representatives of Idenix Pharmaceuticals or designee will review the protocol and CRF with the investigators and their staff.  The study monitor will visit the site to check the completeness of subject records, the accuracy of entries on the CRFs, the adherence to the protocol and to Good Clinical Practice (GCP), and to ensure that study drug is being stored, dispensed, and accounted for according to specifications.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 90, \"end_idx\": 111, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 75.0, \"text\": \"Idenix Pharmaceuticals\"}, {\"start_idx\": 90, \"end_idx\": 111, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 75.0, \"text\": \"Idenix Pharmaceuticals\"}], \"roi_id\": {\"para\": \"21988bb1-0804-4171-8411-7676b1830390\", \"childbox\": \"e10e421e-b300-4539-ab80-f15e6cd0d7c0\", \"subtext\": \"e7b06690-b1f9-46df-baa4-fb026f34d13f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1175, \"\"], [\"\", \"Unmapped\", \"text\", \"Key study personnel must be available to assist the study monitor.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"21988bb1-0804-4171-8411-7676b1830390\", \"childbox\": \"92d3a998-3339-40ca-bab3-c7d0b6bb1e88\", \"subtext\": \"9855acb5-55fd-4e59-b619-34cfd369e244\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1176, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator must maintain source documents for each subject in the study, consisting of case and visit notes (hospital or clinic medical records).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0a256f89-dc54-4f31-94ab-aadf0bc47274\", \"childbox\": \"22ffbf7f-96c7-4eb0-9651-fcc353a3a2e0\", \"subtext\": \"b016f62c-9e82-4a05-8278-438f1a8c4e3b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1177, \"\"], [\"\", \"Unmapped\", \"text\", \"All information on CRFs must be traceable to these source documents in the subject's file.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0a256f89-dc54-4f31-94ab-aadf0bc47274\", \"childbox\": \"7d8f1744-dde4-4f94-8c46-6f08cb25bd35\", \"subtext\": \"b016f62c-9e82-4a05-8278-438f1a8c4e3b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1178, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator must also keep the original signed informed consent form (a signed copy is given to the subject).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0a256f89-dc54-4f31-94ab-aadf0bc47274\", \"childbox\": \"e9f53226-505a-4110-b4d3-4bd5203a1358\", \"subtext\": \"b016f62c-9e82-4a05-8278-438f1a8c4e3b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1179, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator must give the study monitor access to all relevant source documents to confirm their consistency with the CRF entries.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f9d42a40-340c-486e-9cb4-d4d52d7633ea\", \"childbox\": \"5e11a23c-045f-4c80-b4e6-68b3e4666d93\", \"subtext\": \"0e47b478-1b12-4a4a-85e3-3c8de0dc271b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1180, \"\"], [\"\", \"Unmapped\", \"header\", \"9.2 Data collection\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"4ad7fb37-b5a4-4997-82e4-6e6f7a64acbe\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1181, \"\"], [\"\", \"Unmapped\", \"text\", \"Investigational sites will be supplied with instructions on accessing the web-based electronic data capture (EDC) system via secure web portal.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90935b8f-8b1e-4788-945b-a11bb190b28e\", \"childbox\": \"b6bb89b1-0969-497a-bfda-300d1630276c\", \"subtext\": \"3a218b2e-e703-4034-91e9-65ae9bca7c0c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1182, \"\"], [\"\", \"Unmapped\", \"text\", \"Representatives of Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 19, \"end_idx\": 46, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 19, \"end_idx\": 46, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"90935b8f-8b1e-4788-945b-a11bb190b28e\", \"childbox\": \"4f05009d-12f3-443a-8880-cebbfc95de23\", \"subtext\": \"3a218b2e-e703-4034-91e9-65ae9bca7c0c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1183, \"\"], [\"\", \"Unmapped\", \"text\", \"(or designee) will train designated site staff on the EDC system.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90935b8f-8b1e-4788-945b-a11bb190b28e\", \"childbox\": \"f79cf36c-3222-4603-8611-e6c6a35768c5\", \"subtext\": \"3a218b2e-e703-4034-91e9-65ae9bca7c0c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1184, \"\"], [\"\", \"Unmapped\", \"text\", \"Investigational site staff will not be given access to the EDC system until the required training is completed and documented.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90935b8f-8b1e-4788-945b-a11bb190b28e\", \"childbox\": \"1e346a52-cf61-4986-8976-8be75e65eeaa\", \"subtext\": \"3bf6e763-8a6b-4c04-b9dd-bb5303ae6d08\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1185, \"\"], [\"\", \"Unmapped\", \"text\", \"Designated site staff will enter the data required by the protocol into the CRFs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90935b8f-8b1e-4788-945b-a11bb190b28e\", \"childbox\": \"ac9402dc-8cea-4e77-b896-d37ba6bd0f13\", \"subtext\": \"3bf6e763-8a6b-4c04-b9dd-bb5303ae6d08\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1186, \"\"], [\"\", \"Unmapped\", \"text\", \"Automatic validation programs check for data discrepancies in the CRFs and, by generating appropriate error messages, allow modification or verification of the entered data by the site staff.  After database lock, the investigator will receive a compact disc-read only memory (CD-ROM) or digital video disc (DVD) of the subject data for archiving at the investigational site.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"90935b8f-8b1e-4788-945b-a11bb190b28e\", \"childbox\": \"0d65a344-b0d2-4016-a22a-65bc64fd6c4d\", \"subtext\": \"3bf6e763-8a6b-4c04-b9dd-bb5303ae6d08\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1187, \"\"], [\"\", \"Unmapped\", \"header\", \"9.3 Database management and quality control\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"babff9a0-6afa-412e-bc6a-a8268a534b59\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1188, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"4c4d214e-8fa3-46d4-b111-9586ad6e7a8e\", \"childbox\": \"bee41186-b7d6-409d-ad78-2277f78a852f\", \"subtext\": \"97b6a212-0aba-4626-a2aa-28e3d8b00297\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1189, \"\"], [\"\", \"Unmapped\", \"text\", \"representatives (or designee) will review the CRFs entered by investigational site staff for completeness and accuracy and instruct the investigational site staff to make any required corrections or additions.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4c4d214e-8fa3-46d4-b111-9586ad6e7a8e\", \"childbox\": \"33040471-6672-4ae9-bfe3-616d9498b5c1\", \"subtext\": \"97b6a212-0aba-4626-a2aa-28e3d8b00297\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1190, \"\"], [\"\", \"Unmapped\", \"text\", \"Queries will be sent to the investigational site using an electronic data query within the EDC system.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4c4d214e-8fa3-46d4-b111-9586ad6e7a8e\", \"childbox\": \"09fe392d-d67c-4f51-8295-7c4637389179\", \"subtext\": \"4fe1ab44-2d78-45f3-96cf-0230a7f019b0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1191, \"\"], [\"\", \"Unmapped\", \"text\", \"Designated investigational site staff will be required to respond to the query and make any necessary changes to the data.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4c4d214e-8fa3-46d4-b111-9586ad6e7a8e\", \"childbox\": \"5f7a9db2-88b3-4597-8781-0d1c0aad152c\", \"subtext\": \"4fe1ab44-2d78-45f3-96cf-0230a7f019b0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1192, \"\"], [\"\", \"Unmapped\", \"text\", \"Concomitant medications entered into the database will be coded using the WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dbfd4fb7-7043-4db2-ba81-323118186f33\", \"childbox\": \"a7cbaf4d-b415-409b-971d-bda3461aaedf\", \"subtext\": \"01d5b4f9-e93c-4e6c-be9c-8819b50b35f0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1193, \"\"], [\"\", \"Unmapped\", \"text\", \"AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dbfd4fb7-7043-4db2-ba81-323118186f33\", \"childbox\": \"bc766628-c7f7-411a-b4be-410309dc094f\", \"subtext\": \"9d919dcf-4c8e-45c0-9b5d-b747df6fa16f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1194, \"\"], [\"\", \"Unmapped\", \"text\", \"Laboratory samples will be processed through a central laboratory and the results will be sent electronically to Idenix.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 113, \"end_idx\": 118, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}, {\"start_idx\": 113, \"end_idx\": 118, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix\"}], \"roi_id\": {\"para\": \"53ec5081-8a0e-46a8-b18a-01e6dff099f1\", \"childbox\": \"60fee019-4829-49aa-b8d5-a4cd17c612c7\", \"subtext\": \"3e2c2fc2-748e-40f7-8da1-351fce8d1c05\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1195, \"\"], [\"\", \"Unmapped\", \"text\", \"After the above actions have been completed and the database has been declared to be complete and accurate, it will be locked for data analysis.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"78ab934b-0ab0-4eb5-afd0-0849ad3ca346\", \"childbox\": \"3759d308-7d3f-442e-8428-f916b530b721\", \"subtext\": \"4f7a2603-f524-488b-a9a7-574c12b0afb2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1196, \"\"], [\"\", \"Unmapped\", \"text\", \"Any changes to the database after that time can only be made with the approval of Senior Management of Idenix\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 103, \"end_idx\": 108, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix\"}, {\"start_idx\": 103, \"end_idx\": 108, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix\"}], \"roi_id\": {\"para\": \"78ab934b-0ab0-4eb5-afd0-0849ad3ca346\", \"childbox\": \"34b909e0-925a-4ef5-a476-eed25c93757e\", \"subtext\": \"8dbf508c-c042-4b92-a241-7a245bf03650\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1197, \"\"], [\"\", \"Unmapped\", \"text\", \"Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 20, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"b09d4c9a-07f8-4de7-b842-9e3095f9b061\", \"childbox\": \"c9cdbaf4-0f4a-4412-8485-500b812065b9\", \"subtext\": \"9f732396-2024-4e06-9824-4f87550a44c0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1198, \"\"], [\"\", \"Unmapped\", \"header\", \"9.4 Archival of study records\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"c2616793-aaee-49d6-89e7-52c511544647\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1199, \"\"], [\"\", \"Unmapped\", \"text\", \"Essential documents should be retained for a minimum of two years after the last approval of a marketing application in an International Conference on Harmonisation (ICH) region and until there are no pending or contemplated marketing applications in an ICH region or at least two years have elapsed since the formal discontinuation of clinical development of the investigational product.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cea9d712-c4d0-4836-b644-19ee81a8475f\", \"childbox\": \"ef89c216-7cf4-4940-8f79-39ceba370194\", \"subtext\": \"2fdefe62-b318-4041-bd19-e0ef532d727c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1200, \"\"], [\"\", \"Unmapped\", \"text\", \"However, these documents should be retained for a longer period if required by the applicable local requirements.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cea9d712-c4d0-4836-b644-19ee81a8475f\", \"childbox\": \"d4d14c09-9917-4324-9fe8-161a5cba2937\", \"subtext\": \"07003f60-ce2e-4f05-81b1-7241debb07dd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1201, \"\"], [\"\", \"Unmapped\", \"header\", \"10 Statistical analyses\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"110a64bc-06bf-466d-9510-56781be8fcd8\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1202, \"\"], [\"\", \"Unmapped\", \"text\", \"Details of the statistical analyses will be provided in the Statistical Analysis Plan (SAP).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0e1708c1-a532-4ba3-8fa8-6234ba7adfb3\", \"childbox\": \"41f8e1f2-59db-4dc6-9f6a-c48a106456a5\", \"subtext\": \"83c3e4cb-0ca7-4461-a40f-774554d7b1ec\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1203, \"\"], [\"\", \"Unmapped\", \"header\", \"10.1 Populations for analysis\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"66db3855-2dbf-48ba-b7d4-ba9b22d36ecf\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1204, \"\"], [\"\", \"Unmapped\", \"text\", \"The safety population will include all subjects who receive at least one dose of study drug(s).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dbbc4a73-6b82-4a01-8f55-9cc163cfb7cf\", \"childbox\": \"027f4579-5642-4741-be64-3207010aa72a\", \"subtext\": \"a8991762-4318-4de9-926b-c3392ea2c798\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1205, \"\"], [\"\", \"Unmapped\", \"text\", \"Other analysis populations will be defined in the SAP.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9005180a-49bd-4d3c-a206-5fda78e412ae\", \"childbox\": \"7eabaa80-9aef-4ecf-a7b4-82cf12f8f6d0\", \"subtext\": \"42462b87-ddff-49b5-a55c-636180ac3433\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1206, \"\"], [\"\", \"Unmapped\", \"header\", \"10.1.1 Protocol deviations\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"38dc846e-5600-4c77-bfcd-51a4f9d11be4\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1207, \"\"], [\"\", \"Unmapped\", \"text\", \"Departures from the protocol should be avoided, unless required for the safety of the subject.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"60fa7eb5-7a99-487b-b7e6-377417f2ac43\", \"childbox\": \"76765f59-6c27-4878-bf3d-63cb9eaa2c9c\", \"subtext\": \"8e38ccb8-d741-4e1e-98c8-34d03fb7ec37\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1208, \"\"], [\"\", \"Unmapped\", \"text\", \"The following is a list of significant protocol deviations which may exclude subjects from the efficacy analysis:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"60fa7eb5-7a99-487b-b7e6-377417f2ac43\", \"childbox\": \"b230fdb7-1bd3-4efa-8662-fb2eb7e674bb\", \"subtext\": \"8e38ccb8-d741-4e1e-98c8-34d03fb7ec37\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1209, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Subject does not have chronic HCV Genotype 1 or 3 infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3a6f6a3f-e038-43bb-9441-458ccaf21da9\", \"childbox\": \"311f5129-1796-455c-8522-31a0ef6a288c\", \"subtext\": \"ec439e3e-8fe6-42c5-8ca0-9ce697c9f20c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1210, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Subject received another antiviral treatment for HCV during the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"af1212cc-c6ad-4d21-a382-2e51132d6c11\", \"childbox\": \"42a722a3-bd1a-4d94-8ae2-04402f557ab4\", \"subtext\": \"0f6fc872-9048-47a0-9b71-54723f704b95\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1211, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Subject had previously received antiviral treatment for hepatitis C infection.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"008a4b08-6898-4a68-b84c-0ec11d99e472\", \"childbox\": \"caeb6360-f8bf-45e7-ae07-3e1da8a66d50\", \"subtext\": \"981521fc-4009-4bae-80a1-17c9f563a26f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1212, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"008a4b08-6898-4a68-b84c-0ec11d99e472\", \"childbox\": \"63ff4801-d015-4ed0-a7f3-6776c2dfde8f\", \"subtext\": \"576f6d79-223c-45eb-b88f-57fcf23ed7b3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1213, \"\"], [\"\", \"Unmapped\", \"text\", \"Note: Noncirrhotic, Peg-IFN/RBV-na\\u00efve subjects who received investigational treatment in the Idenix-sponsored IDX-04B-001 or IDX-04C-001 clinical trials and are otherwise qualified for entry into this study may enroll in the present study following a 3-month washout period.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 93, \"end_idx\": 108, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"Idenix-sponsored\"}], \"roi_id\": {\"para\": \"008a4b08-6898-4a68-b84c-0ec11d99e472\", \"childbox\": \"63ff4801-d015-4ed0-a7f3-6776c2dfde8f\", \"subtext\": \"6e7694ce-e8d7-4da6-aa9b-2e92a28ea210\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": true, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1214, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"008a4b08-6898-4a68-b84c-0ec11d99e472\", \"childbox\": \"63ff4801-d015-4ed0-a7f3-6776c2dfde8f\", \"subtext\": \"312d7131-db2f-424f-bb91-7153e9c94dc8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1215, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Subject had poor compliance with study drug regimen, as defined in the SAP.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b1d26258-1a9e-4989-b13b-39e817825349\", \"childbox\": \"9175f1f0-d50f-46f3-b4bb-c6ae19055401\", \"subtext\": \"6c2d93fe-63be-49ba-bcd6-29888b72de50\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1216, \"\"], [\"\", \"Unmapped\", \"text\", \"Other protocol deviations which may affect subject safety or demonstrate noncompliance with the protocol include:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f4736633-674c-4245-b055-4c27c4a7ba22\", \"childbox\": \"d0e30bec-e379-46a8-86a9-041c90538729\", \"subtext\": \"a263936b-602b-4315-b10a-b08933c72f55\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1217, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Informed consent issues (for example, study-specific procedures occurred before informed consent form was signed).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"86093237-7a49-4e6a-996e-88e53476f805\", \"childbox\": \"bcdaa848-4c81-4075-9124-b95c1d926061\", \"subtext\": \"e0d40733-71a7-4eea-91f2-1b2e59ab5ee3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1218, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Inclusion/exclusion criteria not met.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b776ec70-d848-4e59-801b-0a2647ee97bf\", \"childbox\": \"a674b8d1-5b72-4a96-b5e0-180d8ba4453f\", \"subtext\": \"4265973d-0d8b-407d-9f92-a4fdd38cd67d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1219, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Randomization error.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"76fc0f3c-6f5c-40e6-85c0-618f6506a8be\", \"childbox\": \"52e0f28a-9e98-4d26-9bb3-e38424a45557\", \"subtext\": \"d0db51d1-daab-4313-bb0b-5dc1003d8c2f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1220, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Prohibited concomitant medication use.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0f8da100-cd26-411a-aa1a-c076f2a6b9d3\", \"childbox\": \"61dd6822-d4cb-4b57-b0eb-4fe2053badcb\", \"subtext\": \"2e1a8359-3a5a-49d1-93ec-aeaac7b17b91\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1221, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Missed safety or laboratory assessment.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4d26f2d5-f980-4b71-af0b-50af861a4d61\", \"childbox\": \"066fc5ac-dc90-47e3-b173-1ac44f95eecc\", \"subtext\": \"d2025abf-73ed-460e-9815-9a2b29450022\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1222, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 AE, SAE or pregnancy reporting procedures not followed.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"13348f36-d314-48e0-ac40-1057f603bc32\", \"childbox\": \"2ab75812-246b-43dc-85f4-0a753ace61bd\", \"subtext\": \"5f9da8b7-407d-4510-a717-84882bff55ac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1223, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Assessments or procedures performed by site personnel who were not appropriately qualified or trained.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a731afa6-760c-4097-b457-fa7881e6b2ef\", \"childbox\": \"1960bbb5-8d69-466d-a3a7-2061ee60f911\", \"subtext\": \"c13b9226-4696-4a71-8420-a01398e9f339\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1224, \"\"], [\"\", \"Unmapped\", \"header\", \"10.2 Subject demographics/other baseline characteristics\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"c61caf89-bb03-4d6a-b03b-2f8495cc6ede\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1225, \"\"], [\"\", \"Unmapped\", \"text\", \"Demographic and baseline characteristics will be summarized using descriptive statistics.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a7b37668-7c56-47d5-a8cc-fba2f886fd46\", \"childbox\": \"2c815736-48c0-4018-9d24-1e6f520f44cd\", \"subtext\": \"395fad78-70d8-482c-aa0c-5052e5b2deb1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1226, \"\"], [\"\", \"Unmapped\", \"header\", \"10.3 Analysis of the primary objective(s)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"c23cc8f6-1270-4ce1-b894-09b12abf21d3\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Follow-up of adverse events\", \"8.2\", \"2\", 1227, \"\"], [\"\", \"Unmapped\", \"header\", \"10.3.1 Safety parameters\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"0c89ae8d-5f70-4f8a-811b-ba6fa01fefb3\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1228, \"\"], [\"\", \"Unmapped\", \"text\", \"The safety endpoints of this study are:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fab21c5d-dd13-4d3c-a779-9b20a37f93f1\", \"childbox\": \"e6b0d906-ca09-46d3-9d82-628cc71883e0\", \"subtext\": \"cd54002c-b0e0-41fc-a16b-11b623d59df5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1229, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Proportion of subjects experiencing SAEs\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6a9a8f66-8b6e-4017-9231-65eb182b2647\", \"childbox\": \"7903e006-7b39-4a9c-b41f-de047a72208d\", \"subtext\": \"a47f57fd-8458-4ad4-bd7e-687b396e8555\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1230, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Proportion of subjects experiencing AEs\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"430abeb2-515d-4d01-8bc4-d43abb077b83\", \"childbox\": \"650d7d88-bc28-42b7-9d55-faa12bdbec28\", \"subtext\": \"9a6597c4-d3ce-42e2-8a2f-7727edf5b0fa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1231, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022 Proportion of subjects experiencing Grade 1-4 laboratory abnormalities\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1ad6e7b1-e361-4141-9f2d-d9cd12b9a15d\", \"childbox\": \"6295891a-f8cb-43d3-ae1a-87e08cbb85ef\", \"subtext\": \"4157fc10-54a0-46a0-bcdf-9eb6c468a74d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1232, \"\"], [\"\", \"Unmapped\", \"text\", \"The proportions of subjects experiencing the above safety endpoints will be tabulated and summarized with descriptive statistics.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"51e5ae29-ff7a-4443-a619-d79e4a0b31e1\", \"childbox\": \"019084f6-6582-41e7-b19b-3db553a6dac5\", \"subtext\": \"19c7ad04-5c83-4cff-af29-9ec1afa90db3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1233, \"\"], [\"\", \"Unmapped\", \"text\", \"Laboratory abnormalities will be graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS (2004), Clarification August 2009).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 50, \"end_idx\": 71, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Division of AIDS Table\"}, {\"start_idx\": 151, \"end_idx\": 170, \"standard_entity_name\": \"OTHER: Person Name\", \"subcategory\": \"OTHER: Person Name\", \"confidence\": 100.0, \"text\": \"Clarification August\"}], \"roi_id\": {\"para\": \"51e5ae29-ff7a-4443-a619-d79e4a0b31e1\", \"childbox\": \"33af1149-7157-4fe1-a38c-8dbde3b84a40\", \"subtext\": \"19c7ad04-5c83-4cff-af29-9ec1afa90db3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1234, \"\"], [\"\", \"Unmapped\", \"header\", \"10.3.2 Antiviral activity\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"ee1b38ea-82e1-4c98-b30d-c085b233a7e8\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1235, \"\"], [\"\", \"Unmapped\", \"text\", \"The key antiviral activity endpoints are:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"27de5904-1b2a-4039-b0d5-f2370cf41422\", \"childbox\": \"964d5184-d53a-4480-8932-782817f9de07\", \"subtext\": \"b1a88501-6112-4b0b-99e1-95f5c5062fe1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1236, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2022\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb395b73-5105-4fdd-b67a-8676ef7d8ed4\", \"childbox\": \"7d15c28e-8be7-4047-817e-493af3d56f8e\", \"subtext\": \"a8f27b32-c5b4-49ef-a1f3-38c5d6335fca\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1237, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb395b73-5105-4fdd-b67a-8676ef7d8ed4\", \"childbox\": \"7d15c28e-8be7-4047-817e-493af3d56f8e\", \"subtext\": \"cb83a009-ccfb-437e-a631-2d5372047407\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1238, \"\"], [\"\", \"Unmapped\", \"text\", \"Proportion of subjects with plasma HCV RNA <LLOQ\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb395b73-5105-4fdd-b67a-8676ef7d8ed4\", \"childbox\": \"7d15c28e-8be7-4047-817e-493af3d56f8e\", \"subtext\": \"d2c0c9a7-94eb-43c8-8671-e020ecb69ba8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1239, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb395b73-5105-4fdd-b67a-8676ef7d8ed4\", \"childbox\": \"7d15c28e-8be7-4047-817e-493af3d56f8e\", \"subtext\": \"8c151d36-de3e-4349-997a-b6153cb4191a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1240, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb395b73-5105-4fdd-b67a-8676ef7d8ed4\", \"childbox\": \"7d15c28e-8be7-4047-817e-493af3d56f8e\", \"subtext\": \"11d3f1b9-3885-4c54-a1b7-17307ee9da7e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1241, \"\"], [\"\", \"Unmapped\", \"text\", \"Primary:\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb395b73-5105-4fdd-b67a-8676ef7d8ed4\", \"childbox\": \"7d15c28e-8be7-4047-817e-493af3d56f8e\", \"subtext\": \"c3a72dfb-16b6-48f7-a4e5-4c406a3e2062\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1242, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"4cbe681f-8142-40d2-aa96-59437cb6fa22\", \"subtext\": \"e93579eb-5180-4533-9100-e8ae3e044e26\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1243, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"4cbe681f-8142-40d2-aa96-59437cb6fa22\", \"subtext\": \"341f5510-557e-4f33-9d93-6cdeb13455f8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1244, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"4cbe681f-8142-40d2-aa96-59437cb6fa22\", \"subtext\": \"08f5421b-dd6e-4617-a190-84cb4281e998\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1245, \"\"], [\"\", \"Unmapped\", \"text\", \"12\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"4cbe681f-8142-40d2-aa96-59437cb6fa22\", \"subtext\": \"867b517c-636d-4d62-bbb0-bd204d2b3388\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1246, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"4cbe681f-8142-40d2-aa96-59437cb6fa22\", \"subtext\": \"b18a0333-b8aa-4167-81ae-d6faac0bcc62\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1247, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"12089107-1330-49e1-ae69-65ddc3d4e0bc\", \"subtext\": \"04bf8c9a-2708-433a-a254-eb2e539a1533\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1248, \"\"], [\"\", \"Unmapped\", \"text\", \"12 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"de5695a3-7705-41e7-8275-d6b1cd7338fc\", \"subtext\": \"04bf8c9a-2708-433a-a254-eb2e539a1533\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1249, \"\"], [\"\", \"Unmapped\", \"text\", \"o\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"de5695a3-7705-41e7-8275-d6b1cd7338fc\", \"subtext\": \"25972961-3aec-45f7-9568-c736f303916f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Courier New\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1250, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"de5695a3-7705-41e7-8275-d6b1cd7338fc\", \"subtext\": \"b8a71ce5-d826-43d1-b51f-fb868fbb51c3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1251, \"\"], [\"\", \"Unmapped\", \"text\", \"Secondary\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e3d14e39-6b2a-4dd6-8180-3e6d3e276b2b\", \"childbox\": \"de5695a3-7705-41e7-8275-d6b1cd7338fc\", \"subtext\": \"fb199fb7-29f5-4c61-975a-15a513473081\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1252, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a38a5086-810d-4aef-bdfe-7beb6a534162\", \"childbox\": \"f5650cda-5113-4857-8b49-b5543bbaa2fe\", \"subtext\": \"b676bedb-27aa-4929-875b-a36b82b1af17\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1253, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a38a5086-810d-4aef-bdfe-7beb6a534162\", \"childbox\": \"f5650cda-5113-4857-8b49-b5543bbaa2fe\", \"subtext\": \"d4f1d5c8-b51f-4139-9cc9-a488366a8e50\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1254, \"\"], [\"\", \"Unmapped\", \"text\", \"Week 4 during treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a38a5086-810d-4aef-bdfe-7beb6a534162\", \"childbox\": \"f5650cda-5113-4857-8b49-b5543bbaa2fe\", \"subtext\": \"c6cd3426-f5a4-4880-ad4c-85c01ed47024\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1255, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e1ccd832-34b6-4f92-a641-b8377fcd2b45\", \"childbox\": \"86c8095c-7d92-49a8-9bf8-07469f2604ca\", \"subtext\": \"b12614d9-5636-4b6d-b839-c77acd528bbb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1256, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e1ccd832-34b6-4f92-a641-b8377fcd2b45\", \"childbox\": \"86c8095c-7d92-49a8-9bf8-07469f2604ca\", \"subtext\": \"e919df31-05d1-4080-b09c-8de3fbeb15c9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1257, \"\"], [\"\", \"Unmapped\", \"text\", \"End of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e1ccd832-34b6-4f92-a641-b8377fcd2b45\", \"childbox\": \"86c8095c-7d92-49a8-9bf8-07469f2604ca\", \"subtext\": \"480fc8c6-4386-4a5e-9614-81c3db468766\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1258, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"fe2d679e-b5e9-4388-ad4a-a6b3df148d17\", \"subtext\": \"e8276ea3-7819-4331-a9f9-c62b247478dc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1259, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"3eeaad3c-a031-4eb2-a07b-a008b775d9de\", \"subtext\": \"4f131f7e-1136-432f-ac88-6c1cfccd9875\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1260, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"3eeaad3c-a031-4eb2-a07b-a008b775d9de\", \"subtext\": \"a2518536-20c8-4f77-8246-c4e714421810\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1261, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"3eeaad3c-a031-4eb2-a07b-a008b775d9de\", \"subtext\": \"dc3ec09e-ead9-4f0f-9b02-057a6cce786a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1262, \"\"], [\"\", \"Unmapped\", \"text\", \"4\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"3eeaad3c-a031-4eb2-a07b-a008b775d9de\", \"subtext\": \"0d897cd9-2af5-4c56-adaa-e61b75600364\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1263, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"3eeaad3c-a031-4eb2-a07b-a008b775d9de\", \"subtext\": \"a8806361-5b09-4e54-8b3a-4ba9acc30e9b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1264, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"69bb7d7c-23eb-44c6-ad7a-c96bcdd1ef41\", \"subtext\": \"d45952f4-a398-42ac-a308-ef1d22df2f01\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1265, \"\"], [\"\", \"Unmapped\", \"text\", \"4 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fc7634ca-50e0-4ba8-b9b2-73cb1b6c8246\", \"childbox\": \"90ad39bf-59be-4f94-bdf6-a2f4e929af39\", \"subtext\": \"d45952f4-a398-42ac-a308-ef1d22df2f01\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1266, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"d59a2598-a897-4334-a857-4d7a17175ecd\", \"subtext\": \"37169550-d64f-4c31-b6a4-d2d0875fe24c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1267, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"58d763b9-1445-46d1-82a3-6dfbb5d59e44\", \"subtext\": \"533dc429-5cf7-46a9-91ac-37efd15a0bc7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1268, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"58d763b9-1445-46d1-82a3-6dfbb5d59e44\", \"subtext\": \"9789dd4f-be36-40bc-ad14-5e8a9f989cf1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1269, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"58d763b9-1445-46d1-82a3-6dfbb5d59e44\", \"subtext\": \"b2895796-c1aa-495f-97d6-1f96bfcccf3b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1270, \"\"], [\"\", \"Unmapped\", \"text\", \"8\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"58d763b9-1445-46d1-82a3-6dfbb5d59e44\", \"subtext\": \"c176bcb0-4b5e-4535-b710-67ca9be14f1b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1271, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"58d763b9-1445-46d1-82a3-6dfbb5d59e44\", \"subtext\": \"88c25d50-35a7-48ec-b830-b40797a3bc9c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1272, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"5eeac385-a051-4fd6-a7e8-0fcb32f873c2\", \"subtext\": \"7d2428df-7dba-4dd2-8f4e-7688f134299f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1273, \"\"], [\"\", \"Unmapped\", \"text\", \"8 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6edb57b8-8105-4be7-bd29-613d3b31a8a8\", \"childbox\": \"d7a57b81-81b9-4d4d-95cd-605a43bcbcec\", \"subtext\": \"7d2428df-7dba-4dd2-8f4e-7688f134299f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1274, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"f40649a4-2d67-4191-9ca3-0f828af28b6d\", \"subtext\": \"6e7157af-0dc5-4ada-b421-16fd28df48e5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Calibri\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1275, \"\"], [\"\", \"Unmapped\", \"text\", \"\\u2212\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"e78a8555-d23a-49df-b9a9-95c6981b3ce6\", \"subtext\": \"5c52b54b-ac3d-48ba-ab8f-de3f4d825c0d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Segoe UI Symbol\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1276, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"e78a8555-d23a-49df-b9a9-95c6981b3ce6\", \"subtext\": \"5ea270e6-61d6-47b7-9077-f54770050a7b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1277, \"\"], [\"\", \"Unmapped\", \"text\", \"SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"e78a8555-d23a-49df-b9a9-95c6981b3ce6\", \"subtext\": \"70d111b5-5b4a-4412-9227-e21507114023\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1278, \"\"], [\"\", \"Unmapped\", \"text\", \"24\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"e78a8555-d23a-49df-b9a9-95c6981b3ce6\", \"subtext\": \"1b7df308-1f96-4bbf-9e15-b1f19d187c61\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1279, \"\"], [\"\", \"Unmapped\", \"text\", \":\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"e78a8555-d23a-49df-b9a9-95c6981b3ce6\", \"subtext\": \"36c3602a-f3b1-4557-b27b-c00df50711a3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1280, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"7470546b-020a-430e-96f7-acb326557849\", \"subtext\": \"d292a705-e2fc-44af-ba08-b4ff330ae0f3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1281, \"\"], [\"\", \"Unmapped\", \"text\", \"24 weeks after the end of treatment\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9d2e2a60-bba3-4b59-bde7-3e7c7c45cf25\", \"childbox\": \"1b6560e7-2b5b-4684-8725-ba15ed1886f0\", \"subtext\": \"d292a705-e2fc-44af-ba08-b4ff330ae0f3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1282, \"\"], [\"\", \"Unmapped\", \"text\", \"Details of the antiviral activity and efficacy analyses will be provided in the SAP.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1390cf35-e2ba-4dcd-9516-539badf3925a\", \"childbox\": \"3de66f45-2c48-42b4-861c-62c1736e943a\", \"subtext\": \"320820e0-2c1e-439f-9b6c-2620614eee22\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1283, \"\"], [\"\", \"Unmapped\", \"header\", \"10.4 Analysis of secondary objective(s)\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"4e601d41-ec9c-4ac6-8130-71b5d34309b1\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Safety parameters\", \"10.3.1\", \"3\", 1284, \"\"], [\"\", \"Unmapped\", \"header\", \"10.4.1 Pharmacokinetic parameters\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"03a6f0ea-13d0-4643-ae29-f5b099a0a2ac\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1285, \"\"], [\"\", \"Unmapped\", \"text\", \"Pharmacokinetic parameters will be summarized using descriptive statistics (arithmetic mean, geometric mean, median, standard deviation (SD), standard error of the mean (SEM), coefficient of variation (CV) %, sample size, minimum and maximum, where applicable).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"dfb24a09-a12d-4bc2-8b88-4c0fe325f695\", \"childbox\": \"6b9a41a7-53d8-4b4c-9f55-61fb3d50d742\", \"subtext\": \"5a476471-e3aa-4fdf-be25-4751783071c4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1286, \"\"], [\"\", \"Unmapped\", \"header\", \"10.4.2 Pharmacokinetic/pharmacodynamic relationships\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"2f4fcb2a-63d3-4a18-a59e-0ea1a8451793\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1287, \"\"], [\"\", \"Unmapped\", \"text\", \"PK/PD analyses will be described in the SAP.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"70183e1e-9843-4cac-8268-5770779f5a29\", \"childbox\": \"65e66552-1442-46db-9c33-2ba66e28cf91\", \"subtext\": \"f4a60b34-6589-4605-8597-5874ef986bf7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1288, \"\"], [\"\", \"Unmapped\", \"header\", \"10.4.3 Emergence of resistance mutations\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"5fb641fc-29a9-4b6d-84a1-c3d0e2229580\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1289, \"\"], [\"\", \"Unmapped\", \"text\", \"The analysis of resistance will be provided in a separate report.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b1bc1268-67f0-49fd-b215-82f29914fdeb\", \"childbox\": \"c66df97c-38a1-4000-bbd5-4e0219f783af\", \"subtext\": \"801e75fd-c1f4-41f8-9644-bccbc77620fc\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1290, \"\"], [\"\", \"Unmapped\", \"header\", \"10.4.4 Durability of SVR and the kinetics of antiviral resistant HCV\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"420e6ed0-add1-419b-97f2-414310aad9fb\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1291, \"\"], [\"\", \"Unmapped\", \"text\", \"The proportion of subjects with sustained SVR, defined as the absence of detectable plasma HCV RNA after SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c001c5fe-33dd-490f-9493-7ab53ce414c6\", \"childbox\": \"e5c1dc0d-48db-493b-91e7-1d01127f6c77\", \"subtext\": \"e156f778-f419-413b-904c-0df264b2f1bb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1292, \"\"], [\"\", \"Unmapped\", \"text\", \"24\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c001c5fe-33dd-490f-9493-7ab53ce414c6\", \"childbox\": \"e5c1dc0d-48db-493b-91e7-1d01127f6c77\", \"subtext\": \"054b7a16-1861-4ff6-95e1-86355f001a1f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1293, \"\"], [\"\", \"Unmapped\", \"text\", \"will be descriptively evaluated over the extended observational follow-on phase (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c001c5fe-33dd-490f-9493-7ab53ce414c6\", \"childbox\": \"e5c1dc0d-48db-493b-91e7-1d01127f6c77\", \"subtext\": \"30afa7ad-124c-4a81-8b28-d78299a133b9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1294, \"\"], [\"\", \"Unmapped\", \"text\", \"The proportion of subjects with detectable resistance mutations with population sequencing will be descriptively evaluated over the extended observational follow-on phase (Table 7-2).\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9e85981c-6207-4283-b175-c402d9e6da6e\", \"childbox\": \"5ef37110-5128-46b1-998d-daaa612af4bb\", \"subtext\": \"289d1c26-89a3-45de-bb18-b5639a388c7a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1295, \"\"], [\"\", \"Unmapped\", \"header\", \"10.5 Missing, unused and spurious data\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"b6fb016a-5552-4558-953f-5f9a06ea5c52\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1296, \"\"], [\"\", \"Unmapped\", \"text\", \"Handling of missing, unused and spurious data will be described in the SAP.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5ea21528-5264-4064-a6e1-19c9f17a9cde\", \"childbox\": \"afb2a7cd-f220-4295-87ec-9c4e42b0678c\", \"subtext\": \"cae47adf-345f-4bfc-8930-e1b7e5c76200\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1297, \"\"], [\"\", \"Unmapped\", \"text\", \"All available safety and PK data will be included in data listings.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5ea21528-5264-4064-a6e1-19c9f17a9cde\", \"childbox\": \"64cd9620-ca89-4d92-863e-09cf4d1be66e\", \"subtext\": \"f97212e6-7ec8-472f-9be9-00d52ddf2cb4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1298, \"\"], [\"\", \"Unmapped\", \"header\", \"10.6 Ongoing data analysis\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"ec94fa65-a944-427b-80fa-379a8467959d\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1299, \"\"], [\"\", \"Unmapped\", \"text\", \"For this early phase study, the Sponsor may perform interim data reviews during the course of the study.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb4fd1c2-0d74-4998-abb6-880265a00c87\", \"childbox\": \"2c7eb87b-7695-4478-a4e0-b1d00610f983\", \"subtext\": \"576c7639-50b1-4002-9d68-37543d74c00b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1300, \"\"], [\"\", \"Unmapped\", \"header\", \"10.7 Sample size consideration\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"2a19b4ca-6a07-444b-9f92-994f12e89ca2\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1301, \"\"], [\"\", \"Unmapped\", \"text\", \"The primary antiviral activity endpoint is the proportion of subjects with undetectable levels of HCV RNA at 12 weeks after the end of treatment (SVR\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20807194-5558-42fa-873f-68ca0d5eaa7a\", \"childbox\": \"2272c4b9-7f9a-48f5-aa80-cc8bba5b9953\", \"subtext\": \"50c6f79c-fde1-4185-8af1-74a7e1cac76e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1302, \"\"], [\"\", \"Unmapped\", \"text\", \"12\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20807194-5558-42fa-873f-68ca0d5eaa7a\", \"childbox\": \"2272c4b9-7f9a-48f5-aa80-cc8bba5b9953\", \"subtext\": \"48212025-0dca-478d-9b12-ca1463359a8e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"subscript\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1303, \"\"], [\"\", \"Unmapped\", \"text\", \").\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20807194-5558-42fa-873f-68ca0d5eaa7a\", \"childbox\": \"2272c4b9-7f9a-48f5-aa80-cc8bba5b9953\", \"subtext\": \"4d956273-eee6-45d0-9256-a403b2794fd5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1304, \"\"], [\"\", \"Unmapped\", \"text\", \"Table 10-1 displays the levels of detection based on the difference in the primary efficacy endpoint vs.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20807194-5558-42fa-873f-68ca0d5eaa7a\", \"childbox\": \"f515b5a0-a098-42a3-9840-422117c4a7e3\", \"subtext\": \"4d956273-eee6-45d0-9256-a403b2794fd5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1305, \"\"], [\"\", \"Unmapped\", \"text\", \"the reference (SOVALDI\\u2122 (2013)), with 80% power at a two-sided significance level of \\u03b1=0.05.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20807194-5558-42fa-873f-68ca0d5eaa7a\", \"childbox\": \"718bae02-4d8d-4163-867c-47ee54f6ab44\", \"subtext\": \"660a0b1b-10b3-46a3-a729-cffc436913d8\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Pharmacokinetic parameters\", \"10.4.1\", \"3\", 1306, \"\"], [\"\", \"Unmapped\", \"header\", \"Table 10-1 Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", {\"IsBold\": false, \"font_size\": 22, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"b8025ff4-bb8e-4aa3-b354-a527c99a77da\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 22, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1307, \"\"], [\"\", \"Unmapped\", \"table\", {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>HCV  genotype</td>\\n      <td>Sample size</td>\\n      <td>SVR 12 observed</td>\\n      <td>Reference</td>\\n      <td>Difference in SVR 12</td>\\n      <td>Power</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>1</td>\\n      <td>60</td>\\n      <td>76%</td>\\n      <td>89% <sup>a</sup></td>\\n      <td>13%</td>\\n      <td>82%</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>3</td>\\n      <td>40</td>\\n      <td>77%</td>\\n      <td>56% <sup>b</sup></td>\\n      <td>21%</td>\\n      <td>80%</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV  genotype\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"3c8329f3-03c1-41aa-a3ff-1acefa1b9f09\\\",\\\"column_roi_id\\\":\\\"70bd93dd-b766-46ea-9859-66efffcf5aa3\\\",\\\"datacell_roi_id\\\":\\\"b6afa684-df50-4a74-be73-72a3530bd31f\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Sample size\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"3c8329f3-03c1-41aa-a3ff-1acefa1b9f09\\\",\\\"column_roi_id\\\":\\\"8b4a5234-7463-4e4b-bd24-b2680f0265f4\\\",\\\"datacell_roi_id\\\":\\\"ade98602-1af8-46ed-99c2-82540b29c52a\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SVR 12 observed\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"3c8329f3-03c1-41aa-a3ff-1acefa1b9f09\\\",\\\"column_roi_id\\\":\\\"584c28b0-63a5-4044-9e2c-902fe53e72d5\\\",\\\"datacell_roi_id\\\":\\\"d8f1fd1d-9834-451f-9690-bf7be3358f47\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Reference\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"3c8329f3-03c1-41aa-a3ff-1acefa1b9f09\\\",\\\"column_roi_id\\\":\\\"8271775e-e98c-43fe-88ae-8b52e65f2a74\\\",\\\"datacell_roi_id\\\":\\\"833e90f9-19a4-4c33-87f6-506492732b15\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Difference in SVR 12 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"3c8329f3-03c1-41aa-a3ff-1acefa1b9f09\\\",\\\"column_roi_id\\\":\\\"7af00ab4-3952-43c6-bfd2-20a0f701fdf1\\\",\\\"datacell_roi_id\\\":\\\"06e976c3-5994-443c-a795-47531253ee0d\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Power\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"3c8329f3-03c1-41aa-a3ff-1acefa1b9f09\\\",\\\"column_roi_id\\\":\\\"fcd9ccf9-6373-4cae-9e4a-451ae96fe3a1\\\",\\\"datacell_roi_id\\\":\\\"086162e1-719d-473a-9ba6-81bf61896b93\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"a3cbf80d-2c89-4a35-a151-ab6fc59866a2\\\",\\\"column_roi_id\\\":\\\"4810d0df-5d36-4183-b44a-d65658d58a55\\\",\\\"datacell_roi_id\\\":\\\"45b142eb-293f-4dd5-ab86-2e0d3ff6517d\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"60\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"a3cbf80d-2c89-4a35-a151-ab6fc59866a2\\\",\\\"column_roi_id\\\":\\\"f1319a2e-c263-4d65-ba6a-decc4d15ce8c\\\",\\\"datacell_roi_id\\\":\\\"890a2ec8-0956-4d81-aa1e-bd4b8ba405c4\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"76%\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"a3cbf80d-2c89-4a35-a151-ab6fc59866a2\\\",\\\"column_roi_id\\\":\\\"cc9a6025-8bac-42ab-a234-63a3a89e7e1b\\\",\\\"datacell_roi_id\\\":\\\"14db593b-61b1-4fd7-bc87-95dc53af5d54\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"89% <sup>a<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"a3cbf80d-2c89-4a35-a151-ab6fc59866a2\\\",\\\"column_roi_id\\\":\\\"77928546-3065-4c71-bece-2972c6301c9a\\\",\\\"datacell_roi_id\\\":\\\"b114aea1-922f-4be7-9d1c-def9c4ddce20\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"13%\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"a3cbf80d-2c89-4a35-a151-ab6fc59866a2\\\",\\\"column_roi_id\\\":\\\"c364e27e-9fd3-4b7e-afe1-6fcc95cbf36f\\\",\\\"datacell_roi_id\\\":\\\"96b7d13f-3bbf-4245-8baf-c59c05e70f89\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"82%\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"a3cbf80d-2c89-4a35-a151-ab6fc59866a2\\\",\\\"column_roi_id\\\":\\\"3e76ce40-ee90-40fc-87f6-5338e866f36b\\\",\\\"datacell_roi_id\\\":\\\"b488ff7e-197d-42fd-ac74-c0e4a51053ee\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"fe14afd0-472e-4615-8966-6f765df39e39\\\",\\\"column_roi_id\\\":\\\"4614bb7d-43b8-419d-9e9f-749a5680b49e\\\",\\\"datacell_roi_id\\\":\\\"eaa6db96-eb90-4d66-bc7d-56638f5f731f\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"40\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"fe14afd0-472e-4615-8966-6f765df39e39\\\",\\\"column_roi_id\\\":\\\"e8983d90-289b-467e-8494-d0c969b9d1d8\\\",\\\"datacell_roi_id\\\":\\\"6d1d741d-1ff9-4b10-a203-ad2b7d2d36d6\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"77%\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"fe14afd0-472e-4615-8966-6f765df39e39\\\",\\\"column_roi_id\\\":\\\"f4b48ea4-4e49-46b2-9fed-2388af2c98a0\\\",\\\"datacell_roi_id\\\":\\\"e7075e64-dd38-48a3-baf4-57ee03e9dfd1\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"56% <sup>b<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"fe14afd0-472e-4615-8966-6f765df39e39\\\",\\\"column_roi_id\\\":\\\"facb79b3-6c46-449b-9ce8-a23ecfb3f3f9\\\",\\\"datacell_roi_id\\\":\\\"49264302-07bb-42c9-8b2a-e1fcfe64e30c\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"21%\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"fe14afd0-472e-4615-8966-6f765df39e39\\\",\\\"column_roi_id\\\":\\\"7e0787a9-2ec3-4d36-ade0-c03c1005fec2\\\",\\\"datacell_roi_id\\\":\\\"67534262-88ff-43dd-86b2-88065c7f0212\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"80%\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"c5151818-c3a6-4771-95be-b09184a2bda6\\\",\\\"row_roi_id\\\":\\\"fe14afd0-472e-4615-8966-6f765df39e39\\\",\\\"column_roi_id\\\":\\\"de778591-4873-4e8c-809c-d4287dd4f0fe\\\",\\\"datacell_roi_id\\\":\\\"aa0302fd-375b-40df-a3d4-de39c5f5396c\\\"},\\\"table_index\\\":15.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"43\", \"TableIndex\": \"16.0\", \"TableName\": \"Table 10-1 Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Header\": [0]}, {\"IsBold\": true, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b6afa684-df50-4a74-be73-72a3530bd31f\", \"childbox\": \"02cd2269-db89-4322-b9f1-62c6f50a44f6\", \"subtext\": \"c9d08fb7-7a2c-42e5-9c33-ee503c131688\"}, \"Bold\": true, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1308, \"\"], [\"\", \"Unmapped\", \"text\", \"a\", {\"IsBold\": false, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1067addb-df0c-43de-babb-03cb053231ce\", \"childbox\": \"70f23db9-194b-49ad-98a4-08d6b2232ab0\", \"subtext\": \"1053a971-aaf1-431e-a8b5-5db4f5c5c564\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"superscript\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1309, \"\"], [\"\", \"Unmapped\", \"text\", \"Response rate for Genotype 1 in NEUTRINO study (SOVALDI\\u2122 +Peg-IFN + RBV x 12 weeks)\", {\"IsBold\": false, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1067addb-df0c-43de-babb-03cb053231ce\", \"childbox\": \"70f23db9-194b-49ad-98a4-08d6b2232ab0\", \"subtext\": \"90487554-510b-4e09-ae11-0328ceb3a7e7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1310, \"\"], [\"\", \"Unmapped\", \"text\", \"b\", {\"IsBold\": false, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1067addb-df0c-43de-babb-03cb053231ce\", \"childbox\": \"70f23db9-194b-49ad-98a4-08d6b2232ab0\", \"subtext\": \"7f1f16c7-867a-429c-a2a2-14bf01e86027\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"superscript\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1311, \"\"], [\"\", \"Unmapped\", \"text\", \"Response rate for Genotype 3 in FISSION study (SOVALDI\\u2122 + RBV x 12 weeks)\", {\"IsBold\": false, \"font_size\": 18, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1067addb-df0c-43de-babb-03cb053231ce\", \"childbox\": \"70f23db9-194b-49ad-98a4-08d6b2232ab0\", \"subtext\": \"423e7b27-5b47-4a27-af68-565f395560cd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 18, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1312, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1067addb-df0c-43de-babb-03cb053231ce\", \"childbox\": \"70f23db9-194b-49ad-98a4-08d6b2232ab0\", \"subtext\": \"dacc2a56-18a2-48e5-b18a-d44203ffdcf5\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"-1  Levels of detection \\u2013 primary efficacy endpoint vs. the reference (SOVALDI\\u2122)\", \"Table 10\", \"3\", 1313, \"\"], [\"\", \"Unmapped\", \"header\", \"11 References\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading1\", \"entity\": [], \"roi_id\": {\"para\": \"b50828a9-b4f2-4cc3-83c1-e875e7a21ef7\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1314, \"\"], [\"\", \"Unmapped\", \"text\", \"[Division of AIDS (2004), Clarification August 2009] Table for Grading the Severity of Adult and Pediatric Adverse Events.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 1, \"end_idx\": 16, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Division of AIDS\"}, {\"start_idx\": 26, \"end_idx\": 45, \"standard_entity_name\": \"OTHER: Person Name\", \"subcategory\": \"OTHER: Person Name\", \"confidence\": 100.0, \"text\": \"Clarification August\"}], \"roi_id\": {\"para\": \"0ad9a71d-70bc-4b97-834c-f19c953538d2\", \"childbox\": \"2a9794ce-f310-4454-a902-22d4caf20e3c\", \"subtext\": \"78486766-6397-411e-8f95-eab06ae86261\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1315, \"\"], [\"\", \"Unmapped\", \"text\", \"[Ribavirin Tablets (2013)] [package insert].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3d8151df-341b-4a14-bdb6-d7072d65370a\", \"childbox\": \"cd02a63b-f966-4e26-b573-fa89dc5f233e\", \"subtext\": \"d392e5db-2f33-48db-b26f-919f52a7615e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1316, \"\"], [\"\", \"Unmapped\", \"text\", \"Pennington, NJ: Zydus Pharmaceuticals USA, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 16, \"end_idx\": 46, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Zydus Pharmaceuticals USA, Inc.\"}], \"roi_id\": {\"para\": \"3d8151df-341b-4a14-bdb6-d7072d65370a\", \"childbox\": \"9fa9d5ea-2584-41e4-a4b4-d406d7e85086\", \"subtext\": \"cbe3dcf3-dd6f-4e42-b1d1-c62c60dc98f0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1317, \"\"], [\"\", \"Unmapped\", \"text\", \"[Lawitz E, et al.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 1, \"end_idx\": 8, \"standard_entity_name\": \"OTHER: Person Name\", \"subcategory\": \"OTHER: Person Name\", \"confidence\": 100.0, \"text\": \"Lawitz E\"}], \"roi_id\": {\"para\": \"aa52dbc7-bb2a-4a7b-b997-51cd9a562592\", \"childbox\": \"59526e7b-8bae-4aab-a9c9-dde93cc55926\", \"subtext\": \"48be1684-07a9-4123-80e4-dd9e1d2cdd30\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1318, \"\"], [\"\", \"Unmapped\", \"text\", \"(2013)] A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Na\\u00efve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aa52dbc7-bb2a-4a7b-b997-51cd9a562592\", \"childbox\": \"9b1311e2-4226-4112-ac37-e62a2c03ae18\", \"subtext\": \"48be1684-07a9-4123-80e4-dd9e1d2cdd30\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1319, \"\"], [\"\", \"Unmapped\", \"text\", \"Presented at HEP DART, December 8\\u201312, 2013, Big Island, HI, USA.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aa52dbc7-bb2a-4a7b-b997-51cd9a562592\", \"childbox\": \"70bc67fe-25a6-44ba-96e0-5b2f50a07293\", \"subtext\": \"42745f59-7a4d-4177-bbb1-3552c2b5c4ca\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1320, \"\"], [\"\", \"Unmapped\", \"text\", \"[SOVALDI\\u2122 (2013)]: [package insert].\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"91dc9566-0c7e-4069-9322-f2e92283d43a\", \"childbox\": \"0bffe7d3-bbb4-4293-af18-49d335cdba60\", \"subtext\": \"453738aa-59ad-453d-a6bf-6fc4b2d492eb\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1321, \"\"], [\"\", \"Unmapped\", \"text\", \"Foster City, CA: Gilead Sciences, Inc.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 10, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Foster City\"}, {\"start_idx\": 17, \"end_idx\": 37, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Gilead Sciences, Inc.\"}], \"roi_id\": {\"para\": \"91dc9566-0c7e-4069-9322-f2e92283d43a\", \"childbox\": \"ee77b062-2378-4037-9c4f-7e0accf723f8\", \"subtext\": \"7b98d031-b60a-41b3-9264-52620d076b5d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1322, \"\"], [\"\", \"Unmapped\", \"text\", \"[World Health Organization (2013)] Hepatitis C.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 1, \"end_idx\": 25, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"World Health Organization\"}], \"roi_id\": {\"para\": \"ed81fb86-16a4-42f1-822f-cb2870924d05\", \"childbox\": \"61df365a-5611-4fea-84b0-e8d41dea2b31\", \"subtext\": \"4f630842-3e26-458d-b28d-e1fd621e7071\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1323, \"\"], [\"\", \"Unmapped\", \"text\", \"World Health Organization Updated July 2013.\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 24, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 62.0, \"text\": \"World Health Organization\"}], \"roi_id\": {\"para\": \"ed81fb86-16a4-42f1-822f-cb2870924d05\", \"childbox\": \"d5f06238-c548-41fc-ac81-7688bd6ae421\", \"subtext\": \"e144fb78-a9e8-4065-baa3-b3d4e4719838\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1324, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ed81fb86-16a4-42f1-822f-cb2870924d05\", \"childbox\": \"695f4785-48d9-40ef-926c-05a1e121064e\", \"subtext\": \"ac60708b-c7cc-4aab-bbb3-4c01c448b5f9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1325, \"\"], [\"\", \"Unmapped\", \"header\", \"Appendix 1:  Administrative procedures\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [], \"roi_id\": {\"para\": \"3e19e4f5-e355-47d3-99e3-d43a10dc79f4\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1326, \"\"], [\"\", \"Unmapped\", \"header\", \"Regulatory and ethical compliance\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"1cd0a131-cd64-4627-96d5-22301c006ad6\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1327, \"\"], [\"\", \"Unmapped\", \"text\", \"This clinical study was designed and shall be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 228, \"end_idx\": 236, \"standard_entity_name\": \"ANY: Address\", \"subcategory\": \"ANY: Address\", \"confidence\": 100.0, \"text\": \"20/EC, US\"}, {\"start_idx\": 223, \"end_idx\": 236, \"standard_entity_name\": \"ANY: Address\", \"subcategory\": \"ANY: Address\", \"confidence\": 100.0, \"text\": \"2001/20/EC, US\"}, {\"start_idx\": 280, \"end_idx\": 306, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Japanese Ministry of Health\"}], \"roi_id\": {\"para\": \"11db499b-fc1a-489b-aae2-9a961172fd63\", \"childbox\": \"808641bc-d6b4-4f08-b9ff-d87bcf05cd0e\", \"subtext\": \"91d2d391-a526-4c84-b6ef-44d3ca649baa\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1328, \"\"], [\"\", \"Unmapped\", \"header\", \"Responsibilities of the investigator and IRB/IEC/REB\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"c590a353-89fc-48ea-82a0-51b4f536b486\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1329, \"\"], [\"\", \"Unmapped\", \"text\", \"The protocol and the proposed informed consent form must be reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board (IRB/IEC/REB) before study start.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"531b5523-20af-4b9a-942f-6b32399126e5\", \"subtext\": \"426d1a44-6348-402a-9d9c-9e5c783e28d0\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1330, \"\"], [\"\", \"Unmapped\", \"text\", \"A signed and dated statement that the protocol and informed consent have been approved by the IRB/IEC/REB must be given to Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 123, \"end_idx\": 150, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 123, \"end_idx\": 150, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"3dc16a8a-6eb1-4032-9488-bc5149878880\", \"subtext\": \"e64f66b9-9cbd-4ef7-858a-73635bbf6a10\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1331, \"\"], [\"\", \"Unmapped\", \"text\", \"or its designated representative(s) before study initiation.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"c40a0b6a-a02e-4298-8cbe-6acda5fb4291\", \"subtext\": \"31498b6f-7459-4b7f-b58d-929b5dc07d48\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1332, \"\"], [\"\", \"Unmapped\", \"text\", \"Prior to study start, the investigator is required to sign the investigator statement page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"254db56d-24c2-4083-935e-a3d1b4ef2e74\", \"subtext\": \"31498b6f-7459-4b7f-b58d-929b5dc07d48\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1333, \"\"], [\"\", \"Unmapped\", \"text\", \"In addition, the investigator agrees to give access to all relevant data and records to Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 88, \"end_idx\": 115, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 88, \"end_idx\": 115, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"c18a8e0f-7b39-493f-ac5b-cb830ccc3041\", \"subtext\": \"2db2864c-730b-473c-834e-28229c3be6d7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1334, \"\"], [\"\", \"Unmapped\", \"text\", \"monitors, auditors, quality assurance representatives, designated agents of Idenix Pharmaceuticals, Inc., IRBs/IECs/REBs, and regulatory authorities as required.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 76, \"end_idx\": 103, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 76, \"end_idx\": 103, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"993ebcfd-7c82-4d84-8b31-db0ed36f8ace\", \"subtext\": \"2db2864c-730b-473c-834e-28229c3be6d7\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1335, \"\"], [\"\", \"Unmapped\", \"text\", \"If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 107, \"end_idx\": 134, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 107, \"end_idx\": 134, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"74810b51-bd66-4f37-9ea4-8dd854356a13\", \"subtext\": \"3616e763-c69a-4a31-8ca2-74f2d95135b3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1336, \"\"], [\"\", \"Unmapped\", \"text\", \"immediately that this request has been made.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8d89c6c8-c741-412c-a3f8-a04debec6713\", \"childbox\": \"b9d5ad59-e9d4-475a-b90b-3e3999e725bb\", \"subtext\": \"1b5ca564-7248-4ad8-b0fd-3e2f07494313\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1337, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator may delegate trial-related duties to qualified members of his or her staff.  Per ICH GCP, the investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4dd79320-5a03-482c-88ea-676a0e211982\", \"childbox\": \"acfe06a3-b0bc-43d5-943e-3fa0b23e29d0\", \"subtext\": \"e598c891-15d2-4ef3-87d0-1029f671eba3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1338, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4dd79320-5a03-482c-88ea-676a0e211982\", \"childbox\": \"3fe72de4-1334-4a4f-b452-e2f625d3c19a\", \"subtext\": \"d7ebca3f-bc12-4616-888d-e449e3de560b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1339, \"\"], [\"\", \"Unmapped\", \"header\", \"Informed consent\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"3068ec77-35d5-4736-b7d5-ed8805892c28\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1340, \"\"], [\"\", \"Unmapped\", \"text\", \"Eligible subjects may only be included in the study after providing written (witnessed, where required by law or regulation), IRB/IEC/REB-approved informed consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable representative of the subject.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"745ddbb4-d008-42e4-85b6-cacc89791a18\", \"subtext\": \"2edd88c4-4a31-4f98-8f56-29752e3ab5c3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1341, \"\"], [\"\", \"Unmapped\", \"text\", \"In cases where the subject\\u2019s representative gives consent, the subject should be informed about the study to the extent possible given his/her understanding.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"cce7d4ed-62df-410a-bd12-a276e4649006\", \"subtext\": \"f1c70a20-d9d1-4fa9-b7fa-1f542e6938ac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1342, \"\"], [\"\", \"Unmapped\", \"text\", \"If the subject is capable of doing so, he/she should indicate assent by personally signing and dating the written informed consent form or a separate assent form.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"a1d8a70c-c714-4c2c-af7f-056e700d18a6\", \"subtext\": \"f1c70a20-d9d1-4fa9-b7fa-1f542e6938ac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1343, \"\"], [\"\", \"Unmapped\", \"text\", \"Informed consent must be obtained before conducting any study-specific procedures (i.e., all of the procedures described in the protocol).\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"d9b13c87-6d12-40d2-bff1-9806ddfff1e1\", \"subtext\": \"6be53c47-736e-469d-8747-fbfb32f25705\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1344, \"\"], [\"\", \"Unmapped\", \"text\", \"The process of obtaining informed consent should be documented in the subject source documents.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"1f3fbaf1-66c0-4a6d-a148-8c8532fa2f95\", \"subtext\": \"0f1fa3f0-bda6-42ff-9b42-0b058b00ee61\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1345, \"\"], [\"\", \"Unmapped\", \"text\", \"Each investigator must retain the original signed and dated informed consent form.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"72221808-4193-4004-b724-ad736b39a484\", \"subtext\": \"0f1fa3f0-bda6-42ff-9b42-0b058b00ee61\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1346, \"\"], [\"\", \"Unmapped\", \"text\", \"A copy of the signed and dated informed consent form will be given to the subject.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fe154107-0a1d-4e56-875c-4b63fa5a88d6\", \"childbox\": \"07e07a2f-c9b8-4139-a54d-ee82efd792b2\", \"subtext\": \"0f1fa3f0-bda6-42ff-9b42-0b058b00ee61\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1347, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8e2369ed-5b26-4944-b5c3-24df2243242b\", \"childbox\": \"deb13e5c-1ad9-4728-8116-869cd261a0a4\", \"subtext\": \"e856cf9a-41da-4091-a706-ff2226eaed7f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1348, \"\"], [\"\", \"Unmapped\", \"text\", \"or its designated representative(s) will provide to investigators in a separate document a proposed informed consent form that complies with the ICH GCP guideline and regulatory requirements and is considered appropriate for this study.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e2369ed-5b26-4944-b5c3-24df2243242b\", \"childbox\": \"d982afff-c0b0-476d-8185-09096758020c\", \"subtext\": \"e856cf9a-41da-4091-a706-ff2226eaed7f\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1349, \"\"], [\"\", \"Unmapped\", \"text\", \"Any changes to the proposed consent form suggested by the investigator must be agreed to by Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 92, \"end_idx\": 119, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 92, \"end_idx\": 119, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8e2369ed-5b26-4944-b5c3-24df2243242b\", \"childbox\": \"1d1ce6d0-0207-479a-aa53-7a785a9823b1\", \"subtext\": \"f59ff6c4-70be-44c1-a5e3-b4b93238dc27\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1350, \"\"], [\"\", \"Unmapped\", \"text\", \"or its designated representative(s) before submission to the IRB/IEC/REB, and a copy of the approved version must be provided to the Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 133, \"end_idx\": 160, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 133, \"end_idx\": 160, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"8e2369ed-5b26-4944-b5c3-24df2243242b\", \"childbox\": \"fc902d22-76e4-41c3-9266-0313dccf915b\", \"subtext\": \"f59ff6c4-70be-44c1-a5e3-b4b93238dc27\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1351, \"\"], [\"\", \"Unmapped\", \"text\", \"monitor or designated representative(s) after IRB/IEC/REB approval.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"8e2369ed-5b26-4944-b5c3-24df2243242b\", \"childbox\": \"1fbcdcfc-8009-47c3-b9e9-6b203523356b\", \"subtext\": \"14aefa7d-89e1-4176-80cf-bc095eaf054c\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1352, \"\"], [\"\", \"Unmapped\", \"header\", \"Amendments to the protocol\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"feb46e2d-19d1-45d8-97f7-8adc897d4a55\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1353, \"\"], [\"\", \"Unmapped\", \"text\", \"To alter the protocol, amendments must be written by Idenix Pharmaceuticals, Inc., and receive approvals from all parties that approved the original protocol (IRB/IEC/REB, and if applicable, the local regulatory authorities) before implementation.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 53, \"end_idx\": 80, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 53, \"end_idx\": 80, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"1815d6d4-cbe4-4ba2-8144-fb8eda52d6aa\", \"childbox\": \"c2035746-56da-4136-9471-112f5485e901\", \"subtext\": \"c65339f5-53e2-44da-bd4d-2de3387e591e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1354, \"\"], [\"\", \"Unmapped\", \"text\", \"However, in cases where an amendment is required for subject safety, an amendment may be implemented prior to IRB/IEC/REB approval.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1815d6d4-cbe4-4ba2-8144-fb8eda52d6aa\", \"childbox\": \"14e43e49-ae95-44a2-86ef-b7320acb91be\", \"subtext\": \"771fb978-a42f-4e04-b17b-77a0a4f9bef4\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1355, \"\"], [\"\", \"Unmapped\", \"text\", \"Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any subject included in this study, even if this action represents a deviation from the protocol.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1815d6d4-cbe4-4ba2-8144-fb8eda52d6aa\", \"childbox\": \"0f578456-75e0-4dcc-8749-301af91af257\", \"subtext\": \"76bd1511-765d-4462-86d5-2276bd1f3552\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1356, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"f1b9ed45-2f04-4c97-ac1e-2e963711e1be\", \"childbox\": \"5ebbcff0-df8a-44ce-93d0-533be0778a3e\", \"subtext\": \"02aeb276-67fd-4f4f-9c13-67cd6f57b9f6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1357, \"\"], [\"\", \"Unmapped\", \"text\", \"may make administrative changes (i.e., changes that do not significantly affect subject safety, the study\\u2019s scope or scientific quality) without a formal protocol amendment.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f1b9ed45-2f04-4c97-ac1e-2e963711e1be\", \"childbox\": \"17786bac-501a-4d20-ae05-23cb838c52f9\", \"subtext\": \"02aeb276-67fd-4f4f-9c13-67cd6f57b9f6\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1358, \"\"], [\"\", \"Unmapped\", \"header\", \"Discontinuation of the study\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"ed19af74-2692-418a-a51d-f6113addbc31\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1359, \"\"], [\"\", \"Unmapped\", \"text\", \"Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 0, \"end_idx\": 27, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"2134012d-d8f3-4e2a-9c86-80b0d58738ad\", \"childbox\": \"7634029b-306f-4c0c-a507-469e68933267\", \"subtext\": \"3362ead9-cf80-4ad9-aeb3-23984e566c2a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1360, \"\"], [\"\", \"Unmapped\", \"text\", \"reserves the right to discontinue this study at any time under any condition.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2134012d-d8f3-4e2a-9c86-80b0d58738ad\", \"childbox\": \"551d0059-80e5-48ba-87e6-7966daa05a2c\", \"subtext\": \"fab63edf-41d3-4114-aaf5-9e466caa6a1e\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1361, \"\"], [\"\", \"Unmapped\", \"header\", \"Study drug supply, storage and tracking\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"b2893533-645a-41e5-b227-d3aa72d2fa97\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1362, \"\"], [\"\", \"Unmapped\", \"text\", \"Study drugs must be received by a designated person at the study site, handled and stored safely and properly, and kept in a secured location to which only the investigator and designated assistants have access.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f054e35-ed98-456e-800e-5968a4132791\", \"childbox\": \"a453c962-1b8b-42c8-8051-dc1746c2175e\", \"subtext\": \"9a33f62a-447b-4141-afd1-e8d3d41b3a39\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1363, \"\"], [\"\", \"Unmapped\", \"text\", \"Upon receipt, all study drugs should be stored according to the instructions specified on the drug labels.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f054e35-ed98-456e-800e-5968a4132791\", \"childbox\": \"2e7751de-93a6-4a2f-a889-c456953d8d4c\", \"subtext\": \"9a33f62a-447b-4141-afd1-e8d3d41b3a39\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1364, \"\"], [\"\", \"Unmapped\", \"text\", \"Drug labels will be in the local language and comply with the legal requirements of each country.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f054e35-ed98-456e-800e-5968a4132791\", \"childbox\": \"77db3203-cb06-4117-9885-3f02d12e9732\", \"subtext\": \"f4ce7f2e-6db6-46dd-8949-5d542d7bcffe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1365, \"\"], [\"\", \"Unmapped\", \"text\", \"Clinical supplies are to be dispensed only in accordance with the protocol.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6f054e35-ed98-456e-800e-5968a4132791\", \"childbox\": \"5606101b-ac0d-4845-bbac-377ffbdca7cd\", \"subtext\": \"f4ce7f2e-6db6-46dd-8949-5d542d7bcffe\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1366, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects will be asked to return all unused study drug and packaging at the end of the study or at the time of study drug discontinuation.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"28b3ee1e-b914-46ba-bb99-060b2e55a620\", \"childbox\": \"8a8f4f9a-6884-4987-b2f1-8c4f91827702\", \"subtext\": \"c164c26b-66af-4fa6-bf9a-db8ec6685673\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1367, \"\"], [\"\", \"Unmapped\", \"text\", \"All empty, partially used containers and unused supplies may be destroyed at the site, retrieved by the study monitor or shipped to a designated facility identified by Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 168, \"end_idx\": 195, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 168, \"end_idx\": 195, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"28b3ee1e-b914-46ba-bb99-060b2e55a620\", \"childbox\": \"e3a74e38-bbd5-43c3-839e-b33f3856a394\", \"subtext\": \"faad1a98-87ad-4254-a542-1367880474a2\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1368, \"\"], [\"\", \"Unmapped\", \"text\", \"according to governmental regulations at the conclusion of this study (or as appropriate during the course of the study), per the instructions of the Sponsor.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"28b3ee1e-b914-46ba-bb99-060b2e55a620\", \"childbox\": \"645ce176-8167-47b5-a626-067e271f3a15\", \"subtext\": \"e89cb70f-3c9e-4bfd-b519-7d79d7553a8d\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1369, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator will keep an accurate accounting of all study medication dispensed, destroyed or returned.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"664087f9-c534-4abb-827d-e6e04b18504d\", \"childbox\": \"655879e8-0906-4f7a-aba5-4ce4e23a348e\", \"subtext\": \"ca8e073b-074f-4f2e-aecd-f8f9afe982f9\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1370, \"\"], [\"\", \"Unmapped\", \"text\", \"Monitoring of drug accountability will be performed by the monitor during site visits and at the completion of the trial.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"664087f9-c534-4abb-827d-e6e04b18504d\", \"childbox\": \"e7a31b90-3548-4aa2-957d-38ec576c0f1b\", \"subtext\": \"ade78250-316f-409f-b643-ed5381d282ab\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1371, \"\"], [\"\", \"Unmapped\", \"header\", \"Confidentiality\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"0ca47537-0796-40e5-ad50-3b4670f716dd\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1372, \"\"], [\"\", \"Unmapped\", \"text\", \"All study findings and documents will be regarded as confidential.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b4dae860-03b5-4138-8ed2-f0af7aca2be9\", \"childbox\": \"7d50e1e3-31fe-4d6c-bde8-3aea384a0bd8\", \"subtext\": \"ab8d97cc-8dc2-4a37-bab2-7600558da031\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1373, \"\"], [\"\", \"Unmapped\", \"text\", \"The investigator and other study personnel must not disclose such information without prior written approval from Idenix Pharmaceuticals, Inc.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 114, \"end_idx\": 141, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 114, \"end_idx\": 141, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"b4dae860-03b5-4138-8ed2-f0af7aca2be9\", \"childbox\": \"a7bacb6f-3a9d-4c25-b2c5-e76811369a71\", \"subtext\": \"6dc2e880-8a2e-4234-b705-95bb7bf99cac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1374, \"\"], [\"\", \"Unmapped\", \"text\", \"Subject confidentiality will be strictly maintained to the extent possible under the law.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0832b78f-423a-4e23-992b-5c54475906d9\", \"childbox\": \"bfee91a0-87b0-4a3b-ab02-700885dfb401\", \"subtext\": \"25da0017-9dcb-46bf-a363-639b2e7694da\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1375, \"\"], [\"\", \"Unmapped\", \"text\", \"Subject names must not be disclosed.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0832b78f-423a-4e23-992b-5c54475906d9\", \"childbox\": \"001a20a3-2c71-404a-87ac-79afd01c49ce\", \"subtext\": \"fa26ffc4-fb7c-47e2-863e-ac5bdc6f3bfd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1376, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects will be identified on the CRFs and other documents submitted to Idenix Pharmaceuticals, Inc., or its designated representative, by their initials and/or assigned subject number.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 73, \"end_idx\": 100, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 73, \"end_idx\": 100, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"0832b78f-423a-4e23-992b-5c54475906d9\", \"childbox\": \"8e336db8-70f5-4392-a1fb-ba813d7449f2\", \"subtext\": \"fa26ffc4-fb7c-47e2-863e-ac5bdc6f3bfd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1377, \"\"], [\"\", \"Unmapped\", \"text\", \"Documents that identify the subject (e.g., the signed informed consent form) should not be submitted to Idenix Pharmaceuticals, Inc., or its designated representative, and must be maintained in confidence by the investigator.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [{\"start_idx\": 104, \"end_idx\": 131, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}, {\"start_idx\": 104, \"end_idx\": 131, \"standard_entity_name\": \"Sponsor Name\", \"subcategory\": \"Sponsor Name\", \"confidence\": 87.0, \"text\": \"Idenix Pharmaceuticals, Inc.\"}], \"roi_id\": {\"para\": \"0832b78f-423a-4e23-992b-5c54475906d9\", \"childbox\": \"4791dbb3-1055-4701-aa5d-2c86e307c1df\", \"subtext\": \"fa26ffc4-fb7c-47e2-863e-ac5bdc6f3bfd\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1378, \"\"], [\"\", \"Unmapped\", \"header\", \"Publication policy\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"8ae065b4-2b0b-427d-8fdc-0936eb8e8816\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1379, \"\"], [\"\", \"Unmapped\", \"text\", \"Any formal presentation or publication of data collected as a direct or indirect result of this Study may be considered as a joint presentation or publication by the investigators and the Sponsor.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9acd4b0c-ff7d-4030-8c47-436eb79d3c25\", \"childbox\": \"129110d7-51ff-4099-ac4f-e2681402ead3\", \"subtext\": \"39e2b95f-fe6f-475e-84d4-27d02b45a018\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1380, \"\"], [\"\", \"Unmapped\", \"text\", \"As is customary for multicenter trials, publication by individual Study sites or investigator/institution will not be allowed prior to the publication of the principal Study abstract(s) and manuscript(s), without the explicit written permission of Sponsor.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9acd4b0c-ff7d-4030-8c47-436eb79d3c25\", \"childbox\": \"f3a6b87b-c7c2-4ca8-aaa2-8bcca3a6a3c6\", \"subtext\": \"5d852160-8a1d-4573-b025-1002ee1e6a1b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1381, \"\"], [\"\", \"Unmapped\", \"text\", \"Sponsor will determine authorship of the principal Study manuscript(s) in conjunction with the investigators.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9acd4b0c-ff7d-4030-8c47-436eb79d3c25\", \"childbox\": \"e683f3a5-1091-4fab-acdc-35bbd5eb62df\", \"subtext\": \"4523d3fe-8c76-4d7b-bb55-c87b95bf6564\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1382, \"\"], [\"\", \"Unmapped\", \"text\", \"All investigators contributing at least one evaluable subject to the Study may be considered as co-authors for the principal Study manuscript(s).\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9acd4b0c-ff7d-4030-8c47-436eb79d3c25\", \"childbox\": \"d66c0273-0e04-4184-897d-566e5403e476\", \"subtext\": \"d27f3c5b-c8f8-4f10-9f26-2e337bbd0cb3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1383, \"\"], [\"\", \"Unmapped\", \"text\", \"For such manuscript(s), masthead roles for investigators will be determined based on subject enrollment and scientific contributions to the Study.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"9acd4b0c-ff7d-4030-8c47-436eb79d3c25\", \"childbox\": \"ccffb91e-6f56-464c-9589-3f446cf7248f\", \"subtext\": \"d27f3c5b-c8f8-4f10-9f26-2e337bbd0cb3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1384, \"\"], [\"\", \"Unmapped\", \"text\", \"Subsequent to publication of the principal Study manuscript(s) and abstract(s), institution and investigator may, consistent with academic and scientific standards, publish or present the results of work performed in accordance with the Study, provided that any proposed publication, presentation, abstract, submission or disclosure (collectively hereinafter \\u201cProposed Publication\\u201d) is first reviewed and commented upon by Sponsor prior to submission for publication or presentation.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8c725b8-dfb3-4670-b0dd-b16d062d2fb5\", \"childbox\": \"be02d9d3-f155-43fd-91a9-f9c7505e4f50\", \"subtext\": \"87ced0ad-3aaa-4d39-8afc-f7da4545de2b\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1385, \"\"], [\"\", \"Unmapped\", \"text\", \"Institution and investigator will submit any Proposed Publication to Sponsor for review and comment at least sixty (60) days prior to submission to a third party.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8c725b8-dfb3-4670-b0dd-b16d062d2fb5\", \"childbox\": \"b53332cd-02a4-41e4-ac9d-e2cf8cdea702\", \"subtext\": \"957ef8be-f5f4-4a64-968e-cd6d728fc9d3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1386, \"\"], [\"\", \"Unmapped\", \"text\", \"If Sponsor believes in good faith that any Proposed Publication contains any proprietary or Confidential Information, Sponsor shall have the right to remove such references to such Confidential Information.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8c725b8-dfb3-4670-b0dd-b16d062d2fb5\", \"childbox\": \"0477aa2a-5a29-468a-a13b-6edc4440447b\", \"subtext\": \"957ef8be-f5f4-4a64-968e-cd6d728fc9d3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1387, \"\"], [\"\", \"Unmapped\", \"text\", \"At the request of Sponsor, each of the institution and investigator agree to withhold submission of a Proposed Publication for an additional period of up to ninety (90) days after receipt of Sponsor\\u2019s comments, in order to allow filing of patent application(s) relating to an invention or otherwise seek protection of information to be published or otherwise disclosed.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b8c725b8-dfb3-4670-b0dd-b16d062d2fb5\", \"childbox\": \"e39a503d-818f-4084-9249-3646fae1a74d\", \"subtext\": \"a16144b5-e617-4c77-84f2-581b24927c08\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1388, \"\"], [\"\", \"Unmapped\", \"header\", \"Financing and insurance\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading5\", \"entity\": [], \"roi_id\": {\"para\": \"24a4cb7a-ee10-466c-b243-59859f0f38fc\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1389, \"\"], [\"\", \"Unmapped\", \"text\", \"In the event of injury resulting from participation in this study, any medical treatment deemed necessary will be provided to subjects to assist in recovery from the injury.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f4c04e9-3a01-4e15-bf17-be3c41aabf00\", \"childbox\": \"7dacef99-52f9-4533-b505-7f8a60fdb1d7\", \"subtext\": \"c786f4c5-0e52-4e73-9edd-1423acaea16a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1390, \"\"], [\"\", \"Unmapped\", \"text\", \"Subjects will not be charged for this care beyond that covered by the subject\\u2019s health insurance.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f4c04e9-3a01-4e15-bf17-be3c41aabf00\", \"childbox\": \"ab4c4275-f2d0-4da2-b43b-4ccfd3633362\", \"subtext\": \"c786f4c5-0e52-4e73-9edd-1423acaea16a\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1391, \"\"], [\"\", \"Unmapped\", \"text\", \"This agreement to provide free medical treatment does not include treatment for illnesses experienced during the study if the illness is not proven to be the direct result of study participation.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f4c04e9-3a01-4e15-bf17-be3c41aabf00\", \"childbox\": \"2d7d7bcc-ba15-4462-aafc-863138046cda\", \"subtext\": \"0f531f84-3657-42cb-b962-974aae453294\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1392, \"\"], [\"\", \"Unmapped\", \"text\", \"No compensation other than free medical treatment will be provided for an injury resulting from participation in this study.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"4f4c04e9-3a01-4e15-bf17-be3c41aabf00\", \"childbox\": \"971d9eab-aec9-40d2-bcd0-c7e7c960488e\", \"subtext\": \"0f531f84-3657-42cb-b962-974aae453294\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1393, \"\"], [\"\", \"Unmapped\", \"text\", \"To the extent subjects are to be compensated for their participation in the study, such compensation will be set forth in the informed consent form.\", {\"IsBold\": false, \"font_size\": 20, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5c870c9a-c4fd-4b4b-9c27-7052c691ee02\", \"childbox\": \"169c28a2-0df6-440c-90c2-c7c90343b2c1\", \"subtext\": \"9b6e4cfa-1126-4b4b-a6a0-7608146dfb24\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"Arial\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 20, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1394, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5c870c9a-c4fd-4b4b-9c27-7052c691ee02\", \"childbox\": \"2b0bfa35-2cb7-41ea-bda5-297bacace4ff\", \"subtext\": \"11a8af59-7e3e-4d9e-8d45-69c0b1a828c1\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"References\", \"11\", \"1\", 1395, \"\"], [\"\", \"Unmapped\", \"header\", \"Appendix 2:  Division of AIDS Table for Grading the Severity of Adult and\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"Heading2\", \"entity\": [{\"start_idx\": 13, \"end_idx\": 34, \"standard_entity_name\": \"ANY: Organization\", \"subcategory\": \"ANY: Organization\", \"confidence\": 87.0, \"text\": \"Division of AIDS Table\"}], \"roi_id\": {\"para\": \"d0a8af53-8aed-4840-82a4-2e5ecc60fea2\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1396, \"\"], [\"\", \"Unmapped\", \"header\", \"Pediatric Adverse Events (December 2004, Clarification August 2009)\", {\"IsBold\": false, \"font_size\": 26, \"font_style\": \"Heading3\", \"entity\": [], \"roi_id\": {\"para\": \"2748cab2-014b-4146-a6a0-1d6a001aa16f\", \"childbox\": \"\", \"subtext\": \"\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": 26, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1397, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3daa9e70-8cae-4adb-b29d-736c2ba0d3c5\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1398, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"6cad933d-6453-4551-9ae0-b84b17b66a96\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1399, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"eea4196c-3bc3-4dd1-81e0-bf7442d2257a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1400, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"473cfa10-05e1-49c2-8757-0caa6c54e8d1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1401, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"84d08ce1-4175-4ab6-b40e-017f824f25ed\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1402, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"70cee2cd-3062-4b8d-8f34-a66cd418062f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1403, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"475a2a40-3c8b-4534-acb4-6e699105ac04\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1404, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e78bb657-75cb-465f-bf34-98be36d09055\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1405, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e39b7688-fb0a-474c-aad4-aeb6978509d7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1406, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a772b25b-a457-4fd0-963f-d2ce1648685e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1407, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c585b545-91b2-45ae-bfba-1083745634af\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1408, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"49484942-dc3a-489b-b46f-8e6eb1b76531\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1409, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"198dd20f-7324-4e47-87b9-55680b8cb12c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1410, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7eb0d537-825d-4ec4-aa6f-75606d548484\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1411, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"281f13df-913b-49aa-ba8f-9140152c670c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1412, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"014d6b6a-975d-40b6-9202-7defa4527c1a\", \"childbox\": \"b835ef86-5497-443b-b751-4faf3f052128\", \"subtext\": \"945731de-3ac6-4966-8c6e-37e701f91705\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1413, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b0aa47ee-5d5a-4aab-85a5-fa44935a67c6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1414, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"1d577c9b-807b-4d19-b6ac-0af91a4cee86\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1415, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5b2be4be-e94f-4e3b-ad89-4ba0fa2ad94f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1416, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"7be50178-052a-4eda-8aa8-86d4f7890480\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1417, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98e06b73-82d7-4fbd-a9aa-3ae02ceb4167\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1418, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"c9fd0695-36fd-46df-ab46-775b58b318ea\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1419, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d2b33170-7bea-4bbc-b1f0-c5e8da505c19\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1420, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"869b561d-cd84-4189-9474-9ac3f3a9774f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1421, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f32ab125-1607-4aaa-a083-7cb37d70dbae\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1422, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3fbc0f78-f4af-4eab-abdc-33cad42f05ed\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1423, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d659b87f-932f-4ccc-8526-a66d475b0cda\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1424, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f179d893-40ab-4b7a-b7d1-d5ba2164197a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1425, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5ab883a9-0200-4a79-98b4-c4461933e830\", \"childbox\": \"45ce4eff-3c00-46ec-b9a0-24ca457e013f\", \"subtext\": \"88fbea7e-8d24-4986-b1ea-92f0a86372b3\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1426, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20a8e353-7872-4596-b3ab-48e8339db4c7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1427, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"f0555335-93d6-4b06-992a-61e5361b9349\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1428, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"3ceb704e-4667-45e9-a01b-3eaeaf5e5958\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1429, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"08cd8e0d-c4b3-4c8b-ab1e-c4c7d3cd17ac\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1430, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"aa91f739-3600-417c-bea0-84c87246f605\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1431, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"cf1af4ba-3c5c-46bf-9016-251ed3b89e1f\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1432, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"d303ebbd-1748-48c7-b23b-72b64c7ae395\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1433, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bafcf47a-3530-48ac-bf59-fe70a62ba298\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1434, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"20f03b65-cb23-453d-bb8d-f4534704140d\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1435, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ec5f0288-5ed2-49ee-8473-932990ccab34\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1436, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98f50d8c-8414-4274-aa24-218a15462c45\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1437, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"5c95ef68-adae-4fa9-b4a0-6af019d085d4\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1438, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"66292d41-e5dd-4595-990b-b7b86af765a1\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1439, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"38f1c7a4-c3f3-4c86-9077-13e19a06d70c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1440, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e444b589-8fe6-4ead-8ccb-33b675869d5c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1441, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"98f54ceb-0068-465d-a210-c7a6b1d41e78\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1442, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"b1ccc5c6-1f38-4a2f-b968-68fc0eca602e\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1443, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"64026aec-0949-4973-93b2-76f383ae5291\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1444, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2db3a6ba-0422-4940-a507-9679b5af0e99\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1445, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"49982867-7c5c-47a4-85da-265543ad1ae7\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1446, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"fb9f3f4a-2d29-4d6e-8bba-bd2db8b75e87\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1447, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"2f345580-8b16-404b-93cf-01df1bb2d0cb\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1448, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"86a5d59c-c8d0-40b7-b20e-d6a507a313d8\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1449, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"93013424-f816-47d4-818c-bd5a4617fe5a\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1450, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"ad1aa5c6-d51a-4316-958e-b3132ef3c82c\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1451, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"0be44634-4ea7-4f54-8684-f410d43faaa6\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1452, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"e92951cd-f7ab-4c24-b078-276f08ababaa\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1453, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"bdcadf2e-3f2f-4bd9-aa22-2210b9d594bd\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1454, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"a6c0d7c6-92a2-4893-bfed-df9c95b03208\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1455, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"741b79f1-c89e-4d99-925e-b3756210396e\", \"childbox\": \"1877a3cd-4ac7-4918-b7d1-d459904b1471\", \"subtext\": \"4c7da9b0-03d5-478f-9f26-b353c05beaac\"}, \"Bold\": false, \"Caps\": false, \"ColorRGB\": 0, \"DStrike\": false, \"Emboss\": false, \"Highlight\": \"\", \"Imprint\": false, \"Italics\": false, \"Outline\": false, \"rFonts\": \"\", \"rStyle\": \"\", \"Shadow\": false, \"Size\": -1, \"SmallCaps\": false, \"Strike\": false, \"Underline\": \"\", \"Vanish\": false, \"VertAlign\": \"\"}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1456, \"\"], [\"\", \"Unmapped\", \"text\", \"\", {\"IsBold\": false, \"font_size\": -1, \"font_style\": \"\", \"entity\": [], \"roi_id\": {\"para\": \"62ed848e-80ea-4220-a441-5ccbe5e00fbe\", \"childbox\": \"\", \"subtext\": \"\"}}, \"Unmapped\", \"Division of AIDS Table for Grading the Severity of Adult and\", \"Appendix 2:\", \"1\", 1457, \"\"]], \"metadata\": {\"protocol_title\": \"08nov modified A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"protocol_title_short\": \"08nov modified\", \"amendment_number\": \"08nov modified\", \"is_amendment\": \"N\", \"trial_phase\": \"08nov modified\", \"sponsor\": \"(CKD)Chong Kun Dang Pharm\", \"sponsor_address\": \"08nov modified\", \"drug\": \"08nov modified\", \"approval_date\": \"\", \"version_number\": \"08nov modified 1\", \"version_date\": \"08nov modified\", \"blinded\": \"08nov modified\", \"compound_number\": \"08nov modified\", \"control\": \"08nov modified\", \"investigator\": \"08nov modified\", \"study_id\": \"08nov modified\", \"number_of_subjects\": \"08nov modified 240\", \"participant_age\": \"08nov modified 65y\", \"participant_sex\": \"08nov modified MALE\", \"exclusion_criteria\": \"08nov modified Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.\", \"inclusion_criteria\": \"08nov modified Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.\", \"indication\": \"ABCC6 deficiency\", \"objectives_section\": \"08nov modified \\u2022 Emergence of resistance mutations during treatment and in the post-treatment period\", \"study_population\": \"08nov modified patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..\", \"entities_in_assessments\": \"\", \"soa_epochs\": \"\", \"assessment_footnote\": \"\", \"upload_date\": \"20211108104415\", \"protocol_number\": \"FEED_TEST2_Summary\", \"study_status\": \"\", \"molecule_device\": \"test\", \"secondary_objectives\": \"\", \"protocol_name\": \"\", \"endpoints\": \"\", \"trial_type_randomized\": \"\", \"accuracy\": \"\"}}", "normalized_soa": "[{\"id\": \"dde41219-60c9-4283-89b0-1d295029d0bc\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Informed Consent\", \"procedure_text\": \"\"}, {\"id\": \"6a83b883-f765-4b9f-b177-539d45be28c7\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X (Day -14 to Day -1)\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"IWR (drug assignment/shipment)\", \"procedure_text\": \"\"}, {\"id\": \"8eb2a49b-79b4-492b-898a-4831c573c914\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"IWR (drug assignment/shipment)\", \"procedure_text\": \"\"}, {\"id\": \"1b49ed69-ec5a-4ae8-9429-09ce612d41cc\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X11\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"IWR (drug assignment/shipment)\", \"procedure_text\": \"\"}, {\"id\": \"e120cc0d-aabf-4bcf-acb9-b0ced1ebfad9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Inclusion/Exclusion Criteria & Medical History\", \"procedure_text\": \"\"}, {\"id\": \"3299a757-f9b2-4afc-a4df-37f4852cc79e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X7\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"bcbaac20-7311-4d7f-b09a-388694e2d046\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X7\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"2\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"c0c09597-c6d5-4b81-b428-b242c9a7ffbd\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"ac69e2ae-af17-44e0-b38c-115944bf806a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"2979c6b7-54e8-4771-9274-6abe8edaa9bf\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"32228427-853d-4e42-b360-d6cb36f2f7b1\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X7\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"123e8517-a06c-4e54-b640-fc3291e5e4b5\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"f6f49d09-7861-4696-ba3e-5d346177fdb3\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"2633f364-75b2-4f1c-9594-fa20242c0ce1\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"73eff2dd-ef89-494f-b623-4fce6db3e0d9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X11\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Study Drug Dosing\", \"procedure_text\": \"\"}, {\"id\": \"0da87ff7-b914-42d4-87fb-c16f3d0e3f3a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HIV-1 and HIV-2 Ab, HBsAg, Hemoglobin A1c\", \"procedure_text\": \"\"}, {\"id\": \"fada656f-3598-488d-8ed7-ebf71ae596b9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"FSH (females of nonchildbearing potential only)\", \"procedure_text\": \"\"}, {\"id\": \"d2788e0d-3ad6-4a64-bd9f-aa62ac475e21\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"90e36301-3fc8-4188-8350-1a4e40876455\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"ee5dc526-f2b1-45be-9a41-825c5f27ee47\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"d405fcfd-930e-42d7-beb3-25d63075701a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"463b997b-2735-431b-a6d3-2193885db943\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"8028010a-1878-4012-a11f-1758c615c1fc\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"5a9a2c29-97ee-4042-ae09-c1d434eb0728\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"454bfd86-c90e-459f-ab28-fe8aa234c632\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"11c43272-3169-4a5c-9774-8fba37be26a8\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"979f4cde-76e3-4772-b64f-09eb1775ca0e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"d9c702f4-affd-4d93-bcbe-d62db12f1d0d\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"2b016587-cd1b-499b-9251-9774eec3a054\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"285fb55f-e205-4ebb-8652-3e641399a226\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Height1 & Weight & BMI1\", \"procedure_text\": \"\"}, {\"id\": \"222ee231-c10b-4689-ab54-994407ab2cb3\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"d9e5bc74-dda3-45d7-9854-98ae72e0ddaf\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"07041ce7-5094-41ea-8088-a11f36955828\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"019b3c77-982b-4b7c-8c4a-3acddc1db99a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"9a47b94a-6e5e-459b-948b-f5dfdc182d8e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"a66474ee-ad19-4d26-a146-19f2cff99f98\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"c08bf60f-7de5-4ed9-9dae-09da7d8f16cc\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"b58e765f-a489-4672-93b1-6cd4e4407ba6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"93d08e0f-0b90-4d69-a787-1cf18063a0d7\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"9b715fc5-f6e7-48d2-8e2e-ec06a3e08991\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"d827564d-3551-479d-a082-fe4352849bda\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"8ea8d880-48c0-4c6f-91c1-b069e523a644\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"b0dac59b-d614-418f-b492-95989cd9c3a7\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Vital Signs (excluding temperature)\", \"procedure_text\": \"\"}, {\"id\": \"c427ca5c-2322-4bfa-bd3a-0dd4404a1dd6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Complete Physical Exam\", \"procedure_text\": \"\"}, {\"id\": \"333bdd5d-c6a8-4ee8-8358-f721c41ea144\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Complete Physical Exam\", \"procedure_text\": \"\"}, {\"id\": \"97161218-7b53-468c-b646-bdf10f4ef7de\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X10\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Complete Physical Exam\", \"procedure_text\": \"\"}, {\"id\": \"a62165d1-f343-40e7-873d-1257fdb595a4\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Complete Physical Exam\", \"procedure_text\": \"\"}, {\"id\": \"fa2248ae-52a3-4ac6-9f5b-d129d02635f1\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"SAE only\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"15431b6b-3216-4053-975f-f7cef5686861\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"SAE only\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"b161812d-2f86-4a53-9158-9e85094deed3\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"21123730-218a-42c0-82e0-23b95d39c9df\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"2\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"dd6c067c-a5c6-4a20-ae9f-f5bf40e82a9d\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"e4d4bf59-7828-4fdb-b8d2-17f4ddbe2e1b\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"4bbe3483-5e1e-44e2-ae5d-d5f432f9827e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"a26ee41c-33b6-46d0-b5b4-d8794f8a630a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"d49d7890-e6b8-4fee-ab97-617b56da55a6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"6c030330-ff3b-4d4e-85f7-54f78971e6d9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"664e8508-0041-4cf2-b4c1-d90505a913d4\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"50ff2efd-6683-4314-b93f-d986073c74c8\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"78289abf-09e9-4903-96c5-a627db4d370f\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"bd0b6be9-6f57-46db-9daa-b36dbade8a8e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"ac01cea3-1b67-40de-ba93-f232032fbf90\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"SAE only\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Adverse Events (with targeted physical exam)3\", \"procedure_text\": \"\"}, {\"id\": \"98f896a1-d561-4629-a554-50f2039530fc\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"6d712ac5-568e-4d76-8281-020da5b2017a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"5d4aa290-8ea3-4bbf-8b27-d7467c9c0404\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"1275590d-f767-4039-bc75-9f6c8deeda8e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"2\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"53838b21-89c5-4407-aff8-46b5f49edf45\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"dca2aaf3-2d2f-413e-8c77-ecfab96a1098\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"0eb2ea2a-ad5b-4a14-88f3-66a5f05e0c88\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"041b0f4d-fe7b-454c-a7f2-4eb9a722d8e9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"ac2bbba8-7de3-4622-b3dc-2c2c9d157cc8\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"240a6aab-3c18-4dd4-8142-92c30f300856\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"92eb5b65-243f-4045-8724-8ab100dd5e07\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"76a1ff6e-493e-4a21-b8b2-67b05be29d34\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"2e797b21-9eb9-4cda-8382-483f9f1ad535\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"40bdbbcd-5f7a-4970-91ba-033b9ec14256\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"30668531-8018-4ebf-9755-5e282d3389de\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"05fabc9b-548e-4023-a8dd-de32f51adf03\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"0d936eb4-4fd1-44ec-a2c4-3ef32781ed57\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Concomitant Medications\", \"procedure_text\": \"\"}, {\"id\": \"35aa559d-9f1b-4aa9-9f87-c53224e180a6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Echocardiogram4\", \"procedure_text\": \"\"}, {\"id\": \"7caa2f9a-0df4-4aa2-8d41-088e14d180a9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"672bb5dc-9367-4743-98ea-8fc3b5041325\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"2753c377-dc4f-4c88-8a90-db2f18cdb151\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"193569f2-c3ce-4cb5-a41b-a8dfa1cb4421\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"d0424c74-a140-445e-b509-456ff6b42f92\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X10\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"77180ff0-26c4-44ed-b4ec-ce6b23a6f351\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"f29448da-d0ac-4320-bc85-a9d19fce3a36\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"12-Lead ECG5\", \"procedure_text\": \"\"}, {\"id\": \"14f41423-35e2-4090-8f1c-7d48c3517593\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"939df382-f2c7-4ca7-9de4-9dd800afb424\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"c2468dde-b394-41eb-b1a2-a6446ea6c425\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2, 6\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"5b56db28-784a-455a-97f7-26aadb9e1437\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"2\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"017b1a6a-79cf-4fca-a53d-6aa6a812947e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"4ea5e7c1-8365-4ef5-9172-7e83096f27a9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"d624d53e-4ae9-4a9d-a255-27eb824eff4b\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"b46bbd9c-455c-454f-a7bd-a121e17af9b4\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"f3c76a5d-aacb-44d6-8077-e9a5f9a7fe6b\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"04cb6e6a-d4ee-4516-9ea6-935a794c73b5\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"c2611b96-c826-47ec-ac4b-9eafa30e2ce2\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"84414624-5bed-42ff-9b13-c6aa1e3fb27d\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"b962309f-ca2c-41f2-8fbc-8c1a1e3cc163\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"0fea6d95-45db-4cbf-849e-298ee7601ab7\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"65f0dfe8-824f-454e-a1e2-ecebc9e1b866\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"761c0d10-d814-40ac-8164-b2f15e9c6472\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"f0970d6c-d3cb-4726-b495-73cd9cac3ccd\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"57f051f6-4256-46ae-b4d9-942032ce62d9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV Genotyping\", \"procedure_text\": \"\"}, {\"id\": \"4ca2f678-a7ff-4f4a-ae77-03a8356d72bb\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Host IL28B\", \"procedure_text\": \"\"}, {\"id\": \"a1c8442b-5056-499c-8e44-a1f27594c369\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"0ae9b86b-5581-4e15-9b9e-65adb4414c3c\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"2\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"62f632c7-67e7-4f2f-9fe9-7d03607153b9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"23bb7736-4b33-43a1-a8f6-cd903d8de2ba\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"5c05f35b-9999-4c82-98f9-68d3714f5dbd\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"f8354b2a-85fc-4d53-8ea4-fab599aedcf8\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"ee720091-9cbe-4742-bed2-5e1199cc49c0\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"180bf522-61bb-4249-831e-652802632380\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"de475687-202f-44ad-8568-357a5d1e47b1\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"2f3a6f5d-0c6d-47b0-ae82-d0501f09ce67\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"56ca8adc-d030-4eaf-afbb-5179bb0eedfe\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"71891e2e-8ee4-4643-bc14-49cd4c76114e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"LM Assessments\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"PK Sample Collection7\", \"procedure_text\": \"\"}, {\"id\": \"8e3793d6-324f-46d9-8fb9-1c1413535257\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"34036827-91ed-4373-9e38-04648a3a5ce1\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"c0c7e1f9-b7c2-4405-9bc8-a3ce469f1359\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"fe1cbef0-9a26-4e57-9502-df87bddfdf6d\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"473c349a-6086-42ca-8e2f-6f6be9540d23\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"9994fcfb-35f0-4f52-9210-37f9ded51c9f\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"dcc7aa4e-59fd-4a2d-a16e-fc7526e81754\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"a17c075d-5ef1-4a24-b9b9-5ff1cdde4a49\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"7122c92b-25b7-468d-a272-f84db2918853\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"eb0561dd-f589-4998-af4a-a7c93b51d560\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"15012e6d-9150-4e49-b99e-c0321757bbd9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"9680b85e-07a8-4386-af36-308f2a1f93ad\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"f240a650-fc40-4a19-a912-20aa3adfd4f9\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Hematology, Clinical Chemistry, GFR, Coagulation\", \"procedure_text\": \"\"}, {\"id\": \"3b622719-15df-4b98-ac68-ae3598e21027\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"FibroTest\", \"procedure_text\": \"\"}, {\"id\": \"fda3baf6-d836-4fbe-9ca2-944a4bf5717c\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Blood thyroid stimulating hormone\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"TSH\", \"procedure_text\": \"\"}, {\"id\": \"7e3742f7-0029-49f4-9a6c-41753fa7abca\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"SCR\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"\", \"procedure_text\": \"\"}, {\"id\": \"06a44452-1c80-43f9-9a85-58d857a71004\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"Pre-TX\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"\", \"procedure_text\": \"\"}, {\"id\": \"463d7ec5-3813-40de-9b40-63e90488cddd\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"Treatment Period\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"\", \"procedure_text\": \"\"}, {\"id\": \"d39a943c-9bc9-493b-bcdf-d60347020598\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"Post EOT Follow-up\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"\", \"procedure_text\": \"\"}, {\"id\": \"d5e843ff-1bfc-46f3-b405-e65db2dda8e5\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Pregnancy Test8\", \"procedure_text\": \"\"}, {\"id\": \"3540b051-bff8-401f-85ff-6e25d7d54a57\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Pregnancy Test8\", \"procedure_text\": \"\"}, {\"id\": \"00cc72c5-2d93-4fba-8674-0cb28a2bcc30\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Pregnancy Test8\", \"procedure_text\": \"\"}, {\"id\": \"ee2de0c4-33ab-4a47-9944-d824b21217d4\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X10\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Pregnancy Test8\", \"procedure_text\": \"\"}, {\"id\": \"2fd58038-3962-4cc4-8706-1bdfb80d5fb2\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Pregnancy Test8\", \"procedure_text\": \"\"}, {\"id\": \"e6148f39-3a9c-4757-942f-e352b6c34b4c\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Pregnancy Test8\", \"procedure_text\": \"\"}, {\"id\": \"95f0f17b-5c5f-4e83-920a-c497f9c91741\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"87649486-3a56-4aef-a556-b4760c675e1a\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"70ee33d0-8c5e-4c7f-bd20-c661883630c6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"886828b8-b92e-4880-9b58-b10f9790085f\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"2\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"4c1e046e-0e34-4954-b5eb-a7794e6651a0\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"e55dd79d-6c4a-41ba-903b-f221008ca0ce\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"113ad986-e2bd-4a22-9ce0-9066d5422d02\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"d95dd85b-b38d-4357-89bd-2a1f8dd07091\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"48613a5b-5c37-43df-8df6-7f29c7eee78c\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"72683a59-3577-4544-9d3c-c5090a318c62\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"330b3ef4-7b17-4580-b0b7-d76d37ee0aef\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"c4982f88-5228-427e-b8ca-52051b558639\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"958b27cb-06ca-4b91-a5cd-f2063b252280\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"f0999b4e-714f-4638-90a8-f2bc9f242049\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"fb6919b3-2a02-44b2-a7b5-e1bc3d55f076\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"b5f2d25f-5f28-4184-879d-191e89372db6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"19e3253c-177f-4391-9e62-d6744b721dfa\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Plasma and/or Serum Stored Samples9\", \"procedure_text\": \"\"}, {\"id\": \"ba02a94d-6a00-41b8-ade6-27d38e260f55\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Screening\", \"cycle\": \"\", \"day\": \"[-75, -7]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"77ea86f3-fd32-43f4-8621-82fff36f5d3c\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Pre-TX\", \"cycle\": \"\", \"day\": \"[-6, -1]\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"ad9b653c-8818-4c5a-a322-e025aa0fbe0b\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X2\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"9e56d0d6-26f6-47b9-a615-0d8957d5ecd3\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"4 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"a545027f-d4df-4ded-96fd-804488a30a79\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"8 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"11f456cc-9498-4614-8268-953b949aae01\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"11 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"6f145e83-3f11-4620-95a6-705cc91814e6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"15 1\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"affdef73-3e34-486f-9568-4278dbc7ef7b\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"22 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"09210050-b6d3-4388-b68c-c9aaad3b2c0b\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Treatment\", \"cycle\": \"\", \"day\": \"29 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"495e410b-b7b7-435d-845d-be178ee22a40\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"43 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"3c179ba0-2999-44f4-a1d3-766cdb49b7d6\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"57 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"dba01282-ce6a-4b89-bd68-71d3a70d4532\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"85 3\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"714a2026-7b32-40bf-9f13-f2c7e3a6704f\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-1 Schedule of assessments \", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"Follow-up\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Urinalysis\", \"procedure_text\": \"\"}, {\"id\": \"06959826-ace8-4da8-8c47-1b58de06ee61\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"HCV RNA Quantitation\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"27a3078b-abdd-4551-b00a-36e9219d386e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"HCV RNA Quantitation\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"e9555d85-6a7e-43ff-a13f-a07845361a3e\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"HCV RNA Quantitation\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"5c060190-438d-41fb-ae48-bb3041ae4cb4\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"HCV RNA Quantitation\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"edcfb700-3579-4983-a583-4969a537da35\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"HCV RNA Quantitation\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"bbc23d56-1f85-42b8-8a9e-8c12d499e8fd\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"HCV RNA Quantitation\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"HCV RNA Quantitation\", \"procedure_text\": \"\"}, {\"id\": \"5e0dc696-b6ca-41cb-a454-1927f5ea90b7\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Stored Plasma Samples\", \"procedure_text\": \"\"}, {\"id\": \"d1ae5bff-f6a8-498d-aafc-5a352b3e58bc\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Stored Plasma Samples\", \"procedure_text\": \"\"}, {\"id\": \"eb90ca40-b46f-4543-a6bd-563f987e54cd\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Stored Plasma Samples\", \"procedure_text\": \"\"}, {\"id\": \"7190c46b-8b57-4c73-9b95-1f4400d953cf\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Stored Plasma Samples\", \"procedure_text\": \"\"}, {\"id\": \"45fc2955-4438-4a9d-b1f9-6d6553e8a51c\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Stored Plasma Samples\", \"procedure_text\": \"\"}, {\"id\": \"7ab57751-f9f6-46ab-98de-b49124195cfb\", \"ProcessVersion\": \"12.29.14.0\", \"ProcessMachineName\": \"CA2SPDML03Q\", \"pname\": \"Protocol-2014-05-08-DOD-V1---000001.pdf\", \"doc_id\": \"0ce056ac-4360-4920-9443-4396b9c2c391\", \"dts\": \"20211109072001\", \"table_link_text\": \"Table 7-2 Schedule of assessments   Extended observational follow-on phase\", \"indicator_text\": \"X\", \"visit\": \"\", \"epoch\": \"\", \"cycle\": \"\", \"day\": \"\", \"week\": \"\", \"window\": \"\", \"year\": \"\", \"month\": \"\", \"roi_id\": \"\", \"assessment\": \"Table Cell\", \"section\": \"\", \"procedure\": \"\", \"assessment_text\": \"Stored Plasma Samples\", \"procedure_text\": \"\"}]", "soa": "[{\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Body weight</td>\\n      <td>Time of dose</td>\\n      <td>Ribavirin dose</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>< 75 kg</td>\\n      <td>AM</td>\\n      <td>2 x 200 mg tablets with food</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td></td>\\n      <td>PM</td>\\n      <td>3 x 200 mg tablets with food</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>\\u2265 75 kg</td>\\n      <td>AM</td>\\n      <td>3 x 200 mg tablets with food</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Body weight\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"07637b76-d6c4-43e1-b3e7-4bb1e56ed0a6\\\",\\\"column_roi_id\\\":\\\"3b9d8d08-bd56-4763-b55f-9aaf28add2ed\\\",\\\"datacell_roi_id\\\":\\\"881912b7-7630-4087-86b2-44c0e8318167\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Time of dose\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"07637b76-d6c4-43e1-b3e7-4bb1e56ed0a6\\\",\\\"column_roi_id\\\":\\\"8bd52dbb-5f46-4a7f-91c8-d57ac92190ff\\\",\\\"datacell_roi_id\\\":\\\"6327b592-1793-4995-a983-a05e26d66d68\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Ribavirin dose\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"07637b76-d6c4-43e1-b3e7-4bb1e56ed0a6\\\",\\\"column_roi_id\\\":\\\"3b571f9d-f5b9-4fe6-b548-432ab158cf63\\\",\\\"datacell_roi_id\\\":\\\"0a168bbe-4c7f-4629-90bb-eaf48381df06\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"< 75 kg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"2ca414c9-6fcf-400d-b8fb-71e2a23c8814\\\",\\\"column_roi_id\\\":\\\"665cfc74-afe6-4250-a8fe-7244752c4089\\\",\\\"datacell_roi_id\\\":\\\"74165040-fcaa-40bf-a572-12bff4b57e80\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"2ca414c9-6fcf-400d-b8fb-71e2a23c8814\\\",\\\"column_roi_id\\\":\\\"bcd1f573-af11-4a5f-ad1c-99c7e97b16be\\\",\\\"datacell_roi_id\\\":\\\"fc76158f-1340-4f78-9f3a-194f0d91e115\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"2 x 200 mg tablets with food\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"2ca414c9-6fcf-400d-b8fb-71e2a23c8814\\\",\\\"column_roi_id\\\":\\\"88cb2d59-a2d2-46d6-895c-13af4b3f1447\\\",\\\"datacell_roi_id\\\":\\\"7ec8478c-a5a7-42f4-99fb-e3ec7760db0a\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"PM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"13818973-9999-4af6-aa5d-eded52ba14fa\\\",\\\"column_roi_id\\\":\\\"68abf511-3a84-4f66-b3f5-e51d7b5379b1\\\",\\\"datacell_roi_id\\\":\\\"fd1a07c2-25b9-400e-b0ff-b653a481ac44\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3 x 200 mg tablets with food\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"13818973-9999-4af6-aa5d-eded52ba14fa\\\",\\\"column_roi_id\\\":\\\"503f70b1-5500-41f4-abb8-57eceb28c727\\\",\\\"datacell_roi_id\\\":\\\"e237777b-5e18-4cc8-ab5b-b9825aee83c0\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"\\\\u2265 75 kg\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"432e7b9e-fe01-41ed-91f6-4ddd76afc89e\\\",\\\"column_roi_id\\\":\\\"34e88111-52ae-41d9-8370-232c7ccd9674\\\",\\\"datacell_roi_id\\\":\\\"7d235f9a-299d-4f7f-ba12-bff824fbfcf3\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"AM\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"432e7b9e-fe01-41ed-91f6-4ddd76afc89e\\\",\\\"column_roi_id\\\":\\\"a6e1b131-b04f-4868-a8c0-208052dc0288\\\",\\\"datacell_roi_id\\\":\\\"62d513d4-3eb8-4be5-b966-9daafa321a1a\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"3 x 200 mg tablets with food\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"e6417bed-714e-4ee7-9ef0-f923dc40184f\\\",\\\"row_roi_id\\\":\\\"432e7b9e-fe01-41ed-91f6-4ddd76afc89e\\\",\\\"column_roi_id\\\":\\\"ba169d3e-e03a-4f80-a7bc-06a87a1cc9f9\\\",\\\"datacell_roi_id\\\":\\\"7397f23d-eccf-4213-9403-71a50717d31b\\\"},\\\"table_index\\\":10.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"26\", \"TableIndex\": \"11.0\", \"TableName\": \"Table 6-1 Ribavirin dosing schedule\", \"Header\": [0]}, {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n      <th>7.0</th>\\n      <th>8.0</th>\\n      <th>9.0</th>\\n      <th>10.0</th>\\n      <th>11.0</th>\\n      <th>12.0</th>\\n      <th>13.0</th>\\n      <th>14.0</th>\\n      <th>15.0</th>\\n      <th>16.0</th>\\n      <th>17.0</th>\\n      <th>18.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td></td>\\n      <td>SCR</td>\\n      <td>Pre-TX</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Treatment Period</td>\\n      <td>Treatment Period</td>\\n      <td>Treatment Period</td>\\n      <td>Treatment Period</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Post EOT Follow-up</td>\\n      <td>Post EOT Follow-up</td>\\n      <td>Post EOT Follow-up</td>\\n      <td>Post EOT Follow-up</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>STUDY DAY \\u21d2  ASSESSMENT \\u21d3</td>\\n      <td>-75 to  -7</td>\\n      <td>-6 to -1</td>\\n      <td>1</td>\\n      <td>2 (opt)</td>\\n      <td>4\\u00b11</td>\\n      <td>8\\u00b11 W1</td>\\n      <td>11\\u00b11</td>\\n      <td>15\\u00b11 W2</td>\\n      <td>22\\u00b13 W3</td>\\n      <td>29\\u00b13 W4</td>\\n      <td>43\\u00b13 W6</td>\\n      <td>57\\u00b13 W8 (EOT) <sup>10</sup></td>\\n      <td>85\\u00b13 W12 (EOT) <sup>11</sup></td>\\n      <td>28\\u00b17 Days Post EOT (SVR 4 )</td>\\n      <td>56\\u00b17 Days Post EOT (SVR 8 )</td>\\n      <td>84\\u00b17 Days Post EOT (SVR 12 )</td>\\n      <td>168\\u00b17 Days Post EOT (SVR 24 )</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Informed Consent</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>IWR (drug assignment/shipment)</td>\\n      <td>X<sup> (Day -14 to Day -1)</sup></td>\\n      <td>X<sup> (Day -14 to Day -1)</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X<sup> 11 </sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>Inclusion/Exclusion Criteria & Medical History</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>Study Drug Dosing</td>\\n      <td></td>\\n      <td></td>\\n      <td>X <sup>7</sup></td>\\n      <td>X <sup>7</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>7</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X<sup> 11 </sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>HIV-1 and HIV-2 Ab, HBsAg, Hemoglobin A1c</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>FSH (females of nonchildbearing potential only)</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td>Height <sup>1</sup> & Weight & BMI <sup>1</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>Vital Signs (excluding temperature)</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>Complete Physical Exam</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X<sup> 10 </sup></td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td>Adverse Events <sup></sup> (with targeted physical exam) <sup>3</sup></td>\\n      <td>SAE only</td>\\n      <td>SAE only</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>SAE only</td>\\n      <td>SAE only</td>\\n      <td>SAE only</td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>Concomitant Medications</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>13</th>\\n      <td>Echocardiogram <sup>4</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>14</th>\\n      <td>12-Lead ECG <sup>5</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X<sup> 2</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X<sup> 10 </sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>15</th>\\n      <td>HCV RNA Quantitation</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X<sup> 2, 6 </sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>16</th>\\n      <td>HCV Genotyping</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>17</th>\\n      <td>Host IL28B</td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>18</th>\\n      <td>PK Sample Collection <sup>7</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>19</th>\\n      <td>Hematology, Clinical Chemistry, GFR, Coagulation <sup></sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>20</th>\\n      <td>FibroTest</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>21</th>\\n      <td>TSH</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>22</th>\\n      <td>Pregnancy Test <sup>8</sup></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n      <td></td>\\n      <td>X<sup> 10 </sup></td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>23</th>\\n      <td>Plasma and/or Serum Stored Samples <sup>9</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>24</th>\\n      <td>Urinalysis</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X <sup>2</sup></td>\\n      <td></td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":\\\"\\\",\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SCR\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"1e801b0d-fa39-47b4-ab9a-3a51f3595826\\\",\\\"datacell_roi_id\\\":\\\"57a33e73-fe9a-4b1b-9240-b925f797c1df\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pre-TX\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"cb658929-10aa-431a-96aa-69802f665825\\\",\\\"datacell_roi_id\\\":\\\"28ab479f-e686-475e-b291-72bd98287353\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Treatment Period\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"e123fdac-4edb-4ff4-a650-5cd1a72a609d\\\",\\\"datacell_roi_id\\\":\\\"20abff4d-7d5a-4398-a84c-15f2a1527f1e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Post EOT Follow-up\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f8453579-e0d9-4d3b-b84e-9eb6b2126ab8\\\",\\\"column_roi_id\\\":\\\"62386b03-a182-40cf-89e7-3835e436d480\\\",\\\"datacell_roi_id\\\":\\\"d13fff55-432d-4b98-b933-b63dc155ff53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"STUDY DAY \\\\u21d2  ASSESSMENT \\\\u21d3 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"a8b05188-082b-4bf5-a21e-4dd0025f9af5\\\",\\\"datacell_roi_id\\\":\\\"709bf40c-a1f3-4923-9104-cb6c017c9898\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"-75 to  -7\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"622a8976-e452-4509-8cf2-38afe57c81fd\\\",\\\"datacell_roi_id\\\":\\\"80520a67-ed6b-4335-a267-18c7877b12d3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"-6 to -1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"9f6139e3-0c99-44c4-9156-cf2a8282827f\\\",\\\"datacell_roi_id\\\":\\\"d77bed2e-157a-42eb-8f19-ecb40bf4c1cb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"08cef0fe-cb0f-41ec-b3e1-963e8c0f190c\\\",\\\"datacell_roi_id\\\":\\\"53b19dde-a894-47a3-937a-e616b9a37da8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"2 (opt)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"13bdb472-2510-4c6d-916c-3fd84f01b61b\\\",\\\"datacell_roi_id\\\":\\\"3cc464f7-e76c-4da5-a480-a65fd6ae79b3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"4\\\\u00b11\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"95177c6f-98fe-4c94-b11a-af4e8614bb58\\\",\\\"datacell_roi_id\\\":\\\"c4ccc303-910f-4ee6-b067-a683a603e3ce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"8\\\\u00b11 W1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"94cec2ac-8c78-4fdd-8f59-32b2e7ce9b94\\\",\\\"datacell_roi_id\\\":\\\"e993aff6-ed36-4a69-97bb-6ba09c075141\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"11\\\\u00b11\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"61d52611-9890-4586-bb31-a002a344ebed\\\",\\\"datacell_roi_id\\\":\\\"1de01484-f8ea-4f76-a696-73042cea8f05\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"15\\\\u00b11 W2\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"8986ce57-96c6-4fe3-894e-987fb9758089\\\",\\\"datacell_roi_id\\\":\\\"8fb75348-c88a-4db8-88fc-d7c2f93b7f28\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"22\\\\u00b13 W3\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"e23798da-f733-4b14-95c5-ba843b14f219\\\",\\\"datacell_roi_id\\\":\\\"0c503bf5-c462-493d-a252-3b69f024cbde\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"29\\\\u00b13 W4\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"39187b1b-8679-4db5-8ad3-1269675c22f1\\\",\\\"datacell_roi_id\\\":\\\"59da473e-98c9-4621-bc1a-0bfdc2f63d23\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"43\\\\u00b13 W6\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"cf7c12ae-250c-4f15-97db-60d156072806\\\",\\\"datacell_roi_id\\\":\\\"69d51f69-3e66-4bfc-9b79-e94fba951187\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"57\\\\u00b13 W8 (EOT) <sup>10<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"1c56216a-dee8-439c-acdb-72cdd0addf90\\\",\\\"datacell_roi_id\\\":\\\"ed23015c-e954-41e6-ab7f-39d2f32c4d95\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"85\\\\u00b13 W12 (EOT) <sup>11<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"f9f3956b-c5c9-47e2-bdaa-945214fa93e7\\\",\\\"datacell_roi_id\\\":\\\"e215db2d-9afb-4768-ac6b-5edc22e35611\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"28\\\\u00b17 Days Post EOT (SVR 4 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"663aaef2-49e6-4d9b-b49f-9cfd99f964b1\\\",\\\"datacell_roi_id\\\":\\\"ba80e523-91ab-4630-ae6f-7f0f60149373\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"56\\\\u00b17 Days Post EOT (SVR 8 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"8c502957-88da-4881-a006-a7059e047fd1\\\",\\\"datacell_roi_id\\\":\\\"557ac7f3-d5e0-4813-9857-0c4d46ba8d29\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"84\\\\u00b17 Days Post EOT (SVR 12 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"4389a1e3-14a9-4a66-9726-be38fbcde56b\\\",\\\"datacell_roi_id\\\":\\\"de2ffbbe-94b9-46a2-a433-3c13df0ea8f3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"168\\\\u00b17 Days Post EOT (SVR 24 )\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"39c5a415-4006-454b-9a6b-bb31aa81fa6a\\\",\\\"column_roi_id\\\":\\\"c8e5e335-2910-430a-b27d-ebc5335970e7\\\",\\\"datacell_roi_id\\\":\\\"de60f474-ed88-4a0c-9092-e90653a10610\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Informed Consent\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d6f69d91-e88c-448d-a994-173ab9899bb3\\\",\\\"column_roi_id\\\":\\\"839489fc-fe1e-41d8-8f29-ed26c7e40b1d\\\",\\\"datacell_roi_id\\\":\\\"26a672a6-bf1e-4972-8e6c-c601354c0c3b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d6f69d91-e88c-448d-a994-173ab9899bb3\\\",\\\"column_roi_id\\\":\\\"c9b27562-7b6e-45eb-add3-eb676fe39fe4\\\",\\\"datacell_roi_id\\\":\\\"aa853df9-d5c3-45fb-bd67-c6192b6c54f2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"IWR (drug assignment\\\\/shipment)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"5ac44db9-97d6-45df-80e0-270ed1b1e56b\\\",\\\"datacell_roi_id\\\":\\\"44a1480c-e2b4-403e-b880-2817f90debbd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> (Day -14 to Day -1)<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"9b242ecd-7801-4a34-a6d5-4ca5921d6c9a\\\",\\\"datacell_roi_id\\\":\\\"89cd3bba-04d2-4b35-83f5-c408725f5ba5\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> (Day -14 to Day -1)<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"9b242ecd-7801-4a34-a6d5-4ca5921d6c9a\\\",\\\"datacell_roi_id\\\":\\\"89cd3bba-04d2-4b35-83f5-c408725f5ba5\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"565bb253-81b5-49f5-b274-e205ba2c8533\\\",\\\"datacell_roi_id\\\":\\\"e855d3fd-c4e4-4d6b-b517-2f5df1601333\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 11 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c0de3321-4011-48b9-82c0-0ad88108cd6a\\\",\\\"column_roi_id\\\":\\\"17f967fd-9205-48f6-8d20-509a3c88a99a\\\",\\\"datacell_roi_id\\\":\\\"77ce8ef6-4a51-40cb-bf6a-500e9f6f1538\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Inclusion\\\\/Exclusion Criteria & Medical History\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d4f99144-a664-47aa-b6ac-7883783cb074\\\",\\\"column_roi_id\\\":\\\"ec3dafed-95d7-48f4-981b-6349073849c6\\\",\\\"datacell_roi_id\\\":\\\"25de6a36-e4d8-4e82-b106-515028cc378a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d4f99144-a664-47aa-b6ac-7883783cb074\\\",\\\"column_roi_id\\\":\\\"490bce2a-6da6-486b-8abb-6eb28392cbea\\\",\\\"datacell_roi_id\\\":\\\"3ed58d28-b150-472a-bde9-0d3f3590060e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"d4f99144-a664-47aa-b6ac-7883783cb074\\\",\\\"column_roi_id\\\":\\\"490bce2a-6da6-486b-8abb-6eb28392cbea\\\",\\\"datacell_roi_id\\\":\\\"3ed58d28-b150-472a-bde9-0d3f3590060e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Study Drug Dosing\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"96d570db-bfe6-4225-a17d-9502ed0993d7\\\",\\\"datacell_roi_id\\\":\\\"4ffead3f-afb0-45b1-82db-c359016e4fa6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>7<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"c516ef85-1db0-43ad-b1b5-73053026c8c9\\\",\\\"datacell_roi_id\\\":\\\"ad893956-2bf3-4582-bdb3-ccbbaec8dc75\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>7<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"efdabde9-895d-4134-8785-a24fbd05d6dd\\\",\\\"datacell_roi_id\\\":\\\"ebbadcb2-6860-4b25-85df-d782280f9c8e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"860ae6f4-bd4b-42ef-94fc-f928401e8cb4\\\",\\\"datacell_roi_id\\\":\\\"2c540b41-ff3f-487e-a448-f93fa5049d10\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"4d392516-f9a4-43c4-b7d3-e6294b3795fd\\\",\\\"datacell_roi_id\\\":\\\"d04feb05-51bc-47ec-9062-0f4effc2ef97\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"d8238632-8444-4b12-9806-fca397f3ba63\\\",\\\"datacell_roi_id\\\":\\\"d6ca8e23-893a-4b02-b2a0-e74e5b904cc9\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>7<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"41f1536a-2359-410f-ae57-64973f321cc2\\\",\\\"datacell_roi_id\\\":\\\"f563b03f-f9a6-4c65-bcf8-129517f84ca6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"37edb22e-346d-4983-bd2f-da4bf73ea51a\\\",\\\"datacell_roi_id\\\":\\\"67c22046-044f-425d-9bfb-e2ae164b5fd3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"de98de69-7d09-4806-afc1-96c915a203eb\\\",\\\"datacell_roi_id\\\":\\\"5dfa0313-a30f-4b3c-9a14-01c00a8c9bfb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"7f4b5817-1044-4978-9eff-0f00397946f0\\\",\\\"datacell_roi_id\\\":\\\"1f5b72ad-e955-4241-a266-d0f38f90357d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 11 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"0f1c1a4a-9927-4796-a2b5-121cb6e5d17b\\\",\\\"column_roi_id\\\":\\\"334adbf9-b0c0-4140-9831-3bf552836f73\\\",\\\"datacell_roi_id\\\":\\\"21d39d1f-2397-4e79-87aa-28e76d9117c9\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HIV-1 and HIV-2 Ab, HBsAg, Hemoglobin A1c\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"b2617bb6-5d94-4593-8a8b-5f988489d016\\\",\\\"column_roi_id\\\":\\\"adc4d96b-08e6-43df-b126-848b09d53b75\\\",\\\"datacell_roi_id\\\":\\\"1bf8634e-a022-4d02-b90c-26247357c888\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"b2617bb6-5d94-4593-8a8b-5f988489d016\\\",\\\"column_roi_id\\\":\\\"1ecfbaaf-cdaf-40df-8a32-81d472db66a8\\\",\\\"datacell_roi_id\\\":\\\"27884d52-22d8-47ae-9fc1-9c0694b0b067\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"FSH (females of nonchildbearing potential only)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"01ebbb90-3753-4bdd-bb20-da9427a90934\\\",\\\"column_roi_id\\\":\\\"885f1fed-36e0-4f22-8a9f-7f79a6f77928\\\",\\\"datacell_roi_id\\\":\\\"23fc22f6-8726-4162-960a-f2a08fbe6cfd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"01ebbb90-3753-4bdd-bb20-da9427a90934\\\",\\\"column_roi_id\\\":\\\"a1deb5d0-4081-448c-b6f1-1d6ea749834c\\\",\\\"datacell_roi_id\\\":\\\"e76e9b69-7426-44eb-bd3c-f18890111ed3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Height <sup>1<\\\\/sup> & Weight & BMI <sup>1<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"967b8522-0202-4590-8d9f-1c6d09d67348\\\",\\\"datacell_roi_id\\\":\\\"6c82b352-c3f3-4a76-ba7c-9e3c8a22eb6e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"cd4bb688-a835-4605-a80a-14fd5eb5a0d0\\\",\\\"datacell_roi_id\\\":\\\"3be78164-4e69-4d41-b86a-264ad1e05391\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"4e44c891-4310-4e69-81c0-eb61599e5c54\\\",\\\"datacell_roi_id\\\":\\\"d72ef135-30f2-455f-8aa6-57fe34fa905c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"83ccbe48-e5bf-4c6f-b9e6-20d5689c3209\\\",\\\"datacell_roi_id\\\":\\\"17261db7-505f-4395-a397-d93f7468a839\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"041eff1e-647b-4929-b21e-602423a6d579\\\",\\\"datacell_roi_id\\\":\\\"83a96b81-b544-4857-b5e4-cdb8ea0f21f4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"7e15d742-561c-4fb1-96c8-816abe7d8eef\\\",\\\"datacell_roi_id\\\":\\\"85723074-7022-4438-a070-8ab773ca13ae\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"a09352cf-2539-4781-8d0a-116975584149\\\",\\\"datacell_roi_id\\\":\\\"233d9e44-8544-4728-a5c1-1253e1889008\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"ffdb0c0f-85d0-4f2e-aff4-4fb84dafd844\\\",\\\"datacell_roi_id\\\":\\\"809d987c-f461-4405-b82e-6c9a284c92d2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"3d6d3338-cf34-482e-9011-c19340501d7c\\\",\\\"datacell_roi_id\\\":\\\"51a16c62-9236-431c-89ec-deeb35be0c94\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"45b0cb60-f74b-462b-9253-f7cbde367846\\\",\\\"datacell_roi_id\\\":\\\"6e059c89-1a52-44f6-b11f-d473405d4fd9\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"994ee668-b35b-4928-a89d-9dabce541494\\\",\\\"datacell_roi_id\\\":\\\"d978592b-d9c3-4ffa-b033-8ccc1ac909f4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"9d4c2724-77de-478d-9d77-4f7029b9e0e0\\\",\\\"datacell_roi_id\\\":\\\"d9c8a235-8e35-4447-beb4-2b254b34e76c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"06126bf5-8c92-4c5c-9628-f5e63d52ff28\\\",\\\"datacell_roi_id\\\":\\\"15f01212-5550-4ab6-80bb-230374a69841\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4538fa0-74c4-47c6-86fa-a38274f821d8\\\",\\\"column_roi_id\\\":\\\"9e39582a-c563-4f15-907a-f926af9c5a7e\\\",\\\"datacell_roi_id\\\":\\\"915ff12d-fa52-427e-b847-fa23455155a4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Vital Signs (excluding temperature)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"7fc7679e-40bd-43eb-8900-6bab02eff144\\\",\\\"datacell_roi_id\\\":\\\"8fe2eea8-4808-4019-a107-7e771a8a9b7c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"f6b45f5e-6a22-4b65-8169-8d205b6b4393\\\",\\\"datacell_roi_id\\\":\\\"214d9a94-f214-4d25-93b7-16043a8727ce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"4040c8aa-6bc6-40d3-ab50-1c9e07e85ecd\\\",\\\"datacell_roi_id\\\":\\\"0486e550-c9a2-48fe-884b-b5315db9f4b7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"1952a47b-2820-4948-b9c8-baa60f2a3147\\\",\\\"datacell_roi_id\\\":\\\"d3b5f316-d756-42b6-bff9-9fdc58bf8ea0\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"c5cac133-48f0-4c66-970d-712a9b205646\\\",\\\"datacell_roi_id\\\":\\\"6ec4c87f-2097-4fda-b932-23196823f590\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"191efb82-ccdd-4462-a019-42287ca6d3b8\\\",\\\"datacell_roi_id\\\":\\\"fb714441-c8b7-4cce-bcbd-3d89341c76fa\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"cfc47cb0-abdb-49db-82dc-37e2d5a5a796\\\",\\\"datacell_roi_id\\\":\\\"b691bf30-6b2e-4d3d-8add-f10c7c0b4c97\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"cdacade0-4caf-4672-88e1-deb5e38f6abe\\\",\\\"datacell_roi_id\\\":\\\"f81b6308-9775-4d81-b2ff-4d77191814f3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"e91a39c7-342f-42dd-b6be-5e8df4db5bb1\\\",\\\"datacell_roi_id\\\":\\\"d94cc14f-c727-4527-93ed-75ac99a850d8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"e600745d-9d06-4d56-aa51-10b1197b8aa1\\\",\\\"datacell_roi_id\\\":\\\"381fe25b-800d-4e5a-bb8c-89d4f2d13508\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"cf88dc6d-4513-4549-8f88-faa0f2b5fdfd\\\",\\\"datacell_roi_id\\\":\\\"035e2fb0-bb54-4345-b932-ac95a0f914c2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"542378a5-4bdf-4941-8871-2ba29b96529e\\\",\\\"datacell_roi_id\\\":\\\"cd8bdf9d-33ae-4d12-b2b3-d77a1ae0f374\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"a42004de-e674-4366-b056-3fd48c79ab68\\\",\\\"datacell_roi_id\\\":\\\"35e819d2-04c0-4231-ac5e-c13bc9ddbaed\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"ffe345ba-0689-4296-8823-2c44ab1cc7bd\\\",\\\"column_roi_id\\\":\\\"d5149688-a3b9-4241-86ad-61eeb150e572\\\",\\\"datacell_roi_id\\\":\\\"ce6f9e22-8ad7-4150-942c-60ecf5cf389a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Complete Physical Exam\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"1c5b08b3-63c4-4941-9807-a1f1e6b7a80d\\\",\\\"datacell_roi_id\\\":\\\"ae40a7cc-555f-4db8-a64b-56cfbb651455\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"2cd99946-8100-4fd5-82ea-ac47811d6c30\\\",\\\"datacell_roi_id\\\":\\\"e50c584e-b566-47fd-85be-ae1cb54ef62d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"aabcaf28-79fd-4ab3-993c-c6c876717af6\\\",\\\"datacell_roi_id\\\":\\\"856ac7dc-c388-4338-a459-3144130fe8eb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 10 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"4415bb96-b7dc-4e59-a82c-78a180283058\\\",\\\"datacell_roi_id\\\":\\\"f09c0fbd-3a9b-49fa-b519-26471b44c7b3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"dc6b0a73-ab9f-40a3-8574-7eb9c569adc7\\\",\\\"column_roi_id\\\":\\\"c5cd1bbc-5509-4f20-b913-005cdc9eab52\\\",\\\"datacell_roi_id\\\":\\\"055a866a-d22b-478b-a575-eefd59fbe4f4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Adverse Events <sup><\\\\/sup> (with targeted physical exam) <sup>3<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"09137094-939e-4e65-ac1c-f2316757bedc\\\",\\\"datacell_roi_id\\\":\\\"9f9f064f-05b8-4d23-88ed-5d84be560dd1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"9fb3fb12-5349-4fb2-becb-1fe25e3f2b4f\\\",\\\"datacell_roi_id\\\":\\\"8174d6aa-10ce-4373-919d-3f3602e4a562\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"feb26dcd-25ce-4cf0-99d9-ccdd84bc31bd\\\",\\\"datacell_roi_id\\\":\\\"aa94f67d-d28f-4015-86bc-c402973b483c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"933d7e4f-d192-4fff-acc8-a6d974e62c0b\\\",\\\"datacell_roi_id\\\":\\\"79f449cc-4fd1-4503-8e4a-703c51eaca53\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"755410dc-5deb-4294-9f9b-9651659b780b\\\",\\\"datacell_roi_id\\\":\\\"bd0f8fc3-0e6a-447a-8e54-1dfcfb1d1f51\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"bb378650-ad85-4fb8-a912-c22540a016d4\\\",\\\"datacell_roi_id\\\":\\\"6b4d6fb9-1d68-490b-828a-fc34607c015d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"1e7e8859-7e06-4eab-8118-017f5abbed05\\\",\\\"datacell_roi_id\\\":\\\"45404fe8-f15a-4e92-89c7-41f47e57cc94\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"5d5ec45f-4e07-4964-9d6a-c9f10e7d8bc2\\\",\\\"datacell_roi_id\\\":\\\"43d67b43-9144-4350-9854-3eaaa9c8fd9e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"51d97d86-4f55-4ab5-b8bc-dcbbb4a12178\\\",\\\"datacell_roi_id\\\":\\\"1e99edc0-a878-4921-abe9-8ed92765a4ea\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"e1ab3c6c-f864-4522-aea3-eb1022a0d480\\\",\\\"datacell_roi_id\\\":\\\"2a764b02-ecd0-400f-a19f-97da93b86f0e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"3d8b6828-b8fa-441a-9f4f-ed3fb3443ad5\\\",\\\"datacell_roi_id\\\":\\\"e5a11ac1-ed22-4649-89db-e7edfeedbc93\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"2e3a6909-9db9-4c99-9f22-d1095c5d0d33\\\",\\\"datacell_roi_id\\\":\\\"5450d0e5-0895-4281-af2e-25817a7f8273\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"21bc5822-87b8-465d-9676-8c053dcc8366\\\",\\\"datacell_roi_id\\\":\\\"a030631f-a0a9-41ee-af60-8dacff26cf0a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"81eb10e3-5de7-4c53-9e6c-226e9c0574ab\\\",\\\"datacell_roi_id\\\":\\\"2561eb45-69ff-45b1-b1f8-58d34e808991\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"2444aa45-8487-4a81-bfd5-2ec7519a3d85\\\",\\\"datacell_roi_id\\\":\\\"2dee2057-8490-4945-9cc1-a8a6041f1175\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"d4ae35ad-3200-42cb-a292-b4d561c69382\\\",\\\"datacell_roi_id\\\":\\\"2aab8f87-fb19-4b99-8a1f-272a381f1ff6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"d4ae35ad-3200-42cb-a292-b4d561c69382\\\",\\\"datacell_roi_id\\\":\\\"2aab8f87-fb19-4b99-8a1f-272a381f1ff6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"SAE only\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"e3ccf594-702d-453b-8265-fb97150fae90\\\",\\\"column_roi_id\\\":\\\"d4ae35ad-3200-42cb-a292-b4d561c69382\\\",\\\"datacell_roi_id\\\":\\\"2aab8f87-fb19-4b99-8a1f-272a381f1ff6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Concomitant Medications\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"7a5df1c7-3a68-4c90-88e5-e3149b07c260\\\",\\\"datacell_roi_id\\\":\\\"431987f0-b3ac-4a52-8dbb-08cdfe5fc16c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"87987f29-63d8-4aec-b031-58323fe7063f\\\",\\\"datacell_roi_id\\\":\\\"88ff2d06-40a0-4530-ade8-a7f6ce269674\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"5c21d7db-7177-4d44-9de6-892b345640a1\\\",\\\"datacell_roi_id\\\":\\\"a4f74c9c-df1b-4b7f-b700-26582342759e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"477d0224-185c-4a4d-8392-9fed3c04cc06\\\",\\\"datacell_roi_id\\\":\\\"eab8f875-a814-4410-981b-6a6599fbf7e8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"009d3037-4644-4b3a-aba9-f7271db5e919\\\",\\\"datacell_roi_id\\\":\\\"70912f1b-6c69-412e-ae5b-94a4e6ffc13b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"75c7ca7b-66e0-420e-88e8-e6f75b8025c9\\\",\\\"datacell_roi_id\\\":\\\"3a5d1b72-b3da-4ca5-bd26-0c7f64447765\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"3f0caf85-9cd9-4e47-bfcf-c673d154bb11\\\",\\\"datacell_roi_id\\\":\\\"3ffedd45-8a67-4ca1-b394-ef35eeeb84dd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"0d27c99b-3bdf-4cf6-920e-51d06275d76c\\\",\\\"datacell_roi_id\\\":\\\"b94fd708-0393-4ec8-b46f-0d2b0f2f6697\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"e1ef8e98-df77-401d-a77e-11a5b68f09af\\\",\\\"datacell_roi_id\\\":\\\"8528fc77-736c-473a-9465-abb177e9e4b4\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"f189fc18-6cd6-43c8-9358-2355f17489b7\\\",\\\"datacell_roi_id\\\":\\\"53aef581-df7f-4b04-a05e-1d7ab03be0c8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"2904cd17-0dab-4b12-9170-c5333c7f3a04\\\",\\\"datacell_roi_id\\\":\\\"38d615ff-4bfb-4eeb-b14f-b541b8232f47\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"7d40a692-6311-449a-b7bd-b9931970c9d7\\\",\\\"datacell_roi_id\\\":\\\"cf93eae2-97e0-4fa7-8da0-d38a80a1e318\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"a8a1c338-f933-49e3-bf77-cf9ce13b8c0c\\\",\\\"datacell_roi_id\\\":\\\"79026822-cf86-4d2c-9d0a-435388156d70\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"55a2e6a2-3718-454a-b25c-a5f006d0a5a7\\\",\\\"datacell_roi_id\\\":\\\"a9c4796c-c1d1-4a52-a988-7cb64f5d20f7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"8a99c40f-ecde-4084-87c8-12ea52a4286c\\\",\\\"datacell_roi_id\\\":\\\"28be0043-ec75-445b-b5f3-73a1065cf54b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"22bc1055-c05b-4e1c-a783-f801635666f9\\\",\\\"datacell_roi_id\\\":\\\"f06907ae-3784-4de6-b4e2-b3b6d7b0713f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"f43d98ef-5189-4696-a00f-a9c16314cc9a\\\",\\\"datacell_roi_id\\\":\\\"93296b5d-47af-485c-984b-5aa6643dc5d3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"a5794d1f-bb7c-46f3-841b-9c2acf0d00ed\\\",\\\"column_roi_id\\\":\\\"5b55426b-9dfd-45bf-b494-86b46bed1ec1\\\",\\\"datacell_roi_id\\\":\\\"33419b6c-27a3-4c9f-ae59-b5565556fb3a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Echocardiogram <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4457acf-1deb-4695-b8c3-41e8143559a0\\\",\\\"column_roi_id\\\":\\\"188d99d0-4f68-4820-b5a4-6beaf92c4880\\\",\\\"datacell_roi_id\\\":\\\"61cc6976-c27c-4bb9-ac4b-9bb310ceadeb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4457acf-1deb-4695-b8c3-41e8143559a0\\\",\\\"column_roi_id\\\":\\\"a63f010b-3839-4f11-a6d7-a6f4db998d36\\\",\\\"datacell_roi_id\\\":\\\"96bdb292-ac52-4713-b03e-97eda75a9c51\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"c4457acf-1deb-4695-b8c3-41e8143559a0\\\",\\\"column_roi_id\\\":\\\"a63f010b-3839-4f11-a6d7-a6f4db998d36\\\",\\\"datacell_roi_id\\\":\\\"96bdb292-ac52-4713-b03e-97eda75a9c51\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"12-Lead ECG <sup>5<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"9f0b8043-4a95-4415-9a5e-cc6b833c43a2\\\",\\\"datacell_roi_id\\\":\\\"3fda0317-1fb5-4c2c-9b53-c2eee3596540\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"4a0e8496-d289-4792-859c-7b9663869497\\\",\\\"datacell_roi_id\\\":\\\"4ece5a9a-26ad-4676-b4d9-75bad3178cfd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"e8193307-a187-43fb-86cc-fe11b0c86965\\\",\\\"datacell_roi_id\\\":\\\"653b33d6-1e21-4a7b-a50c-8ff915f1f247\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 2<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"67dc46d6-01a9-49f2-9bb5-31cc21a8522e\\\",\\\"datacell_roi_id\\\":\\\"0f07cb71-e276-46c3-a088-7d3529fa9bd6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"9fe69256-2e1e-406c-bdef-d85aa038ada4\\\",\\\"datacell_roi_id\\\":\\\"d67ecbd4-ec9a-484a-9544-008ae26505d1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 10 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"644bfd27-74c2-4ef7-9ffb-725b05a7b03c\\\",\\\"datacell_roi_id\\\":\\\"8343f791-0710-4dad-be26-8e7ed2d5beeb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"a1898b36-eb61-488c-82d1-1aed0c34f699\\\",\\\"datacell_roi_id\\\":\\\"3837237b-148b-4509-9be2-b42833a4fa10\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"efe42f46-a539-4874-8de1-2844352783a5\\\",\\\"column_roi_id\\\":\\\"cbf39403-a21a-4e71-83e9-5297c464d0a5\\\",\\\"datacell_roi_id\\\":\\\"523530a6-3782-4e25-a429-33454994c3dd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV RNA Quantitation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"c7c604d7-d8cf-4d52-8cb8-8cc5a87ea30b\\\",\\\"datacell_roi_id\\\":\\\"42b4786f-cede-4eae-84da-18e298162c9d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"4f2542d5-b188-41cd-a97f-e34ac33a5880\\\",\\\"datacell_roi_id\\\":\\\"53328735-c943-40b1-9dcb-3e308a5a0341\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"9fc9a061-02ad-4928-ad00-4b3e2da4de98\\\",\\\"datacell_roi_id\\\":\\\"0c5b7c9b-ebfe-4423-ae10-7e67844cf343\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 2, 6 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"ee7d5011-480a-4f50-bb57-4a7f4dd8a7f0\\\",\\\"datacell_roi_id\\\":\\\"4bb122d6-1602-4e37-b705-5661aadfa123\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"7c50fa85-5410-4eb0-8a9c-65fefb3b29d1\\\",\\\"datacell_roi_id\\\":\\\"021187be-c186-47da-8a46-ecb4b8f5c880\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"0706902d-71b2-4cc2-b0a9-6ae843c258a9\\\",\\\"datacell_roi_id\\\":\\\"4e85d3b7-9da5-4ee8-a8a8-ba168b5e0b95\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"cc50b624-8711-42f9-88eb-10465d9471e6\\\",\\\"datacell_roi_id\\\":\\\"ea1fc0d9-ee3d-449d-b891-fbf859e780ce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"2acf2f89-7d5a-4b2b-81b5-cc1ce70a0185\\\",\\\"datacell_roi_id\\\":\\\"b7397db4-8b11-42aa-b2cc-5b8d85c32bd3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"cb72c9eb-5a34-4958-bc27-0718c70d337b\\\",\\\"datacell_roi_id\\\":\\\"422cba2e-aa6d-4815-83ac-113f9b056d9c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"d6159f0e-2066-4efe-8c2b-28c51592b579\\\",\\\"datacell_roi_id\\\":\\\"29440c1c-8b7d-4439-9a17-2efed42b5486\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"410aab82-a00c-451f-a92f-b7a49314a983\\\",\\\"datacell_roi_id\\\":\\\"f1c42d24-f10a-4346-9cf3-5947709a6573\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"9f262621-e842-416b-ae41-c281ec96ff62\\\",\\\"datacell_roi_id\\\":\\\"fa1eec34-4e1d-4fd6-ac7c-fc56dfa8398c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"a26d05cc-5ca2-4e30-854b-44d599d86e11\\\",\\\"datacell_roi_id\\\":\\\"e8baa958-91ab-4c61-a567-62cd6293f4f6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"561f558c-c760-4c82-8967-475489ae4b24\\\",\\\"datacell_roi_id\\\":\\\"f04c332a-19dd-48aa-b865-799ba8fc3c74\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"f64ab053-211a-40ea-9030-872e39f2925d\\\",\\\"datacell_roi_id\\\":\\\"a7fc47b4-baea-428c-af8f-9e1c617fc58d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"a7f2debf-e933-4892-bf1c-dbabda97d706\\\",\\\"datacell_roi_id\\\":\\\"e0ba9365-3f79-4486-bea4-bb57020181ed\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"9638cdaf-7cb5-4e04-baef-684bf6f0a991\\\",\\\"datacell_roi_id\\\":\\\"71ad2f18-cafa-48d1-a1bc-4c95cdbbaa97\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"3bde75a5-9c5c-467a-9f15-daad351a74ae\\\",\\\"column_roi_id\\\":\\\"8a27efbb-58ce-4900-b809-974911977a2c\\\",\\\"datacell_roi_id\\\":\\\"32b84b1f-12c7-4d08-8ee0-bfb231286858\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV Genotyping\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"09815511-ed90-4423-850a-b460ec502a88\\\",\\\"column_roi_id\\\":\\\"b4e770fc-edb5-4eeb-89c9-5c3686a2557f\\\",\\\"datacell_roi_id\\\":\\\"a2242fa2-fbe2-49f5-a130-0911e2ebd2fc\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"09815511-ed90-4423-850a-b460ec502a88\\\",\\\"column_roi_id\\\":\\\"be420234-98df-4f08-84d1-d9e443592d6c\\\",\\\"datacell_roi_id\\\":\\\"8d4f15f6-58b1-435b-b5ca-663a64652713\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Host IL28B\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"748503eb-7339-40fc-b448-cceba395784e\\\",\\\"column_roi_id\\\":\\\"32a0b1c1-f699-4ea2-bb1e-802964638b7a\\\",\\\"datacell_roi_id\\\":\\\"061eafc5-e911-42d2-abe9-261bee9a57a8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"748503eb-7339-40fc-b448-cceba395784e\\\",\\\"column_roi_id\\\":\\\"bea236b8-51a1-4c09-9d44-8b30fa9e1be4\\\",\\\"datacell_roi_id\\\":\\\"432d0688-0dd4-4987-b78c-faa14a375450\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"PK Sample Collection <sup>7<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"b45411e7-2b01-44ae-8843-b289d6836f9a\\\",\\\"datacell_roi_id\\\":\\\"aba882c1-88ed-4b87-8932-2fa333f9374f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"565990ac-6527-455b-961e-7c3f8c9b5264\\\",\\\"datacell_roi_id\\\":\\\"0d20a939-878a-4b10-8225-ad7a915ce67a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"456d8467-00f2-47b9-9d9a-2cd2c5198606\\\",\\\"datacell_roi_id\\\":\\\"068803b0-6f96-4306-a4d9-e46ddc137ade\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"60e28192-0586-4fb2-8949-2cc4cf1cfdb2\\\",\\\"datacell_roi_id\\\":\\\"8dc3c161-1f97-454b-a3b6-798368eafed6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"30afcb60-9a60-4de0-83e7-3eb1ffc1a311\\\",\\\"datacell_roi_id\\\":\\\"fc6f2724-3ab0-404a-b819-b2bd999d953b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"9c2f3afc-eaef-4f04-a3ae-c2c92c970cd7\\\",\\\"datacell_roi_id\\\":\\\"c7419d36-b64a-4c60-b13d-972ce98285fa\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"1a8347b5-88ac-4d81-aa33-fcc1ea1fd6e6\\\",\\\"datacell_roi_id\\\":\\\"00e8fafa-aecb-4888-b55a-9897a4bac10f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"53559c71-7c12-472c-b6f3-2babbfbb5a2b\\\",\\\"datacell_roi_id\\\":\\\"f7068af1-d7ce-4251-9a1c-f7cea8b34db2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"91567dce-2b53-486e-90e6-290e5cd97a6a\\\",\\\"datacell_roi_id\\\":\\\"9df333fa-500d-4b33-9f9a-ebf23bc65e9f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"70609a68-cb7b-4adf-8cb6-4959d3628004\\\",\\\"datacell_roi_id\\\":\\\"5c6d9b00-6e8f-48a5-a29c-7d046946b46b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"955f0731-7811-44f1-bf6c-c165ef134561\\\",\\\"datacell_roi_id\\\":\\\"8781aeda-ec1f-425a-8a56-140407628166\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"036131a0-5f9c-45af-a701-395570aab775\\\",\\\"datacell_roi_id\\\":\\\"13bf3e4c-2458-4f48-9e72-de7e846fd408\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"80c9939e-f994-4057-900d-9a41edad8bae\\\",\\\"column_roi_id\\\":\\\"f27bf6d1-cc49-4de7-87b4-adda93eab7f8\\\",\\\"datacell_roi_id\\\":\\\"54a2255b-1b8a-45d8-9386-ccb98830ad3d\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Hematology, Clinical Chemistry, GFR, Coagulation <sup><\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"6a899bf3-be86-4cd1-bc57-bcff845b0485\\\",\\\"datacell_roi_id\\\":\\\"c32d1644-1916-4834-88b2-f63882902ac2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"bb8e2979-1c25-469c-9d0a-a6958b83d7be\\\",\\\"datacell_roi_id\\\":\\\"56226d8e-39e4-4d90-940a-41648e2a5d39\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"2af0551a-5d16-460e-8888-99009f5f1ba1\\\",\\\"datacell_roi_id\\\":\\\"8e70bc46-37c5-459b-b7f9-b13f64ad9dfb\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"77f4a5fb-d622-49ed-b1fb-2f54ba3d04ce\\\",\\\"datacell_roi_id\\\":\\\"9911805f-ee2a-4709-9779-36cdcddf0cea\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"e7cef2dc-36d4-48f4-a177-2ead1377207f\\\",\\\"datacell_roi_id\\\":\\\"747eb240-1646-4c18-a8c7-4528ec61bca7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"229079d3-ccfd-4a34-abf4-15f337b005ff\\\",\\\"datacell_roi_id\\\":\\\"93e06157-7473-4fc6-8836-d66011e8d7fa\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"0d6d2f5e-0956-423e-bff1-5270fabe61ab\\\",\\\"datacell_roi_id\\\":\\\"e0421169-7c2e-43fd-8009-e71b463a8732\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"e04d834a-a2c5-4a30-8af2-94c7a0fd0160\\\",\\\"datacell_roi_id\\\":\\\"3158cacf-a1ca-4069-a2cc-8fb4ea89fcb1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"348d293f-41d3-478e-ae39-63ee89240659\\\",\\\"datacell_roi_id\\\":\\\"85fffd5e-870d-4c7c-8e60-93527a70ca80\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"77a551c1-8756-472d-819f-a07cd140d1b3\\\",\\\"datacell_roi_id\\\":\\\"15fbb9ef-aaac-47e1-99c6-842f41d44dba\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"5e978d4f-4a45-4b21-874b-09a346c273de\\\",\\\"datacell_roi_id\\\":\\\"3c3de1c4-97e6-40f3-ab95-391161f44e8e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"025de810-6026-4105-929d-cd486feaeafb\\\",\\\"datacell_roi_id\\\":\\\"ba0e749a-b08e-4075-b75e-92cf7f187267\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"c19cff3f-2f61-402c-85a1-373185b28f64\\\",\\\"datacell_roi_id\\\":\\\"b59a0aa5-0144-43ed-bb7d-79e235326fce\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"f63e0f47-0375-4697-a3f0-35f3c4f3c989\\\",\\\"column_roi_id\\\":\\\"4d08c3e0-7224-4034-af2e-b96d67b743f4\\\",\\\"datacell_roi_id\\\":\\\"357e876f-8d2b-4ef8-b85d-6ca0c89245f7\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"FibroTest\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"40808a4a-8cbd-48b7-82ea-5860c93bca1f\\\",\\\"column_roi_id\\\":\\\"60e08319-711a-4e1a-a288-91111c17104b\\\",\\\"datacell_roi_id\\\":\\\"32bc2ef8-d569-46e0-b6ab-d46011f7b9f6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"40808a4a-8cbd-48b7-82ea-5860c93bca1f\\\",\\\"column_roi_id\\\":\\\"5f146903-1ef3-499d-a5fe-4e94d86474e7\\\",\\\"datacell_roi_id\\\":\\\"5bc2ebe3-e446-4963-a6da-7b54d198c887\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"TSH\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"71fd8876-0c4a-43b1-a28f-b4302fe7ce4d\\\",\\\"column_roi_id\\\":\\\"270228a7-3ab9-49e7-8122-0801903c372d\\\",\\\"datacell_roi_id\\\":\\\"0df03380-91fb-4188-861b-ffb840175928\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"507afa7a-da0d-49ae-857b-bd481fc399db\\\",\\\"row_roi_id\\\":\\\"71fd8876-0c4a-43b1-a28f-b4302fe7ce4d\\\",\\\"column_roi_id\\\":\\\"c32b6046-7ac5-41e4-af55-246e3a0ec89d\\\",\\\"datacell_roi_id\\\":\\\"0655d982-f809-465b-9fcd-39f7f3321edd\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":\\\"\\\",\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":\\\"\\\",\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":\\\"\\\",\\\"14.0\\\":\\\"\\\",\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pregnancy Test <sup>8<\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"998936af-ba5e-4ec3-9374-eb03d078c225\\\",\\\"datacell_roi_id\\\":\\\"c4def994-9977-42df-9a8d-4b28ff40b095\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"e504dd8c-24d3-496b-9c28-f787353fcf65\\\",\\\"datacell_roi_id\\\":\\\"8b23cc83-b87d-4209-abb3-30c7b7e80923\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\",\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"681f14b5-9a24-4557-9374-389070cc8dac\\\",\\\"datacell_roi_id\\\":\\\"3d7f95f5-5bbf-4d51-a58b-9e2750f5b7ae\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":\\\"\\\",\\\"7.0\\\":\\\"\\\",\\\"8.0\\\":\\\"\\\",\\\"9.0\\\":\\\"\\\",\\\"10.0\\\":\\\"\\\",\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"152509b8-af60-4686-a664-b53399e26a02\\\",\\\"datacell_roi_id\\\":\\\"84513341-f1d5-4dc0-b5b6-62d6a320504e\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":\\\"\\\",\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X<sup> 10 <\\\\/sup>\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"a7a0c6ae-1c95-4535-83c3-a76701113176\\\",\\\"datacell_roi_id\\\":\\\"251b3a37-fdb6-47fe-8303-a6e824fe5f9f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"87026149-772e-4d36-998d-a5cd2a5e6a2d\\\",\\\"datacell_roi_id\\\":\\\"b3f2de37-2a1d-4d58-bacd-082ab617eb18\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":\\\"\\\",\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"bfee4ae4-a6c2-4100-b48b-7c9ac6aab69f\\\",\\\"column_roi_id\\\":\\\"da926df7-f429-4b99-8cc2-59dfd7941408\\\",\\\"datacell_roi_id\\\":\\\"164b332c-b340-431c-bbf0-471cd11ce756\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Plasma and\\\\/or Serum Stored Samples <sup>9<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"4d9f09cf-6b45-4cda-9fda-27c907a1a1ad\\\",\\\"datacell_roi_id\\\":\\\"6a65e55e-4eb8-42de-8ae2-be6d3b77200c\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"ab443f65-da12-493a-b6b5-3b671f329740\\\",\\\"datacell_roi_id\\\":\\\"64ae7744-fc88-4da3-be05-dc98bca3de18\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"7fbac492-bfee-48ee-b3ef-9f73a087e8fe\\\",\\\"datacell_roi_id\\\":\\\"1c5789d8-314b-41e9-9b33-0e4b7b05e449\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"d0243c16-4e5a-48b5-89a9-e63818561d3f\\\",\\\"datacell_roi_id\\\":\\\"a58dd5a6-1e68-4f45-9cf9-a3c2b3254362\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"0f99e3aa-e3bf-44c5-8264-9d56f90ee7f6\\\",\\\"datacell_roi_id\\\":\\\"b3af2591-5612-4e76-b3f7-49278b5ebbca\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"9a75dbb4-283b-4170-af5d-76fcd6bdc172\\\",\\\"datacell_roi_id\\\":\\\"6165d699-6a67-45d5-9747-c5d1d19869d8\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"930f6d57-81de-4e37-8ac9-47767505b619\\\",\\\"datacell_roi_id\\\":\\\"aab60d1c-3021-4432-8ba0-82ea321d7835\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"9476702c-28e6-49c5-8e20-edb68fe7908e\\\",\\\"datacell_roi_id\\\":\\\"44476a3c-f689-4512-962b-9d0ca5201cdf\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"17f2b418-e49a-46c0-ba1d-5411c5152188\\\",\\\"datacell_roi_id\\\":\\\"cc2ef3de-decf-4c48-985a-adea0f33229a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"c10216b3-9333-4b15-8493-570bb314ab80\\\",\\\"datacell_roi_id\\\":\\\"d5bb82bf-fb1b-4302-acd5-7dde2f3d7a7f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"2d96bf81-55e9-4d32-9704-961dac033ab5\\\",\\\"datacell_roi_id\\\":\\\"4f746187-b5d3-4509-a2cd-9932de24117f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"1f5241c6-94f4-4d1a-bd7b-02ea9b253d99\\\",\\\"datacell_roi_id\\\":\\\"f2f8065f-6f21-4085-9d72-fec086f1de18\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"96e2348a-7322-4ead-beae-5058b76db2c5\\\",\\\"datacell_roi_id\\\":\\\"5e0af5b1-a981-4b01-ac40-940e5563ae60\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"ad1a1ab1-f0fb-4739-bcaf-1f5cb182ce01\\\",\\\"datacell_roi_id\\\":\\\"fbcc3eb4-bbf1-4dce-bddd-c8312a1350de\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"1c4c762e-f371-4240-b18f-2d53ca910de8\\\",\\\"datacell_roi_id\\\":\\\"989ead58-33f2-4154-9f9b-6f84f46efb61\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"8a1af937-4c35-4a3b-813c-87ed9d72622f\\\",\\\"datacell_roi_id\\\":\\\"ee7d527e-7d2d-476c-b33e-18f84a9f8f20\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"17.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"322b6196-5699-463c-a9f4-077339fc8a62\\\",\\\"datacell_roi_id\\\":\\\"9a088b2d-7f90-428c-b3fe-10e979c5cc6a\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"18.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"34b5c0ae-55ce-42d1-a51c-67f424b1ca2c\\\",\\\"column_roi_id\\\":\\\"e89ce0b6-e483-4a66-967f-5b17e446388c\\\",\\\"datacell_roi_id\\\":\\\"b00fef68-8364-45f8-a873-eabfc01e3ce6\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Urinalysis\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"6aa1f0ad-181a-4d5b-8d5f-38528aca620e\\\",\\\"datacell_roi_id\\\":\\\"4d6a0f49-ab80-4aa2-bd09-e93403652e20\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"db086ca3-7eb6-435c-95ee-1bab502db907\\\",\\\"datacell_roi_id\\\":\\\"9811cbf1-753e-4c90-8cc6-7618c410cf17\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"162b0574-41a1-444c-8a6e-2ba03e305174\\\",\\\"datacell_roi_id\\\":\\\"288fa44a-0db5-486f-830b-1cc3955ebdd2\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X <sup>2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"f200fa10-5098-4ec3-923b-431146edc9c2\\\",\\\"datacell_roi_id\\\":\\\"b718311a-37e9-491a-91ad-f3a0fad34b46\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":\\\"\\\",\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"8e53cd7e-8e60-4450-8ff7-781b005311e0\\\",\\\"datacell_roi_id\\\":\\\"e52ee90b-fcaf-42d1-9a53-7b21532ecd4b\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"602c1818-a5df-44f7-8a95-17d4f8d265be\\\",\\\"datacell_roi_id\\\":\\\"e29c3de2-0a19-4875-b4f2-020c19055669\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"8.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"71270f93-030b-4d2c-ae1b-749fe9a9bcd1\\\",\\\"datacell_roi_id\\\":\\\"465f2ea8-26c9-4070-ad6c-ce06e4d58bd3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"9.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"7cd65510-deed-41c3-b75f-e862bfad15e5\\\",\\\"datacell_roi_id\\\":\\\"85fdd49b-581b-4495-a9e2-d691cfe116c3\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"10.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"7ba7c8f4-d136-4338-908e-83d30889ad13\\\",\\\"datacell_roi_id\\\":\\\"aea9b038-6581-49af-93bd-9bb040566b32\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"11.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"9c990110-fcb6-4ce2-9246-8ee8c7dfca15\\\",\\\"datacell_roi_id\\\":\\\"72976f49-fb6d-43ba-903b-4ddf3b15da07\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"12.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"4207fb4c-dde1-47ad-9aa8-503f58eb84f1\\\",\\\"datacell_roi_id\\\":\\\"6d2faebc-6340-4eb9-bf6c-1bf874cbcfc1\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"13.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"8ad4303c-7620-437e-83c0-523d3554d6a8\\\",\\\"datacell_roi_id\\\":\\\"2da6e3e8-3491-4165-9926-59789a070e4f\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"14.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"6b34a902-a9e8-4b99-8da0-aa4d5b25ba18\\\",\\\"datacell_roi_id\\\":\\\"c451ad4a-543b-400f-9f20-ad1e43db0920\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"15.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"795e0404-f8f2-4f45-b991-27ba2f8387aa\\\",\\\"row_roi_id\\\":\\\"dc9a9a73-5b9d-4b33-9a80-48d675114385\\\",\\\"column_roi_id\\\":\\\"50d45da4-3888-4f4e-a78d-5977e5e9d843\\\",\\\"datacell_roi_id\\\":\\\"16065a7a-4970-485e-ab50-616b37bad6ff\\\"},\\\"table_index\\\":11.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"16.0\\\":\\\"\\\",\\\"17.0\\\":\\\"\\\",\\\"18.0\\\":\\\"\\\"}]\", \"SectionHeaderPrintPage\": \"29\", \"TableIndex\": \"12.0\", \"TableName\": \"Table 7-1 Schedule of assessments (Schedule of Assessment)\", \"AttachmentListProperties\": [{\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 0.0, \"AttachmentId\": \"af987d26-4070-11ec-8bde-005056ab6469\", \"Key\": \"1\", \"Text\": \"Table 7-1 Schedule of assessments SCR=Screening Period; Pre-TX=Pre-Treatment Period; W=Week; opt=optional; EOT=End of Treatment; SVR=Sustained Virologic Response; IWR=Interactive Web Response; FSH=Follicle Stimulating Hormone; BMI=Body Mass Index; IL28B=interleukin-28B; GFR= Glomerular Filtration Rate\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 1.0, \"AttachmentId\": \"afb1d4df-4070-11ec-aed1-005056ab6469\", \"Key\": \"1\", \"Text\": \"1. Height will be measured at Screening only. BMI will be calculated at Screening only.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 2.0, \"AttachmentId\": \"afb1d4eb-4070-11ec-be0d-005056ab6469\", \"Key\": \"3\", \"Text\": \"3. SAEs will be reported from time of informed consent through 168 days post EOT visit.  Nonserious AEs will be recorded from time of first dose of study drug through 28 days post EOT visit.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 3.0, \"AttachmentId\": \"afb1d4f1-4070-11ec-931c-005056ab6469\", \"Key\": \"4\", \"Text\": \"4. Echocardiogram to be scheduled during Screening period but not performed until subject qualifies for entry into the study.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 4.0, \"AttachmentId\": \"afb1f928-4070-11ec-a64c-005056ab6469\", \"Key\": \"5\", \"Text\": \"5. Three consecutive ECG determinations collected within 5 minutes apart from each other at each scheduled time point.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 5.0, \"AttachmentId\": \"afb1f92e-4070-11ec-9dd7-005056ab6469\", \"Key\": \"6\", \"Text\": \"6. If optional intensive PK assessments are performed on Day 1, HCV RNA determinations will be time-matched up to and including the 8 h PK timepoint.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 6.0, \"AttachmentId\": \"afb22038-4070-11ec-889a-005056ab6469\", \"Key\": \"7\", \"Text\": \"7. Refer to Table 7-3 for PK schedule. Study drugs must be taken while in the clinic on Day 1 for all subjects, and on Days 2 and 15 for those subjects who elect to participate in the optional PK sampling timepoints ( Table 7-3 ). \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 7.0, \"AttachmentId\": \"afb22053-4070-11ec-828e-005056ab6469\", \"Key\": \"8\", \"Text\": \"8. Pregnancy tests should be performed at the indicated visits; however, additional tests should be done if required by the local standard of care. A serum pregnancy test will be conducted during Screening, and a urine pregnancy test will be conducted on Day 1, prior to dosing. In addition, per the local standard of care, male subjects may be queried at each visit to ensure their female  partners have not become pregnant. \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 8.0, \"AttachmentId\": \"afb24760-4070-11ec-81c8-005056ab6469\", \"Key\": \"9\", \"Text\": \"9. Stored plasma samples will be dedicated for HCV antiviral resistance testing.  In addition, stored plasma or serum samples may be used for testing safety or PK parameters.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 9.0, \"AttachmentId\": \"afb24766-4070-11ec-bc94-005056ab6469\", \"Key\": \"10\", \"Text\": \"10. Applies to Groups A and C only.  Last dose of study drugs for Groups A and C is Day 56.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 8 visit.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"507afa7a-da0d-49ae-857b-bd481fc399db\", \"AttachmentIndex\": 10.0, \"AttachmentId\": \"afb26e2f-4070-11ec-b571-005056ab6469\", \"Key\": \"11\", \"Text\": \"11. Applies to Groups B, D, E and F only. Last dose of study drugs for Groups B, D, E and F is Day 84.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 12 visit.\", \"qc_change_type\": \"\", \"entities\": []}], \"FootnoteText_0\": \"1 Table 7-1 Schedule of assessments SCR=Screening Period; Pre-TX=Pre-Treatment Period; W=Week; opt=optional; EOT=End of Treatment; SVR=Sustained Virologic Response; IWR=Interactive Web Response; FSH=Follicle Stimulating Hormone; BMI=Body Mass Index; IL28B=interleukin-28B; GFR= Glomerular Filtration Rate\", \"FootnoteText_1\": \"1 1. Height will be measured at Screening only. BMI will be calculated at Screening only.\", \"FootnoteText_2\": \"3 3. SAEs will be reported from time of informed consent through 168 days post EOT visit.  Nonserious AEs will be recorded from time of first dose of study drug through 28 days post EOT visit.\", \"FootnoteText_3\": \"4 4. Echocardiogram to be scheduled during Screening period but not performed until subject qualifies for entry into the study.\", \"FootnoteText_4\": \"5 5. Three consecutive ECG determinations collected within 5 minutes apart from each other at each scheduled time point.\", \"FootnoteText_5\": \"6 6. If optional intensive PK assessments are performed on Day 1, HCV RNA determinations will be time-matched up to and including the 8 h PK timepoint.\", \"FootnoteText_6\": \"7 7. Refer to Table 7-3 for PK schedule. Study drugs must be taken while in the clinic on Day 1 for all subjects, and on Days 2 and 15 for those subjects who elect to participate in the optional PK sampling timepoints ( Table 7-3 ). \", \"FootnoteText_7\": \"8 8. Pregnancy tests should be performed at the indicated visits; however, additional tests should be done if required by the local standard of care. A serum pregnancy test will be conducted during Screening, and a urine pregnancy test will be conducted on Day 1, prior to dosing. In addition, per the local standard of care, male subjects may be queried at each visit to ensure their female  partners have not become pregnant. \", \"FootnoteText_8\": \"9 9. Stored plasma samples will be dedicated for HCV antiviral resistance testing.  In addition, stored plasma or serum samples may be used for testing safety or PK parameters.\", \"FootnoteText_9\": \"10 10. Applies to Groups A and C only.  Last dose of study drugs for Groups A and C is Day 56.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 8 visit.\", \"FootnoteText_10\": \"11 11. Applies to Groups B, D, E and F only. Last dose of study drugs for Groups B, D, E and F is Day 84.  Subjects in these groups will enter the post-EOT follow-up phase after the Week 12 visit.\", \"Header\": [0, 1]}, {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n      <th>5.0</th>\\n      <th>6.0</th>\\n      <th>7.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>STUDY DAY \\u21d2  ASSESSMENT \\u21d3</td>\\n      <td>252\\u00b114 Days Post EOT</td>\\n      <td>336\\u00b114 Days Post EOT (48 Weeks Post EOT)</td>\\n      <td>420\\u00b114 Days Post EOT</td>\\n      <td>504\\u00b114 Days Post EOT (72 Weeks Post EOT)</td>\\n      <td>588\\u00b114 Days Post EOT</td>\\n      <td>672\\u00b114 Days Post EOT (96 Weeks Post EOT)</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>HCV RNA Quantitation</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Stored Plasma Samples</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n      <td>X</td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"STUDY DAY \\\\u21d2  ASSESSMENT \\\\u21d3 \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"00c71948-657b-40ff-8309-ab8ec3eb0424\\\",\\\"datacell_roi_id\\\":\\\"b648faf6-5cdf-45b1-ad5d-09ef61f6ddab\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"252\\\\u00b114 Days Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"a6f2a5de-99c1-4e8e-bb81-95f5efc18017\\\",\\\"datacell_roi_id\\\":\\\"97197e8f-62c4-4076-aef6-e4785e9f9c81\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"336\\\\u00b114 Days Post EOT (48 Weeks Post EOT)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"a2bbb68d-35e5-450a-800a-31fbcba6ee1b\\\",\\\"datacell_roi_id\\\":\\\"d78db493-4cc1-4f4f-9af1-66ab03e20916\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"420\\\\u00b114 Days Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"b2b2559f-700d-4b45-956c-b7255be9b7af\\\",\\\"datacell_roi_id\\\":\\\"21292269-2e32-4969-adcb-85d9eb6ca06d\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"504\\\\u00b114 Days Post EOT (72 Weeks Post EOT)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"822f3acd-60c0-47dd-b6f3-064db0171f9b\\\",\\\"datacell_roi_id\\\":\\\"ec99ba7a-477e-43ba-b6ad-48e452e9181c\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"588\\\\u00b114 Days Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"f40602c6-5b5e-45fe-862c-fe9760a5427c\\\",\\\"datacell_roi_id\\\":\\\"9eaf9446-7105-4d7a-9de8-33878f73dbab\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"672\\\\u00b114 Days Post EOT (96 Weeks Post EOT)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"f4ffd769-bbeb-4fc4-8416-48d24351a257\\\",\\\"column_roi_id\\\":\\\"79731687-bef6-49b8-b039-43d682a26a56\\\",\\\"datacell_roi_id\\\":\\\"9a7c205d-c756-463b-bf27-f7158228c219\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"HCV RNA Quantitation\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"a525394b-b8a9-47de-a6f8-7ca995f5de99\\\",\\\"datacell_roi_id\\\":\\\"ae5a4895-dbae-4e43-a042-16a34839fb51\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"e300fef5-ab22-414a-b379-07d37be1954a\\\",\\\"datacell_roi_id\\\":\\\"37c99e4b-4974-429d-a037-988f1d86d04c\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"c88155b1-eec1-4cfe-b331-68f3333c08be\\\",\\\"datacell_roi_id\\\":\\\"b4398b34-66ef-475e-803d-85b61b5cb278\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"2122521c-98bf-4d50-95c0-ae06cdd59f0e\\\",\\\"datacell_roi_id\\\":\\\"cb30198b-9b44-43ae-8c7d-96dc100814fa\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"bf263fd3-6bbd-4275-ac2a-9bdb04004d9f\\\",\\\"datacell_roi_id\\\":\\\"8e639674-df7b-45b3-91c0-9d385719f932\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"0767f6fa-0be5-4cab-bf28-e7449436c57a\\\",\\\"datacell_roi_id\\\":\\\"8a2232c0-a0ad-4cb2-88c0-5feba163a567\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"687dea52-cd02-440e-8e70-e5c8aaa364b6\\\",\\\"column_roi_id\\\":\\\"95743e12-fdd3-4d1f-b28f-ca11654414c3\\\",\\\"datacell_roi_id\\\":\\\"60bfc0b7-743c-4b83-90ab-c10dbc11c274\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Stored Plasma Samples\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"2617a6c3-53ef-4e4f-8a64-5ee61ee2fd6c\\\",\\\"datacell_roi_id\\\":\\\"01764d2f-72d9-45d9-8a8b-961dc1e8d09e\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"9b848208-538a-413f-9c00-1ed55ad32c48\\\",\\\"datacell_roi_id\\\":\\\"ef7ce881-9b87-4ea5-b0ed-9f7fd11a341d\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"86421f6d-7ab7-4747-8c48-fcb93161c8d3\\\",\\\"datacell_roi_id\\\":\\\"3fe69cbe-44d2-449e-bac9-2fc29286e69d\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"4.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"25e6ce87-3ebe-491e-aa08-edaf1e57bc76\\\",\\\"datacell_roi_id\\\":\\\"a83c570b-9004-432e-8dc8-61e454349148\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"5.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"57bf2c9a-c4f0-446c-99d4-9700ecf29632\\\",\\\"datacell_roi_id\\\":\\\"01a4613b-eef8-44a4-9dc1-c997fcdc2d81\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"6.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"ff3a25e8-3b2f-48af-8a78-c5034dc80650\\\",\\\"datacell_roi_id\\\":\\\"09896c1b-9373-4ede-a87a-47132445ebe9\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"7.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"X\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\\\",\\\"row_roi_id\\\":\\\"c557a125-4c34-4fff-8fe7-ddfc1ba6df74\\\",\\\"column_roi_id\\\":\\\"3262718b-182a-4366-9977-17c8543fa7e5\\\",\\\"datacell_roi_id\\\":\\\"31a4406c-c623-43b3-ade1-41bca442017f\\\"},\\\"table_index\\\":13.0,\\\"qc_change_type\\\":\\\"\\\"}}]\", \"SectionHeaderPrintPage\": \"30\", \"TableIndex\": \"14.0\", \"TableName\": \"Table 7-2 Schedule of assessments \\u2013 Extended observational follow-on phase(Schedule of Assessment)\", \"AttachmentListProperties\": [{\"TableId\": \"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\", \"AttachmentIndex\": 0.0, \"AttachmentId\": \"afb26e38-4070-11ec-a945-005056ab6469\", \"Key\": \"\", \"Text\": \"Table 7-2 Schedule of assessments  Extended observational follow-on phase\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"4c4a81c9-57c8-4e1e-af52-21e7100cf52a\", \"AttachmentIndex\": 1.0, \"AttachmentId\": \"afb358b0-4070-11ec-967e-005056ab6469\", \"Key\": \"\", \"Text\": \"Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\", \"qc_change_type\": \"\", \"entities\": []}], \"FootnoteText_0\": \" Table 7-2 Schedule of assessments  Extended observational follow-on phase\", \"FootnoteText_1\": \" Subjects who initiate another HCV treatment will not be followed in the extended observational follow-on phase.\", \"Header\": [0]}, {\"Table\": \"<table border=\\\"1\\\" class=\\\"dataframe\\\">\\n  <thead>\\n    <tr style=\\\"text-align: right;\\\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Visit</td>\\n      <td>Mandatory PK schedule <sup>1</sup></td>\\n      <td>Optional PK schedule <sup>1, 2</sup></td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Day 1</td>\\n      <td>Predose (0 h) and at least 1 h post dose prior to leaving clinic</td>\\n      <td>Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h <sup></sup>  (HCV RNA timepoints to be timematched to PK timepoints) <sup>3</sup></td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Day 2</td>\\n      <td></td>\\n      <td>Predose (0 h) to be obtained no later than 28 h after the Day 1 dose</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Day 4</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>Day 8 (Week 1)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>Day 11</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>Day 15 (Week 2)</td>\\n      <td>Any time during visit <sup>4, 5</sup></td>\\n      <td>Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h</td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>Day 22 (Week 3)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td>Day 29 (Week 4)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>Day 43 (Week 6)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>Day 57 (Week 8)</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td>Day 85 (Week 12)</td>\\n      <td>Any time during visit <sup>4, 6</sup></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>28-Day Post EOT</td>\\n      <td>Any time during visit <sup>4</sup></td>\\n      <td></td>\\n    </tr>\\n  </tbody>\\n</table>\", \"TableProperties\": \"[{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Visit\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"d100c104-d49c-4f3e-907d-32787476ad2a\\\",\\\"column_roi_id\\\":\\\"b2743ee7-c248-45b9-a809-035ba90eab06\\\",\\\"datacell_roi_id\\\":\\\"1851c8c1-0dc7-413d-a26a-3b5eb60b467c\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Mandatory PK schedule <sup>1<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"d100c104-d49c-4f3e-907d-32787476ad2a\\\",\\\"column_roi_id\\\":\\\"bc8f0fb4-ae7d-4b65-9c46-63b61d49b88f\\\",\\\"datacell_roi_id\\\":\\\"223ad18d-b4d6-4218-a89c-eeccd5cb6f07\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Optional PK schedule <sup>1, 2<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"d100c104-d49c-4f3e-907d-32787476ad2a\\\",\\\"column_roi_id\\\":\\\"c66e47d4-af0b-495c-9401-134f9e60160a\\\",\\\"datacell_roi_id\\\":\\\"03a19be0-3ed4-4b9e-9ca5-3b5b37d7406e\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 1\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"dc2af793-d158-42ea-b0b6-aaffc662b257\\\",\\\"column_roi_id\\\":\\\"f1d40d52-6732-4dba-b28a-3208d2af3064\\\",\\\"datacell_roi_id\\\":\\\"7582a036-4ade-4f7d-a1bf-a25fa0ff39b4\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Predose (0 h) and at least 1 h post dose prior to leaving clinic\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"dc2af793-d158-42ea-b0b6-aaffc662b257\\\",\\\"column_roi_id\\\":\\\"bcfd39d5-ff90-425a-8e42-2961f3f41294\\\",\\\"datacell_roi_id\\\":\\\"7d2dbb2e-9aee-45ca-ad2e-a2aa28864549\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h <sup><\\\\/sup>  (HCV RNA timepoints to be timematched to PK timepoints) <sup>3<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"dc2af793-d158-42ea-b0b6-aaffc662b257\\\",\\\"column_roi_id\\\":\\\"82f2fbbd-8158-4246-8b62-6221cb84aef6\\\",\\\"datacell_roi_id\\\":\\\"50874e33-9241-4190-9ac8-2de050a777b9\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 2\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"087069bf-3dee-4ea6-95bc-5db45a8a208f\\\",\\\"column_roi_id\\\":\\\"6418e92b-2889-4c29-ad8e-230b31a8ea5a\\\",\\\"datacell_roi_id\\\":\\\"fc2704f7-afcd-4e4c-a3cd-8864b13f938b\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":\\\"\\\",\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Predose (0 h) to be obtained no later than 28 h after the Day 1 dose\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"087069bf-3dee-4ea6-95bc-5db45a8a208f\\\",\\\"column_roi_id\\\":\\\"8f5f5a3e-c10c-4609-be8d-7527be3ed228\\\",\\\"datacell_roi_id\\\":\\\"bec5b120-8e0f-4567-b5aa-0a21682451f9\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 4\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"feb70bd4-bfe5-4171-995d-b32125112175\\\",\\\"column_roi_id\\\":\\\"629b19ac-bcc1-4fee-9e9b-04d08c981e5c\\\",\\\"datacell_roi_id\\\":\\\"e8ae00df-5546-4091-ae2e-33c2930938e3\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"feb70bd4-bfe5-4171-995d-b32125112175\\\",\\\"column_roi_id\\\":\\\"2d15d4ef-16aa-4970-bb8c-b3356a3b8370\\\",\\\"datacell_roi_id\\\":\\\"16f83176-2593-4434-a0a2-b5291b2c642d\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 8 (Week 1)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1cd3358c-aac0-4158-901b-34fd957b2f43\\\",\\\"column_roi_id\\\":\\\"a2b49ae5-3652-473b-a72d-f39337d8e590\\\",\\\"datacell_roi_id\\\":\\\"4310450f-3617-4803-b190-7bc3074e9275\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1cd3358c-aac0-4158-901b-34fd957b2f43\\\",\\\"column_roi_id\\\":\\\"e7a994be-abca-446d-b302-71f49d2b0af4\\\",\\\"datacell_roi_id\\\":\\\"c622dd2c-3141-4c61-bffe-638a63ff4433\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 11\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"ca4d5259-d758-439f-8102-068ba0786aee\\\",\\\"column_roi_id\\\":\\\"14cbb8fb-7f95-47b8-bbf3-afb7b9ca4a62\\\",\\\"datacell_roi_id\\\":\\\"4d3a937b-64df-4373-b057-752df344c706\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"ca4d5259-d758-439f-8102-068ba0786aee\\\",\\\"column_roi_id\\\":\\\"ec04a55a-7783-4814-9aa1-3159c774e579\\\",\\\"datacell_roi_id\\\":\\\"b42d6c41-1dfc-4a7d-ba79-eceb1ff4aa4a\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 15 (Week 2)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"2aa5ff57-f31e-424f-a927-264dbab9ccf7\\\",\\\"column_roi_id\\\":\\\"98bd1692-6457-4cfb-9cf5-2072044210a1\\\",\\\"datacell_roi_id\\\":\\\"9eae9152-f83f-46fa-ae30-ee6435228835\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4, 5<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"2aa5ff57-f31e-424f-a927-264dbab9ccf7\\\",\\\"column_roi_id\\\":\\\"e1e7b8c6-7539-4e19-94b9-f064cdbf7382\\\",\\\"datacell_roi_id\\\":\\\"40e37822-e3f4-4811-a650-84535da49b91\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Pre- (0 h) and post dose at 0.5, 1, 2, 3, 4, 5, 6, 8 h\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"2aa5ff57-f31e-424f-a927-264dbab9ccf7\\\",\\\"column_roi_id\\\":\\\"cbe20238-be7c-4790-aa9e-a8f277981980\\\",\\\"datacell_roi_id\\\":\\\"2dcee231-d9b9-486c-be8a-4301a4015932\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"}},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 22 (Week 3)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"cba23932-5e14-4c78-ae38-e194b669204c\\\",\\\"column_roi_id\\\":\\\"1012dc08-6fb6-46d2-829c-c6ca0218b89c\\\",\\\"datacell_roi_id\\\":\\\"d21aeb9d-f069-458e-ad94-16c90fdb2a09\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"cba23932-5e14-4c78-ae38-e194b669204c\\\",\\\"column_roi_id\\\":\\\"9cbbfdb4-1327-4041-80e3-22c898688a51\\\",\\\"datacell_roi_id\\\":\\\"8790b856-63a9-4962-b829-7dd9f8c6746f\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 29 (Week 4)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1b5ff819-9302-46a7-a876-0c1ed611da33\\\",\\\"column_roi_id\\\":\\\"77c14c8e-4cb4-45af-9d76-d6c1f7b30225\\\",\\\"datacell_roi_id\\\":\\\"41d1cb53-4bb8-4ec8-9937-34e45622245f\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"1b5ff819-9302-46a7-a876-0c1ed611da33\\\",\\\"column_roi_id\\\":\\\"5ed4300a-5509-479e-82f4-616639b8cfd5\\\",\\\"datacell_roi_id\\\":\\\"99c45fd6-5dce-461f-a369-1e56b4ac52f9\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 43 (Week 6)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"3c38e9fc-a15a-4db0-81a0-aa3dc3d5ba4e\\\",\\\"column_roi_id\\\":\\\"0f64ef3b-772f-44f5-9251-3cefa880640c\\\",\\\"datacell_roi_id\\\":\\\"522190b3-7a6f-4e35-9b64-fd2b7cbf54cf\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"3c38e9fc-a15a-4db0-81a0-aa3dc3d5ba4e\\\",\\\"column_roi_id\\\":\\\"97c1afee-a967-4e9a-b952-189392c751f0\\\",\\\"datacell_roi_id\\\":\\\"4c8aadbd-f49e-4c2a-a949-0eb4f638c756\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 57 (Week 8)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"9d4bc3eb-2896-457e-a98f-49a521e809bd\\\",\\\"column_roi_id\\\":\\\"59f77455-6245-4043-894b-e643528e1d87\\\",\\\"datacell_roi_id\\\":\\\"cffa73cc-8e9a-484c-83cb-06d1e499a807\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"9d4bc3eb-2896-457e-a98f-49a521e809bd\\\",\\\"column_roi_id\\\":\\\"46e78e3c-d98c-46e5-8a1b-472c5811f36d\\\",\\\"datacell_roi_id\\\":\\\"849c212a-733d-4f32-bd56-8961a78557f1\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Day 85 (Week 12)\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"a9396f88-ca93-4862-b64f-00aef52b4977\\\",\\\"column_roi_id\\\":\\\"b60de049-d2c5-47cc-a467-792f6b5ef348\\\",\\\"datacell_roi_id\\\":\\\"cf15f723-7abe-40de-b45f-bf43d73b94cc\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4, 6<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"a9396f88-ca93-4862-b64f-00aef52b4977\\\",\\\"column_roi_id\\\":\\\"f237b9dc-0ae0-48c5-80a1-e5f3139aa14b\\\",\\\"datacell_roi_id\\\":\\\"b99690e5-3853-4f3f-98f6-b7e73d5c175b\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"},{\\\"1.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"28-Day Post EOT\\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"c4778e57-05a4-4619-bd05-1ca8a0b8fd7c\\\",\\\"column_roi_id\\\":\\\"262e246d-b4a2-4f70-a053-0f8ac2bae68f\\\",\\\"datacell_roi_id\\\":\\\"961ae110-8cdb-4df5-99d7-04f7ed52873c\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"2.0\\\":{\\\"entities\\\":[],\\\"content\\\":\\\"Any time during visit <sup>4<\\\\/sup> \\\",\\\"roi_id\\\":{\\\"table_roi_id\\\":\\\"75c99cf7-9943-4371-9263-a8f5154fb2b3\\\",\\\"row_roi_id\\\":\\\"c4778e57-05a4-4619-bd05-1ca8a0b8fd7c\\\",\\\"column_roi_id\\\":\\\"817c7a2b-195d-4338-a7a1-6b935031cc6a\\\",\\\"datacell_roi_id\\\":\\\"a1582fb4-f2e5-4b0a-a850-77ee4f127609\\\"},\\\"table_index\\\":14.0,\\\"qc_change_type\\\":\\\"\\\"},\\\"3.0\\\":\\\"\\\"}]\", \"SectionHeaderPrintPage\": \"31\", \"TableIndex\": \"15.0\", \"TableName\": \"Table 7-3 Schedule of PK assessments\", \"AttachmentListProperties\": [{\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 0.0, \"AttachmentId\": \"afb3cdf5-4070-11ec-8d47-005056ab6469\", \"Key\": \"1\", \"Text\": \"Table 7-3 Schedule of PK assessments\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 1.0, \"AttachmentId\": \"afb57bf4-4070-11ec-b61f-005056ab6469\", \"Key\": \"1\", \"Text\": \"1 Timepoints are relative to the last study drug dosing.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 2.0, \"AttachmentId\": \"afb57bfa-4070-11ec-8c82-005056ab6469\", \"Key\": \"2\", \"Text\": \"2 Optional schedule, open to all subjects, will assess one or all of the following: predose (trough) on Day 2, and/or intensive PK on Days 1 and/or 15. \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 3.0, \"AttachmentId\": \"afb57c09-4070-11ec-8f10-005056ab6469\", \"Key\": \"3\", \"Text\": \"3 HCV RNA samples should be obtained within 10 min following the PK sample.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 4.0, \"AttachmentId\": \"afb57c0f-4070-11ec-9df7-005056ab6469\", \"Key\": \"4\", \"Text\": \"4 Time of PK sampling, time of last dose, and time of last meal will be recorded.\", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 5.0, \"AttachmentId\": \"afb5a29e-4070-11ec-adf3-005056ab6469\", \"Key\": \"5\", \"Text\": \"5 A single sample at any time during the Day 15 visit will be obtained from subjects not participating in the intensive PK sampling. \", \"qc_change_type\": \"\", \"entities\": []}, {\"TableId\": \"75c99cf7-9943-4371-9263-a8f5154fb2b3\", \"AttachmentIndex\": 6.0, \"AttachmentId\": \"afb5a2ad-4070-11ec-ad48-005056ab6469\", \"Key\": \"6\", \"Text\": \"6 Day 85 (Week 12) visit applies only to Groups B, D, E and F. For plasma PK samples, all predose timepoints must be drawn within 30 minutes prior to dosing. For intensive PK sampling, blood samples will be collected within a 5 min window for timepoints 4 h and a window of 10 min for time points > 4h.\", \"qc_change_type\": \"\", \"entities\": []}], \"FootnoteText_0\": \"1 Table 7-3 Schedule of PK assessments\", \"FootnoteText_1\": \"1 1 Timepoints are relative to the last study drug dosing.\", \"FootnoteText_2\": \"2 2 Optional schedule, open to all subjects, will assess one or all of the following: predose (trough) on Day 2, and/or intensive PK on Days 1 and/or 15. \", \"FootnoteText_3\": \"3 3 HCV RNA samples should be obtained within 10 min following the PK sample.\", \"FootnoteText_4\": \"4 4 Time of PK sampling, time of last dose, and time of last meal will be recorded.\", \"FootnoteText_5\": \"5 5 A single sample at any time during the Day 15 visit will be obtained from subjects not participating in the intensive PK sampling. \", \"FootnoteText_6\": \"6 6 Day 85 (Week 12) visit applies only to Groups B, D, E and F. For plasma PK samples, all predose timepoints must be drawn within 30 minutes prior to dosing. For intensive PK sampling, blood samples will be collected within a 5 min window for timepoints 4 h and a window of 10 min for time points > 4h.\", \"Header\": [0, 1]}]", "summary": "{\"index\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30], \"columns\": [\"field_name\", \"field_value\", \"field_header\"], \"data\": [[\"protocol_name\", \"\", \"Protocol Name\"], [\"protocol_number\", \"FEED_TEST2_Summary\", \"Protocol Number\"], [\"protocol_title\", \"08nov modified A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection\", \"Protocol Title\"], [\"protocol_title_short\", \"08nov modified\", \"Protocol Title Short\"], [\"is_amendment\", \"N\", \"Is Amendment\"], [\"amendment_number\", \"08nov modified\", \"Amendment Number\"], [\"trial_phase\", \"08nov modified\", \"Trial Phase\"], [\"sponsor\", \"(CKD)Chong Kun Dang Pharm\", \"Sponsor\"], [\"sponsor_address\", \"08nov modified\", \"Sponsor Address\"], [\"drug\", \"08nov modified\", \"Drug\"], [\"approval_date\", \"\", \"Approval Date\"], [\"version_number\", \"08nov modified 1\", \"Version Number\"], [\"version_date\", \"08nov modified\", \"Version Date\"], [\"blinded\", \"08nov modified\", \"Blinded\"], [\"compound_number\", \"08nov modified\", \"Compound Number\"], [\"control\", \"08nov modified\", \"Control\"], [\"investigator\", \"08nov modified\", \"Investigator\"], [\"study_id\", \"08nov modified\", \"Study Id\"], [\"number_of_subjects\", \"08nov modified 240\", \"Number Of Subjects\"], [\"participant_age\", \"08nov modified 65y\", \"Participant Age\"], [\"participant_sex\", \"08nov modified MALE\", \"Participant Sex\"], [\"exclusion_criteria\", \"08nov modified Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.\", \"Exclusion Criteria\"], [\"inclusion_criteria\", \"08nov modified Subjects with test results which do not meet the above inclusion/exclusion criteria may have the underlying test repeated once if it is thought to represent a laboratory error, a reversible, clinically insignificant intermittent condition, or is not consistent with the subject\\u2019s historical values. If inclusion/exclusion criteria are not met after the repeat test, the subject should be considered a screen failure and should not be enrolled in the study.\", \"Inclusion Criteria\"], [\"indication\", \"ABCC6 deficiency\", \"Indication\"], [\"primary_objectives\", \"08nov modified \\u2022 Emergence of resistance mutations during treatment and in the post-treatment period\", \"Primary Objectives\"], [\"secondary_objectives\", \"\", \"Secondary Objectives\"], [\"study_status\", \"\", \"Study Status\"], [\"study_population\", \"08nov modified patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..\", \"Study Population\"], [\"endpoints\", \"\", \"Endpoints\"], [\"trial_type_randomized\", \"\", \"Trial Type Randomized\"], [\"molecule_device\", \"test\", \"Molecule Device\"]], \"metadata\": {\"accuracy\": \"\"}}"}}